Compilation of abstract titles from ASCO Annual Meeting 2021 (oral, poster discussion, posters, mains track by cancer types only)

Table of Content

I. ORAL PRESENTATIONS

Plenary Session

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Lung Cancer—Non-Small Cell Metastatic

Sarcoma

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Pediatric Oncology I

Melanoma/Skin Cancers

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Breast Cancer—Local/Regional/Adjuvant

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Breast Cancer—Metastatic

Central Nervous System Tumors

Genitourinary Cancer—Kidney and Bladder

Gynecologic Cancer

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Gastrointestinal Cancer—Colorectal and Anal

Head and Neck Cancer

Developmental Therapeutics—Immunotherapy
Genitourinary Cancer—Prostate, Testicular, and Penile ................................................................. 62
Hematologic Malignancies—Plasma Cell Dyscrasia ........................................................................ 65

II. POSTER DISCUSSION PRESENTATIONS ..................................................................................... 69
Central Nervous System Tumors .................................................................................................... 69
Developmental Therapeutics—Immunotherapy .............................................................................. 72
Gastrointestinal Cancer—Colorectal and Anal .............................................................................. 76
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary ................................. 79
Genitourinary Cancer—Kidney and Bladder .................................................................................. 83
Genitourinary Cancer—Prostate, Testicular, and Penile ................................................................. 86
Gynecologic Cancer ......................................................................................................................... 90
Head and Neck Cancer ................................................................................................................... 94
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant .............. 97
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia ................................. 100
Hematologic Malignancies—Plasma Cell Dyscrasia ..................................................................... 103
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers ...................... 107
Lung Cancer—Non-Small Cell Metastatic ...................................................................................... 110
Melanoma/Skin Cancers .................................................................................................................. 114
Pediatric Oncology ......................................................................................................................... 117
Sarcoma ........................................................................................................................................... 120
Pediatric Oncology II ....................................................................................................................... 124

III. POSTER PRESENTATIONS ........................................................................................................ 127
Breast Cancer—Local/Regional/Adjuvant ....................................................................................... 127
Breast Cancer—Metastatic .............................................................................................................. 145
Central Nervous System Tumors ................................................................................................... 166
Developmental Therapeutics—Immunotherapy ............................................................................. 176
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology ....................... 212
Gastrointestinal Cancer—Colorectal and Anal ............................................................................. 242
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary ............................... 265
Genitourinary Cancer—Kidney and Bladder .................................................................................. 301
Genitourinary Cancer—Prostate, Testicular, and Penile ............................................................... 320
Gynecologic Cancer ......................................................................................................................... 338
Head and Neck Cancer ................................................................................................................... 357
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant............... 375
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia..................................... 383
Hematologic Malignancies—Plasma Cell Dyscrasia........................................................................ 396
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers......................... 405
Lung Cancer—Non-Small Cell Metastatic ....................................................................................... 421
Melanoma/Skin Cancers .................................................................................................................... 446
Pediatric Oncology .......................................................................................................................... 463
Sarcoma ............................................................................................................................................. 469
I. ORAL PRESENTATIONS

Plenary Session
Sunday, June 6, 7:00 PM - 10:00 PM CEST

Back to Program

Showing 17 Presentations

https://meetinglibrary.asco.org/session/13668

Chair

CHAIR
Norah Lynn Henry, MD, PhD, FASCO, FACP | University of Michigan

Chair

CHAIR
Lori J. Pierce, MD, FASTRO, FASCO | University of Michigan

OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer.

AUTHOR(S)

ABSTRACT
LBA1

Discussion

DISCUSSANT
Nadine M. Tung, MD | Beth Israel Deaconess Medical Center

Panel Question and Answer with Drs. Pierce, Henry, Tutt and Tung

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology

JUPITER-02: Randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).

AUTHOR(S)
Rui-hua Xu, Hai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, Chaosu Hu, Kunyu Yang, Jiyu Wen, Jin-Gao Li, Yingrui Shi, Feng Jin, Ruilian Xu, Jianji Pan, Shenhong Qu, Ping Li, Chunjhong Hu, Yi-Chun Liu, Yi Jiang, Xia He, Hung-Ming Wang, Wan-Teck Lim
Panel Question and Answer with Drs. Pierce, Henry, Xu, and Chan

Panel Discussion

DISCUSSANT
Anthony T. C. Chan, MD | The Chinese University of Hong Kong, Prince of Wales Hospital

Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274).

AUTHOR(S)

Panel Question and Answer with Drs. Pierce, Henry, Mileshkin, and Odunsi

Panel Discussion

DISCUSSANT
Kunle Odunsi, MD, PhD | The University of Chicago

Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).

AUTHOR(S)

Panel Question and Answer with Drs. Pierce, Henry, Morris, and Taplin

Panel Discussion

DISCUSSANT
Mary-Ellen Taplin, MD, FASCO | Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.

AUTHOR(S)
Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Yen-Hwa Chang, Jaroslav Hajek, Stefan N. Symeonides, Jae-Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross-Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Eric (Pingye) Zhang, Jaqueline Willemann Rogerio, Kentaro Imai, David I. Quinn, Thomas Powles

ABSTRACT
LBAS

Discussion

DISCUSSANT
Rana R. McKay, MD | University of California San Diego, Moores Cancer Center

Panel Question and Answer with Drs. Pierce, Henry, Choueiri, and McKay

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Friday, June 4, 5:00 PM - 8:00 PM CEST

Back to Program

Showing 17 Presentations

https://meetinglibrary.asco.org/session/13619

Chair
CHAIR
Lisa A. Kachnic, FASTRO, MD | Boston Medical Center

Chair
CHAIR
Gregory Michael Cote, MD, PhD | Massachusetts General Hospital


AUTHOR(S)

ABSTRACT
3000

First-in-human biomarker-driven phase I trial of the potent and selective glutaminase-1 (GLS1) inhibitor IACS-6274 (IPN60090) in patients (pts) with molecularly selected advanced solid tumors.

AUTHOR(S)
Timothy A. Yap, Ecaterina E. Dumbrava, Jordi Rodon Ahnert, David S. Hong, Shubham Pant, Daniel D. Karp, Sarina Anne A. Pihapaul, Vivek Subbiah, Apostolia M. Tsimberidou, Siqing Fu, Filip Janku, Sandra Montez, Majd T. Ahmad-Taha, Darlene Guerrero, Natalya N. Nazarenko, Yan Moore, Michael Soth, Jeff Kovacs, Timothy P. Heffernan, Philip Jones

ABSTRACT
3001

Phase 2 study of DRD2 antagonist/ClpP agonist ONC201 in neuroendocrine tumors.

AUTHOR(S)
Peter M. Anderson, Janette Gortz

ABSTRACT
3002

New Directions in Targeting Metabolism and Stress Response
DISCUSSANT
Dwight Hall Owen, MD | Division of Medical Oncology, Department of Internal Medicine, Ohio State University

Panel Question and Answer with Drs. Kachnic, Cote, Falchook, Yap, Anderson and Owen

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology

Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions.

AUTHOR(S)
Alison M. Schram, Eileen M. O’Reilly, Grainne M. O’Kane, Koichi Goto, Dong-Wan Kim, Cindy Neuzillet, Patricia Martin-Romano, Michaël Duruisseaux, Misako Nagasaka, Jordi Rodon, Benjamin A. Weinberg, Kumiko Umemoto, Sai-Hong I. Ou, Teresa Macarulla, Christelle De La Fouchardiere, Andrew K. Joe, Ernesto Wasserman, Viktoriya Stalbovskaya, Jim Ford

ABSTRACT
3003

MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors.

AUTHOR(S)
Funda Meric-Bernstam, John Hainsworth, Ron Bose, Howard A. Burris III, Claire F. Friedman, Razelle Kurzrock, Charles Swanton, Yong Wang, Jonathan Levy, Katja Schulze, Richard Price, Arisha Patel, Christopher Sweeney

ABSTRACT
3004

Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.

AUTHOR(S)
Irene Brana, Geoffrey Shapiro, Melissa L. Johnson, Helena A. Yu, Debbie Robbrecht, Daniel S. Tan, Lillian L. Siu, Hironobu Minami, Neeltje Steeghs, Thomas Hengelage, Eugene Tan, Kelly Biette, Kun Xu, Susan E. Moody, Maria Jove

ABSTRACT
3005

HER2: A SHP(2) That Hasn’t Sailed

DISCUSSANT
Ignacio Garrido-Laguna, MD, PhD | Huntsman Cancer Institute, University of Utah

Panel Question and Answer with Drs. Kachnic, Cote, Schram, Meric-Bernstam, Brana, and Garrido-Laguna

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology

A phase Ib trial of belvarafenib in combination with cobimetinib in patients with advanced solid tumors: Interim results of dose-escalation and patients with NRAS-mutant melanoma of dose-expansion.

AUTHOR(S)
Sang Joon Shin, Jeeyun Lee, Tae Min Kim, Jin-Soo Kim, Yu Jung Kim, Yong Sang Hong, Sun Young Kim, Jeong Eun Kim, Dae Ho Lee, Yoon-hee Hong, Young Su Noh, Song Kim, Eunhye Baek, Sujin Jung, Paul Rhee, Jinjoo Kim, Jennifer Eng-Wong, Vikram Malhi, Sharareh Monemi, Tae Won Kim

ABSTRACT
3007

BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: Phase 1 study results.

AUTHOR(S)

ABSTRACT
3008

New Twists on Old Targets

DISCUSSANT
Ulka N. Vaishampayan, MD | University of Michigan Cancer Center

Panel Question and Answer with Drs. Kachnic, Cote, Lynch, Shin, Schoffski, and Vaishampayan

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology
Lung Cancer—Non-Small Cell Metastatic
Friday, June 4, 7:00 PM - 10:00 PM CEST

Back to Program

Showing 17 Presentations

https://meetinglibrary.asco.org/session/13658

Chair

CHAIR
Christine L. Hann, MD, PhD | Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center

Chair

CHAIR
Raymond U. Osarogiagbon, FACP, MBBS | Baptist Cancer Center, Multidisciplinary Thoracic Oncology Department

First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.

AUTHOR(S)

ABSTRACT
9000

Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis.

AUTHOR(S)
Oladimeji Akinboro, Jonathon J. Vallejo, Pallavi S. Mishra-Kalyani, Erin A. Larkins, Nicole L. Drezner, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Harpreet Singh

ABSTRACT
9001

Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150.

AUTHOR(S)
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Makoto Nishio, Tony S. Mok, Martin Reck, Gene G. Finley, Wei Yu, Hina Patel, Nindhana Paranthaman, Ilze Bara, Howard West

ABSTRACT
9002
Optimizing Effective and Safe Deployment of Immune Checkpoint Inhibitors for Patients With NSCLC

DISCUSSANT
Mary Weber Redman, PhD | SWOG Statistical Center, Fred Hutchinson Cancer Research Center

Panel Question and Answer with Drs. Hann, Osarogiagbon, Reck, Akinboro, Socinski, and Redman

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology

Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer.

AUTHOR(S)
Ferdinandos Skoulidis, Bob T. Li, Ramaswamy Govindan, Grace K. Dy, Geoffrey Shapiro, Joshua Bauml, Martin H. Schuler, Alfredo Addeo, Terufumi Kato, Benjamin Besse, Abraham Anderson, Agnes Ang, Gataee Ngarmchamnanrith, Qui Tran, Vamsidhar Velcheti

ABSTRACT
9003

Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices.

AUTHOR(S)

ABSTRACT
9004

Racial disparities in biomarker testing and clinical trial enrollment in non-small cell lung cancer (NSCLC).

AUTHOR(S)
Debora S. Bruno, Lisa M. Hess, Xiaohong Li, Eric W. Su, Yajun E. Zhu, Monaliben Patel

ABSTRACT
9005

Biomarker Testing for Lung Cancer in 2021: Further Precision but Still Not Meeting the Mark for Equitable Distribution

DISCUSSANT
Christine M. Lovly, MD, PhD | Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center

Panel Question and Answer with Drs. Hann, Osarogiagbon, Skoulidis, Robert, Bruno, and Lovly

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology
Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.

AUTHOR(S)

ABSTRACT
9006
Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).

AUTHOR(S)
Pasi A. Janne, Christina S. Baik, Wu-Chou Su, Melissa L. Johnson, Hidetoshi Hayashi, Makoto Nishio, Dong-Wan Kim, Marianna Koczywas, Kathryn A. Gold, Conor E. Steuer, Haruyasu Murakami, James Chih-Hsin Yang, Sang-We Kim, Michele Vigliotti, Zhenhao Qi, Yang Qiu, Lihui Zhao, David W. Sternberg, Channing Yu, Helena A. Yu

ABSTRACT
9007
Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations.

AUTHOR(S)

ABSTRACT
9008
New Drugs and Novel Combinations to Combat EGFR TKI Resistance

DISCUSSANT
Nicolas Girard, MD, PhD | Institut Curie

Panel Question and Answer with Drs. Hann, Osarogiagbon, Bauml, Janne, Yang, and Girard

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology
TK216 for relapsed/refractory Ewing sarcoma: Interim phase 1/2 results.

AUTHOR(S)

ABSTRACT
11500

Efficacy of dose intensification in induction therapy for localized Ewing sarcoma: Italian Sarcoma Group (ISG) and Associazione Italiana Ematologia ed Oncologia Pediatrica (AIEOP) ISG/AIEOP EW-1 study.

AUTHOR(S)
Roberto Luksch, Giuseppe M. Milano, Francesco Barretta, Alessandra Longhi, Emanuela Palmerini, Nadia Puma, Sebastian D. Asaftei, Marta G. Podda, Giovanni Grignani, Gianni Bisogno, Rossella Bertulli, Luca Coccoli, Angela Tamburini, Carla Manzitti, Virginia Ferreesi, Maurizio Mascarin, Marco Rabusin, Stefano Ferrari, Piero Picci, Franca Fagioli

ABSTRACT
11501


AUTHOR(S)
Uta Dirksen, Andreas Ranft, Daniel Baumhoer, Henk van den Berg, Bénédicte Brichard, Hans-Theodor Eich, Hans Gelderblom, Jendrik Hardes, Wolfgang Hartmann, Heribert Juergens, Attila Kollar, Jarmila Kruseova, Thomas Kuehne, Ruth L. Ladenstein, Andreas Leithner, Arne Streitbuerger, Beate Timmermann, Per-Ulf Tunn, Dimosthenis Androu

ABSTRACT
11502

Something Old, Something New: Improving Outcomes for Ewing Sarcoma
Panel Question and Answer with Drs. Thornton, Conley, Ludwig, Luksch, Dirksen, and DuBois

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology

P10015/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE).

AUTHOR(S)
Scott Schuetze, Karla V. Ballman, Kristen N. Ganjoo, Elizabeth J. Davis, Jeffrey A. Morgan, Gabriel Tinoco, Melissa A. Burgess, Brian A. Van Tine, Edwin Choy, Dale R. Shepard, Ciara M. Kelly, Richard F. Riedel, Margaret von Mehren, Brittany L. Siontis, Steven Attia, Gary K. Schwartz, Hari A. Deshpande, Erin Kozlowski, Helen X. Chen, Brian Rubin

ABSTRACT
11503

SPEARHEAD-1: A phase 2 trial of afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.

AUTHOR(S)
Sandra P. D’Angelo, Brian A. Van Tine, Steven Attia, Jean-Yves Blay, Sandra J. Strauss, Claudia M. Valverde Morales, Albiruni R. Abdul Razak, Erin Van Winkle, Trupti Trivedi, Swethajit Biswas, Dennis Williams, Elliot Norry, Dejka M. Araujo

ABSTRACT
11504

A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma.

AUTHOR(S)
Brian A. Van Tine, Sant P. Chawla, Jonathan C. Trent, Breelyn A. Wilky, Rashmi Chugh, Bartosz Chmielowski, Shivaani Kummar, Atrayee Basu Mallick, Neeta Somaiah, Lee D. Cranmer, Mark Agulnik, Vicki L. Keedy, Silvia Stacchiotti, Bruno Vincenzi, Giuseppe Badalamenti, Brittany L. Siontis, Steven Attia

ABSTRACT
11505

Later-Phase Studies in Rare Sarcoma Subtypes Are Possible

DISCUSSANT
Robin Lewis Jones, MD, MBBS, MRCP, BSc | Royal Marsden Hospital and Institute of Cancer Research

Panel Question and Answer with Drs. Thornton, Conley, Schuetze, D'Angelo, Van Tine, and Jones

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology

NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.

AUTHOR(S)

**ABSTRACT**

11506

**PD1 inhibition in soft-tissue sarcomas with tertiary lymphoid structures: A multicenter phase II trial.**

**AUTHOR(S)**
Antoine Italiano, Alban Bessede, Emmanuelle Bompas, Sophie Piperno-Neumann, Christine Chevreau, Nicolas Penel, Francois Bertucci, Maud Toulmonde, Carine A. Bellera, Jean-Philippe Guegan, Catherine Sautes-Fridman, Antoine Bougoüin, Coralie Cantarel, Francois Le Loarer, Jean-Yves Blay, Wolf-Herman Fridman

**ABSTRACT**

11507

**Phase II trial of pegylated arginine deimine in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.**

**AUTHOR(S)**
Brian A. Van Tine, Angela C. Hirbe, Jingqin Luo, Peter J. Oppelt, Mia C. Weiss, Vanessa A. Eulo, Jacqui Toeniskoetter, Sasha Haarberg, Sarah Abaricia, Tyler Ruff, John S. Bomalaski, Amanda Johnston, Chih-Ling Kuo, Chiung-Fang Shiu, Matthew Ingham, Nam Bui, Sant P. Chawla, Gary K. Schwartz, Kristen N. Ganjoo

**ABSTRACT**

11508

**From Bench to Clinic: Novel Mechanisms, Novel Targets**

**DISCUSSANT**
Breelyn A. Wilky, MD | University of Colorado

**Panel Question and Answer with Drs. Thornton, Conley, Ingham, Italiano, Van Tine, and Wilky**

**PANEL SPEAKER**
Panel Discussion | American Society of Clinical Oncology

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Friday, June 4, 8:30 PM - 11:30 PM CEST

**Back to Program**

Showing 17 Presentations

[https://meetinglibrary.asco.org/session/13643](https://meetinglibrary.asco.org/session/13643)
Chair

CHAIR
Patrick William Burke, MD | Univ of Michigan

Chair

CHAIR
Milos Miljkovic, MD, MSc | Center for Cancer Research, National Cancer Institute

OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON).

AUTHOR(S)

ABSTRACT
7000

Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study.

AUTHOR(S)
Nicholas J. Short, Hagop M. Kantarjian, Marina Konopleva, Nitin Jain, Xuelin Huang, Farhad Ravandi, William G. Wierda, Gautam Borthakur, Koji Sasaki, Ghayas C. Issa, Yesid Alvarado, Naveen Pemmaraju, Guillermo Garcia-Manero, Jennifer Thankachan, Rebecca Garris, Elias Jabbour

ABSTRACT
7001

Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).

AUTHOR(S)
Bijal D. Shah, Armin Ghabadi, Olalekan O. Oluwole, Aaron Logan, Nicolas Boissel, Ryan D. Cassaday, Edouard Forcade, Michael R. Bishop, Max S. Topp, Dimitrios Tzachanis, Kristen M. O’Dwyer, Martha L. Arellano, Yi Lin, Maria R. Baer, Gary J. Schiller, Jinhui Dong, Tong Shen, Francesca Milletti, Behzad Kharabi Masouleh, Roch Houot

ABSTRACT
7002

Targeting BCR/ABL and Beyond

DISCUSSANT
Matthew Joseph Wieduwilt, MD, PhD | University of California, San Diego

Panel Question and Answer with Drs. Burke, Miljkovic, Cortes, Short, Shah and Wieduwilt

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology
The results of multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302).

**AUTHOR(S)**
Taiga Nishihori, Qaiser Bashir, Marcelo C. Pasquini, Michael Martens, Juan Wu, Melissa Alsina, Yvonne A. Efebera, Cristina Gasparetto, Nancy Geller, Sergio Giralt, John Koreth, Philip L. McCarthy, Emma C. Scott, Edward A. Stadtmauer, David H. Vesole, Parameswaran Hari

**ABSTRACT**
7003

Letermovir prophylaxis and cytomegalovirus reactivation in adult allogeneic hematopoietic cell transplant recipients with graft versus host disease.

**AUTHOR(S)**
Delaney Wolfe, Qiuhong Zhao, Emma G. Siegel, Marcin M. Puto, Yvonne A. Efebera, Justin C. Tossey

**ABSTRACT**
7004

Prospective longitudinal evaluation of microbiome diversity in patients with hematological malignancy undergoing allogeneic hematopoietic stem cell transplantation (HSCT).

**AUTHOR(S)**
Emily Walsh, Anastasia Tsakmaklis, Liyang Diao, Jessica Bryant, Mary-Jane Lombardo, Barbara McGovern, Lisa von Moltke, Matthew R. Henn, Christopher B. Ford, Maria J. Vehreschild

**ABSTRACT**
7005

Allografting: Tackling Disease, Bugs, and Microbiome

**DISCUSSANT**
Miguel-Angel Perales, MD | Memorial Sloan Kettering Cancer Center

**Panel Question and Answer with Drs. Burke, Miljkovic, Nishihori, Wolfe, Walsh, and Perales**

**PANEL SPEAKER**
Panel Discussion | American Society of Clinical Oncology

Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) miDH1 acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial.

**AUTHOR(S)**

**ABSTRACT**
7006
Efficacy and safety of aspacytarabine (BST-236) as a single-agent, first-line therapy for patients with acute myeloid leukemia unfit for standard chemotherapy.

AUTHOR(S)

ABSTRACT
Phase 1 first-in-human study of irreversible FLT3 inhibitor FF-10101-01 in relapsed or refractory acute myeloid leukemia.

AUTHOR(S)

ABSTRACT
New Versions of Approved Antileukemia Agents: Do They Advance Patient Care?

DISCUSSANT
Guru Subramanian Guru Murthy, MD | Medical College of Wisconsin

Panel Question and Answer with Drs. Burke, Miljkovic, De Botton, Altman, Levis, and Murthy

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology

Pediatric Oncology I
Saturday, June 5, 4:00 PM - 7:00 PM CEST

Back to Program

Showing 17 Presentations

https://meetinglibrary.asco.org/session/13666

Chair
The efficacy and safety of anti-CLL1 based CAR-T cells in children with relapsed or refractory acute myeloid leukemia: A multicenter interim analysis.

AUTHOR(S)
Hui Zhang, Chaoke Bu, Zhiyong Peng, min luo, Chunfu Li

ABSTRACT
Donor-derived CD7 CAR T cells for T-cell acute lymphoblastic leukemia.

AUTHOR(S)
Jing Pan, Biping Deng, Zhuojun Ling, Weiliang Song, Jinlong Xu, Jiajia Duan, Zelin Wang, Alex Chang, Xiaoming Feng

ABSTRACT
Driving Progress in Leukemia With New CARs

DISCUSSANT
Rayne H. Rouce, MD | Texas Children's Hospital

Panel Question and Answer with Drs. Donoghue, Maude, Zhang, Pan, and Rouce

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology

Targeted gene expression classifier identifies pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients at high risk for end induction minimal residual disease positivity.

AUTHOR(S)

ABSTRACT

AUTHOR(S)

ABSTRACT
Minimal residual disease at end of induction and consolidation remain important prognostic indicators for newly diagnosed children and young adults with very high-risk (VHR) B-lymphoblastic leukemia (B-ALL): Children’s Oncology Group AALL1131.

**AUTHOR(S)**

**ABSTRACT**
10004

**Refining Risk-Adapted Therapy in Pediatric Leukemia**

**DISCUSSANT**
Rob Pieters, MD | Princess Maxima Center for Pediatric Oncology

**Panel Question and Answer with Drs. Donoghue, Maude, Meyer, Gossai, Salzer, and Pieters**

**PANEL SPEAKER**
Panel Discussion | American Society of Clinical Oncology

**Clinical impact of molecular tumor profiling in pediatric, adolescent, and young adult patients with extra-cranial solid malignancies: An interim report from the GAIN/iCat2 study.**

**AUTHOR(S)**

**ABSTRACT**
10005

**Integrated whole-exome and transcriptome analysis of 250 treatment-refractory or relapsed (R/R) childhood solid tumors.**

**AUTHOR(S)**
Sara A. Byron, William P. Hendricks, Abhinav B. Nagulapally, Karl Dykema, Jeffrey Bond, Hsien-Chao Chou, Jun S. Wei, Xinyu Wen, Hue V. Reardon, Sara Nasser, Tyler Izatt, Daniel Enriquez, Apurva M. Hegde, Szabolcs Szelinger, Jonathan J. Keats, Rebecca F. Halperin, Javed Khan, Giselle L. Saulnier Sholler, Jeffrey M. Trent

**ABSTRACT**
10006

**Factors impacting enrollment on NCI-COG Pediatric MATCH trial treatment protocols.**

**AUTHOR(S)**
Donald W. Parsons, Katherine A. Janeway, David R. Patton, Jennifer Lee, Brent Coffey, Paul M. Williams, Sinchita Roy-Chowdhuri, Gregory J. Tsongalis, Mark Routbort, Nilsa C. Ramirez, Lauren Saguil, Jin Piao, Todd A. Alonzo, Stacey L. Berg, Elizabeth Fox, Douglas S. Hawkins, Margaret M. Mooney, Naoko Takebe, James V. Tricoli, Nita Seibel

**ABSTRACT**
10007
Selumetinib in patients with tumors with MAPK pathway alterations: Results from Arm E of the NCI-COG pediatric MATCH trial.

AUTHOR(S)
Carl E. Allen, Olive Eckstein, Paul M. Williams, Sinchita Roy-Chowdhuri, David R. Patton, Brent Coffey, Joel M. Reid, Jin Piao, Lauren Saguilig, Todd A. Alonzo, Stacey L. Berg, Alok Jaju, Elizabeth Fox, Douglas S. Hawkins, Margaret M. Mooney, Naoko Takebe, James V. Tricoli, Katherine A. Janeway, Nita Seibel, Donald W. Parsons

ABSTRACT
10008

Precision Oncology: Moving From Discovery to Implementation

DISCUSSANT
Birgit Geoerger, MD, PhD | Gustave Roussy Cancer Center, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay

Panel Question and Answer with Drs. Church, Byron, Parsons, Allen, and Geoerger

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology

Melanoma/Skin Cancers
Sunday, June 6, 2:00 PM - 5:00 PM CEST

Back to Program
Showing 17 Presentations

https://meetinglibrary.asco.org/session/13661

Chair

CHAIR
Grant A. McArthur, MBBS, PhD, FRACP | Melanoma and Skin Service and Cancer Therapeutics Program, Peter MacCallum Cancer Centre

Chair

CHAIR
Georgia Beasley, MD | Duke University

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.
AUTHOR(S)


ABSTRACT

9500

Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.

AUTHOR(S)


ABSTRACT

9501

Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma.

AUTHOR(S)


ABSTRACT

9502

The Evolving Role of Systemic Therapy in Stage III Melanoma

DISCUSSANT

Alexander M. Menzies, MBBS, FRACP, PhD | Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals

Panel Question and Answer with Drs. Beasley, McArthur, Eggermont, Grossmann, Amaria, and Menzies

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).
AUTHOR(S)

ABSTRACT
9503
Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.

AUTHOR(S)

ABSTRACT
9504
Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy.

AUTHOR(S)

ABSTRACT
9505
Novel Therapeutic Strategies as the Next Step for Advanced Melanoma

DISCUSSANT
Jason J. Luke, MD, FACP | UPMC Hillman Cancer Center


PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology

CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.

AUTHOR(S)
Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma.

AUTHOR(S)

Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets).

AUTHOR(S)

Informing Clinical Practice: Long-Term Updates of Pivotal Trials

DISCUSSANT
Sunandana Chandra, MD | Division of Hematology Oncology, Northwestern University Feinberg School of Medicine

Panel Question and Answer with Drs. Beasley, McArthur, Wolchok, Dummer, Long, and Chandra

_PANEL SPEAKER_
Panel Discussion | American Society of Clinical Oncology
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Sunday, June 6, 2:00 PM - 5:00 PM CEST

Back to Program

Showing 17 Presentations

https://meetinglibrary.asco.org/session/13655

Chair

CHAIR
Chandra Prakash Belani, MD | Penn State Cancer Institute

Chair

CHAIR
Estelamari Rodriguez, MD, MPH | Sylvester Comprehensive Cancer Center, University of Miami

IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).

AUTHOR(S)

ABSTRACT


AUTHOR(S)
Hirohito Tada, Tetsuya Mitsudomi, Takeharu Yamanaka, Kenji Sugio, Masahiro Tsuboi, Isamu Okamoto, Yasuo Iwamoto, Noriaki Sakakura, Shunichi Sugawara, Shinji Atagi, Toshiaki Takahashi, Hidetoshi Hayashi, Moriihito Okada, Hiroshige Yoshioka, Hidetoshi Inokawa, Kazuhisa Takahashi, Masahiko Higashiyama, Ichiro Yoshino, Kazuhiko Nakagawa

ABSTRACT
CTONG1103: Final overall survival analysis of the randomized phase 2 trial of erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small cell lung cancer.

AUTHOR(S)
Yi-Long Wu, Wenzhao Zhong, Ke-Neng Chen, Chun Chen, Fan Yang, Xue-Ning Yang, Chundong Gu, Weimin Mao, Qun Wang, Gui-Bin Qiao, Ying Cheng, Lin Xu, Changli Wang, Mingwei Chen, Hong-Hong Yan, Ri-qiang Liao, Xuchao Zhang, Jinji Yang, Si-yang Liu, Qing Zhou

ABSTRACT
8502

Role of Targeted Therapy and Immunotherapy in Resected Non-Small Cell Lung Cancer

DISCUSSANT
Zofia Piotrowska, MD | Massachusetts General Hospital Cancer Center

Panel Question and Answer with Drs. Belani, Rodriguez, Wakelee, Tada, Wu, and Piotrowska

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology

Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).

AUTHOR(S)
Jonathan Spicer, Changli Wang, Fumihiro Tanaka, Gene B. Saylors, Ke-Neng Chen, Moishe Liberman, Everett E. Yokes, Nicolas Girard, Shun Lu, Mariano Provencio, Tetsuya Mitsudomi, Mark M. Awad, Enriqueta Felip, Patrick M. Forde, Scott Swanson, Julie R. Brahmer, Keith Kerr, Cécile Dorange, Junliang Cai, Stephen Broderick

ABSTRACT
8503

Video-assisted thoracoscopic versus open lobectomy in patients with early-stage lung cancer: One-year results from a randomized controlled trial (VIOLET).

AUTHOR(S)
Eric K. Lim, Tim J. Batchelor, Joel Dunning, Michael Shackcloth, Vladimir Anikin, Babu Naidu, Elizabeth Belcher, Mahmoud Loubani, Vipin Zamvar, Rosie A. Harris, Lucy Dabner, Holly E. McKeon, Sangeetha Paramasivan, Alba Realpe, Daisy Elliot, Paulo De Sousa, Jane M. Blazeby, Chris A. Rogers

ABSTRACT
8504
Assessing Surgical Outcomes in Resectable Non-Small Cell Lung Cancer

DISCUSSANT
Valerie W. Rusch, MD | Memorial Sloan Kettering Cancer Center

Panel Question and Answer with Drs. Belani, Rodriguez, Spicer, Lim, and Rusch

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology

Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)/RTOG 0538.

AUTHOR(S)

ABSTRACT
8505

Stereotactic ablative radiotherapy in operable stage I NSCLC patients: Long-term results of the expanded STARS clinical trial.

AUTHOR(S)
Joe Y. Chang, Reza J. Mehran, Lei Feng, Peter Balter, Stephen McRae, Donald A. Berry, Jack A. Roth

ABSTRACT
8506

Emerging Trends in Radiation for Localized Lung Cancers

DISCUSSANT
Ramesh Rengan, MD, PhD | Department of Radiation Oncology, University of Washington

A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma.

AUTHOR(S)

ABSTRACT
8507

Salvage Therapy in Mesothelioma
DISCUSSANT

Anna K. Nowak, PhD, MBBS, FRACP | Sir Charles Gairdner Hospital

Panel Question and Answer with Drs. Belani, Rodriguez, Bogart, Chang, Rengan, Fennell, and Nowak

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Breast Cancer—Local/Regional/Adjuvant
Sunday, June 6, 2:00 PM - 5:00 PM CEST

Back to Program

Showing 17 Presentations

https://meetinglibrary.asco.org/session/13604

Chair

CHAIR

Frederique Madeleine Penault-Llorca, MD, PhD | Centre Jean Perrin

Chair

CHAIR

Richard C. Zellars, MD | Department of Radiation Oncology, Indiana University School of Medicine

Outcome of patients with an ultralow risk 70-gene signature in the MINDACT trial.

AUTHOR(S)

Josephine Lopes Cardozo, Caroline Drukker, Marjanka Schmidt, Laura van 't Veer, Anuska Glas, Anke Witteveen, Fatima Cardoso, Martine J. Piccart-Gebhart, Coralie Poncet, Emiel J. Rutgers

ABSTRACT

500
Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG oncology/NSABP B-42.

AUTHOR(S)

ABSTRACT
501

Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial.

AUTHOR(S)

ABSTRACT
502

How Much, How Long: Optimizing Adjuvant Therapy Through Genomics

DISCUSSANT
Fabrice Andre, MD, PhD | Gustave Roussy

Panel Question and Answer with Drs. Zellars, Penault-Llorca, Cardozo, Mamounas, Rastogi, and Andre

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology

De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results.

AUTHOR(S)

ABSTRACT
503
Prognostic impact of recurrence score, endocrine response and clinical-pathological factors in high-risk luminal breast cancer: Results from the WSG-ADAPT HR+/HER2- chemotherapy trial.

AUTHOR(S)
Oleg Gluz, Ulrike Nitz, Matthias Christgen, Michael Braun, Kerstin Luedtke-Heckenkamp, Maren Darsow, Helmut Forstbauer, Jochem Potenberg, Christoph Uleer, Eva-Maria Grischke, Bahriye Aktas, Claudia Schumacher, Christine zu Eulenburg, Katarzyna Jozwiak, Ronald E. Kates, Monika Graeser, Rachel Wuerstlein, Hans H. Kreipe, Sherko Kuemmel, Nadia Harbeck

ABSTRACT
504

Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study.

AUTHOR(S)

ABSTRACT
505

Subtype-Directed De-escalation

DISCUSSANT
Lisa A. Carey, MD, FASCO | University of North Carolina

Panel Question and Answer with Drs. Zellars, Penault-Llorca, Harbeck, Gluz, Litton, and Carey

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology

Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neoadjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).

AUTHOR(S)
Sibylle Loibl, Andreas Schneeweiss, Jens B. Huober, Michael Braun, Julia Rey, Jens U. Blohmer, Jenny Furlanetto, Dirk M. Zahm, Claus Hanusch, Jörg Thomalla, Christian Jackisch, Peter Staib, Theresa Link, Kerstin Rhiem, Christine Solbach, Peter A. Fasching, Nicole Burchardi, Carsten Denkert, Michael Untch

ABSTRACT
506
Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 trial.

AUTHOR(S)

ABSTRACT
A randomized phase III post-operative trial of platinum-based chemotherapy (P) versus capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EA1131

AUTHOR(S)

ABSTRACT
New Opportunities in High-Risk Early-Stage Disease

DISCUSSANT
Melinda L. Telli, MD | Stanford University School of Medicine

Panel Question and Answer with Drs. Zellars, Penault-Llorca, Lloibl, Chien, Mayer, and Telli

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Saturday, June 5, 7:45 PM - 10:45 PM CEST

Back to Program

Showing 17 Presentations

https://meetinglibrary.asco.org/session/13625

Chair
CHAIR

Steven Ades, MD, MSCE, FRCPC | Fletcher Allen Health Care/UVM

Chair
CHAIR

Marcus Smith Noel, MD | Georgetown Lombardi Cancer Center

ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).

AUTHOR(S)
Ruihua Xu, Huiyan Luo, Jin Lu, Yuxian Bai, Teng Mao, Jun Wang, Qingxia Fan, Yiping Zhang, Kuaile Zhao, Zhendong Chen, Shegan Gao, Jiancheng Li, Zhihao Fu, Kangsheng Gu, Zhihua Liu, Lin Wu, Xiaodong Zhang, Yi Zhu, Qing Yang, Jianjun Zou

ABSTRACT

4000

Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.

AUTHOR(S)
Ian Chau, Yuichiro Doki, Jaffer A. Ajani, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih-Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez F. Braghiroli, Eva Holtved, Ioannis Xynos, Xuan Liu, Ming Lei, Kaoru Kondo, Ken Kato, Yuko Kitagawa

ABSTRACT

LBA4001

First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal...
adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649.

AUTHOR(S)
Markus H. Moehler, Kohei Shitara, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda S. Campos Bragagnoli, Tianshu Liu, Michael Schenker, Patricio E. Yanez, Mustapha Tehfe, Mingshun Li, Dana Cullen, Arteid Memaj, Ming Lei, Hong Xiao, Yelena Y. Janjigian, Jaffer A. Ajani

ABSTRACT
4002

Finding First-Line Chemoimmunotherapy for Gastroesophageal Cancer

DISCUSSANT
David Cunningham, MD | The Royal Marsden NHS Foundation Trust

Panel Question and Answer with Drs. Noel, Ades, Xu, Chau, Moehler, and Cunningham

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology

Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577.

AUTHOR(S)

ABSTRACT
4003

Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452).

AUTHOR(S)

ABSTRACT
4004
Multicenter, randomized phase II study of neoadjuvant pembrolizumab plus chemotherapy and chemoradiotherapy in esophageal adenocarcinoma (EAC).

AUTHOR(S)
Manish A. Shah, Khaldoun Almhanna, Syma Iqbal, Prashant Thakkar, Bryan J. Schneider, Rhonda Yantiss, Yiru Wu, Emma Futamura, Jeffrey L. Port, Cathy Spinelli, Sandiporto Sarkar, Paul J. Christos, Gagandeep Brar, Doron Betel, Nicholas J. Sanfilippo, Nasser K. Altorki

ABSTRACT

Panels

Perioperative Treatment of Gastroesophageal Cancer: 2021 and Beyond

DISCUSSANT
Manisha Palta, MD | Duke University Medical Center, Department of Radiation Oncology

Panel Question and Answer with Drs. Noel, Ades, Kelly, Reynolds, Shah, and Palta

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): Multicenter comparative randomized phase 2b study (NIFTY).

AUTHOR(S)
Changhoon Yoo, Kyu-Pyo Kim, Ilhwan Kim, Myoung Joo Kang, Jaekyung Cheon, Byung Woog Kang, Hyewon Ryu, Jae Ho Jeong, Ji Sung Lee, Kyung Won Kim, Baek-Yeol Ryoo

ABSTRACT

Hepatic arterial infusion chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase 3 trial (The FOHAIC-1 study).

AUTHOR(S)
Ning Lyu, Ming Zhao

ABSTRACT

Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond

AUTHOR(S)
Shaohua Li, Chong Zhong, Qiang Li, Jingwen Zou, Qiaoxuan Wang, Changzhen Shang, Yuan Cheng, Mingrong Cao, Huakun Huang, Jie Mei, Lianghe Lu, Rongce Zhao, Wenping Lin, Yuhua Wen, Zhixing Guo, Yihong Ling, Lie Zheng, Wei Wei, Rongping Guo

ABSTRACT
4008

Beyond Traditional Therapy for Liver Cancer

DISCUSSANT
Mark Yarchoan, MD | Hospital of the University of Pennsylvania

Panel Question and Answer with Drs. Noel, Ades, Yoo, Lyu, Li, and Yarchoan

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology

Breast Cancer—Metastatic
Saturday, June 5, 7:30 PM - 10:30 PM CEST

Back to Program
Showing 17 Presentations

https://meetinglibrary.asco.org/session/13607

Chair

CHAIR
Olwen Mary Hahn, MD | University of Chicago Medical Center

Chair
Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3.

AUTHOR(S)
Massimo Cristofanilli, Hope S. Rugo, Seock-Ah Im, Dennis J. Slamon, Nadia Harbeck, Igor Bondarenko, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Hiroji Iwata, Ben O'Leary, Eustratios Bananis, Yuan Liu, Xin Huang, Sindy Kim, Marijose Lechuga, Nicholas C. Turner

ABSTRACT

Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).

AUTHOR(S)
Dennis J. Slamon, Patrick Neven, Stephen K. Chia, Guy H. Jerusalem, Michelino De Laurentiis, Seock-Ah Im, Katarina Petrakova, Giulia V. Bianchi, Miguel Martin, Arnd Nusch, Gabe S. Sonke, Luis de la Cruz-Merino, J. T. Beck, Craig Wang, Uday Deore, Arunava Chakravartty, Juan Pablo Zarate, Tetiana Taran, Peter A. Fasching

ABSTRACT

Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study.

AUTHOR(S)
Binghe Xu, Qingyuan Zhang, Pin Zhang, Xichun Hu, Wei Li, Zhongsheng Tong, Tao Sun, Yuee Teng, Xinhong Wu, Quchang Ouyang, Xi Yan, Jing Cheng, Qiang Liu, Jifeng Feng, Xiaojia Wang, Xiaoyu Zhu, Fei Wu, Xiao Zhang, Jianjun Zou

ABSTRACT

Solidifying CDK4/6 Inhibitors in Advanced Breast Cancer

DISCUSSANT
Otto Metzger, MD | Dana-Farber Cancer Institute

Panel Question and Answer with Drs. Brufsky, Hahn, Cristofanilli, Slamon, Xu, and Metzer
Panel Discussion | American Society of Clinical Oncology

**Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial.**

**AUTHOR(S)**
Zhongyu Yuan, Jia-Jia Huang, Xin Hua, Jian-Li Zhao, Ying Lin, Yuan-Qi Zhang, Zhiyong Wu, Lehong Zhang, XiWen Bi, Wen Xia, Yong-yi Zhong, Shu-Sen Wang, Fei Xu, Ruoxi Hong, Kuikui Jiang, Yanxia Shi, Cong Xue, Xin An

**ABSTRACT**

1003

Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC).

**AUTHOR(S)**
Geoffrey J. Lindeman, Rebecca Bowen, Katarzyna J. Jerzak, Xinni Song, Thomas Decker, Frances M. Boyle, Steven L. McCune, Anne Armstrong, Catherine M. Shannon, Gianfilippo Bertelli, Tharu M. Fernando, Rupal Desai, Kushagra Gupta, Jerry Y. Hsu, Aulde Flechais, Aditya Bardia

**ABSTRACT**

1004

Treatment-related side effects and views about dosage assessment to sustain quality of life: Results of an advocate-led survey of patients with metastatic breast cancer (MBC).

**AUTHOR(S)**
Anne L. Loeser, Jeffrey M. Peppercorn, Mark E. Burkard, Kevin Kalinsky, Hope S. Rugo, Aditya Bardia

**ABSTRACT**

1005

Leveraging Oral Therapy in Advanced Breast Cancer

**DISCUSSANT**

William John Gradishar, FACP, FASCO, MD | Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Panel Question and Answer with Drs. Brufsky, Hahn, Yuan, Lindeman, Gradishar, and Ms. Loeser

Panel Discussion | American Society of Clinical Oncology
The tumor microenvironment (TME) and atezolizumab + nab-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130.

AUTHOR(S)

ABSTRACT
1006

Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): A prospective, single-arm, phase 2 study.

AUTHOR(S)
Li Chen, Shao Zhimin, Zhonghua Wang, Wentao Yang, Yizhou Jiang, Jianjun Zou, Jiong Wu, Genhong Di, Guangyu Liu, Keda Yu, Lei Fan, Junjie Li, Yifeng Hou, Zhen Hu, Canming Chen, Xiaoyan Huang, Ayong Cao, Xin Hu, Songyang Wu, Shen Zhao

ABSTRACT
1007

Randomized multicenter trial of 3 weekly cabazitaxel versus weekly paclitaxel chemotherapy in the first-line treatment of HER2 negative metastatic breast cancer (MBC).

AUTHOR(S)
Amit Bahl, Jeremy Braybrooke, Alicia Bravo, Emily Foulstone, Jessica Ball, Mark Churn, Sidharth Dubey, Saiqa Spensley, Rebecca Bowen, Simon Waters, Pippa Riddle, Duncan Wheatley, Peter Stephens, Janine Mansi, Pavel Bezecny, Srinivasan Madhusudan, Mark Verrill, Alison Markham, Sylvia Pearson, William Wilson

ABSTRACT
1008

Refining Treatment Options for Triple-Negative Breast Cancer

DISCUSSANT
Marleen Kok, MD | Netherlands Cancer Institute

Panel Question and Answer with Drs. Brufsky, Hahn, Emens, Chen, Bahl, and Kok

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology
Central Nervous System Tumors
Monday, June 7, 2:00 PM - 5:00 PM CEST

Back to Program
Showing 17 Presentations

https://meetinglibrary.asco.org/session/13613

Chair

CHAIR

Evanthia Galanis, MD | Mayo Clinic

Chair

CHAIR

E. Antonio Chiocca, MD, PhD | Brigham and Women’s Hospital

Alliance A071601: Phase II trial of BRAF/MEK inhibition in newly diagnosed papillary craniopharyngiomas.

AUTHOR(S)

Priscilla K. Brastianos, Erin Twohy, Susan M. Geyer, Elizabeth R. Gerstner, Timothy J. Kaufmann, Michael Ruff, Daniela A. Bota, David A. Reardon, Adam L. Cohen, Macarena I. De La Fuente, Glenn J. Lesser, Jian L. Campian, Pankaj Agarwalla, Priya Kumthekar, Daniel P. Cahill, Helen A. Shih, Paul D. Brown, Sandro Santagata, Frederick G. Barker II, Evanthia Galanis

ABSTRACT

2000

ALK inhibitors for treatment of adult-onset neuroblastoma.

AUTHOR(S)

Jessica Stiefel, Brian H. Kushner, Ellen M. Basu, Stephen S. Roberts, Shakeel Modak

ABSTRACT

2001

Efficacy and safety of larotrectinib in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system tumors.

AUTHOR(S)


ABSTRACT

2002
Targeting Common Mutations in Rare CNS Tumors

DISCUSSANT
Jaishri O’Neill Blakeley, MD | Johns Hopkins School of Medicine

Panel Question and Answer with Drs. Galanis, Chiocca, Brastianos, Steifel, Perreault, and Blakeley

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology

The 1994 National Cancer Institute’s strategy to fund multi-institutional, multidisciplinary consortia to design and conduct early phase clinical trials in patients with high grade gliomas.

AUTHOR(S)

ABSTRACT
2003


AUTHOR(S)

ABSTRACT
2004

A Phase 0 ‘trigger’ trial of CDK4/6 plus ERK1/2 inhibitors in recurrent glioblastoma.

AUTHOR(S)
Nader Sanai, Yu-Wei Chang, Tigran Margaryan, Anita DeSantis, Mackenna Elliott, Chelsea Pennington-Krygier, Garry Hook, Wonsuk Yoo, An-Chi Tien, Artak Tovmasyan, Shwetal Mehta

ABSTRACT
2005
Evaluating the benefit of adaptive randomization in the CC-115 arm of the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGHt): A phase II randomized Bayesian adaptive platform trial in newly diagnosed MGMT unmethylated glioblastoma.

AUTHOR(S)
Rifaquat Rahman, Lorenzo Trippa, Geoffrey Fell, Eudocia Q. Lee, Isabel Arrillaga-Romany, Mehdi Touat, Jan Drappatz, Evanthia Galanis, Manmeet S. Ahluwalia, Howard Colman, Louis B. Nabors, Jaroslaw T. Hепel, David Schiff, Mary R. Welch, David M. Meredith, E. Antonio Chiocca, David A. Reardon, Keith L. Ligon, Brian M. Alexander, Patrick Y. Wen

ABSTRACT
2006

Reassessment of Drug Evaluation in GBM

DISCUSSANT
Mark R. Gilbert, MD | National Cancer Institute at the National Institutes of Health

Panel Question and Answer Drs. Galanis, Chiocca, Grossman, Roth, Sanai, Rahman, and Gilbert

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology

Olaparib in recurrent IDH-mutant high-grade glioma (OLAGLI).

AUTHOR(S)
Francois Ducray, Marc Sanson, Olivier L. Chinot, Maxime Fontanilles, Romain Rivoirard, Laure Thomas-Maisonuneuve, Stephanie Cartalat, Emeline Tabouret, Alice Bonneville-Levard, Amelie Darlix, Roxana Ameli, David Meyronet, Francois Gueyffier, Laurent Remontet, Delphine Maucort-Boulch, Caroline Dehais, Jerôme Honnorat

ABSTRACT
2007

Impact of mutant IDH (mIDH) inhibition on DNA hydroxymethylation, tumor cell function, and tumor immune microenvironment (TIME) in resected mIDH1 lower-grade glioma (LGG).

AUTHOR(S)
Min Lu, Timothy F. Cloughesy, Patrick Y. Wen, Ania Tassinari, Sung Choe, Dongwei Zhu, Islam Hassan, Lori Steelman, Shuchi S. Pandya, Bin Wu, Ingo K. Mellinghoff

ABSTRACT
2008

Developing Targeted Treatments for IDH-Mutant Glioma
Genitourinary Cancer—Kidney and Bladder
Monday, June 7, 2:00 PM - 5:00 PM CEST

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426

AUTHOR(S)

ABSTRACT
4500
CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies.

AUTHOR(S)

ABSTRACT
4501

Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC).

AUTHOR(S)
Robert J. Motzer, Camillo Porta, Boris Alekseev, Sun Y. Rha, Toni K. Choueiri, Maria Jose Mendez-Vidal, Sung-Hoo Hong, Anil Kapoor, Jeffrey C. Goh, Masatoshi Eto, Jinyi Wang, Janice Pan, Alemseged Ayele Asfaw, Cixin S. He, Kalgi Mody, David Cella

ABSTRACT
4502

Expanding VEGF Blockade Combination Therapeutic Options in Advanced Renal Cell Carcinoma

DISCUSSANT
Andrea B. Apolo, MD | National Cancer Institute, National Institutes of Health

Panel Question and Answer with Drs. Rodriguez, Geynisman, Rini, Tannir, Motzer, and Apolo

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology


AUTHOR(S)
Matt D. Galsky, Siamak Daneshmand, Kevin G. Chan, Tanya B. Dorff, Jeremy P. Cetnar, Brock O Neil, Anishka D'souza, Ronac Mamtani, Christos Kyriakopoulos, Philip Garcia, Sudeh Izadmehr, Menggang Yu, Qianqian Zhao, Reza Mehrazin, Sara C. Lewis, John Sfakianos, Sumanta K. Pal

ABSTRACT
Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial.

AUTHOR(S)
Arjun V. Balar, Matthew I. Milowsky, Peter H. O'Donnell, Ajjai S. Alva, Marisa Kollmeier, Tracy L. Rose, Sean Pitroda, Samuel D. Kaffenberger, Jonathan E. Rosenberg, Kaitlyn Francese, Tsvia Hochman, Judith D. Goldberg, Sarah Griglun, Dayna Leis, Gary D. Steinberg, James Wysock, Peter B. Schiff, Nicholas J. Sanfilippo, Samir Taneja, William C. Huang

ABSTRACT

Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial.

AUTHOR(S)
Xavier Garcia del Muro, Begoña P. Valderrama, Ana Medina, M. Andres Cuellar, Olatz Etxaniz, Regina Gironés Sarrió, María Jose Juan-Fita, Ferran Ferrer, Isabel Miras Rodríguez, Guillermo Lendínez-Cano, Roberto de Haro Piedra, Arturo Candal Gomez, Venancio Chantada Abal, Oscar Bulsán, Salvador Villà, José Luis Pontones, Erica Collado, José L. Domínguez-Escrig, Yashmina Murria, Francesc Vigués

ABSTRACT

Steps Toward a Bladder-Intact Cure for Muscle-Invasive Bladder Cancer

DISCUSSANT
Andrea Necchi, MD | Fondazione IRCCS Istituto Nazionale dei Tumori

Panel Question and Answer with Drs. Rodriguez, Geynisman, Galsky, Balar, Garcia del Muro, and Necchi

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology

A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.

AUTHOR(S)

ABSTRACT
First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study.

AUTHOR(S)
Peter H. O'Donnell, Arjun V. Balar, Jacqueline Vuky, Daniel Castellano, Joaquim Bellmunt, Thomas Powles, Dean F. Bajorin, Petros Grivas, Noah M. Hahn, Elizabeth R. Plimack, Jin Zhi Xu, James L. Godwin, Blanca Homet Moreno, Ronald De Wit

ABSTRACT
4508

Inducible T-cell co-stimulatory (ICOS) receptor agonist, feladilimab (fela), alone and in combination (combo) with pembrolizumab (P): Results from INDUCE-1 urothelial carcinoma (UC) expansion cohorts (ECs).

AUTHOR(S)
Arjun V. Balar, Victor Moreno, Eric Angevin, Hui K. Gan, Maria Vieito, Antoine Italiano, Riccardo Danielli, Erminia Massarelli, Frans Opdam, Michael J. Chisamore, Debra Rogan, Xiao Ji, Courtney Henry, Catherine E. Ellis, Marc S. Ballas, Axel Hoos, Francesco Ricci

ABSTRACT
4519

Conundrums in First-Line Urothelial Carcinoma: Is More Always Better?

DISCUSSANT
Shilpa Gupta, MD | Cleveland Clinic Taussig Cancer Institute

Panel Question and Answer with Drs. Rodriguez, Geynisman, Pal, O'Donnell, Balar, and Gupta

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology

Gynecologic Cancer
Monday, June 7, 2:00 PM - 5:00 PM CEST

Back to Program
Showing 17 Presentations

https://meetinglibrary.asco.org/session/13634
Efficacy and safety results from neopembrov study, a randomized phase II trial of neoadjuvant chemotherapy (CT) with or without pembrolizumab (P) followed by interval debulking surgery and standard systemic therapy ± P for advanced high-grade serous carcinoma (HGSC): A GINECO study.

Author(s)

Isabelle L. Ray-Coquard, Aude Marie Savoye, Marie-ange Mouret-Reynier, Sylvie Chabaud, Olfa Derbel, Elsa Kalbacher, Marianne Leheurteur, Alejandra Martinez, Corina Cornila, Mathilde Martinez, Leila Bengrine, Frank Priou, Nicolas Cloarec, Laurence Venat-Bouvet, Frederic Selle, Dominique Berton, Olivier Collard, Florence Joly, Olivier Tredisn

Abstract

Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): A multicenter open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO (AGO-OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890).

Author(s)

Jacobus Pfisterer, Florence Joly, Gunnar Kristensen, Joern Rau, Sven Mahner, Patricia Pautier, Ahmed El-Balat, Jean Emmanuel Kurtz, Ulrich Canzler, Jalid Sehouli, Martin L. Heubner, Andreas D. Hartkopf, Klaus Baumann, Annette Hasenburg, Lars C. Hanker, Antje Belau, Barbara Schmalfeldt, Dominik Denschlag, Tjoung-Won Park-Simon, Philipp Harter

Abstract

Maintenance vigil immunotherapy in newly diagnosed advanced ovarian cancer: Efficacy assessment of homologous recombination proficient (HRP) patients in the phase IIb VITAL trial.

Author(s)

ABSTRACT

5502

First Impressions Are Lasting: Optimizing Upfront Therapy of Ovarian Cancer

DISCUSSANT

Carol Aghajanian, MD | Memorial Sloan Kettering Cancer Center

Panel Question and Answer with Drs. Moore, Grisham, Ray-Coquard, Pfisterer, Rocconi, and Aghajanian

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Phase 3, randomized, single-dose, open-label study to investigate the safety and efficacy of pafolacianine sodium injection (OTL38) for intraoperative imaging of folate receptor positive ovarian cancer.

AUTHOR(S)


ABSTRACT

5503

Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis.

AUTHOR(S)

David M. O’Malley, Ana Oaknin, Ursula A. Matulonis, Gina Mantia-Smaldone, Peter C. Lim, Cesar M. Castro, Diane M. Provencher, Sanaz Memarzadeh, Patrick A. Zweidler-McKay, Jiuzhou Wang, Brooke Esteves, Kathleen N. Moore, Lucy Gilbert

ABSTRACT

5504

EFFORT: EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer.

AUTHOR(S)

Expanding the Landscape of Novel Targets in Recurrent Ovarian Cancer

DISCUSSANT
Amit M. Oza, MD | Princess Margaret Cancer Centre, University of Toronto

Panel Question and Answer with Drs. Moore, Grisham, Tanyi, O'Malley, Westin, and Oza

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology

Intensive versus minimalist follow-up in patients treated for endometrial cancer: A multicentric randomized controlled trial (The TOTEM study—NCT00916708).

AUTHOR(S)
Paolo Zola, Giovannino Ciccone, Elisa Piovano, Luca Fusco, Elena Peirano, Daniela Di Cuonzo, Anna M. Perrone, Vincenzo D. Mandato, Laura Zavallone, Francesca Chiodinelli, Roberto Berretta, Serena Loda, Mario Valentano Menada, Stefano Greggi, Marco Adorni, Enrico Busato, Marco Marinaccio, Giuseppe Comerci, Massimiliano Fambrini, Annamaria Ferrero

ABSTRACT

Victoria: A multicentric, randomized, open-label, phase I/II of mTOR inhibitor (VISTUSERTIB) combined with anastrozole in patients with hormone receptor-positive advanced/metastatic endometrial cancer—A CLIPP program INCA in collaboration with GINECO group.

AUTHOR(S)

ABSTRACT

Pertuzumab plus trastuzumab (P+T) in patients (Pts) with uterine cancer (UC) with ERBB2 or ERBB3 amplification, overexpression or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

AUTHOR(S)

ABSTRACT
Fine-Tuning the Diagnosis and Treatment of Recurrent Endometrial Cancer

DISCUSSANT
TBD | TBD

Panel Question and Answer with Drs. Moore, Grisham, Zola, Heudel, Ali-Ahmad

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Monday, June 7, 5:30 PM - 8:30 PM CEST

Back to Program

Showing 17 Presentations

https://meetinglibrary.asco.org/session/13648

Chair
CHAIR
Mary Jo Lechowicz, MD | Emory University, Winship Cancer Institute

Chair
CHAIR
Leslie Popplewell, MD | City of Hope

First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia.

AUTHOR(S)

ABSTRACT
**Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study.**

**AUTHOR(S)**

**ABSTRACT**

First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).

**AUTHOR(S)**
Sikander Ailawadhi, Asher Alban A. Chanan-Khan, Zi Chen, Bo Huang, Marina Konopleva, Danielle M. Brander, David Rizzieri, Masa Lasica, Constantine S. Tam, Costas K. Yannakou, H. M. Prince, Matthew S. Davids, Zhicong He, Ming Lu, Mohammad Ahmad, Mingyu Li, Zhiyan Liang, Boyd Mudenda, Dajun Yang, Yifan Zhai

**ABSTRACT**

On Target: Optimizing CLL Therapy

**DISCUSSANT**
Jacqueline Claudia Barrientos, MD, MS | Hofstra Northwell School of Medicine

**Panel Question and Answer with Drs. Popplewell, Lechowicz, Byrd, Ghia, Ailawadhi, and Barrientos**

**PANEL SPEAKER**
Panel Discussion | American Society of Clinical Oncology

ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS.

**AUTHOR(S)**
**ABSTRACT 7503**

Real-world (RW) treatment (tx) patterns and outcomes of 3,455 previously untreated mantle cell lymphoma (MCL) patients (pts) in U.S. routine clinical practice.

**AUTHOR(S)**
Peter Martin, Michael Wang, Anita Kumar, Keqin Qi, Katherine Daly, Lori Parisi, Angeline Zhu, Gilles A. Salles

**ABSTRACT 7504**

The combination of venetoclax, lenalidomide, and rituximab in patients with newly diagnosed mantle cell lymphoma induces high response rates and MRD undetectability.

**AUTHOR(S)**
Tycel Phillips, Alexey V. Danilov, David A. Bond, Alex F. Herrera, Kami J. Maddocks, Sumana Devata, Yasmin Karimi, Shannon Carty, Ryan A. Wilcox, Mark S. Kaminski, Sami N. Malek, Moshe Talpaz, Leslie Popplewell

**ABSTRACT 7505**

Upfront Therapy for Mantle Cell Lymphoma: Can We Do Better?

**DISCUSSANT**
Brian K. Link, MD | University of Iowa Carver College of Medicine

Panel Question and Answer with Drs. Popplewell, Lechowicz, Smith, Martin, Phillips, and Link

**PANEL SPEAKER**
Panel Discussion | American Society of Clinical Oncology

Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of CALGB 51101 (Alliance).

**AUTHOR(S)**
Tracy Batchelor, Sharmila Giri, Amy S. Ruppert, Nancy L. Bartlett, Eric D. Hsi, Bruce D. Cheson, Lakshmi Nayak, John P. Leonard, James L. Rubenstein

**ABSTRACT 7506**
CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL).

AUTHOR(S)

ABSTRACT
7507

Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 Elara trial.

AUTHOR(S)

ABSTRACT
7508

Fine-Tuning Intensity in Lymphoma Treatment

DISCUSSANT
Sonali M. Smith, MD, FASCO | The University of Chicago

Panel Question and Answer with Drs. Popplewell, Lechowicz, Batchelor, LaCasce, Schuster, and Smith

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology

Gastrointestinal Cancer—Colorectal and Anal
Monday, June 7, 7:15 PM - 10:15 PM CEST

Back to Program
Showing 16 Presentations

https://meetinglibrary.asco.org/session/13622
Chair

CHAIR
Tanios S. Bekaii-Saab, MD, FACP | Division of Hematology/Oncology, Mayo Clinic

Chair

CHAIR
Cathy Eng, MD, FACP, FASCO | The University of Texas MD Anderson Cancer Center

Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).

AUTHOR(S)

ABSTRACT
3500
The randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13).

AUTHOR(S)

ABSTRACT
3501
Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).

AUTHOR(S)

ABSTRACT
3502
Personalizing First-Line Therapy for Every Patient

DISCUSSANT
Nilofer Saba Azad, MD | Department of Oncology, Johns Hopkins Sidney Kimmel Cancer Center

Panel Question and Answer with Drs. Bekaii-Saab, Eng, Andre, Tsuji, Stintzing, and Azad

Panel Discussion | American Society of Clinical Oncology

Maintenance therapy with 5-fluoruracil/leucovorin (5FU/LV) plus panitumumab (pmab) or 5FU/LV alone in RAS wildtype (WT) metastatic colorectal cancer (mCRC) - the PANAMA trial (AIO KRK 0212).

AUTHOR(S)

ABSTRACT
3503

Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial.

AUTHOR(S)

ABSTRACT
3504

When Less Is More: Maintenance Strategies

DISCUSSANT
Wen Wee Ma, MBBS | Division of Medical Oncology, Mayo Clinic

Panel Question and Answer with Drs. Bekaii-Saab, Eng, Modest, Adams, and Ma

Panel Discussion | American Society of Clinical Oncology
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).

**AUTHOR(S)**


**ABSTRACT**

3505

Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial.

**AUTHOR(S)**

Andrea Sartore-Bianchi, Filippo Pietrantonio, Sara Lonardi, Benedetta Mussolin, Francesco Rua, Elisabetta Fenocchio, Alessio Amatu, Salvatore Corallo, Chiara Manai, Federica Tosi, Paolo Manca, Francesca Daniel, Valter Torri, Angelo Vanzulli, Giovanni Cappello, Caterina Marchiò, Anna Sapino, Silvia Marsoni, Salvatore Siena, Alberto Bardelli

**ABSTRACT**

3506

The TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer.

**AUTHOR(S)**

Yasutoshi Kuboki, Tetsuji Terazawa, Toshiki Masuishi, Masato Nakamura, Jun Watanabe, Hitoshi Ojima, Yudai Shinohara, Masahito Kotaka, Hiroki Haru, Takashi Ohta, Eiji Oki, Yu Sunakawa, Soichiro Ishihara, Hiroya Taniguchi, Takako E. Nakajima, Satoshi Morita, Kuniaki Shirao, Takayuki Yoshino

**ABSTRACT**

3507

Expanding Therapeutic Strategies in Second Line and Beyond: More to Learn

**DISCUSSANT**

Guillem Argiles, MD | Vall d’Hebron University Hospital

**Panel Question and Answer with Drs. Bekaii-Saab, Eng, Yoshino, Sartore-Bianchi, Kuboki, and Argiles**

**PANEL SPEAKER**

Panel Discussion | American Society of Clinical Oncology
Head and Neck Cancer
Monday, June 7, 8:45 PM - 11:45 PM CEST

Back to Program

Showing 16 Presentations

https://meetinglibrary.asco.org/session/13637

Chair
CHAIR
Roselle B. De Guzman, MD | Manila Central University-FDTMF Hospital

Chair
CHAIR
Jochen H. Lorch, MD | Dana-Farber Cancer Institute

Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial.

AUTHOR(S)
Li Zhang, Yunpeng Yang, Song Qu, Jin-Gao Li, Chaosu Hu, Mingjun Xu, Weidong Li, Ting Zhou, Liangfang Shen, Hui Wu, Jin Yi Lang, Guangyuan Hu, Zhanxiong Luo, Zhichao Fu, Shenhong Qu, Ben Zhang, Qing Yang, Xiaojing Zhang, Jianjun Zou, Wenfeng Fang

ABSTRACT

6000

Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Results from the phase 3 COSMIC-311 trial.

AUTHOR(S)
Marcia S. Brose, Bruce Robinson, Steven I. Sherman, Barbara Jarzab, Chia-Chi Lin, Fernanda Vaisman, Ana Hoff, Erika Hitre, Daniel W. Bowles, Leonardo Faoro, Kamalika Banerjee, Jennifer Oliver, Bhumsuk Keam, Jaume Capdevila

ABSTRACT

6001

A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic salivary gland cancers (R/M SGCs).

AUTHOR(S)
Targeted Therapy for Recurrent/Metastatic Head and Neck Cancers

DISCUSSANT

Nicole Grace Chau, MD | BC Cancer Agency

Panel Question and Answer with Drs. Lorch, De Guzman, Zhang, Brose, Burman, and Chau

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.

AUTHOR(S)

Jun Ma, Yu-Pei Chen, Ying Sun, Qin Zhou, Kun-Yu Yang, Feng Jin, Xiao-Dong Zhu, Mei Shi, Guoqing Hu, Yan Sun, Hong-Fen Wu, Hui Wu, Qin Lin, Hui Wang, Ye Tian, Ning Zhang, Xicheng Wang, Liangfang Shen, Fangyun Xie, Xu Liu

Adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized controlled phase III trial.

AUTHOR(S)

Jingjing Miao, Lin Wang, Sze Huey Tan, Jin-Gao Li, Junlin Yi, Ye Zhang, Xiaochang Gong, Xiang Yanqun, Qiu-Yan Chen, Mingyuan Chen, Xing Lv, Weixiong Xia, Lin-Quan Tang, Xiao-Wu Deng, Xiang Guo, Hai-Qiang Mai, Fei Han, Melvin L. Chua, Chong Zhao

Induction or Adjuvant Therapy for Nasopharyngeal Carcinoma

DISCUSSANT

Herbert H. F. Loong, MBBS | The Chinese University of Hong Kong

Panel Question and Answer with Drs. Lorch, De Guzman, Ma, Miao, and Loong

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology
Association of pathological response to neoadjuvant pembrolizumab with tumor PD-L1 expression and high disease-free survival (DFS) in patients with resectable, local-regionally advanced, head and neck squamous cell carcinoma (HNSCC).

**AUTHOR(S)**

**ABSTRACT**
6006

Primary results of the phase II CheckRad-CD8 trial: First-line treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T-cell infiltration.

**AUTHOR(S)**

**ABSTRACT**
6007

Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC).

**AUTHOR(S)**

**ABSTRACT**
6008

Pathologic Responses As Predictors of Clinical Benefit

**DISCUSSANT**
Lisa Rooper | John Hopkins University

**Panel Question and Answer with Drs. Lorch, De Guzman, Wise-Draper, Hecht, Uppaluri, and Rooper**
Developmental Therapeutics—Immunotherapy
Monday, June 7, 9:00 PM - 12:00 AM CEST

Back to Program

Showing 16 Presentations

https://meetinglibrary.asco.org/session/13616

Chair
CHAIR
Amita Patnaik, MD | START

Chair
CHAIR
Gerald Steven Falchook, MD | Sarah Cannon Research Institute


AUTHOR(S)

ABSTRACT
2500

Phase II evaluation of the triple combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16 positive malignancies.

AUTHOR(S)
Julius Strauss, Charalampos S. Floudas, Houssein Abdul Sater, Michell Manu, Elizabeth Lamping, Deneise C. Francis, Lisa M. Cordes, Jenn Marte, Renee N. Donahue, Caroline Jochems, Jason Redman, Ravi A. Madan, Marijo Bilusic, Fatima Karzai, Scott Norberg, Christian S. Hinrichs, Lauren V. Wood, Frank K. Bedu-Addo, Jeffrey Schlom, James L. Gulley

ABSTRACT
2501

**AUTHOR(S)**


**ABSTRACT**

2502

**Going Viral: Virus Targeted Immunotherapy**

**DISCUSSANT**

John Robert Hyngstrom, FACS, MD | The Univ of Utah

**Panel Question and Answer with Drs. Falchook, Patnaik, Cook, Strauss, Ho, and Hyngstrom**

**PANEL SPEAKER**

Panel Discussion | American Society of Clinical Oncology

**Phase 1 study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with advanced solid tumors.**

**AUTHOR(S)**

Dan Liu, Jifang Gong, Tianshu Liu, KunYan Li, Xianli Yin, Yunpeng Liu, Yongsheng Wang, Linna Wang, Wenliang Wang, Yanyan Zhang, Lin Shen

**ABSTRACT**

2503

**COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies (NCT03667716).**

**AUTHOR(S)**


**ABSTRACT**

2504
Preliminary clinical and biologic results of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab, in advanced solid tumors (KEYNOTE A36).

AUTHOR(S)

ABSTRACT
2505
Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs.

AUTHOR(S)
Anthony W. Tolcher, James A. Reeves Jr., Meredith McKeon, Bartosz Chmielowski, Joseph T. Beck, Montaser F. Shaheen, Neeta Somaiah, Melissa Wilson, Alexander I. Spira, Joseph J. Drabick, Yuefen Tang, Robert Winkler, Mingyu Li, Mohammad Ahmad, Ming Lu, Zhiyan Liang, Dajun Yang, Yifan Zhai

ABSTRACT
2506
Panel Question and Answer with Drs. Falchook, Patnaik, Liu, Vaena, Park, and Tolcher

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology

Safety and efficacy of a novel anti-CD20/CD19 bi-specific CAR T-cell therapy (C-CAR039) in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL).

AUTHOR(S)
Aibin Liang, Lili Zhou, Ping Li, Wenjuan Yu, Min Yang, Yangyang Xu, Shiguang Ye, Judy Zhu, Jiaqi Huang, Yan Zhang, Lanfang Li, Jing Zhao, Jing Li, Chengxiao Zheng, Kevin Zhu, Liping Lan, Huilai Zhang, Daobin Zhou, Yihong Yao, Jie Jin

ABSTRACT
2507
Safety and efficacy of a novel anti-CD20 chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL) patients after failing CD19 CAR-T therapy.

AUTHOR(S)
Aibin Liang, Shiguang Ye, Ping Li, Jiaqi Huang, Shigui Zhu, Xin Yao, Lili Zhou, Yangyang Xu, Judy Zhu, Chengxiao Zheng, Shiyi Chen, Liping Lan, Xiaoteng Lv, Yutian Wei, Michael Humphries, Yihong Yao

ABSTRACT

2508

CD20-Directed CAR T

DISCUSSANT

Tara K. Gregory, MD | Rocky Mtn Blood and Marrow Transplant Prog

Panel Question and Answer with Drs. Falchook, Patnaik, Liang, and Gregory

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Genitourinary Cancer—Prostate, Testicular, and Penile

Tuesday, June 8, 2:00 PM - 5:00 PM CEST

Back to Program

Showing 16 Presentations

https://meetinglibrary.asco.org/session/13631

Chair

CHAIR

Joaquin Mateo, MD, PhD | Vall d’Hebron Institute of Oncology and Vall d’Hebron University Hospital

Chair

CHAIR

Eugene Shenderov, MD, PhD | Johns Hopkins University School of Medicine

A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.

AUTHOR(S)
ABSTRACT

5000

SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691).

AUTHOR(S)


ABSTRACT

5001

Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis.

AUTHOR(S)

Silke Gillessen, Ananya Choudhury, Alejo Rodriguez-Vida, Franco Nole, Enrique Gallardo Diaz, Thierry A. Roumeuguere, Gedske Daugaard, Yohann Loriot, Fred Saad, Raymond S. McDermott, Anouk Neven, Beatrice Fournier, Bertrand F. TOMBAL

ABSTRACT

5002

Can We Define the Standard of Therapy for First-Line Metastatic Hormone-Sensitive Prostate Cancer?

DISCUSSANT

Lisa Horvath, PhD, MBBS, FRACP | Sydney Cancer Centre

Panel Question and Answer with Drs. Shenderov, Mateo, Fizazi, Agarwal, Gillessen, and Horvath

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Ancestral characterization of the genomic landscape, comprehensive genomic profiling utilization, and treatment patterns may inform disparities in advanced prostate cancer: A large-scale analysis.
AUTHOR(S)
Smruthy Sivakumar, Jessica K. Lee, Jay A. Moore, Julia Hopkins, Justin Newberg, Alexa B. Schrock, Randy Vince, Idalid I. Franco, Crystal S. Seldon, JENNIFER MILLS, Jeffrey M. Venstrom, Brandon A. Mahal

ABSTRACT
5003

Association of increased intensity of prostate-specific antigen screening in younger African American men with improved prostate cancer outcomes.

AUTHOR(S)
Edmund M. Qiao, Nikhil V. Kotha, Vinit Nalawade, Alexander S. Qian, Rohith S. Voora, Tyler J. Nelson, Tyler F. Stewart, John K. Parsons, Brent S. Rose

ABSTRACT
5004

A prospective Validation of the genomic classifier defines high-metastasis risk in a subset of African American men with early localized prostate cancer: VanDAAM study.

AUTHOR(S)
Kosj Yamoah, Jasreman Dhillon, Peter A. Johnstone, Julio M. Pow-Sang, Elai Davicioni, Angelina Fink, Amanda C. DeRenzis, G. Daniel Grass, Roger Li, Brandon J. Manley, Kenneth L. Gage, Evangelia Katsoulakis, Ryan J. Burri, Andrew Leone, Cesar E. Ercole, Joshua D. Palmer, Neha Vapiwala, Curtiland Deville, Timothy Rebbeck, Adam P. Dicker

ABSTRACT
5005

Disparities in Prostate Cancer: Are We Making Progress?

DISCUSSANT
Peter C. Black, MD | Vancouver Prostate Centre, University of British Columbia

Panel Question and Answer with Drs. Shenderov, Mateo, Sivakumar, Qiao, Yamoah, and Black

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology

Testicular cancer in the cisplatin era: Causes of death and mortality rates in a population-based cohort.

AUTHOR(S)
Ragnhild Hellesnes, Tor Åge Myklebust, Sophie D. Fossa, Roy M. Bremnes, Asa Karlsdottir, Oivind Kvammen, Torgrim Tandstad, Tom Wilsgaard, Helene F. Negard, Hege Sagstuen S. Haugnes

ABSTRACT
Late relapse of germ cell tumors: Detection and treatment outcomes.

AUTHOR(S)
Noah H. Richardson, Sandra K. Althouse, Ryan Ashkar, Clint Cary, Timothy A. Masterson, Richard Foster, Nasser H. Hanna, Lawrence H. Einhorn, Nabil Adra

ABSTRACT

Late Relapses and Toxicities in Testicular Cancer: Good and Bad News?

DISCUSSANT
Siamak Daneshmand, MD | USC Norris Comprehensive Cancer Center

Panel Question and Answer with Drs. Shenderov, Mateo, Hellesnes, Richardson, and Daneshmand

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology

Hematologic Malignancies—Plasma Cell Dyscrasia
Tuesday, June 8, 2:00 PM - 5:00 PM CEST

Back to Program
Showing 17 Presentations

https://meetinglibrary.asco.org/session/13649

Chair

CHAIR
Philip L. McCarthy, MD | Roswell Park Cancer Institute

Chair

CHAIR
Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM).

**AUTHOR(S)**

**ABSTRACT**

8000

Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial.

**AUTHOR(S)**

**ABSTRACT**

8001

Carfilzomib-based induction/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in high-risk patients.

**AUTHOR(S)**
Francesca Gay, Roberto Mina, Delia Rota-Scalabrini, Monica Galli, Angelo Belotti, Elena Zamagni, Luca Bertamini, Renato Zambello, Barbara Gamberi, Giovanni De Sabbata, Giuseppe Pietrantuono, Andrea Capra, Anna Pascarella, Anna Marina Liberati, Salvatore Palmieri, Angela Cuoghi, Massimo Offidani, Michele Cavo, Pellegrino Musto, Mario Boccadoro

**ABSTRACT**

8002

Evolution of Modern Total Therapy in Myeloma

**DISCUSSANT**
Gordon Cook | St James’s Institute of Oncology, Leeds Teaching Hospitals NHS Trust and University of Leeds

Panel Question and Answer with Drs. McCarthy, Lentzsch, Yong, Kaiser, Gay, and Cook
Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study.

AUTHOR(S)
Efstathios Kastritis, Vaishali Sanchorawala, Giampaolo Merlini

ABSTRACT
8003
Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2.

AUTHOR(S)
Philippe Moreau, Pieter Sonneveld

ABSTRACT
8004
What More Can Anti-CD38 Monoclonal Antibodies Offer?

DISCUSSANT
Caitlin Costello, MD | Department of Medicine, Division of Blood and Marrow Transplantation, Moores Cancer Center, University of California San Diego

Panel Question and Answer with Drs. McCarthy, Lentzsch, Kastritis, Moreau, and Costello

Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1.

AUTHOR(S)

ABSTRACT
Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).

AUTHOR(S)

ABSTRACT

Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).

AUTHOR(S)

ABSTRACT

Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).

AUTHOR(S)

ABSTRACT

Let's Take a T-Cell-fy...

DISCUSSANT
Surbhi Sidana, MD | Cleveland Clinic Foundation

Panel Question and Answer with Drs. McCarthy, Lentzsch, Usmani, Bahlis, Krishnan, Berdeja, and Sidana

PANEL SPEAKER
Panel Discussion | American Society of Clinical Oncology
II. POSTER DISCUSSION PRESENTATIONS

Central Nervous System Tumors

Back to Program

Showing 16 Presentations

https://meetinglibrary.asco.org/session/13614

Long-term results of the GEINO 1401 TRIAL: Randomizing patients to stop or to continue temozolomide until 12 cycles.

AUTHOR(S)
Marta Domenech, Carles Fabregat-Franco, Carlos Mesia, Anna Esteve, Sonia D. Berron, Estela Pineda, Regina Gironés Sarrió, Ramon De las peñas, Jose Fuster, Miriam Alonso, Clara Olier, Pedro Perez, Alfonso Berrocal, Marta Covela Rúa, Ainhoa Hernandez Gonzalez, Cristina Carrato, Carolina Sanz, José M. Sepulveda Sánchez, Carmen Balana

ABSTRACT
2013

Preliminary results of the abemaciclib arm in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGHt): A phase II platform trial using Bayesian adaptive randomization.

AUTHOR(S)
Eudocia Q. Lee, Lorenzo Trippa, Geoffrey Fell, Rifaquat Rahman, Isabel Arrillaga-Romany, Mehdi Touat, Jan Drappatz, Mary R. Welch, Evanthia Galanis, Manmeet S. Ahluwalia, Howard Colman, Louis B. Nabors, Jaroslaw T. Hepel, David Schiff, David M. Meredith, E. Antonio Chiocca, David A. Reardon, Keith L. Ligon, Brian M. Alexander, Patrick Y. Wen

ABSTRACT
2014

Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM).

AUTHOR(S)
Manmeet S. Ahluwalia, Yasmeen Rauf, Hong Li, Patrick Y. Wen, David M. Peereboom, David A. Reardon

ABSTRACT
2015

Digital measurement of functional status of patients with glioblastoma.

AUTHOR(S)

ABSTRACT

2016

Superior overall survival (OS) and disease-free survival (DFS) predictions for patients with glioblastoma multiforme (GBM) using Cellworks Singula: myCare-022-03.

AUTHOR(S)

ABSTRACT

2017

Refining GBM Treatment

DISCUSSANT
Susan Marina Chang, MD | University of California, San Francisco

A multisite clinical trial of spectroscopic MRI-guided radiation dose escalation for newly-diagnosed glioblastomas.

AUTHOR(S)
Hui-Kuo G. Shu, Eric A. Mellon, Lawrence Kleinberg, Saumya S. Gurbani, Karthik K. Ramesh, Mohammed Goryawala, Sulaiman A. Sheriff, Vicki Huang, Peter B. Barker, Andrew Maudsley, Eduard Schreibmann, Brent D. Weinberg, Hyunsuk Shim

ABSTRACT

2018

Gene expression signature to predict radiation response in lower-grade gliomas.

AUTHOR(S)
David C. Qian, Joseph A. Marascio, Stewart G. Neill, Kimberly B. Hoang, Jeffrey J. Olson, Bree R. Eaton, Hui-Kuo G. Shu, Jim Zhong

ABSTRACT

2019
Optimizing Radiation Therapy for Glioma

DISCUSSANT

Jann Nagina Sarkaria, MD | Mayo Clinic

Comparison of immune microenvironment between primary lung tumors and paired brain metastatic tumors.

AUTHOR(S)

Likun Chen, Lihong Wu, Meichen Li, Huan Chen, Lijia Wu, Pei Hao, Ji He

ABSTRACT

2020

Profiling of immune checkpoint biomarkers by multiplex immunofluorescence in breast cancer brain metastases.

AUTHOR(S)

Gaia Griguolo, Anna Tosi, Valentina Guarneri, Maria Vittoria Dieci, Susan Fineberg, Annavera Ventura, Luc Bauchet, Jack Jacob, Valerie Rigau, William Jacot, Antonio Rosato, Amelie Darlix, Pierfranco Conte

ABSTRACT

2021

Phase 1, 2 trial of concurrent anti-PD1 and stereotactic radiosurgery for melanoma and non-small cell lung cancer brain metastases (NCT02858869).

AUTHOR(S)

Mohammad K. Khan, Tahseen Nasti, Troy Kleber, David H. Lawson, Melinda L. Yushak, Jeffrey M. Switchenko, David Wallington, Taofeek K. Owonikoko, Suresh S. Ramalingam, Khadija Kirmani, Rafi Ahmed

ABSTRACT

2022

A phase II trial combining nivolumab and stereotactic brain radiosurgery for treatment of brain metastases in patients with NSCLC.

AUTHOR(S)

Philip Wong, Marie Florescu, Marc-Emile Plourde, Valerie Panet-Raymond, Michel Pavic, Scott P. Owen, Laurence Masson-Cote, Cynthia Menard, Bertrand Routy, Mustapha Tehfe, Normand Blais, David Roberge, Laura Masucci

ABSTRACT

2023

Immune Checkpoint Inhibitors and SRS: Triggering Synergy?

DISCUSSANT
Multi-center, single arm phase II study of the dual mTORC1/mTORC2 inhibitor vistusertib for patients with recurrent or progressive grade II-III meningiomas.

AUTHOR(S)

ABSTRACT
2024

Targeted Treatment for Meningioma

DISCUSSANT
Warren P. Mason, MD | Princess Margaret Cancer Centre, University Health Network

Developmental Therapeutics—Immunotherapy

Back to Program

Showing 16 Presentations

https://meetinglibrary.asco.org/session/13617

Phase Ib study of the anti-TGF-β monoclonal antibody (mAb) NIS793 combined with spartalizumab (PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid tumors.

AUTHOR(S)
Todd M. Bauer, Chia-Chi Lin, Richard Greil, Maria-Elisabeth Goebeler, Marie Luise Huetter-Kroenke, Ignacio Garrido-Laguna, Armando Santoro, Antonella Perotti, Anna Spreafico, Thomas Yau, Markus Joerger, Viviana Cremasco, Mirek Dostalek, Marc Pelletier, Louise Barys, Darlene Lu, Vicky Katsanou, Claire Fabre, Toshihiko Doi

ABSTRACT
2509

Safety, pharmacokinetic and pharmacodynamic results from dose escalation of SAR439459, a TGFβ inhibitor, as monotherapy or in combination with cemiplimab in a phase 1/1b study.
A U T H O R(S)

A B S T R A C T
Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer.

A U T H O R(S)

A B S T R A C T
Overcoming Resistance by Targeting Tumor Microenvironment

D I S C U S S A N T
Maria De Miguel, MD, PhD | START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro

BDB001, an intravenously administered toll-like receptor 7 and 8 (TLR7/8) agonist, in combination with pembrolizumab in advanced solid tumors: Phase 1 safety and efficacy results.

A U T H O R(S)

A B S T R A C T
ARTISTRY-1: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors.

A U T H O R(S)
Valentina Boni, Ira S. Winer, Lucy Gilbert, Ulka N. Vaishampayan, Seth D. Rosen, Jameel Muzaffar, Anna Spreatico, David F. McDermott, Quincy S. Chu, Olivier Dumas, Aman Chauhan, Arvind Chaudhry, Piotr Tomczak, MD, Deborah S. Bruno, Yangchun Du, Ilda Bidollari, Jessicca M. Rege, Marc S. Ernstoff, James F. Strauss, Vamsidhar Velcheti

A B S T R A C T
Preliminary results of a phase 1b study of fruquintinib plus sintilimab in advanced colorectal cancer.

AUTHOR(S)
Ye Guo, Weijie Zhang, Jieer Ying, Yanqiao Zhang, Yueyin Pan, Wensheng Qiu, Weiguo Su, Panfeng Tan, Hongyan Yin, Yan Wang, Yang Luo, Hui Zhou, Jin Li

ABSTRACT

Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study.

AUTHOR(S)
Jermaine Coward, Anna R. Mislang, Sophia Frentzas, Charlotte R. Lemech, Adnan Nagrial, Xiaoping Jin, Baiyong Li, Zhongmin M. Wang, Kon Yew Kwek, Yu Xia

ABSTRACT

Retooling the Tumor Microenvironment: Old Drugs, New Tricks

DISCUSSANT
Bartosz Chmielowski, MD, PhD | Division of Hematology-Oncology, David Geffen School of Medicine at UCLA


AUTHOR(S)

ABSTRACT

First-in-human phase 1 dose escalation study of HX009, a novel recombinant humanized anti-PD-1 and CD47 bispecific antibody, in patients with advanced malignancies.

AUTHOR(S)
Afalah Roohullah, Vinod Ganju, Faming Zhang, Lei Zhang, Ting Yu, Kate Wilkinson, Adam Cooper, Paul de Souza

ABSTRACT
Phase I INSIGHT platform trial: Advanced safety and efficacy data from stratum D evaluating feasibility and safety of eftilagimod alpha (soluble LAG-3 protein) combined with avelumab in advanced solid tumors.

AUTHOR(S)
Thorsten O. Goetze, Daniel W. Mueller, Mohammad-Reza Rafiyan, Dragan Kiselicki, Timursah Habibzade, Marina Schaaf, Regina Eickhoff, Elke Jäger, Salah-Eddin Al-Batran

ABSTRACT

2518

Bridging the Divide Between Innate and Adaptive Immunity

DISCUSSANT
Matthew R. Zibelman, MD | Fox Chase Cancer Center

Pan cancer analysis of the intra-tumoral microbiome's correlation with racial disparities.

AUTHOR(S)
Wei Tse Li, Matthew Uzelac, Jaideep Chakladar, Lindsay M. Wong, Aditi Gnanasekar, Abby C. Lee, Daniel John, Jay P. Lopez, Weg M. Ongkeko

ABSTRACT

2519

Safety and efficacy of neoadjuvant pembrolizumab in mismatch repair deficient localized/locally advanced solid tumors.

AUTHOR(S)
Kaysia Ludford, Kanwal P. Raghav, Mariela A. Blum Murphy, Nicole D. Fleming, Douglas A. Nelson, Michael S. Lee, Brandon G. Smaglo, Y. Nancy You, Matthew M. Tillman, Carlos Kamiya-Matsuoka, Selvi Thirumurthi, Craig Messick, Benny Johnson, Eduardo Vilar Sanchez, Arvind Dasari, Jane V. Thomas, Wai C. Foo, Wei Qiao, Scott Kopetz, Michael J. Overman

ABSTRACT

2520

Microbiome Racial Disparities and Neoadjuvant Strategies

DISCUSSANT
Jarushka Naidoo, MBBCh, MHS | Johns Hopkins Kimmel Comprehensive Cancer Center and Bloomberg-Kimmel Institute for Cancer Immunotherapy
CCTG CO.28 primary endpoint analysis: Neoadjuvant chemotherapy, excision and observation for early rectal cancer, the NEO trial.

AUTHOR(S)

ABSTRACT
3508
Survival and organ preservation according to clinical response after total neoadjuvant therapy in locally advanced rectal cancer patients: A secondary analysis from the organ preservation in rectal adenocarcinoma (OPRA) trial.

AUTHOR(S)

ABSTRACT
3509
Moving Toward Organ Preservation in Rectal Cancer

DISCUSSANT
Karyn Beth Stitzenberg, MD, MPH | The University of North Carolina at Chapel Hill

A multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR): The final reports.

AUTHOR(S)
Jing Jin, Yuan Tang, Chen Hu, Yong Cai, Yuan Zhu, Guanghui Cheng, Hongyan Zhang, Xin Wang, Suyu Zhu, Jun Wang, Gaofeng Li, Jialin Yang, Kuan Zhang, Yihebali Chi, Haitao Zhou, Lichun Wei, Wenling Wang, Shixin Liu, Yuanhong Gao, Ye-Xiong Li

ABSTRACT
Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA study.

AUTHOR(S)
Lisa Salvatore, Maria Bensi, Salvatore Corallo, Francesca Bergamo, Ilaria Pellegrini, Cosimo Rasola, Beatrice Barelli, Emiliano Tamburini, Giovanni Randon, Sara Galuppo, Alessandra Boccaccino, Massimo Giuseppe Viola, Alessandra Aurieri, Elena Fea, Cecilia Barbara, Sara Bustreo, Valeria Smiroldo, Brunella Barbaro, Maria Antonietta Gambacorta, Giampaolo Tortora

ABSTRACT

Phase II trial of neoadjuvant mFOLFOX 6 with panitumumab (P) in T3 rectal cancer with clear mesorectal fascia (MRF) and KRAS, NRAS, BRAF, PI3KCA wild type (4WT). GEMCAD 1601 PIER trial.

AUTHOR(S)
Carlos Fernandez-Martos, Carles Pericay, Joan Maurel, Ana Virgili, Jaume Capdevila, Javier Gallego, Ruth Vera, Nuria Rodriguez-Salas, Ferran Losa, Manuel Valladares, Ana Vivancos, Juan Ayuso, Monique Maas, Fernando Martínez, Marcos Melian, Xabier García de Albéniz

ABSTRACT

Optimizing Neoadjuvant Therapy for Locally Advanced Rectal Cancer

DISCUSSANT
A. William Blackstock, MD, FASCO | Wake Forest School of Medicine

Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study.

AUTHOR(S)

ABSTRACT

Rarity of acquired mutations (MTs) after first-line therapy with anti-EGFR therapy (EGFRi).

AUTHOR(S)
Christine M. Parseghian, Ryan Sun, Stefania Napolitano, Van K. Morris II, Jason Henry, Jason Willis, Eduardo Vilar Sanchez, Kanwal P. Raghav, Agnes Ang, Scott Kopetz

**ABSTRACT**

3514

*Immune signatures to affect overall survival (OS) and response to bevacizumab (Bev) or cetuximab (Cet) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance).*

**AUTHOR(S)**

Federico Innocenti, Akram Yazdani, Xueping Qu, Fang-Shu Ou, Scott Van Buren, Omar Kabbarah, Charles D. Blanke, Alan P. Venook, Heinz-Josef Lenz, Benjamin G. Vincent

**ABSTRACT**

3515

*Examination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08.*

**AUTHOR(S)**


**ABSTRACT**

3516

*Molecular Determinants of Resistance and Sensitivity for Targeted Therapy*

**DISCUSSANT**

James M. Cleary, MD | Dana Farber Cancer Institute

*Early-onset stage II/III colorectal adenocarcinoma in the IDEA database: Treatment adherence, toxicities, and outcomes from adjuvant fluoropyrimidine and oxaliplatin.*

**AUTHOR(S)**


**ABSTRACT**

3517
Prevalence of fertility discussions between young adult colorectal cancer survivors and their providers.

**AUTHOR(S)**

Julia Stal, Serena Yi, Sally Cohen-Cutler, Phuong Gallagher, Afsaneh Barzi, Joel Milam, David R. Freyer, Heinz-Josef Lenz, Kimberly A. Miller

**ABSTRACT**

3518

**Microbiome signature, global methylation and immune landscape in early onset colorectal cancer.**

**AUTHOR(S)**

Ning Jin, Xiaokui Mo, Rebecca Hoyd, Ayse Selen Yilmaz, YunZhou Liu, Malvenderjit Jagjit Singh, Mitchell Muniak, Heather Hampel, Daniel Spakowicz

**ABSTRACT**

3519

**Unraveling the Complexities in the Care of Patients With Early-Onset Colorectal Cancer**

**DISCUSSANT**

Andrea Cercek, MD | Memorial Sloan Kettering Cancer Center

---

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

[Back to Program](https://meetinglibrary.asco.org/session/13626)

Showing 16 Presentations

**RATIONALE 302:** Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.
AUTHORS
Lin Shen, Ken Kato, Sung-Bae Kim, Jaffer A. Ajani, Kuaile Zhao, Zhiyong He, Xinmin Yu, Yongqian Shu, Qi Luo, Jufeng Wang, Zhendong Chen, Zuoxing Niu, Jong M. Sun, Chen-Yuan Lin, Hiroki Hara, Roberto Pazo-Cid, Christophe Borg, Liyun Li, Aiyang Tao, Eric Van Cutsem

ABSTRACT
4012
Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study.

AUTHORS
Yelena Y. Janjigian, Akihito Kawazoe, Patricio E. Yanez, Suxia Luo, Sara Lonardi, Oleksii Kolesnik, Olga Barajas, Yuxian Bai, Lin Shen, Yong Tang, Lucjan Wyrwicz, Kohei Shitara, Shukui Qin, Eric Van Cutsem, Josep Tabernero, Lie Li, Chie-Schin Shih, Pooja Bhagia, Hyun Cheol C. Chung

ABSTRACT
4013
Phase III trial comparing XELOX regimen (oxaliplatin plus capecitabine) versus EOX regimen (epirubicin, oxaliplatin and capecitabine) as first-line treatment for advanced gastric cancer: EXELOX trial.

AUTHORS
Weijian Guo, Xiaodong Zhu, Mingzhu Huang, Yusheng Wang, Zhiyu Chen, Wanjing Feng, Yifu He, Xiaowei Zhang, Xin Liu, Chencheng Wang, Wen Zhang, Jieer Ying, Jun Wu, Lei Yang, Yanru Qin, Xiaoying Zhao, Wenhua Li, Zhe Zhang, Lixin Qiu, XiaoFeng Wang

ABSTRACT
4014
Maintenance durvalumab after first-line platinum-based chemotherapy in advanced oesophago-gastric (OG) adenocarcinoma: Results from the PLATFORM trial.

AUTHORS
Caroline Fong, Bijal Patel, Clare Peckitt, Elli Bourmpaki, Katharina von Loga, Ruwaida Begum, Michael Davidson, Gayathri Anandappa, Catherine Cafferkey, David J. Watkins, Sheela Rao, Tom Waddell, Jonathan Wadsley, Fareeda Coxon, Tom Roques, Carys Morgan, Charlotte Rees, Naureen Starling, Ian Chau, David Cunningham

ABSTRACT
4015
Systemic Options for Gastroesophageal Cancer

DISCUSSANT
Preoperative chemoradiotherapy to improve overall survival in pancreatic cancer: Long-term results of the multicenter randomized phase III PREOPANC trial.

AUTHOR(S)
Casper H. Van Eijck, Eva Versteijne, Mustafa Suker, Karin Groothuis, Marc G. Besselink, Olivier R. Busch, Bert A. Bonsing, Bas Groot Koerkamp, Ignace H. de Hingh, Sebastiaan Festen, Gijs A. Patijn, Judith de Vos-Geelen, Aeilko H. Zwinderman, Cornelis J. Punt, Geertjan van Tienhoven

ABSTRACT
4016
Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407).

AUTHOR(S)
Masato Ozaka, Makoto Ueno, Hiroshi Ishii, Junki Mizusawa, Hiroshi Katayama, Tomoko Kataoka, Takuji Okusaka, Masafumi Ikeda, Haruo Miwa, Shuichi Kaneko, Tomohiro Maesono, Nobumasa Mizuno, Tomohisa Yamamoto, Yasuyuki Kawamoto, Akiko Todaka, Ken Kamata, Terumasa Hisano, Nao Fujimori, Junji Furuse

ABSTRACT
4017
Shifting the Dial for Localized Pancreatic Cancer

DISCUSSANT
Naureen Starling, BSc, FRCP, MD | The Royal Marsden Hospital NHS Foundation Trust

Masitinib plus gemcitabine as first-line treatment of pancreatic cancer with pain: Results from phase 3 study AB12005.

AUTHOR(S)
Joel Ezenfis, Olivier Hermine

ABSTRACT
4018
Gemcitabine (Gem) and nab-paclitaxel (NP) ± nivolumab (nivo) ± CD40 agonistic monoclonal antibody APX005M (Sotigalimab), in patients (Pts) with untreated metastatic pancreatic adenocarcinoma (mPDAC): Phase (Ph) 2 final results.

AUTHOR(S)

**ABSTRACT**

4019

**KG 4/2015: A randomized, controlled, multicenter, open-label phase III clinical trial of GV1001 with gemcitabine/capecitabine in previous untreated, eotaxin-high patients with advanced pancreatic ductal adenocarcinoma.**

**AUTHOR(S)**

Jung Hyun Jo, Yong-Tae Kim, Ho Soon Choi, Ho Gak Kim, Hong Sik Lee, Young Woo Choi, Dong Uk Kim, Kwang Hyuck Lee, Eui Joo Kim, Jeong Ho Han, Seung Ok Lee, Chang-Hwan Park, Eun Kwang Choi, Kyong Joo Lee, Jae Yong Cho, Woo Jin Lee, Si Young Song

**ABSTRACT**

4020

**Novel Systemic Approaches for Metastatic Pancreatic Cancer**

**DISCUSSANT**

Benjamin Adam Weinberg, MD | Georgetown University Hospital

**High CXCR4 expression in pancreatic ductal adenocarcinoma as characterized by an inflammatory tumor phenotype with potential implications for an immunotherapeutic approach.**

**AUTHOR(S)**


**ABSTRACT**

4021

**Identification and prognostic impact of PBRM1 mutations in biliary tract cancers: Results of a comprehensive molecular profiling study.**

**AUTHOR(S)**


**ABSTRACT**

4022

**Multimodal profiling of biliary tract cancers detects potentially actionable biomarkers and differences in immune signatures between subtypes.**
A U T H O R(S)
Kabir Mody, Nilofer S. Azad, Prerna Jain, Sherif El-Refai, Rachna T. Shroff, Robin Kate Kelley, Anthony B. El-Khoueiry, Denise Lau, Gregory B. Lesinski, Mark Yarchoan

A B S T R A C T
4023
How Can We Use Multi-omic Profiling of Pancreatobiliary Cancers?

D I S C U S S A N T
Sumera Ilyas, MBBS, BA | Mayo Clinic

Genitourinary Cancer—Kidney and Bladder

Back to Program

Showing 15 Presentations

https://meetinglibrary.asco.org/session/13629

Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial.

A U T H O R(S)

A B S T R A C T
4509
Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC) (HCRN GU16-260-Cohort B).

A U T H O R(S)
Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer.

AUTHOR(S)
Cristina Suarez Rodriguez, James Larkin, Poulam M. Patel, Begoña P. Valderrama, Alejo Rodriguez-Vida, Hilary Glen, Fiona Thistlethwaite, Christy Ralph, Gopalakrishnan Srinivasan, Maria Jose Mendez-Vidal, Abigail Carter, Charlotte Tyson, Aaron Prendergast, Kelly Mousa, Thomas Powles

Making Strides in the Treatment of Non-Clear Cell Carcinoma: Are We Ready for Adaptive and Biomarker-Driven Strategies?

DISCUSSANT
Deepak Kilari, MD | Medical College of Wisconsin


AUTHOR(S)
Xinan Sheng, Dingwei Ye, Ai-Ping Zhou, Xin Yao, Hong Luo, Zhisong He, Zengjun Wang, Yingchao Zhao, Zhigang Ji, Qing Zou, Chaohong He, Jianming Guo, Xinhua Tu, Ziling Liu, Benkang Shi, Ben Liu, Peng Chen, Qiang Wei, Fang-Jian Zhou, Jun Guo

First results of a randomized phase IB study comparing nivolumab/ipilimumab with or without CBM-588 in patients with metastatic renal cell carcinoma.

AUTHOR(S)

Novel Strategies to Improve Outcomes in Advanced Renal Cell Carcinoma

DISCUSSANT
Guillermo de Velasco, MD, PhD | Department of Oncology, Hospital 12 de Octubre
Outcomes of patients who progressed while receiving avelumab + axitinib (A + Ax) and received subsequent treatment (Tx) in JAVELIN Renal 101.

AUTHOR(S)
Laurence Albiges, Martin H. Voss, Brian I. Rini, Gwenaëlle Gravis, Marc-Oliver Grimm, Paul D. Nathan, Georg A. Bjarnason, Yoshihiko Tomita, Konstantin Penkov, Bradley McGregor, Bo Huang, Despina Thomaidou, Mariangela Mariani, Alessandra Di Pietro, Toni K. Choueiri

ABSTRACT

Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 trial.

AUTHOR(S)

ABSTRACT


AUTHOR(S)
Jaleh Fallah, Haley Gittleman, Chana Weinstock, Erik Bloomquist, Elaine Chang, Daniel L. Suzman, Sundeep Agrawal, Amna Ibrahim, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani

ABSTRACT

Unanswered Questions in the Management of Advanced Renal Cell Carcinoma

DISCUSSANT
Anil Kapoor, MD | Juravinski Cancer Centre, McMaster University

Neoadjuvant atezolizumab (A) with gemcitabine and cisplatin (GC) in patients (pts) with muscle-invasive bladder cancer (MIBC): A multicenter, single-arm, phase 2 trial.

AUTHOR(S)

ABSTRACT
PrE0807: A phase Ib feasibility trial of neoadjuvant nivolumab (N) without or with lirilumab (L) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).

AUTHOR(S)

ABSTRACT
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial.

AUTHOR(S)

ABSTRACT
Novel Immunotherapy Approaches Across the Spectrum of Urothelial Cancer Stages

DISCUSSANT
Bishoy Morris Faltas, MD | Weill Cornell Medicine

Genitourinary Cancer—Prostate, Testicular, and Penile

Back to Program

Showing 16 Presentations

https://meetinglibrary.asco.org/session/13632
The CADMUS trial: A paired cohort, blinded study comparing multiparametric ultrasound targeted biopsies with multiparametric MRI targeted biopsies in the detection of clinically significant prostate cancer.

AUTHOR(S)
Alistair Grey, Rebecca Scott, Bina Shah, Peter Acher, Sidath Liyanage, Menelaos Pavlou, Rumana Omar, Frank Chinegwundoh, Prasad Patki, Diane Campbell, Taimur T. Shah, Sami Hamid, Chris Brew-Graves, Nim Arumainayagam, Alex Chapman, David Eldred-Evans, Alex Freeman, Mathias Winkler, Mark Emberton, Hashim U. Ahmed

ABSTRACT
5008

MRI and targeted biopsies compared to transperineal mapping biopsies for targeted ablation in recurrent prostate cancer after radiotherapy: Primary outcomes of the FORECAST trial.

AUTHOR(S)

ABSTRACT
5009

Validation of the decipher genomic classifier (GC) in SAKK 09/10: A phase III randomized trial of dose-escalated salvage radiotherapy (SRT) after radical prostatectomy (RP).

AUTHOR(S)

ABSTRACT
5010

Have We Optimized the Detection and Risk Stratification in Men With Localized Prostate Cancer?

DISCUSSANT
Samir Taneja, MD | NYU Langone Health

Radiation and androgen deprivation therapy with or without docetaxel in the management of non-metastatic unfavorable-risk prostate cancer: A prospective randomized trial.

AUTHOR(S)
**ABSTRACT**

### 5011

**Interim results of aasur: A single arm, multi-center phase 2 trial of apalutamide (A) + abiraterone acetate + prednisone (AA+P) + leuprolide with stereotactic ultra-hypofractionated radiation (UHRT) in very high risk (VHR), node negative (N0) prostate cancer (PCa).**

**AUTHOR(S)**

Sean M. McBride, Daniel E. Spratt, Marisa Kollmeier, Wassim Abida, Han Xiao, Susan F. Slovin, Channing J. Paller, Curtiland Deville, Robert B. Den, Jason W. Hearn, Howard I. Scher, Michael J. Zelefsky, Dana E. Rathkopf

### 5012

**Is There a Role for Systemic Therapy Intensification With Radiotherapy in Locally Advanced Prostate Cancer?**

**DISCUSSANT**

Neha Vapiwala, MD, FACR | University of Pennsylvania

**Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC).**

**AUTHOR(S)**

Johann S. De Bono, Lawrence Fong, Tomasz M. Beer, Xin Gao, Daniel M. Geijnisman, Howard A. Burris III, James F. Strauss, Kevin D. Courtney, David I. Quinn, David J. VanderWeele, Yifah Yaron, Che-Leung Law, Mark N. Stein

### 5013

**COMBAT-CRPC: COncurrent adMinistration of Bipolar Androgen Therapy (BAT) and nivolumab in men with metastatic castration-resistant prostate cancer (mCRPC).**

**AUTHOR(S)**

Phase I study of $^{225}$Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).

**AUTHOR(S)**

**ABSTRACT**

5015

**Novel Approaches to Metastatic Prostate Cancer: Are We Making Progress?**

**DISCUSSANT**
Julie N Graff, MD | OHSU Knight Cancer Institute

**Hearing loss after cisplatin-based chemotherapy: Patient-reported outcomes versus audiometric assessments.**

**AUTHOR(S)**

**ABSTRACT**

5016

**Immunity to childhood vaccines following high dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) for germ cell tumors (GCT) with comparison to Hodgkin lymphoma (HL).**

**AUTHOR(S)**

**ABSTRACT**

5017

**Surveillance after complete response in patients with metastatic non-seminomatous germ-cell tumor (NSGCT).**

**AUTHOR(S)**
Jennifer King, Sandra K. Althouse, Clint Cary, Timothy A. Masterson, Richard Foster, Ryan Ashkar, Nasser H. Hanna, Lawrence H. Einhorn, Nabil Adra

**ABSTRACT**
Effect of pretreatment central adiposity on the cardiometabolic risk of male germ cell tumor survivors after cisplatin-based chemotherapy.

AUTHOR(S)
Andreas G. Wibmer, Darren R. Feldman, Carol Chen, Maria Bromberg, Paul C. Dinh Jr., Junting Zheng, Marinela Capanu, Lois B. Travis, Hebert A. Vargas

ABSTRACT

Survivorship Challenges in Testicular Cancer: Are There Factors We Can Modify?

DISCUSSANT
Timothy D. Gilligan, FASCO, MD, MS | Cleveland Clinic Taussig Cancer Institute

Evaluation of a RAD51 functional assay in advanced ovarian cancer, a GINECO/GINEGEPS study.

AUTHOR(S)
Felix Blanc-Durand, Elisa Yaniz, Catherine Genestie, Etienne Rouleau, Dominique Berton, Alain Lortholary, Nathalie Dohollou, Christophe Desauw, Michel Fabbro, Emmanuelle Malaurie, Nathalie Bonichon-Lamichhane, Coraline Dubot, Jean-Emanuel Kurtz, Gaetan De Rauglaudre, Nadia Raban, Cyril Abeddaim, Gwenael Ferron, Marie-Christine Kaminsky, Alba Llop-Guevara, Alexandra Leary

ABSTRACT

Progression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab (bev) with olaparib/placebo maintenance in the phase III PAOLA-1/ENGOT-ov25 trial.
AUTHOR(S)

Patricia Pautier, Philipp Harter, Carmela Pisano, Claire Cropet, Susana Hernando Polo, Regina Berger, Takashi Matsumoto, Ignace Vergote, Nicoletta Colombo, Trine J. Noettrup, Georges Garnier, Peter Hillemanns, Claudio Zamagni, Antonio Gonzalez Martin, Claudia Lefeuvre-Plesse, Dominik Denschlag, Alain Lortholary, Jalid Sehouli, Frederic Selle, Isabelle L. Ray-Coquard

ABSTRACT

5514

Olaparib treatment (Tx) in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Overall survival (OS) results from the phase II LIGHT study.

AUTHOR(S)

Cara A. Mathews, Fiona Simpkins, Karen A. Cadoo, Ying L. Liu, Diane M. Provencher, Colleen McCormick, Adam ElNaggar, Alon D. Altman, Lucy Gilbert, Destin Black, Nashwa Kabil, James Bennett, Jiefen Munley, Judy Yu, Carol Aghajanian

ABSTRACT

5515

Choosing Wisely: Selecting the Right Population at the Right Time for DNA-Damaging Therapy

DISCUSSANT

Elizabeth M. Swisher, MD | University of Washington School of Medicine

Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer.

AUTHOR(S)


ABSTRACT

5516

Subgroup analysis of rucaparib versus chemotherapy as treatment for BRCA-mutated, advanced, relapsed ovarian carcinoma: Effect of platinum sensitivity in the randomized, phase 3 study ARIEL4.

AUTHOR(S)


ABSTRACT
Niraparib efficacy and safety in patients with BRCA mutated (BRCAm) ovarian cancer: Results from three phase 3 niraparib trials.

AUTHOR(S)
Antonio Gonzalez Martin, Ursula A. Matulonis, Jacob Korach, Mansoor R. Mirza, Kathleen N. Moore, Divya Gupta, Stanislav Lechpammer, Bradley J. Monk

ABSTRACT

A Tale of Three PARP Inhibitors

DISCUSSANT
Debra L. Richardson, MD | Stephenson Cancer Center at the University of Oklahoma Health Sciences Center

Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC).

AUTHOR(S)

ABSTRACT

An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer (KGOG 3045, AMBITION).

AUTHOR(S)
Jung-Yun Lee, Byoung-Gie Kim, Jae-Weon Kim, Jung Bok Lee, Eunhyang Park, Sung Hoon Kim, Chel Hun Choi, Hee Seung Kim

ABSTRACT

Dendritic cell vaccine (DCVAC) combined with chemotherapy (CMT) in patients with newly diagnosed epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Biomarker exploratory analysis of a phase 2, open-label, randomized, multicenter trial.

AUTHOR(S)
Lukas Rob, David Cibula, Pawel Knapp, Peter Mallmann, Jaroslav Klat, Lubos Minar, Pavel Bartos, Josef Chovanec, Petr Valha, Marek Pluta, Zdenek Novotny, Jiri Spacek, Bohuslav Melichar, Dariusz Kieszko, Jitka Fucikova, Tereza Hrniciarova, Roman P. Korolkiewicz, Marek Hraska, Jirina Bartunkova, Radek Spisek
ABSTRACT

5521

Using Biomarkers to Improve Outcomes in Ovarian Cancer

DISCUSSANT

Rebecca Christian Arend, MD | University of Alabama at Birmingham

Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer.

AUTHOR(S)

Judith Michels, François Ghiringhelli, Jean-Sebastien Frenel, Caroline Brard, Benoit You, Anne Floquet, Lauriane Eberst, Rastilav Bahleda, Catherine Genestie, Corinne Balleyguier, Sophie Broutin, Patricia Pautier, Emeline Colomba, Fanny Pommeret, Christophe Massard, Aurelien Marabelle, Alexandra Leary

ABSTRACT

5522

A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).

AUTHOR(S)

Dana M. Roque, Stefania Bellone, Eric R. Siegel, Natalia Buza, Elena Bonazzoli, Adele Guglielmi, Luca Zammataro, Nupur Nagarkatti, Samir Zaidi, Jungsoo Lee, Peter E. Schwartz, Elena Ratner, Ludmil B. Alexandrov, Akiko Iwasaki, Yong Kong, Eric Song, Weilai Dong, Julia A. Elvin, Jungmin Choi, Alessandro Santin

ABSTRACT

5523

Anlotinib plus sintilimab in patients with recurrent advanced cervical cancer: A prospective, multicenter, single-arm, phase II clinical trial.

AUTHOR(S)

Qin Xu, Chuanben Chen, Yang Sun, Zhangzhou Huang, Yibin Lin, Jing Liu, Li Li, Zirong Li, Junping Pan, Ying Chen

ABSTRACT

5524

Checkpoint Inhibitors Across the Spectrum of Gynecologic Cancers

DISCUSSANT

Oladapo O. Yeku, MD, PhD, FACP | Memorial Sloan Kettering Cancer Center
Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311).

AUTHOR(S)

ABSTRACT
6010
Nivolumab, nabpaclitaxel, and carboplatin followed by risk/response adaptive de-escalated locoregional therapy for HPV-associated oropharyngeal cancer: OPTIMA II trial.

AUTHOR(S)
Ari Rosenberg, Nishant Agrawal, Alexander T. Pearson, Tanguy Y. Seiwert, Zhen Gooi, Elizabeth A. Blair, Daniel Ginat, Adam Howard, Jeffrey Chin, Sara Kochanny, Evgeny Izumchenko, Aditya Juloori, Daniel J. Haraf, Everett E. Vokes

ABSTRACT
6011
De-intensification Approaches for HPV-Positive Head and Neck Cancers

DISCUSSANT
Anthony C. Nichols, MD | Western University and London Health Sciences Centre

Randomized trial of radiotherapy with weekly cisplatin or cetuximab in low risk HPV associated oropharyngeal cancer (TROG 12.01): A Trans-Tasman Radiation Oncology Group study.

AUTHOR(S)
Danny Rischin, Madeleine T. King, Lizbeth M. Kenny, Sandro Porceddu, Christopher Wratten, Andrew Macann, James E. Jackson, Mathias Bressel, Alan Herschtal, Fisher Richard, Tsien Fua, Charles Lin, Chen-Shin Liu, Brett G. Hughes, Margie McGrath, Lachlan McDowell, June Corry
**ABSTRACT**

6012

**TRYHARD, a randomized phase II trial (RTOG Foundation 3501) of concurrent accelerated radiation plus cisplatin (cis) with or without lapatinib (Lap) for stage III-IV Non-HPV head and neck carcinoma (HNC).**

**AUTHOR(S)**


**ABSTRACT**

6014

**Lessons Learned From Negative Trials**

**DISCUSSANT**

Douglas Adkins, MD | Washington University School of Medicine

**Randomized phase II trial of ficlatuzumab with or without cetuximab in pan-refractory, advanced head and neck squamous cell carcinoma (HNSCC).**

**AUTHOR(S)**


**ABSTRACT**

6015

**Phase II trial of soluble EphB4-albumin in combination with PD-1 antibody (pembrolizumab) in relapsed/refractory head neck squamous cell carcinoma.**

**AUTHOR(S)**

Alexandra Jackovich, Barbara J. Gitlitz, Justin Wayne W. Tiu-lim, Vinay Duddalwar, Kevin G. King, Anthony B. El-Khoueiry, Jacob S. Thomas, Denice Tsao-Wei, David I. Quinn, Parkash S. Gill, Jorge J. Nieva

**ABSTRACT**

6016

**Efficacy of concurrent cetuximab (CTX) and nivolumab (NIVO) in previously untreated recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).**

**AUTHOR(S)**
Christine H. Chung, Nabil F. Saba, Conor E. Steuer, Jiannong Li, Priyanka Bhatia, Matthew Johnson, Jude Masannat, Maria Poole, Dirk Hoening, Feifei Song, Juan C. Hernandez-Prera, Helen Molina, Bruce Wenig, Joaquim Farinhas, Julie A. Kish, Jameel Muzaffar, Kedar Kirtane, James W. Rocco, Michael J. Schell, Marcelo R. Bonomi

ABSTRACT

6017

**Novel Combinations in Recurrent/Metastatic Head and Neck Cancers**

**DISCUSSANT**

Hyunseok Kang, FACP, MD, MPH | University of California, San Francisco

*A randomized phase II trial of diffusion-weighted MR imaging-guided radiotherapy plus chemotherapy versus standard chemoradiotherapy in locoregional advanced nasopharyngeal carcinoma.*

**AUTHOR(S)**

Feng Liu, Shengnan Fu, Yanzhu Chen, Ouying Yan, Lili He, Cuihong Jiang, Xiangwei Wu, Yaqian Han, Hui Wang

ABSTRACT

6018

**The 30 ROC trial: Precision intra-treatment imaging guiding major radiation reduction in human papillomavirus related oropharyngeal cancer.**

**AUTHOR(S)**


ABSTRACT

6019

**Image-Based Risk-Adapted Radiotherapy: It's Not Just Black and White!**

**DISCUSSANT**

Quynh-Thu Le, MD | Stanford University
Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study.

**AUTHOR(S)**
Carlo Gambacorti-Passerini, Tim H. Brümmendorf, Dong-Wook Kim, Yeow Tee Goh, Irina S. Dyagil, Katia Pagnano, Arpad Batai, Anna G. Turkina, Eric Leip, Simon Purcell, Jocelyn M. Leone, Andrea Viqueira, Jorge E. Cortes

**ABSTRACT**
7009

Phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS).

**AUTHOR(S)**

**ABSTRACT**
7010

Venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with therapy-related myeloid neoplasms, antecedent myelodysplastic syndromes, or myelodysplastic/myeloproliferative neoplasms.

**AUTHOR(S)**
Vinod Pullarkat, Keith Pratz, Hartmut Dohner, Christian Recher, Michael J. Thirman, Courtney D. Dinardo, Pierre Fenaux, Andre C. Schuh, Andrew H. Wei, Arnaud Pigneux, Jun Ho Jang, Gunnar Julisson, Kazuhiro Miyazaki, Dominik Selleslag, Martha L. Arellano, Kiran Naqvi, Jun Yu, Jean Ridgeway, Jalaja Potluri, Marina Konopleva

**ABSTRACT**
7011

Beyond Dose Intensity: Targeted Therapy of Myeloid Malignancies

**DISCUSSANT**
Ami B. Patel, MD | Huntsman Cancer Institute, University of Utah
A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.

**AUTHOR(S)**
Curtis A. Lachowiez, Gautam Borthakur, Sanam Loghavi, Zhihong Zeng, Tapan M. Kadia, Lucia Masarova, Koichi Takahashi, George D. Tippett, Samantha Smith, Jacqueline S. Garcia, Prithviraj Bose, Elias Jabbour, Farhad Ravandi, Naval G. Daver, Guillermo Garcia-Manero, Bilyana Stoiiova, Paresh Vyas, Hagop M. Kantarjian, Marina Konopleva, Courtney D. Dinardo

**ABSTRACT**

7012

Follow-up of patients with FLT3-mutated R/R AML in the phase 3 ADMIRAL trial.

**AUTHOR(S)**

**ABSTRACT**

7013

Prognostic factors of overall (OS) and relapse-free survival (RFS) for patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy (IC): Multivariate analyses from the QUAZAR AML-001 trial of oral azacitidine (Oral-AZA).

**AUTHOR(S)**
Gail J. Roboz, Andrew H. Wei, Farhad Ravandi, Christopher Pocock, Pau Montesinos, Hervé Dombret, Kimmo Porkka, Ignazia La Torre, Barry Skikne, Jianhua Zhong, Keshava Kumar, C. L. Beach, Hartmut Dohner

**ABSTRACT**

7014

A mixed methods study exploring the role of perceived side effects on treatment decision-making in older adults with acute myeloid leukemia (AML).

**AUTHOR(S)**

**ABSTRACT**

7016

A registry-based, observational safety study of inotuzumab ozogamicin (InO) treatment in patients (pts) with B-cell precursor acute lymphoblastic leukemia (ALL) who proceeded to hematopoietic stem cell transplant (HSCT).
Priorities in Focus: Safety First

DISCUSSANT
Leland L. Metheny, MD | Adult Hematologic Malignancies and Stem Cell Transplant Program, University Hospitals Seidman Cancer Center

Measurable residual disease response in acute myeloid leukemia treated with venetoclax and azacitidine.

AUTHOR(S)
Keith Pratz, Brian A. Jonas, Vinod Pullarkat, Christian Recher, Andre C. Schuh, Michael J. Thirman, Jacqueline S. Garcia, Courtney D. Dinardo, Vladimir Vorobyev, Nicola Fracchiolla, Su-Peng Yeh, Jun Ho Jang, Muhit Ozcan, Kazuhito Yamamoto, Arpad Illes, Ying Zhou, Monique Dail, Brenda Chyla, Jalaja Potluri, Hartmut Dohner

Predictive phosphoproteomic signatures for midostaurin plus chemotherapy response in FLT3 mutant positive acute myeloid leukaemia.

AUTHOR(S)
Arran D. Dokal, Andrea Arruda, Ryan Smith, Calum Greenhalgh, Francesca Patella, Pedro M. Casado-Izquierdo, Bela Wrench, Jane Theaker, Andrew Thompson, Mark D. Minden, John G. Gribben, David J. Britton, Pedro R. Cutillas

High dimensional mapping of temporal evolution within the marrow microenvironment in response to FLT3 inhibitor therapy.

AUTHOR(S)
Matthew Newman, Sunil K. Joshi, Daniel Bottomly, Shannon McWeeney, Brian J. Druker, Evan Lind, Elie A. Traer

Building a Better Map: Advances in Biomarkers for AML

DISCUSSANT
Chris Hourigan | National Heart Lung and Blood Institute at the National Institutes of Health
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Back to Program

Showing 16 Presentations

https://meetinglibrary.asco.org/session/13646

Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Elevate-TN four-year follow up.

AUTHOR(S)

ABSTRACT
7509

Copanlisib + rituximab versus rituximab + placebo in patients with relapsed follicular (FL) or marginal zone lymphoma (MZL): Subset analysis from the phase III CHRONOS-3 trial.

AUTHOR(S)
Matthew J. Matasar, Marcelo Capra, Muhit Özcan, Fangfang Lv, Wei Li, Eduardo Yanez, Katya Sapunarova, Tongyu Lin, Jie Jin, Wojciech Jurczak, Aryan Hamed, Ming-Chung Wang, Lidia Mongay Soler, Anjun Cao, Charles Phelps, Barrett H. Childs, Yuankai Shi, Pier L. Zinzani

ABSTRACT
7510

Obinutuzumab (G)-atezolizumab (atezo)-lenalidomide (len) for the treatment of relapsed/refractory (R/R) follicular lymphoma (FL): Final analysis of a phase Ib/II trial.

AUTHOR(S)
Nilanjan Ghosh, Gilles A. Salles, Izidore S. Lossos, Maria Lia Palomba, Amitkumar Mehta, Olivier Casasnovas, Don A. Stevens, Sudhakar Katakam, Andrea Knapp, Tina Nielsen, Franck Morschhauser

ABSTRACT
7511

Alternatives to Chemotherapy for Indolent B-Cell Malignancies


**DISCUSSANT**

Carla Casulo, MD | University of Rochester Medical Center-James P. Wilmot Cancer Center

**Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.**

**AUTHOR(S)**


**ABSTRACT**

7512

Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

**AUTHOR(S)**

Johannes Düll, Kami J. Maddocks, Eva Gonzalez-Barca, Wojciech Jurczak, Anna Marina Liberati, Aleš Obr, Gianluca Gaidano, Pau Abrisqueta, Marc André, Martin H. Dreyling, Tobias Menne, Maren Dirnberger-Hertweck, Johannes Weirather, Sumeet V. Ambarkhane, Gilles A. Salles

**ABSTRACT**

7513

Multicenter phase II study of romidepsin plus lenalidomide for patients with previously untreated peripheral T-cell lymphoma (PTCL).

**AUTHOR(S)**

Jia Ruan, Jasmine M. Zain, Brett Palmer, Borko Jovanovic, Xinlei Mi, Alok Swaroop, Jane Winter, Leo I. Gordon, Reem Karmali, Barbara Pro

**ABSTRACT**

7514

Lenalidomide Combinations for Aggressive Lymphoma

**DISCUSSANT**

Eliza Anne Hawkes, FRACP, MBBS, MD | Austin Health and Olivia Newton-John Cancer Research Institute

Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20-containing chemoimmunotherapy (POD24).
Preliminary safety and efficacy of PBCAR0191, an allogeneic, off-the-shelf CD19-targeting CAR-T product, in relapsed/refractory (r/r) CD19+ NHL.

Engineered immunostimulatory cells can convert PBMCs from chronic lymphocytic leukemia (CLL) patients into potent tumor killing immune cells.


ABSTRACT

7519

Promising tolerability and efficacy results from dose-escalation in an ongoing phase Ib/II study of mosunetuzumab (M) with polatuzumab vedotin (Pola) in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (B-NHL).

AUTHOR(S)

L. E. Budde, Nilanjan Ghosh, Julio C. Chavez, Izidore S. Lossos, Amitkumar Mehta, Kathleen A. Dorritie, Manali K. Kamdar, Raluca Negricea, Song Pham, Maria Hristopoulos, Ling-Yuh Huw, Carol E. O’Hear, Yasuhiro Oki, Iris To, Catherine S. Magid Diefenbach

ABSTRACT

7520

More Specifics About Bispecifics

DISCUSSANT

Mazyar Shadman, MD, MPH | Univ of Washington

Hematologic Malignancies—Plasma Cell Dyscrasia

Back to Program

Showing 15 Presentations

https://meetinglibrary.asco.org/session/13650

MASS-FIX versus standard methods to predict for PFS and OS among multiple myeloma patients participating on the STAMINA trial.

AUTHOR(S)


ABSTRACT
Analysis of minimal residual disease in bone marrow by NGF and in peripheral blood by mass spectrometry in newly diagnosed multiple myeloma patients enrolled in the GEM2012MENOS65 clinical trial.

AUTHOR(S)
Noemi Puig, Bruno Paiva, Teresa Contreras, M. Teresa Cedena, Laura Rosiñol, Joaquín Martínez, Albert Oriol, Maria Jesus Blanchard, Rafael Rios, María B. Ilfigo, Anna Sureda Balari, Hernández-Garcia Miguel Teodoro, Javier de La Rubia, Isabel Krsnik, Moraleda José María, Alberto Orfao, Joan Blade, Jesús F. San-Miguel, Juan José Lahuerta, Maria-Victoria Mateos

ABSTRACT
Interim analysis of a phase 2 minimal residual disease (MRD)-adaptive trial of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for newly diagnosed multiple myeloma (MM).

AUTHOR(S)

ABSTRACT
Prospective comparison of whole body MRI and FDG PET/CT for detection of multiple myeloma and correlation with markers of disease burden: Results of the iTIMM trial.

AUTHOR(S)

ABSTRACT
MRD Negativity: Going With the Flow, NGS, Mass-Spec, or PET?

DISCUSSANT
Jens Hillengass, MD, PhD | Roswell Park Cancer Institute

CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.
AUTHOR(S)
Mounzer Agha, Adam D. Cohen, Deepu Madduri, Yael C. Cohen, Michel Delforge, Jens Hillengass, Hartmut Goldschmidt, Katja Weisel, Marc-Steffen Raab, Christof Scheid, Jordan M. Schecter, Kevin C. De Braganca, Helen Varsos, Liwei Wang, Martin Vogel, Marlene Carrasco-Alfonso, Muhammad Akram, Xiaoling Wu, Tonia Nesheiwat, Hermann Einsele

ABSTRACT
8013
Long-term follow-up results of a multicenter first-in-human study of the dual BCMA/CD19 Targeted FasT CAR-T GC012F for patients with relapsed/refractory multiple myeloma.

AUTHOR(S)
Hua Jiang, Baoxia Dong, Li Gao, Li Liu, Jian Ge, Aili He, Lu Li, Jing Lu, Xiequn Chen, Martina A. Sersch, Lianjun Shen, Xun Ye, Hua Zhang, Yi Zhao, Jia Liu, Weijun Fu

ABSTRACT
8014
Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain, for the treatment of subjects with relapsed and refractory multiple myeloma.

AUTHOR(S)

ABSTRACT
8015
Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.

AUTHOR(S)

ABSTRACT
8016
CARs in Myeloma: Heading Into a Traffic Jam?

DISCUSSANT
Yi Lin, MD, PhD | Division of Hematology, Mayo Clinic
Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM).

**AUTHOR(S)**

**ABSTRACT**
8017

Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).

**AUTHOR(S)**

**ABSTRACT**
8018

Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study.

**AUTHOR(S)**

**ABSTRACT**
8019

Oral ixazomib-dexamethasone versus oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial.

**AUTHOR(S)**

**ABSTRACT**
8020

Navigating Relapsed Myeloma Therapy: Need a New Map Again
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Real-world multiomic characterization of small cell lung cancer subtypes to reveal differential expression of clinically relevant biomarkers.

Author(s)

Abstract
8508
Signatures of plasticity and immunosuppression in a single-cell atlas of human small cell lung cancer.

Author(s)

Abstract
8509
Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).
On the Horizon: Personalized Therapy for Small Cell Lung Cancer

DISCUSSANT

Nagla Fawzy Abdel Karim, MD | The University of Cincinnati

Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.

AUTHOR(S)

David R. Spigel, Corinne Faivre-Finn, Jhanelle E. Gray, David Vicente, David Planchard, Luis G. Paz-Ares, Johan F. Vansteenkiste, Marina C. Garassino, Rina Hui, Xavier Quantin, Andreas Rimner, Yi-Long Wu, Mustafa Ozguroglu, Ki Hyeong Lee, Terufumi Kato, Maike de Wit, Euan Macpherson, Michael Newton, Piruntha Thiyagarajah, Scott J. Antonia

KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC.

AUTHOR(S)

Salma K. Jabbour, Ki Hyeong Lee, Nicolaj Frost, Valeriy V. Breder, Dariusz M. Kowalski, Issam A. Alawin, Evgeny Levchenko, Noemi Reguart, Alex Martinez-Marti, Baerin Houghton, Jean-Baptiste Paoli, Sufia Safina, Keunchil Park, Takefumi Komiya, Amy Sanford, Vishal Boolell, Hong Liu, Ayman Samkari, Steven M. Keller, Martin Reck

AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC).

AUTHOR(S)


Sequential or Concurrent Immunoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer

DISCUSSANT
Racial differences in incidence, outcomes, and genomic alterations in small cell lung cancer.

**AUTHOR(S)**
Leyla Bayat, Pingfu Fu, Shufen Cao, Afshin Dowlati

**ABSTRACT**

Impact of socioeconomic disparities on diagnosis and overall survival in small cell lung cancer: A National Cancer Database analysis.

**AUTHOR(S)**
Logan Roof, Wei Wei, Katherine Tullio, Nathan A. Pennell, James Stevenson

**ABSTRACT**


**AUTHOR(S)**
Michelle J. Lee, Eric Chang, Manan Shah, Sanjay R. Jain

**ABSTRACT**

Evaluating Health Disparities in Lung Cancer

**DISCUSSANT**
David Cooke | UC Davis Health System

Residual ctDNA after treatment predicts early relapse in patients with early-stage NSCLC.

**AUTHOR(S)**
Davina Gale, Katrin Heider, Malcolm Perry, Giovanni Marsico, Andrea Ruiz-Valdepeñas, Viona Rundell, Jerome Wulff, Garima Sharma, Karen Howarth, David Gilligan, Susan Harden, Doris M. Rassl, Robert Rintoul, Nitzan Rosenfeld

**ABSTRACT**

Leveraging phased variants for personalized minimal residual disease detection in localized non-small cell lung cancer.

**AUTHOR(S)**
ABSTRACT

Early detection of lung cancer using cfDNA fragmentation.

AUTHOR(S)


ABSTRACT

Evolving Applications of Circulating Tumor DNA in Lung Cancer

DISCUSSANT

Vamsidhar Velcheti, MD, FACP, FCCP | Cleveland Clinic Foundation

Lung Cancer—Non-Small Cell Metastatic

Back to Program

Showing 16 Presentations

https://meetinglibrary.asco.org/session/13659

Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).

AUTHOR(S)

Shun Lu, Xiaorong Dong, Hong Jian, Jianhua Chen, Gongyan Chen, Yuping Sun, Yinghua Ji, Ziping Wang, Jianhua Shi, Junguo Lu, Shaoshui Chen, Guojun Zhang, Dongqing Lv, Chunling Liu, Juan Li, Xinmin Yu, Zhong Lin, Zhuang Yu, Zhehai Wang, Jiuwei Cui

ABSTRACT

9013
Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.

**AUTHOR(S)**
Suresh S. Ramalingam, Caicun Zhou, Tae Min Kim, Sang-We Kim, James Chih-Hsin Yang, Gregory J. Riely, Tarek Mekhail, Danny Nguyen, Maria Rosario García Campelo, Enriqueta Felip, Sylvie Vincent, Shu Jin, Veronica Bunn, Jianchang Lin, Huamao M. Lin, Minal Mehta, Pasi A. Janne

**ABSTRACT**

9014

**Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial.**

**AUTHOR(S)**
Julien Mazieres, Claire Lafitte, Charles Ricordel, Laurent Greillier, Jean-Louis Pujol, Gerard Zalcman, Charlotte Domblides, Jeannick Madelaine, Jaafar Bennouna, Celine Mascaux, Denis Moro-Sibilot, François Pinquié, Alexis Cortot, Josiane Otto, Jacques Cadranel, Alexandra Langlais, Franck Morin, Virginie Westeel, Benjamin Besse

**ABSTRACT**

9015

**Expanding the Breadth and Scope of ErbB Inhibition in Lung Cancer: New Ways to Target EGFR and HER2 Mutations**

**DISCUSSANT**
Helena Alexandra Yu, MD | Memorial Sloan Kettering Cancer Center

**Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.**

**AUTHOR(S)**
Luis G. Paz-Ares, Tudor-Eliade Ciuleanu, Jong-Seok Lee, Laszlo Urban, Reyes Bernabe Caro, Keunchil Park, Hiroshi Sakai, Yuichiro Ohe, Makoto Nishio, Adam Pluzanski, Suresh S. Ramalingam, Julie R. Brahmer, Hossein Borghaei, Kenneth J. O'Byrne, Matthew D. Hellmann, Arteid Memaj, Judith Bushong, Phuong Tran, Martin Reck

**ABSTRACT**

9016

**Effect of antibiotic therapy on immunotherapy outcomes for non-small cell lung cancer: Analysis from the Veterans Health Administration Database.**

**AUTHOR(S)**

ABSTRACT

9017

Association of a very high tumor mutational load with increased CD8+ and PD-1+ T-cell infiltration and improved clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels in non-small cell lung cancer.

AUTHOR(S)


ABSTRACT

9018

Intestinal Akkermansia muciniphila predicts overall survival in advanced non-small cell lung cancer patients treated with anti-PD-1 antibodies: Results a phase II study.

AUTHOR(S)

Lisa Derosa, Bertrand Routy, Laurence Zitvogel, Andrew M. Thomas, Gerard Zalcman, Sylvie Friard, Julien Mazieres, Clarisse Audigier-Valette, Denis Moro-Sibilot, Francois Goldwasser, Corentin Richard, Francois Ghiringhelli, Fabrice Barlesi, Arielle Elkrief, Carolina Alves Costa Silva, David Planchard, Nicola Segata, Stephanie Martinez, Jean-Charles Soria, Benjamin Besse

ABSTRACT

9019

Bringing More Precision to Immune Checkpoint Inhibitor Therapy in Patients With NSCLC

DISCUSSANT

Anne-Marie C. Dingemans, MD, PhD | Erasmus MC Cancer Institute, University Medical Center Rotterdam, department of Respiratory Medicine

Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study.

AUTHOR(S)

Juergen Wolf, Edward B. Garon, Harry J. Groen, Daniel S. Tan, Anna Robeva, Sylvie Le Mouhaer, Mariana Carbini, Andrea Chassot-Agostinho, Rebecca S. Heist

ABSTRACT

9020
Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp).

AUTHOR(S)
Xiuning Le, Luis G. Paz-Ares, Jan Van Meerbeeck, Santiago Viteri, Carlos Cabrera Galvez, David Vicente Baz, Young-Chul Kim, Jin-Hyoung Kang, Karl-Maria Schumacher, Niki Karachaliou, Svenja Adrian, Rolf Bruns, Paul K. Paik

ABSTRACT
9021

MET in NSCLC: Are We Finally Meeting the Mark?

DISCUSSANT
Giulia Pasello, MD | Istituto Oncologico Veneto IOV IRCCS

Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC).

AUTHOR(S)
Hiroshige Yoshioka, Toyoaki Hida, Hiroshi Nokihara, Masahiro Morise, Young Hak Kim, Koichi Azuma, Takashi Seto, Yuichi Takiguchi, Makoto Nishio, Toru Kumagai, Katsuyuki Hotta, Satoshi Watanabe, Koichi Goto, Miyako Satouchi, Toshiyuki Kozuki, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Nobuyuki Yamamoto, Takuya Yoshimoto, Tomohide Tamura

ABSTRACT
9022

Clinicogenomic real-world data analysis of patients (pts) with KRAS G12C-mutant advanced non-small cell lung cancer (aNSCLC) from the natural history cohort of the Blood First Assay Screening Trial (BFAST).

AUTHOR(S)

ABSTRACT
9023

A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A).

AUTHOR(S)

ABSTRACT
The ABCs of Lung Cancer Biomarkers in 2021: ALK, BRCA1/2, and KRAS G12C

DISCUSSANT

Mark M. Awad, MD, PhD | Massachusetts General Hospital

Melanoma/Skin Cancers

Back to Program

Showing 14 Presentations

https://meetinglibrary.asco.org/session/13662

Phase II study of ceralasertib (AZD6738), in combination with durvalumab in patients with metastatic melanoma who have failed prior anti-PD-1 therapy.

AUTHOR(S)

Minsuk Kwon, Seung Tae Kim, Simon Smith, Claire Smith, Peter G. Mortimer, Bienvenu LoembE, Iwanka Kozarewa, Emma Dean, Jeeyun Lee

ABSTRACT

9514

Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.

AUTHOR(S)

Omid Hamid, Ding Wang, Tae Min Kim, Sang-We Kim, Nehal J. Lakhani, Melissa L. Johnson, Roman Groisberg, Kyriakos P. Papadopoulos, John M. Kaczmar, Mark R. Middleton, Alexander I. Spira, Stephen K. Williamson, Guilherme Rabinowits, Rodolfo Gutierrez, Meredith McKean, Shuquan Chen, James Cassidy, Jayakumar Mani, Tasha N. Sims, Glenn Kroog

ABSTRACT

9515

Emerging Therapeutic Approaches for the Management of Metastatic Melanoma

DISCUSSANT

Siwen Hu-Lieskovyan, MD, PhD | University of California, Los Angeles
Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511.

AUTHOR(S)

ABSTRACT
9516

Avelumab in patients with previously treated Merkel cell carcinoma (JAVELIN Merkel 200): Updated overall survival data after more than five years of follow up.

AUTHOR(S)
Paul Nghiem, Shailender Bhatia, Andrew S. Brohl, Omid Hamid, Janice M. Mehert, Patrick Terheyden, Kent C. Shih, Isaac Brownell, Celeste Lebbe, Karl D. Lewis, Gerald P. Linette, Michele Milella, Huiling Xiong, Guelder Guezel, Sandra P. D'Angelo

ABSTRACT
9517

Refining Therapies to Maximize Long-Term Benefit in Advanced Skin Cancers

DISCUSSANT
Ragini Reiney Kudchadkar, MD | Winship Cancer Institute

Intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD).

AUTHOR(S)

ABSTRACT
9519

Phase II Study of TRIplet combination Nivolumab (N) with Dabrafenib (D) and Trametinib (T) (TRIDeNT) in patients (pts) with PD-1 naïve or refractory BRAF-mutated metastatic melanoma (MM) with or without active brain metastases.

AUTHOR(S)

ABSTRACT
An immunogenomic analysis of melanoma brain metastases (MBM) compared to extracranial metastases (ECM).

**AUTHOR(S)**
Lucy Kennedy, Amanda E. Van Swearingen, Jeff Sheng, Dadong Zhang, Xiaodi Qin, Eric S. Lipp, Swaminathan Kumar, Gao Zhang, Brent A. Hanks, Michael A. Davies, Kouros Owzar, Carey K. Anders, April K. Salama

**ABSTRACT**

The Evolving Management of Melanoma CNS Metastases

**DISCUSSANT**
Priscilla Kaliopi Brastianos, MD | Massachusetts General Hospital and Harvard Medical School

Characterizing the tumor and immune landscape of melanoma patients treated with combined checkpoint blockade and MAPK targeted therapy.

**AUTHOR(S)**
Liron Zisman, Donald P. Lawrence, David F. McDermott, Mofei Liu, Elizabeth I. Buchbinder, Irena Gushterova, Anna L. Goyne, Justine V. Cohen, David M. Miller, Thomas LaSalle, Emily Blaum, Dennie T. Frederick, Tatyana Sharova, Genevieve M. Boland, Anita Giobbie-Hurder, Moshe Sade-Feldman, Keren Yizhak, Nir Hacohen, Ryan J. Sullivan

**ABSTRACT**

Effects of baseline lactate dehydrogenase (LDH), interferon gamma (IFN-g) expression, and tumor mutational burden (TMB) on treatment response to first-line atezolizumab (A) + vemurafenib (V) and cobimetinib (C) in \textit{BRAF}\textsuperscript{V600} mutation-positive advanced melanoma.

**AUTHOR(S)**
Caroline Robert, Karl D. Lewis, Paolo A. Ascierto, Rodrigo R. Munhoz, Gabriella Liszkay, Luis de la Cruz-Merino, Judit Olah, Paola Queirolo, Jacek Mackiewicz, Ivor Caro, Kalpith Shah, Harper Forbes, Haocheng Li, Christian Hertig, Yibing Yan, Edward F. Mckenna Jr., Ralf Gutzmer, Grant A. McArthur

**ABSTRACT**

TMB and \textit{BRAF} mutation status are independent predictive factors in stage IIIC/D/IV melanoma patients receiving adjuvant PD-1 antibodies.

**AUTHOR(S)**
Andrea Forschner, Julia Eckardt, Peter Martus, Sorin Armeanu-Ebinger, Stephan Ossowski, Irina Bonzheim, Thomas Eigentler, Teresa M. Amaral, Lukas Flatz, Claus Garbe, Christopher Schroeder
ABSTRACT

Integration of Biomarkers Associated With BRAF-Targeted Therapy and Immunotherapy

DISCUSSANT

Dirk Schadendorf, MD | Department of Dermatology, University of Essen; German Cancer Consortium (DKTK), Partner Site Essen

Pediatric Oncology

Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.

AUTHOR(S)

Katherine Tarlock, Xiaowei Liu, Charles G. Minard, Sarah Menig, Joel M. Reid, Emasenyie Isikwei, Sharon Bergeron, Terzah M. Horton, Elizabeth Fox, Brenda Weigel, Todd M. Cooper

ABSTRACT

Phase 1 study of pevonedistat (MLN4924) a NEDD8 activating enzyme inhibitor, in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).

AUTHOR(S)

Jennifer Foster, Joel M. Reid, Charles G. Minard, Emasenyie Isikwei, Xiaowei Liu, Stacey L. Berg, Sarah G. Injac, Elizabeth Fox, Brenda Weigel

ABSTRACT

Low-dose metronomic topotecan and pazopanib in children with recurrent or refractory solid tumors: A C17 Canadian phase I trial (TOPAZ).
Leveraging Novel Combinations in Early-Phase Trials

**DISCUSSANT**
Tanya Maria Trippett, MD | Memorial Sloan Kettering Cancer Center

**Abstract**
10020

**Title:**
Naxitamab and GM-CSF for consolidation of high-risk neuroblastoma (HR-NB) patients in complete remission.

**Authors:**
Jaume Mora, Alicia Castañeda, Sara Perez-Jaume, Maite Gorostegui, Vicente Santa-María, Juan Pablo Muñoz, Amalia Varo, Salvador Mañe

**Abstract**
10021

**Title:**
Efficacy of naxitamab in patients with refractory/relapse (R/R) high-risk neuroblastoma (HR-NB) by bone/bone marrow (BM) evaluation, potential sites of residual disease.

**Authors:**
Brian H. Kushner, Daniel A. Morgenstern, Karsten Nysom, Melissa K. Bear, Karen Tornøe, Nedjad Losic, Jaume Mora

**Abstract**
10022

**Title:**
Updated outcomes for patients with completely resected pulmonary recurrent osteosarcoma: A report from the Children’s Oncology Group.

**Authors:**
Alexander J. Chou, Mark D. Krailo, Ruxu Han, Allen Buxton, Damon R. Reed, Richard G. Gorlick, Steven G. DuBois, Michael Isakoff, Katherine A. Janeway, Pooja Hingorani

**Abstract**
10023

**Title:**
Inflammatory myofibroblastic tumor: A multi-institutional study from the pediatric surgical oncology research collaborative.

**Authors:**

---

118
Approaches to Achieving and Consolidating Remission in Neuroblastoma and Sarcoma

DISCUSSANT
Ami Vijay Desai, MD, MSCE | University of Chicago Medical Center

Household material hardship and parental distress in a multicenter clinical trial for pediatric acute lymphoblastic leukemia.

AUTHOR(S)
Puja J. Umaretiya, Victoria B. Koch, Kristen E. Stevenson, Peter D. Cole, Lisa M. Gennarini, Justine Kahn, Kara M. Kelly, Thai-Hoa Tran, Bruno Michon, Jennifer J. Welch, Joanne Wolfe, Lewis B. Silverman, Kira O. Bona

Financial hardship in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).

AUTHOR(S)

Financial Hardship for Patients, Families, and Survivors of Pediatric Cancer

DISCUSSANT
Yousuf Zafar, MD, MHS, FASCO | Duke Cancer Institute

Low-dose radiation to cardiac substructures and late-onset cardiac disease: A report from the Childhood Cancer Survivor Study (CCSS).

AUTHOR(S)
Efficacy of clinical breast examination in chest-irradiated female survivors of childhood Hodgkin lymphoma (HL).

AUTHOR(S)

ABSTRACT
10028

Neurocognitive outcomes in survivors of early adolescent and young adult (eAYA) hematologic cancers from the Childhood Cancer Survivor Study (CCSS).

AUTHOR(S)

ABSTRACT
10029

Minimizing Late Effects of Radiation in Children

DISCUSSANT
Christine E. Hill-Kayser, MD | Hospital of the University of Pennsylvania

Sarcoma
Back to Program

Showing 16 Presentations

https://meetinglibrary.asco.org/session/13680

A phase II trial of sitravatinib, a multireceptor tyrosine kinase inhibitor, in patients with advanced well-differentiated/dedifferentiated liposarcoma.

AUTHOR(S)
Phase 1 trial of seclidemstat (SP-2577) in patients with relapsed/refractory Ewing sarcoma.

AUTHOR(S)
Damon R. Reed, Sant P. Chawla, Bhuvana Setty, Leo Mascarenhas, Paul A. Meyers, Jonathan Metts, Douglas J. Harrison, David Loeb, Brian D. Crompton, David S. Wages, David D. Stenehjem, Daniela Y. Santiesteban, Nadeem Q. Mirza, Steven G. DuBois

Outcomes in the dedifferentiated liposarcoma cohort of SAR-096, a phase II trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS).

AUTHOR(S)
Margaret von Mehren, Sujana Movva, Elizabeth A. Handorf, Priscilla Merriam, Jeffrey A. Morgan, Edwin Choy, Eric D. Tetzlaff, Emma Barker, Allisa C. Harley, April King, Sahar Matloob, Erika Jerome, Lori Rink, Suzanne George

Are We Hitting the Target? New Approaches in Sarcoma Care

DISCUSSANT
Benjamin Nacev, MD, PhD | Memorial Sloan Kettering Cancer Center

Eribulin and gemcitabine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A multicenter, single-arm, phase 2-trial.

AUTHOR(S)
Chang Gon Kim, Jin-Hee Ahn, Jeong Eun Kim, Jee Hung Kim, Min Kyung Jeon, Sun Y. Rha, Hyo Song Kim

Phase (Ph) 1b/2 evaluation of olaratumab in combination with gemcitabine and docetaxel in advanced soft tissue sarcoma (STS).

AUTHOR(S)
Steven Attia, Victor M. Villalobos, Nadia Hindi, Brian A. Van Tine, Andrew J. Wagner, Bartosz Chmielowski, Donna E. Levy, Matteo Ceccarelli, Robin L. Jones, Mark A. Dickson
Updated results of European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 1202 cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma.

AUTHOR(S)

ABSTRACT
11518

Rethinking Cytotoxic Chemotherapy in Soft-Tissue Sarcomas

DISCUSSANT
Vicki Leigh Keedy, MD, MSc | Vanderbilt University Medical Center

Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).

AUTHOR(S)

ABSTRACT
11519

High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: The French AcSé pembrolizumab study from Unicancer.

AUTHOR(S)

ABSTRACT
11520

Safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794) in advanced myxoid/round cell liposarcoma (MRCLS) following high lymphodepletion (Cohort 2): Interim analysis.

AUTHOR(S)
Sandra P. D'Angelo, Mihaela Druta, Brian A. Van Tine, David A. Liebner, Scott Schuetze, Aisha N. Hasan, Andrew P. Holmes, Anne Huff, Gurseet S. Kapoor, Stefan Zajic, Neeta Somaiah

ABSTRACT
**Immunotherapy for Rare Sarcomas**

**DISCUSSANT**

Anna Maria Frezza, MD | Adult Mesenchymal and Rare Tumor Unit, Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori

*A phase II, open-label, randomized trial of durvalumab (D) with olaparib (O) or cediranib (C) in patients (pts) with leiomyosarcoma (LMS).*

**AUTHOR(S)**


**ABSTRACT**

**Demographics, outcomes, and risk factors for patients (Pts) with sarcoma and COVID-19: A multi-institutional cohort analysis.**

**AUTHOR(S)**


**ABSTRACT**

**Randomized, double-blind, placebo (PL)-controlled, phase III trial of pimitespib (TAS-116), an oral inhibitor of heat shock protein 90 (HSP90), in patients (pts) with advanced gastrointestinal stromal tumor (GIST) refractory to imatinib (IM), sunitinib (SU) and regorafenib (REG).**

**AUTHOR(S)**

Yoshitaka Honma, Yukinori Kurokawa, Akira Sawaki, Yoichi Naito, Shiro Iwagami, Hideo Baba, Yoshito Komatsu, Toshihiko Doi

**ABSTRACT**

**2020: Immunotherapy, Targeted Therapy, and COVID-19**

**DISCUSSANT**

Suzanne George, MD | Dana-Farber Cancer Institute/Harvard Medical School
Oral selpercatinib in pediatric patients (pts) with advanced RET-altered solid or primary CNS tumors: Preliminary results from the phase 1/2 LIBRETTO-121 trial.

AUTHOR(S)
Daniel A. Morgenstern, Leo Mascarenhas, Martin Campbell, David S. Ziegler, Karsten Nysom, Michela Casanova, Alberto S. Pappo, Catherine M. Albert, Meng Xia, Scott S. Barker, Jennifer Wright, Theodore W. Laetsch

ABSTRACT
10009

Phase 2 trial of cabozantinib in children and young adults with refractory sarcomas, Wilms tumor, and rare tumors: Children's Oncology Group Study (ADVL1622).

AUTHOR(S)
Srivandana Akshintala, Brigitte C. Widemann, Donald A. Barkauskas, David Hall, Joel M. Reid, Stephan D. Voss, AeRang Kim, Elizabeth Fox, Brenda Weigel

ABSTRACT
10010

Pilot study of nivolumab in pediatric patients with hypermutant cancers.

AUTHOR(S)
Daniel A. Morgenstern, Natalie B. Collins, Rebecca Deyell, Rina Dvir, Melissa Edwards, Cecile Faure-Conter, Timothy E. Hassall, Lauren Sambira, Emily L. Taylor, Uri Tabori, Eric Bouffet

ABSTRACT
10011

Changes in ctDNA levels after MIBG therapy in patients with relapsed or refractory neuroblastoma.

AUTHOR(S)

ABSTRACT
Next-Generation Sequencing for Next-Generation Trials

DISCUSSANT

Neerav Shukla | Memorial Sloan Kettering Cancer Center

Mortality among five-year survivors of childhood cancer: Results over five decades of follow-up in the Childhood Cancer Survivor Study.

AUTHOR(S)

ABSTRACT

Genetic and treatment risks for diabetes mellitus (DM) in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS) and St. Jude Lifetime (SJLIFE) cohorts.

AUTHOR(S)
Melissa A. Richard, Sogol Mostoufi-Moab, Nisha Rathore, Austin L. Brown, Stephen J. Chanock, Danielle N. Friedman, Maria M. Gramatges, Rebecca M. Howell, Kala Kamdar, Wendy M. Leisenring, Lillian R. Meacham, Lindsay M. Morton, Kevin C. Oeffinger, Leslie L. Robison, Yadav Sapkota, Charles A. Sklar, Yutaka Yasui, Gregory T. Armstrong, Smita Bhatia, Philip Lupo

ABSTRACT

Exercise and QUality diet After Leukemia (The EQUAL Study): An intervention trial in the Childhood Cancer Survivor Study (CCSS).

AUTHOR(S)
Emily S. Tonorezos, Jeanne M. Clark, Chaya S. Moskowitz, Jennifer S. Ford, Gregory T. Armstrong, Joanne F. Chou, Nidha Z. Mubdi, Aaron McDonald, Charles A. Sklar, Lakshmi Ramanathan, Leslie L. Robison, Kevin C. Oeffinger

ABSTRACT

Risk Factors for Early Mortality in Cancer Survivors: What Is Modifiable?

DISCUSSANT
Karen Elizabeth Effinger, MD, MS | Department of Pediatrics, Emory University and Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta

Racial disparities in pediatric cancer care in the United States: An analysis of the Kids' Inpatient Database.
AUTHOR(S)
Sujith Baliga, Dukagjin Blakaj, Vedat Yildiz, Pranav Puri, Joshua D. Palmer

ABSTRACT


AUTHOR(S)

ABSTRACT

Childhood Cancer Disparities: From Diagnosis to Survivorship

DISCUSSANT
Julie Wolfson, MD, MSHS | University of Alabama at Birmingham
III. POSTER PRESENTATIONS

Breast Cancer—Local/Regional/Adjuvant

Showing 82 Presentations

https://meetinglibrary.asco.org/session/13606

**Predict the benefit of metronomic capecitabine maintenance in early-stage triple-negative breast cancer: Results from the SYSUCC-001 study.**

**AUTHOR(S)**
Zhongyu Yuan, Xin Hua, Wang-Zhong Li, Heng Huang, Li Cai, Ying Lin, Leihong Zhang, Qianjun Chen, Jia-Jia Huang, XiWen Bi, Wen Xia, Shu-Sen Wang, Fei Xu, Ruoxi Hong, Kuikui Jiang, Yanxia Shi, Cong Xue, Xin An, Jun Tang, Xi Wang

**ABSTRACT**

521

**Efficacy and safety analysis of Chinese patients in monarchE: Abemaciclib combined with adjuvant endocrine therapy for high risk HR+, HER2- early breast cancer.**

**AUTHOR(S)**
Shao Zhimin, Qingyuan Zhang, Chuan-gui Song, Quanchang Ouyang, Zhenzhen Liu, Qiang Liu, Jifeng Feng, Joanne W. Chiu, Ling-Ming Tseng, Chenxi Qian

**ABSTRACT**

522

**Association of statin use with clinical outcomes in patients with triple-negative breast cancer.**

**AUTHOR(S)**
Malgorzata Nowakowska, Xiudong Lei, Mikayla R. Thompson, Simona F. Shaitelman, Mackenzie Wehner, Wendy A. Woodward, Sharon H. Giordano, Kevin T. Nead

**ABSTRACT**
The prognostic performance of PREDICT+ in patients (pts) with HER2-positive (HER2+) early-stage breast cancer (EBC).

AUTHOR(S)
Elisa Agostinetto, Lieveke Ameye, Samuel Martel, Philippe G. Aftimos, Noam Ponde, Christian Maurer, Sarra El-Abed, Yingbo Wang, Maria Lourdes Vicente, Saranya Chumsri, Judith Bliss, Judith R. Kroep, Marco Colleoni, Fausto Petrelli, Lucia Del Mastro, Alvaro Moreno-Aspitia, Martine J. Piccart-Gebhart, Marianne Paesmans, Evandro de Azambuja, Matteo Lambertini

ABSTRACT
Retrospective cohort study of estrogen receptor low positive early breast cancer using real world data.

AUTHOR(S)
Shahla Bari, Hung T. Khong, Brian J. Czerniecki, Ricardo L. Costa

ABSTRACT
Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.

AUTHOR(S)

ABSTRACT
Bone safety profile of steroidal aromatase inhibitor in comparison to non-steroidal aromatase inhibitors in postmenopausal women with breast cancer: A network meta-analysis.

AUTHOR(S)
Shanshan Chen, Bo Lan, Dan Lv, Fei Ma

ABSTRACT
The impact of COVID-19 on breast cancer stage at diagnosis.

AUTHOR(S)
Maxwell Lloyd, Sarah Jo Stephens, Julian C. Hong, Ted A. James, Tejas Mehta, Abram Recht, Daphna Spiegel
Efficacy of epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes as adjuvant chemotherapy in triple-negative breast cancer: 8.1 years median follow-up on a randomized clinical trial.

Author(s)
Fangchao Zheng, Feng Du, Yongsheng Wang, Xue Wang, Jiayu Wang, Jian Yue, Fei Ma, Ying Fan, Binghe Xu, Peng Yuan


Author(s)
Julia E. McGuinness, Vicky Ro, Simukayi Mutasa, Richard Ha, Katherine D. Crew

Breast Cancer Index and prediction of benefit from extended endocrine therapy based on treatment compliance: An IDEAL study.

Author(s)
Gerrit-Jan Liefers, Iris Noordhoek, Kai Treuner, Hein Putter, Jenna Wong, Yi Zhang, Elma Meershoek – Klein Kranenbarg, Cornelis J. Van De Velde, Catherine A. Schnabel

A validated model to predict low recurrence risk distinguished by 21-gene recurrence score in hormone receptor-positive invasive breast cancer patients.

Author(s)
Yasue Tsuchida, Sachiko Ohde, Ryota Nakamura, Yoko Kanada, Sakiko Miura, Masafumi Takimoto, Seigo Nakamura, Naoki Kanomata, Hideko Yamauchi, Naoki Hayashi

Clinical trial testing superiority of combination plinabulin (Plin) and pegfilgrastim (Peg) versus peg alone in breast cancer treated with high-risk febrile neutropenia
risk chemotherapy (chemo): Final results of the phase 3 protective-2 in chemo-induced neutropenia (CIN) prevention.

AUTHOR(S)
Douglas W. Blayney, Yuankai Shi, Hryhorii Adamchuk, David Feng, Qingyuan Zhang, Lihua Du, Lan Huang, Ramon Mohanlal

ABSTRACT
533
Cost-effectiveness of the Oncotype DX Breast Recurrence Score test in postmenopausal women with node-positive early breast cancer based on the RxPONDER trial.

AUTHOR(S)
Vladislav Berdunov, Steve Millen, Andrew Paramore, Sarah Reynia, Nina Fryer, Jane Griffin, Nadia Georges

ABSTRACT
534
Outcome and immune landscape of HER2-positive invasive lobular carcinoma in the North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) trial.

AUTHOR(S)
Saranya Chumsri, Zhuo Li, Tracy Shachner, Pooja Advani, Kostandinos Sideras, Alvaro Moreno-Aspitia, Gerardo Colon-Otero, Keith L. Knutson, Aziza Nassar, Edith A. Perez

ABSTRACT
535
Dose escalation for mitigating diarrhea: Ranked tolerability assessment of anti-diarrheal regimens in patients receiving neratinib for early-stage breast cancer.

AUTHOR(S)

ABSTRACT
536
Clinical validation of EndoPredict in premenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer.

AUTHOR(S)
De-escalation of five years adjuvant endocrine therapy duration in patients with ER-low positive (immunohistochemical 1% to 10%) early-stage breast cancer: A propensity-matched analysis from the prospectively maintained database.

AUTHOR(S)
Keda Yu, Yuwen Cai, Zhiming Shao

Comprehensive genomic profiling (CGP) of 275 male breast cancer (BC) tissue (TBx) and liquid (LBx) biopsies: Comparative analysis to a female cohort (FBC) and therapeutic considerations.

AUTHOR(S)
Arun Kadamkulam Syriac, Allison Clark, Mehrad Tavallai, Dexter X. Jin, Ethan Sokol, Kimberly McGregor, Jeffrey S. Ross, Natalie Danziger, Jose P. Leone

Association between treatment duration and overall survival in early-stage HER2+ breast cancer patients receiving extended adjuvant therapy with neratinib in the ExteNET trial.

AUTHOR(S)
Beverly Moy, Masato Takahashi, Shoichiro Ohtani, Ewa Chmielowska, Naohito Yamamoto, Bruno P. Coudert, Feng Xu, Alvin F. Wong, Arlene Chan

PD-L1 expression and TOP3A mutation as prognostic factors for adjuvant chemotherapy in triple negative breast cancer.

AUTHOR(S)
Xue Wang, Peng Yuan, Feng Du, Lina Cui, Fangchao Zheng, Jian Yue, Bei Zhang, Jiayu Wang, Ying Fan, Fei Ma, Binghe Xu
Final five-year median follow-up safety data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating the use of HER2/neu peptide GP2 + GM-CSF vs. GM-CSF alone after adjuvant trastuzumab in HER2 positive women with operable breast cancer.

AUTHOR(S)
Snehal Patel, David McWilliams, Christine T. Fischette, Jaye Thompson, Mira Patel, F. J. Daugherty

ABSTRACT
542

Survival following locoregional recurrence in breast cancer by clinical subtype.

AUTHOR(S)
Kirsten Allen, Caroline A. Lohrisch, Dan Le, Rekha M. Diopee, Caroline Speers, Alan Nichol, Sara K. Taylor

ABSTRACT
543

Potential non-drug cost differences associated with the use of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in the treatment of HER2-positive early breast cancer patients in Western Europe and the United States.

AUTHOR(S)
Federico Manevy, Gabriele Filkauskas, Pierre Levy, Judy Fredriksson, Jesse Sussell

ABSTRACT
544

Impact of endocrine therapy on overall survival in ER negative/PR positive locoregional breast cancer: An analysis of the National Cancer Database.

AUTHOR(S)
Vidya Kollu, Kohei Osterloth, Andrew J. Borgert, Susan M. Frankki, Benjamin M. Parsons

ABSTRACT
545

Chemotherapy induced profound neutropenia (PN) in patients (pt) with breast cancer (BC) after chemotherapy and plinabulin (Plin) plus pegfilgrastim (Peg) combination versus (vs) peg alone: Final phase 3 results from protective-2 (BPI-2358-106).

AUTHOR(S)
Yuankai Shi, Douglas W. Blayney, Hryhorii Adamchuk, Qingyuan Zhang, Lihua Du, Lan Huang, Ramon Mohanlal

**ABSTRACT**

546

**Head-to-head comparison of single agent (SA) plinabulin (Plin) versus pegfilgrastim (Peg) for the prevention of chemotherapy-induced neutropenia (CIN) in the phase 3 trial PROTECTIVE-1.**

**AUTHOR(S)**

Douglas W. Blayney, Yuankai Shi, Igor Bondarenko, Stephan Ogenstad, Qingyuan Zhang, Lihua Du, Lan Huang, Ramon Mohanlal

**ABSTRACT**

547

**Long-term outcomes of patients with node-negative (N0), triple-negative breast cancer (TNBC) who did not receive adjuvant chemotherapy according to stromal TILs (sTILs).**

**AUTHOR(S)**


**ABSTRACT**

548

**Validation of the RSClin risk calculator using the National Cancer Database (NCDB).**

**AUTHOR(S)**

Frederick Howard, Alexander T. Pearson, Rita Nanda, Olufunmilayo I. Olopade, Dezheng Huo

**ABSTRACT**

549

**Molecular characterization of luminal breast tumors in African American women.**

**AUTHOR(S)**

Yael Simons, Mohamed Hassan, George Chlipala, Oana C. Danciu, Vijayakrishna K. Gadi, Manmeet Singh, Gayatry Mohapatra, Kent Hoskins

**ABSTRACT**

550

**Population-based estimates of the age-specific cumulative risk of breast cancer for pathogenic variants in CHEK2: Findings from the Australian Breast Cancer Family Registry.**
AUTHOR(S)

ABSTRACT
551

Use of a high-sensitivity anti-Mullerian hormone (AMH) assay to determine ovarian function after chemotherapy for early breast cancer.

AUTHOR(S)
Florian Clatot, Kelsey Thomas, Matteo Lambertini, Nathalie Olympios, Orianne Duhamel, Anne Perdrix, Richard Anderson

ABSTRACT
552

A gp78/AMFR protein-driven gene signature that predicts breast cancer outcome.

AUTHOR(S)

ABSTRACT
553

Neoadjuvant talazoparib (TALA) in patients (pts) with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor BRCA mutational status and zygosity and overall mutational landscape in a phase 2 study.

AUTHOR(S)

ABSTRACT
554

ER and immune-related signatures define benefit to palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ breast cancer patients in the NA-PHER2 trial.

AUTHOR(S)
Giampaolo Bianchini, Matteo Dugo, Balazs Gyorffy, Giancarlo Bisagni, Marco Colleoni, Mauro Mansutti, Claudio Zamagni, Lucia Del Mastro, Stefania Zambelli, Antonio Frassoldati, Luca Licata, Barbara Galbardi, Maria O. Biasi, Lucia Viganò, Alberta Locatelli, Chanel Smart, Giuseppe Viale, Pinuccia Valagussa, Maurizio Callari, Luca Gianni

ABSTRACT
Dysregulation of soluble immune checkpoint proteins in newly-diagnosed early breast cancer patients.

**AUTHOR(S)**
Bernardo L. Rapoport, Helen C. Steel, Teresa Smit, Liezl Heyman, Annette J. Theron, Luyanda L. Kwofie, Carol Benn, Ronald Anderson

**ABSTRACT**
Genomic characteristics of breast cancer to predict response of neoadjuvant chemotherapy and long-term prognosis.

**AUTHOR(S)**
Ji-Yeon Kim, Kyunghee Park, Woong-Yang Park, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Se-Kyung Lee, Zhengyan Kan, Yeon Hee Park

**ABSTRACT**
MamaPred: A new and innovative approach to determine recurrence risk in HR+/HER2- early-stage breast cancer using HTG EdgeSeq technology.

**AUTHOR(S)**
Jose Antonio Lopez Guerrero, Carlos Loucera, Marta Ramírez-Calvo, María Peña, Antonio Fernandez-Serra, Angel Guerrero-Zotano, José Palacios, Octavio Burgues, Sonia Servitja, Ignacio Tusquets, Gloria Peiro, Begoña Bermejo, Joan Albanell, Antonio Llombart-Cussac, Joaquin Dopazo

**ABSTRACT**
Gene expression associated with lymphovascular invasion and genomic risk in early-stage breast cancer.

**AUTHOR(S)**
Nina D'Abreo, Abhinav Rohatgi, Douglas K. Marks, Heather Kling, Josien Haan, William Audeh

**ABSTRACT**
Race, subjective social status and metabolic syndrome in women with breast cancer.

**AUTHOR(S)**
Giampaolo Greco, Emily J. Gallagher, Derek Leroith, Sylvia Lin, Radhi Yagnik, Sheldon M. Feldman, Brigid K. Killelea, Neil B. Friedman, Melissa L. Pilewskie, Lydia Choi, Nina A. Bickell
Association of allograft rejection response score with biological cancer aggressiveness and with better survival in triple-negative breast cancer (TNBC).

AUTHOR(S)
Masanori Oshi, Lan Le, Fernando A. Angarita, Yoshihisa Tokumaru, Li Yan, Ryusei Matsuyama, Itaru Endo, Kazuaki Takabe

Association of changes of pro-inflammatory markers with physical function in women with breast cancer receiving chemotherapy.

AUTHOR(S)

Molecular profiles of genomically high risk ER+ HER2- breast cancer tumors classified as functionally basal or luminal B by the 80-gene signature.

AUTHOR(S)

Characterization of the tumor immune microenvironment of triple negative breast cancer (TNBC) patients who self-identify as African American (AA) or non-African American (NonAA).

AUTHOR(S)
Kim Blenman, Michal Marczyk, Tao Qing, Tess O'Meara, Vesal Yaghoobi, Vasiliki Pelekanou, Yalai Bai, Emily Reisenbichler, Xiaotong Li, Vignesh Gunasekharan, Eiman Y. Ibrahim, David L. Rimm, Lajos Pusztai, Kimberly Cole

Whole transcriptome analysis comparing HR+ HER2- breast cancer tumors from patients < 50 years and >50 years.
AUTHOR(S)

ABSTRACT
565

Long-term results of simplified lymphatic microsurgical preventing healing approach (SLYMPHA) for the prevention of breast cancer-related clinical lymphedema after axillary lymph node dissection.

AUTHOR(S)
Tolga Ozmen, Christina Layton, Orli Friedman-Eldar, Siarhei Melnikau, Susan Kesmodel, Eli Avisar

ABSTRACT
514

Adding carbon nanoparticles to dual-tracers for the sentinel node evaluation after neoadjuvant chemotherapy in patients with pretreatment node-positive breast cancers: The TT-SLNB trial.

AUTHOR(S)
Jie Chen, jiqiao Yang, Tao He, Yunhao Wu, Xian Jiang, Zhoukai Fu, Qing Lv, Shan Lu, Xiaodong Wang, Hongjiang Li, Jing Wang

ABSTRACT
566

Clinicopathologic features of breast cancers diagnosed in females treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort.

AUTHOR(S)
Stephanie M. Wong, Lissa Ajjamada, Anna Weiss, Ipshita Prakash, Sonia Skamene, Jean-Francois Boileau, Michael N. Pollak, Mark Basik

ABSTRACT
567

Impact of patient, tumour and treatment factors on psychosocial outcomes in invasive breast cancer.

AUTHOR(S)
David W. Lim, Helene Retrouvey, Isabel Kerrebijn, Kate Butler, Anne C. O'Neill, Tulin D. Cil, Toni Zhong, Stefan O. Hofer, David R. McCready, Kelly A. Metcalfe

ABSTRACT
Survival in male breast cancer (MaBC) over the past three decades.

AUTHOR(S)
Jose P. Leone, Rachel A. Freedman, Julieta Leone, Michael J. Hassett, Sara M. Tolaney, Carlos T. Vallejo, Bernardo A. Leone, Eric P. Winer, Nancy U. Lin

ABSTRACT

Role of 21-gene recurrence score in patients age ≥70 with T1N0 ER/PR+ HER2-breast cancer treated with breast-conserving surgery and endocrine therapy.

AUTHOR(S)
Neil C. Chevli, Waqar Haque, Kevin T. Tran, Andrew M. Farach, Mary R. Schwartz, Charles E. Geyer Jr., Sandra S. Hatch, E. Brian Butler, Bin S. Teh

ABSTRACT

Trends in breast cancer mortality according to molecular subtypes: A population-based study.

AUTHOR(S)
Yunan Han, Shuai Xu, Graham A. Colditz, Adetunji T. Toriola

ABSTRACT

Pyrotinib as neoadjuvant therapy for HER2+ breast cancer: A multicenter, randomized, controlled, phase II trial.

AUTHOR(S)
Xiaowen Ding, Wenju Mo, Xiaohong Xie, Ouchen Wang, Yuqin Ding, Shuai Zhao, Xiangming He, Weiliang Feng, Dehong Zou, Hongjian Yang

ABSTRACT

Racial differences and trends in pathologic complete response following neoadjuvant chemotherapy for breast cancer.

AUTHOR(S)
Sung Jun Ma, Brian Yu, Lucas M. Serra, Austin Bartl, Mark Farrugia, Austin Iovoli, Oluwadamilola T. Oladeru, Joseph Miccio, Saif Aljabab, Simon Fung-Kee-Fung, Daphne A. Haas-Kogan, Anurag K. Singh

ABSTRACT

AUTHOR(S)
Sung Jun Ma, Brian Yu, Lucas M. Serra, Austin Bartl, Mark Farrugia, Austin Iovoli, Oluwadamilola T. Oladeru, Joseph Miccio, Saif Aljabab, Simon Fung-Kee-Fung, Daphne A. Haas-Kogan, Anurag K. Singh

ABSTRACT
Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2–) operable breast cancer (BC).

AUTHORS
Heather M. Moore, Valentina Boni, Meritxell Bellet, Begoña Bermejo De Las Heras, Maria Gión Cortés, Catherine Oakman, Peter Schmid, Xuan Bich Trinh, Duncan Wheatley, Komal L. Jhaveri, Peter Kabos, Elgene Lim, Thierry Velu, Ciara Metcalfe, Mary R. Gates, Ching-Wei Chang, John Bond, Leonard D. Goldstein, Jennifer O. Lauchle, Aditya Bardia

ABSTRACT
A phase 2 trial of talimogene laherparepvec (TVEC) in combination with neoadjuvant chemotherapy for the treatment of nonmetastatic triple-negative breast cancer.

AUTHORS

ABSTRACT
Pathological complete response rate and survival in patients with BRCA-associated triple-negative breast cancer after 12 weeks of de-escalated neoadjuvant chemotherapy: Translational results of the WSG-ADAPT TN randomized phase II trial (NCT01815242).

AUTHORS
Abstract

Evaluation of sensitivity to endocrine therapy index (SET2,3) for response to neoadjuvant endocrine therapy (NET) and subsequent prognosis.

Author(s)
William F. Symmans, Lili Du, Tanya L. Hoskin, Meenakshi Anurag, Cynthia X. Ma, Isabelle Bedrosian, Kelly Hunt, Matthew J. Ellis, Vera J. Suman

Abstract


Author(s)
Ornella Garrone, Andrea Abbona, Antonella Falletta, Matteo Paccagnella, Nicoletta Croce, Paola Vanella, Fiorella Ruatta, Daniela Rubini, Anna Maria Vandone, Antonio Votero Prina, Nerina Denaro, Marco C. Merlano

Abstract

Independent validation of simbiosys tumorscope to predict response to neoadjuvant chemotherapy (NACT) in early breast cancer (EBC).

Author(s)
Gong He, Frederick Howard, Tushar Pandey, Hiroyuki Abe, Rita Nanda

Abstract

Phase II prospective open label study of neoadjuvant pertuzumab, trastuzumab, and nab-paclitaxel in patients with HER-2 positive advanced breast cancer.

Author(s)
Sayeh M. Lavasani, Susan E. Yost, Paul H. Frankel, Christopher Ruel, Mireya Murga, Aileen Tang, Norma Martinez, Laura Kruper, Lusine Tumyan, Dan Schmolze, Francesca Menghi, Edison T. Liu, Christina H. Yeon, Yuan Yuan, James R. Waisman, George Somlo, Joanne E. Mortimer
Computational features of tumor-infiltrating lymphocyte architecture of residual disease after chemotherapy on H&E images as prognostic of overall and disease-free survival for triple-negative breast cancer.

**AUTHOR(S)**

**ABSTRACT**

Impact of dendritic cell vaccines added to neoadjuvant CT on pathological complete responses in early breast cancer patients according to PD-L1 expression.

**AUTHOR(S)**
Ignacio Ortego, Angel M. Vizcay, Susana De La Cruz, Belén Pérez-Solans, Sandra Rubio, Javier Blanco, Miguel A. Idoate, Laura Hato, Susana Inoges Sancho, Ascension Lopez Diaz de Cerio, Salvador Martin-Algarra, Marta Santisteban

**ABSTRACT**

Impact of different sequencing strategies of talazoparib and carboplatin combination upon efficacy and toxicity in BRCA-wild type and BRCA-mutant triple-negative breast cancer models.

**AUTHOR(S)**
Michele Beniey, Alexia Cotte, Audrey Hubert, Nelly Bechir, Takrima Haque, Danh Tran-Thanh, Saima N. Hassan

**ABSTRACT**

Treatment Efficacy Score (TES), a continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between trial arms in the I-SPY 2 trial.

**AUTHOR(S)**
Michal Marczyk, Anna Mrukwa, Christina Yau, Denise M. Wolf, Laura van ’t Veer, Laura Esserman, William F. Symmans, Lajos Pusztai

**ABSTRACT**

Does timing of chemotherapy impact breast satisfaction after breast conservation therapy and mastectomy with immediate reconstruction?
**AUTHORS**

Kate R. Pawloski, Tracy-Ann Moo, Varadan Sevilimedu, Jonas A. Nelson, Paula Garcia, Laurie J. Kirstein, Monica Morrow, Audree B. Tadros

**ABSTRACT**

589

The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC).

**AUTHORS**


**ABSTRACT**

590

Multi-gene prognostic assays and age-related differences in prediction of pathologic complete response to neoadjuvant chemotherapy and survival in breast cancer.

**AUTHORS**

Kent Hanson, Kent Hoskins, Naomi Y. Ko, Gregory S. Calip

**ABSTRACT**

591

Neoadjuvant atezolizumab (atezo) and nab-paclitaxel (nab-p) in patients (pts) with triple-negative breast cancer (TNBC) with suboptimal clinical response to doxorubicin and cyclophosphamide (AC).

**AUTHORS**


**ABSTRACT**

592

Automated, IHC/FISH-free, H&E histopathology image-based HER2 amplification, tumor infiltrating lymphocyte (TIL) and tumor heterogeneity profiling in breast cancer.

**AUTHORS**

Satabhisa Mukhopadhyay, Tathagata Dasgupta, Nicolas M. Orsi, Michele Cummings, Angelene Berwick
ABSTRACT

593

Investigating survivin as a novel target in black women with breast cancer.

AUTHOR(S)
Andrea Walens, Linnea T. Olsson, Sarah Van Alsten, Lisa A. Carey, Melissa A. Troester, Yara Abdou

ABSTRACT

594

A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.

AUTHOR(S)

ABSTRACT

TPS595
eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer.

AUTHOR(S)
Sara M. Tolaney, Lesley Fallowfield, Peter A. Kaufman, Eva M. Ciruelos, Mary C. Gainford, Yi Lu, Karla Hurt, Heather A. Wasserstrom, Yanyun Chen, Shom Goel

ABSTRACT

TPS596
ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer.

AUTHOR(S)

ABSTRACT

TPS597
ADAPTlate: A randomized, controlled, open-label, phase III trial on adjuvant dynamic marker—Adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant
endocrine therapy in (clinical or genomic) high-risk, HR+/HER2- early breast cancer.

AUTHOR(S)

ABSTRACT
TPS598

Optima: Optimal personalised treatment of early breast cancer using multi-parameter analysis, an international randomized trial of tumor gene expression test-directed chemotherapy treatment in a largely node-positive population.

AUTHOR(S)

ABSTRACT
TPS599

Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy (ATNEC).

AUTHOR(S)

ABSTRACT
TPS600

A single-arm confirmatory study to evaluate the efficacy of nonsurgical therapy for HER2-positive early breast cancer with clinical complete response after primary systemic therapy: (JCOG1806: AMATERAS-BC study).

AUTHOR(S)
Tomomi Fujisawa, Tadahiko Shien, Hiroji Iwata, Hideo Shigematsu, Taro Shibata, Keita Sasaki, Yuko Takahashi

ABSTRACT
TPS601
Phase III postneoadjuvant study evaluating sacituzumab govitcan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.

AUTHOR(S)
Frederik Marmé, Elmar Stickeler, Jenny Furlanetto, Carsten Denkert, Marcus Schmidt, Mattea Reinisch, Toralf Reimer, Wolfgang Janni, Michael Untch, Bruno V. Sinn, Volker Moebus, Laura Michel, Laura Schoellhorn, Sabine Schmatloch, Julia Rey, Sibyle Loibl

ABSTRACT
TPS602

TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer.

AUTHOR(S)
Sara A. Hurvitz, Parvin F. Peddi, Merry L. Tetef, Nicholas P. McAndrew, Aashini K. Master, Maggie L. DiNome, Minna K. Lee, Lisa S. Wang, Laura Spring, Christine Kivork, James Chauv, Aditya Bardia

ABSTRACT
TPS603

A prospective, randomized, multicenter, double-blinded, placebo-controlled phase III trial of the HER2/neu peptide GP2 + GM-CSF versus bacteriostatic saline/WFI placebo as adjuvant therapy after any trastuzumab-based therapy in HER2-positive women with operable breast cancer.

AUTHOR(S)
Snehal Patel, David McWilliams, Christine T. Fischette, Jaye Thompson, F. J. Daugherty, C. K. Osborne, Mothaffar F. Rimawi

ABSTRACT
TPS604

Breast Cancer—Metastatic
Back to Program

Showing 87 Presentations

https://meetinglibrary.asco.org/session/13609
Serial circulating tumor DNA samples from patients with metastatic breast cancer and BRCA1/2 mutations.

AUTHOR(S)

Katharine Collier, David Tallman, Zachary Weber, Marcy Haynam, Elizabeth J. Adams, Janet Jenison, Sarah Asad, Maryam B. Lustberg, Mathew A. Cherian, Bhuvaneswari Ramaswamy, Sagar D. Sardesai, Nicole O. Williams, Robert Wesolowski, Jeffrey B. VanDeusen, Margaret E. Gatti-Mays, Ashley Pariser, Amir Mortazavi, Daniel G. Stover

ABSTRACT


AUTHOR(S)

Kun Wang, XiWen Bi, Guangyu Liu, Takayuki Ueno, Shintaro Takao, Sung Hoon Sim, Young-Hyuck Im, Seock-Ah Im, Sung Gwe Ahn, Jeong Eon Lee, Yeon Hee Park, Manabu Futamura, Masakazu Toi, Yasuhiro Fujiwara, Mari Saito-Oba, Yuko Kitagawa, Masahiko Nishiyama, Shigeru Imoto

ABSTRACT

Refining neutropenia risk assessment in patients treated with first-line endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (MBC) through a cell-free DNA workflow (cfDNA).

AUTHOR(S)

lorenza Palmero, Roberta Mazzeo, Silvia Buriolla, Lorenzo Allegri, Lucia Bortot, Alessandra Franzoni, Anna Michelotti, Elisabetta Camilla Stefani, Giulia Turra, Miriam Zilli, Paola Di Nardo, Rossana Roncato, Marta Bonotto, Erika Cecchin, Barbara Belletti, Giuseppe Toffoli, Lorenzo Gerratana, Gustavo Baldassarre, Giuseppe Damante, Fabio Puglisi

ABSTRACT

Identification of pathogenic CDK12 alterations in cell-free DNA (cfDNA) from patients with breast cancer.

AUTHOR(S)


ABSTRACT

Characterization of long-term responders following treatment with talazoparib (TALA) or physician’s choice of chemotherapy (PCT) in the phase 3 embraca trial.

**ABSTRACT**

1029

**Deep proteomic analysis of plasma exosomes in patients with advanced, hormone receptor-positive breast cancer treated with palbociclib and tamoxifen.**

**AUTHOR(S)**

Xiuyuan Ma, Yu Gao, Gayatry Mohapatra, Louis Coleman, Yael Simons, Cristina I. Truica, Anne H. Blaes, Jatin Rana, Pavankumar Tandra, Lauren Green, Li C. Liu, Menggang Yu, Deborah Toppmeyer, Ruth O’Regan, Kari B. Wisinski, Oana C. Danciu, Kent Hoskins

**ABSTRACT**

1030

**A retrospective study of characteristics and survival in patients with breast cancer brain metastases classified by subtype using NCI SEER registry.**

**AUTHOR(S)**

Monika Devanaboyina, Morgan M. Bailey, Danae M. Hamouda

**ABSTRACT**

1031

**Overcoming the breast tumor microenvironment by targeting MDSCs through CAR-T cell therapy.**

**AUTHOR(S)**

Saisha A. Nalawade, Paul Shafer, Pradip Bajgain, Katie McKenna, Arushana Ali, Lauren Kelly, Jarrett Joubert, Norihiro Watanabe, Ann Leen, Robin Parihar, Juan Fernando Vera Valdes, Valentina Hoyos Velez

**ABSTRACT**

1032

**Uncovering the differential impact of ESR1 and PIK3CA codon variants on the clinical phenotype of metastatic breast cancer (MBC) through circulating tumor DNA (ctDNA) next-generation sequencing (NGS).**

**AUTHOR(S)**

Lorenzo Gerratana, Andrew A. Davis, Marko Velimirovic, Paolo D’Amico, Ami N. Shah, Katherine Clifton, Qiang Zhang, Charles S. Dai, Carolina Reduzzi, Whitney L. Hensing, Marta Bonotto, Roberta Mazzeo, Firas H. Wehbe, Alessandra Franzoni, Barbara Belletti, Amir Behdad, Cynthia X. Ma, Fabio Puglisi, Aditya Bardia, Massimo Cristofanilli

**ABSTRACT**

1033
Molecular characterization of the Ras-MAPK pathway in metastatic breast cancer.

AUTHOR(S)

ABSTRACT
1034
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor SHR6390 combined with pyrotinib and letrozole in patients with human epidermal growth factor receptor 2-positive (HER2+), hormone receptor positive (HR+) metastatic breast cancer (MBC): Phase Ib study results.

AUTHOR(S)
Jian Zhang, Yanchun Meng, Biyun Wang, Leiping Wang, Jun Cao, Zhonghua Tao, Ting Li, Wenqing Yao, Xichun Hu

ABSTRACT
1035
Concordance of HER2+ status by IHC/ISH and ERBB2 status by NGS in a real-world clinicogenomic database and analysis of outcomes in patients (pts) with metastatic breast cancer (mBC).

AUTHOR(S)
Cheryl D. Cho-Phan, Jeremy Snider, Liangliang Zhang, Kimberly McGregor, Alexa B. Schrock, Emily Castellanos

ABSTRACT
1036
Pyrotinib plus capecitabine for HER2-positive metastatic breast cancer patients with brain metastases (PERMEATE): A multicenter, single-arm phase II study.

AUTHOR(S)
Min Yan, Quchang Ouyang, Tao Sun, Limin Niu, Jin Yang, Li Li, Yuhua Song, Chunfang Hao, Zhanhong Chen

ABSTRACT
1037
Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpressing solid tumors: Results from two phase 1 clinical trials.

AUTHOR(S)
Safety of trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive locally advanced or metastatic breast cancer (mBC): Final results from KAMILLA Cohorts 1 (global) and 2 (Asia).

Comparison of therapy benefit from standard anti-HER2 directed approaches in metastatic breast cancer (MBC) between initially HER2-positive patients and patients initially HER2-negative with switch to HER2-positive.

Impact of extracranial disease status on survival after initial central nervous system (CNS) involvement and radiation therapy in HER2+ breast cancer brain metastases (BCBM).

Phase I study of LZM005, a HER2 antibody, as monotherapy or in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.
Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).

AUTHOR(S)

Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer.

AUTHOR(S)

68Ga-HER2 affibody PET/CT imaging as an option in patients whose HER2 status of any tumor in the body needs to be deciphered.

AUTHOR(S)
Haitao Miao, Yuyun Sun, Xichun Hu, Shaoli Song, Jian Zhang

Clinicopathological characteristics of exceptional responders who achieve durable remissions beyond five years (DR5) in HER2+(H+) metastatic breast cancer (MBC).

AUTHOR(S)
Darko Skrobo, Naomi Walsh, Jose Berenguer, Janice M. Walshe, Michaela J. Higgins, David W. Fennelly, Jo Ballot, Cecily Quinn, Giuseppe Gullo, John Crown
Efficacy of CDK4/6i in the visceral crisis setting: Result from a real-world database.

AUTHOR(S)
Shaheenah S. Dawood, Kaylen Brzozowski

Real-world cost-effectiveness of pertuzumab (P) with trastuzumab + chemo (T+Chemo) in patients (pts) with metastatic breast cancer (MBC): A population-based retrospective cohort study by the Canadian Real-world Evidence for Value in Cancer Drugs (CanREValue) collaboration.

AUTHOR(S)
Wei Fang Dai, Jaclyn M. Beca, Chenthila Nagamuthu, Ning Liu, Maureen E. Trudeau, Craig Earle, Claire De Oliveira, Kelvin K. Chan

A phase 1b study of chemoimmunotherapy with pegylated liposomal doxorubicin and pembrolizumab in estrogen receptor-positive, endocrine-resistant breast cancer.

AUTHOR(S)
Alberto A. Gabizon, Nathan Cherny, Rut Isacson, Areen Abu Remilah, Alberto Gabizon, Hilary Shmeeda, Ora Rosengarten

A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study.

AUTHOR(S)
Correlation between work productivity loss (WPL) and European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) domains from the MONALEESA-7 (ML-7) trial of premenopausal women with HR+/HER2- advanced breast cancer (ABC).

AUTHOR(S)
Debu Tripathy, Tristan Curteis, Sara A. Hurvitz, Denise A. Yardley, Fabio Franke, Govind Babu Kanakasetty, Paul Wheatley-Price, Young-Hyuck Im, Radost Pencheva, David Chandiwana, Purnima Pathak, Brad Lanoue, Nadia Harbeck

ABSTRACT
1051
The association of HER2 low expression with the efficacy of CDK4/6 inhibitor in hormone receptor positive HER2 negative metastatic breast cancer.

AUTHOR(S)
Kelvin K. Bao, Leone Sutanto, Shirley S. Tse, Ka Man Cheung, Jeffrey C. Chan

ABSTRACT
1052
Resistance to CDK4/6 inhibitors (CDK4/6i): The clinical usefulness of liquid biopsy in metastatic breast cancer (mBC).

AUTHOR(S)
Lucrezia Raimondi, Laura Di Benedetto, Giuseppe Naso, Filippo M. Raimondi, Arianna Di Rocco, Laura Giaconi, Rachele Lazzeroni, Gian Paolo Spinelli

ABSTRACT
1053
Long-term (LT) disease control in patients (pts) with hormone receptor-positive (HR+), PIK3CA-altered advanced breast cancer (ABC) treated with alpelisib (ALP) + fulvestrant (FUL).

AUTHOR(S)
Dejan Juric, Fabrice Andre, Udaiveer Panwar, Filip Janku, Yen-Shen Lu, Howard A. Burris III, Josefina Cruz Jurado, Zsuzsanna Papai, Salomon M. Stemmer, Josep Tabernero, Johan Ahlgren, Marianne Leheurteur, Ines Lorenzo, Dragana Jankovic, Cornelia Quadt, Huilin Hu, Xueying Chen, Hope S. Rugo

ABSTRACT
1054
Overall survival in patients with breast cancer treated with a CDK 4/6 inhibitor plus fulvestrant: A U.S. Food and Drug Administration pooled analysis.

AUTHOR(S)
Jennifer J. Gao, Joyce Cheng, Tatiana M. Prowell, Erik Bloomquist, Shenghui Tang, Suparna B. Wedam, Melanie E. Royce, Danielle Krol, Christy Osgood, Gwynn Ison, Rajeshwari Sridhara, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani

ABSTRACT

1055

A single-arm phase II trial of palbociclib in combination with tamoxifen as first-line therapy for metastatic hormone receptor-positive breast cancer.

AUTHOR(S)

Oana C. Danciu, Kent Hoskins, Cristina I. Truica, Anne H. Blaes, Deimante Tamkus, Jatin Rana, Pavankumar Tandra, Lauren Green, Menggang Yu, Qianqian Zhao, Deborah Toppmeyer, Ruth O'Regan, Kari B. Wisinski

ABSTRACT

1056

A phase Ib study of xentuzumab plus abemaciclib and fulvestrant in patients (pts) with advanced hormone receptor-positive (HR+), HER2-negative breast cancer (BC) with visceral or non-visceral disease.

AUTHOR(S)

Douglas Yee, Patricia LoRusso, Marie Paule Sablin, Aleix Prat, Agostina Stradella, Meri Utriainen, Mafalda Oliveira, Kan Yonemori, Yoichi Naito, Molly C. Hardebeck, Marta Puig, Joy Hu, Tsvetan N. Blyukov, Hiroji Ikawa

ABSTRACT

1057

AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).

AUTHOR(S)

Sarat Chandarlapaty, Hannah M. Linden, Patrick Neven, Katarina Petrakova, Aditya Bardia, Peter Kabos, Sofia A. Braga, Valentina Boni, Alice Gosselin, Sylvaine Cartot-Cotton, Séverine Doroumian, Marina Celanovic, Patrick Cohen, Gautier Paux, Mario Campone

ABSTRACT

1058

Systematic review and meta-analysis of post-progression outcomes in ER+/HER2-metastatic breast cancer after treatment with endocrine therapy and CDK 4/6 inhibitors within randomized clinical trials.

AUTHOR(S)

Elisabetta Munzone, Eleonora Pagan, Vincenzo Bagnardi, Emilia Montagna, Giuseppe Cancelli, Silvia Dellapasqua, Monica Iorfida, Manuelita Mazza, Marco Colleoni
ABSTRACT

1059

Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve.

AUTHOR(S)


ABSTRACT

1060

Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor + (HR+), HER2- metastatic breast cancer (MBC) not previously treated with a taxane.

AUTHOR(S)

Lee S. Schwartzberg, Igor Bondarenko, Sara M. Tolaney, Andrew D. Seidman, Joyce O'Shaughnessy, Yaroslav V. Shparyk, Chi-Feng Chung, Yen-Shen Lu, Nuria Chic, Lawrence C. Panacci, Yee Soo Chae, Sabela Recalde, Yevhen Hotko, Patricia Gomez, Gail L. Wright, Noshir A. Dacosta, Sina Vatandoust, Joseph P. O'Connell, Thomas Wei, Hope S. Rugo

ABSTRACT

1061

Endocrine therapy-based strategies with different endocrine sensitivity statuses for hormone receptor positive/HER2 negative metastatic breast cancer: A network meta-analysis.

AUTHOR(S)

Jiani Wang, Yiqun Han, Jiayu Wang, Binghe Xu

ABSTRACT

1062

Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2- advanced breast cancer: Phase 1 results.

AUTHOR(S)

Alpelisib and fulvestrant efficacy in HR-positive HER2-negative PIK3CA-mutant advanced breast cancer: Data from the French early access program.

AUTHOR(S)
Diana Bello, Alexandre Bertucci, Thibault De La Motte Rouge, Cyriac Blonz, Sarra Akla, Julien Grenier, Caroline Bailleux, Marc Antoine Benderra, Helene Simon, Isabelle Desmoulins, Zoé Tharin, Emmanuelle Renaud, Suzette Delaloge, Marion Bertho, Paul H. Cottu, Anthony Goncalves, François-Clément Bidard, Florence Lerebours

Landscape of GATA3 mutations identified from circulating tumor DNA clinical testing and their impact on disease outcomes in estrogen receptor-positive (ER+) metastatic breast cancers treated with endocrine therapies.

AUTHOR(S)
Marko Velimirovic, Lorenzo Gerratana, Andrew A. Davis, Charles S. Dai, Ju Cheng, A. John Iafrate, Bruce A. Chabner, Massimo Cristofanilli, Aditya Bardia

On-treatment derived neutrophil-to-lymphocyte ratio and response to palbociclib and letrozole: Analysis of a multicenter retrospective cohort and the PALOMA-2 study.

AUTHOR(S)
Chang Gon Kim, Min Hwan Kim, Jee Hung Kim, Seul-Gi Kim, Gun Min Kim, Tae Yeong Kim, Won-Ji Ryu, Jeeye Kim, Hyung Seok Park, Seho Park, Youngup Cho, Byeong-Woo Park, Seung Il Kim, Joon Jeong, Joohyuk Sohn

Phase I safety and efficacy study of autophagy inhibition with hydroxychloroquine to augment the antiproliferative and biological effects of preoperative palbociclib plus letrozole for estrogen receptor-positive, HER2-negative metastatic breast cancer (MBC).

AUTHOR(S)
Akshara Singareeka Raghavendra, Danielle Kwiatkowski, Senthil Damodaran, Nicole M. Kettner, David L. Ramirez, Dan S. Gombos, Kelly Hunt, Yu Shen, Khandan Keyomarsi, Debu Tripathy
Real-world (rw) clinical outcomes on alpelisib (ALP) in patients (pts) with breast cancer (BC) and PIK3CA mutations (PIK3CAm).

AUTHOR(S)
Hope S. Rugo, Kira Raskina, Alexa B. Schrock, Mason A. Israel, Ethan Sokol, Smruthy Sivakumar, Ashley Ward, James Creedon, Geoffrey R. Oxnard, Kimberly McGregor, Jeffrey M. Venstrom, Hanna Tukachinsky

ABSTRACT

Stereotactic radiosurgery (SRS) for brain metastasis (BM) in hormone receptor positive (HR+) HER2 negative breast cancer (BC).

AUTHOR(S)
Akshara Singareeka Raghavendra, Chao Gao, Fuchenchu Wang, Ran An, Yan Wang, Dima Suki, Amy B. Heimberger, Debu Tripathy, Jing Li, Nuhad K. Ibrahim

ABSTRACT

Efficacy of AI and palbociclib in ER+ HER2- advanced breast cancer patients relapsing during adjuvant tamoxifen: An exploratory analysis of the PADA-1 trial.

AUTHOR(S)
François-Clément Bidard, Florence Dalenc, Thibault De La Motte Rouge, Barbara Pistilli, Caroline Cheneau, Catherine Delbaldo, Olfa Derbel, Claire Garnier Tixidre, Nathalie Marques, Sandrine Marques, Lionel Moreau, Frederique Berger, Anne-Claire Hardy-Bessard, Suzette Delaloge, Thomas Bachelot

ABSTRACT

Real-world quality of life (QoL) in black, indigenous and people of color (BIPOC) treated with palbociclib (PAL) and endocrine therapy for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): A subgroup analysis from POLARIS.

AUTHOR(S)
Gabrielle B. Rocque, Joanne L. Blum, Aldemar Montero, Meghan S. Karuturi, Kenneth Manning, Lloyd Shabazz, Christopher Gallagher, Lara Zuberi, Joseph C. Cappelleri, Marc Drucker, Yao Wang, Debu Tripathy

ABSTRACT
Relative risk of pneumonitis or interstitial lung disease (ILD) associated with the use of cyclin-dependent kinase inhibitors (CDK4/6i): A systematic review and meta-analysis of phase 3 randomized controlled trials.

AUTHOR(S)
Nusrat Jahan, Sariya Wongsaengsak, Shabnam Rehman, Myriam Vinan-Vega, Lukman A. Tijani, Fred L. Hardwicke

ABSTRACT
1072

Confirmed tumor response by molecular subtype in patients with metastatic breast cancer: Sub-analysis from a phase 3 clinical study comparing oral paclitaxel and encequidar to IV paclitaxel.

AUTHOR(S)
Gerardo A. Umanzor Funez, Hope S. Rugo, Jorge Umanzor, Francisco Barrios, Rosa Vasallo, Suyapa A. Bejarano, Julio R. Ramirez, Luis E. Fein, Ruben D. Kowalyszyn, Hui Wang, David Cutler

ABSTRACT
1073

A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer.

AUTHOR(S)
Jiayu Wang, Binghe Xu, Tao Sun, Quchang Ouyang, Yiqun Han, Qing Li, Pin Zhang, Fei Ma, Yang Luo, Ying Fan, Ruigang Cai, Qiao Li, Bo Lan, Hongnan Mo, Jiani Wang, Yiqun Li

ABSTRACT
1074

Apatinib plus vinorelbine versus vinorelbine for advanced triple-negative breast cancer with failed first or second-line treatment: The NAN trial.

AUTHOR(S)
Doudou Li, Zhonghua Tao, Biyun Wang, Leiping Wang, Jun Cao, Xichun Hu, Jian Zhang

ABSTRACT
1075

Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC).

AUTHOR(S)
**ABSTRACT**

1076

Assessment of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) cohort by agent in the phase 3 ASCENT study of patients (pts) with metastatic triple-negative breast cancer (mTNBC).

**AUTHOR(S)**

Joyce O’Shaughnessy, Kevin Punie, Mafalda Oliveira, Filipa Lynce, Sara M. Tolaney, Florence Dalenc, Priyanka Sharma, Michaela L. Tsai, Aditya Bardia, Javier Cortes, Michael A. Danso, Stephanie Henry, Alejandra T. Perez, Sara A. Hurvitz, Kevin Kalinsky, Quan Hong, Martin S. Olivo, Loretta Itri, Hope S. Rugo

**ABSTRACT**

1077

A phase I/IB study of ipatasertib in combination with carboplatin or carboplatin/paclitaxel or capecitabine and atezolizumab in patients with metastatic triple-negative breast cancer.

**AUTHOR(S)**

Yuan Yuan, Susan E. Yost, Paul H. Frankel, Christopher Ruel, Mireya Murga, Aileen Tang, Norma Martinez, James R. Waisman, Daphne B. Stewart, Niki H. Patel, Joanne E. Mortimer

**ABSTRACT**

1078

A phase II trial of stereotactic radiation therapy and in situ oncolytic virus therapy in metastatic triple-negative breast cancer (mTNBC) patients followed by pembrolizumab (STOMP).

**AUTHOR(S)**

Kai Sun, Joe E. Ensor Jr., Yitian Xu, Licheng Zhang, Carlo Guerrero, Polly A. Niravath, Tejal A. Patel, Charles E. Geyer Jr., Dharamvir Jain, Bin S. Teh, Andrew M. Farach, Mark Sultenfuss, Nakul Gupta, Mary R. Schwartz, Susan Haley, Jamie Mejia, E. Brian Butler, Eric Bernicker, Shu-Hsia Chen, Jenny C. Chang

**ABSTRACT**

1079

Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC).

**AUTHOR(S)**
Efficacy of DAN-222, a novel investigational polymeric nanoparticle with topoisomerase I inhibitor, as monotherapy in breast cancer models and when combined with PARP inhibitor.

Author(s)
Ashley P. Wright, Jodi D. Bradley, Timothy Hagerty, Emily A. Wyatt

miR-503-5p induces doxorubicin resistance in triple-negative breast cancer.

Author(s)
Iris Garrido-Cano, Anna Adam-Artigues, Ana Lameirinhas, Birlipta Pattanayak, Eduardo Tormo, Vera Mónica Miranda-Gonçalves, Catarina Macedo-Silva, Federico Rojo, Sandra Zazo, Juan Madoz-Gürpide, Octavio Burgues, Cristina Hernando, Maite Martínez, Santi Moragón, Begoña Bermejo De Las Heras, Ana Lluch, Carmen Jerónimo, Pilar Eroles, Juan Miguel Cejalvo

Distant metastases after diagnosis: Racial disparities in breast cancer outcomes.

Author(s)
Julia Blanter, Ilana Ramer, Justina Ray, Emily J. Gallagher, Nina A. Bickell, Amy Tiersten

A randomized phase Ib/IIa study of CApecitabine plus Radium-223 in breast cancer patients with BONe metastases (CARBON): Final efficacy results.

Author(s)
The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis.

A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation.

Survival time in urban center breast cancer patients with CNS metastasis with or without visceral metastasis.

Clinical and pathological characteristics of breast cancer with resected brain metastasis.

Clinical outcomes in patients (pts) with a history of central nervous system (CNS) metastases receiving talazoparib (TALA) or physician’s choice of chemotherapy (PCT) in the phase 3 EMBRACA trial.
AUTHOR(S)

ABSTRACT

Genomic evaluation of tumor mutational burden-high (TMB-H) versus TMB-low (TMB-L) metastatic breast cancer to reveal unique mutational features.

AUTHOR(S)

ABSTRACT

Decreased enrollment of patients with advanced lobular breast cancer compared to ductal breast cancer in interventional clinical trials.

AUTHOR(S)

ABSTRACT

Systemic chemotherapy in patients with brain only metastatic breast cancer: A retrospective analysis.

AUTHOR(S)
Akshjot Puri, Charisma Mylavarapu, Joe E. Ensor Jr., Parveen Parveen, Ivo Tremont-Lukats, Jenny C. Chang, Polly A. Niravath

ABSTRACT

Metastasectomy versus radiation of secondary sites in stage IV breast cancer.

AUTHOR(S)
Nadeem Bilani, Leah Elson, Elizabeth B. Elimimian, Hong Liang, Diana Saravia, Zeina A. Nahleh

ABSTRACT

Survival among patients with untreated metastatic breast cancer.

AUTHOR(S)
Jennifer K. Plichta, Samantha M. Thomas, Sarah Sammons, Susan G. McDuff, Gayle DiLalla, Gretchen G. Kimmick, Eun-Sil S. Hwang

**ABSTRACT**

1095

Trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07).

**AUTHOR(S)**

Fabrice Andre, Erika P. Hamilton, Sherene Loi, Peter Schmid, Carey K. Anders, Tinghui Yu, Sarice Boston, Celina M. D'Cruz, Pia Herbolsheimer, Komal L. Jhaveri

**ABSTRACT**

TPS1096

HER2CLIMB-04: Phase 2 open label trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ unresectable locally advanced or metastatic breast cancer with and without brain metastases (trial in progress).

**AUTHOR(S)**

Ian E. Krop, Jorge Ramos, Chiyu Zhang, Erika P. Hamilton

**ABSTRACT**

TPS1097

Trial in progress: A phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+ breast cancer (TBCRC 050).

**AUTHOR(S)**

Erica M. Stringer-Reasor, Yufeng Li, Felicia Witherspoon, Jennifer M. Specht, Jesus D. Anampa Mesias, Rita Nanda, Elizabeth C. Dees, Antonio C. Wolff, Ian E. Krop, Nancy U. Lin, Mothaffar F. Rimawi, Eddy S. Yang

**ABSTRACT**

TPS1098

Trial in progress: Phase I/II study of radiation therapy followed by intrathecal trastuzumab/pertuzumab in the management of HER2+ breast leptomeningeal disease.

**AUTHOR(S)**

Kamran A. Ahmed, Youngchul Kim, Michelle DeJesus, Priya Kumthekar, Nicole O. Williams, Joshua D. Palmer, Pierre Giglio, Adrienne A. Boire, John Arrington, Solmaz Sahebjam, Marilin Rosa, Hatem H. Soliman, Hsiang-Hsuan M. Yu, Hyo S. Han, Peter A. Forsyth
ABSTRACT

TPS1099

acelERA Breast Cancer (BC): Phase II study evaluating efficacy and safety of giredestrant (GDC-9545) versus physician's choice of endocrine monotherapy in patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer (LA/mBC).

AUTHORS

Miguel Martin, Elgene Lim, Mariana Chavez Mac Gregor, Mahesh Shivhare, Graham Ross, Monika Patre, Laura Roncoroni, Maria Louka, Joohyuk Sohn

ABSTRACT

TPS1100

SERENA-4: A phase 3 comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease.

AUTHORS

Seock-Ah Im, Erika P. Hamilton, Antonio Llombart Cussac, Richard D. Baird, Johannes Ettl, Matthew P. Goetz, Hiroji Iwata, Anil A. Joy, Patrick Neven, Vincent Haddad, Andrew S. Walding, Manuel Selvi Miralles, Cynthia H. Bartlett, Fabrice Andre

ABSTRACT

TPS1101

Saci-IO HR+: Randomized phase II trial of sacituzumab govitecan (SG) +/-pembrolizumab in PD-L1+ hormone receptor-positive (HR+) / HER2- metastatic breast cancer (MBC).

AUTHORS

Ana Christina Garrido-Castro, Tanya E. Keenan, Tianyu Li, Paulina Lange, Catherine Callahan, Jennifer Guerriero, Nabihah Tayob, Leilani Anderson, Daniel G. Stover, Keerthi Gogineni, Lisa A. Carey, Rita Nanda, Eric P. Winer, Elizabeth A. Mittendorff, Sara M. Tolaney

ABSTRACT

TPS1102

persevERA Breast Cancer (BC): Phase III study evaluating the efficacy and safety of giredestrant (GDC-9545) + palbociclib versus letrozole + palbociclib in patients (pts) with estrogen-receptor-positive, HER2-negative locally advanced or metastatic BC (ER+/HER2- LA/mBC).

AUTHORS
Nicholas C. Turner, Komal L. Jhaveri, Aditya Bardia, Naoki Niikura, Veronique Dieras, Carlos H. Barrios, Seock-Ah Im, Volkmar Mueller,Meritxell Bellet, Ching-Wei Chang, Graham A. Ross, Monika Patre, Sherene Loi

**ABSTRACT**

**TPS1103**

**AMEERA-5:** A randomized, double-blind phase III study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer.

**AUTHOR(S)**

Aditya Bardia, Javier Cortes, Sara A. Hurvitz, Suzette Delaloge, Hiroji Iwata, Shao Zhimin, Dheepak Kanagavel, Patrick Cohen, Qianying Liu, Sylvaine Cartot-Cotton, Vasiliki Pelekanou, Joyce O'Shaughnessy

**ABSTRACT**

**TPS1104**

**BEGONIA:** Phase 1b/2, open-label, platform study of the safety and efficacy of durvalumab (D) ± paclitaxel (P) with novel oncology therapies for first-line metastatic triple-negative breast cancer (mTNBC): Addition of arm 7, D + datopotamab deruxtecan (Dato-DXd; DS-1062).

**AUTHOR(S)**

Peter Schmid, Ana T. Nunes, Hannah Dry, Rachel Dougherty, Vatsala Karwe, Urban J. Scheuring

**ABSTRACT**

**TPS1105**

**Saci-IO TNBC:** Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1- metastatic triple-negative breast cancer (mTNBC).

**AUTHOR(S)**


**ABSTRACT**

**TPS1106**

**Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2).**

**AUTHOR(S)**
TPS1107

**NBE-002: A novel anthracycline-based antibody-drug conjugate (ADC) targeting ROR1 for the treatment of advanced solid tumors—A phase 1/2 clinical trial.**

**AUTHOR(S)**

Anthony W. Tolcher, Funda Meric-Bernstam, Meredith McKean, Roger R. Beerli, Lorenz Waldmeier, Rémy Gebleux, Ina Hellmann, Pawel Chrom, Ulf Grawunder

TPS1108

**A phase II clinical trial of talazoparib monotherapy for PALB2 mutation-associated advanced breast cancer.**

**AUTHOR(S)**

Joshua J. Gruber, Wyatt Gross, Alex McMillan, James M. Ford, Melinda L. Telli

TPS1110

**Phase II multicenter study of talazoparib for somatic BRCA1/2 mutant metastatic breast cancer.**

**AUTHOR(S)**


TPS1111

**Multi-center randomized study of pembrolizumab/carboplatin versus carboplatin alone in patients with chest wall disease from breast cancer: TBCRC 044.**

**AUTHOR(S)**

Central Nervous System Tumors

Radiosurgery dose reduction for brain metastases on immunotherapy (RADREMI): Early results from a multicenter phase I trial.

AUTHOR(S)
Shearwood McClelland, Tim Lautenschlaeger, Kevin Shiue, Amy C. Miller, Yong Zang, Kathryn I. Lauer, Nasser H. Hanna, Ryan Rhome, Namita Agrawal, Paul Anthony, Mu Shan, Jerry J. Jaboin, Gordon A. Watson

ABSTRACT
2025
Changes in the blood-brain barrier properties in vitro after treatment with sera from breast cancer patients with primary cancer and visceral, bone or cerebral metastases.

AUTHOR(S)
Carolin J. Curtaz, Schmitt Constanze, Patrick Meybohm, Achim Wöckel, Malgorzata Burek

ABSTRACT
2026

AUTHOR(S)
Katarzyna J. Jerzak, Michael Rosen, Xin Y. Wang, Rania Chehade, Bo Zhang, Refik Saskin, Sunit Das, Hany Soliman, Arjun Sahgal, Kelvin K. Chan

ABSTRACT
2027
The efficacy and clinical survival outcome of different first-line treatments in EGFR-mutant non-small cell lung cancer with brain metastases.

AUTHOR(S)
Huijuan Wang, Ruyue Xing, Mina Zhang, Xiaojuan Zhang, Jinpo Yang, Mengmeng Li, Zhiyong Ma
ABSTRACT

2028

Heterogeneity of HER2 expression in circulating tumor cells of patients with breast cancer brain metastases and impact on brain disease control.

AUTHOR(S)


ABSTRACT

2029

Outcomes of immunotherapy (ICI) alone vs tyrosine kinase inhibitors (TKI) alone versus ICI and TKI combined in renal cell carcinoma brain metastasis.

AUTHOR(S)

Patrick J. O'Shea, Vineeth Tatineni, Yasmeen Rauf, Xuefei Jia, Erin S. Murphy, Samuel T. Chao, John H. Suh, David M. Peereboom, Manmeet S. Ahluwalia

ABSTRACT

2030

Outcomes of first-generation versus third-generation epidermal growth factor receptor (EGFR) inhibitors in non-small cell lung cancer with brain metastases (NSCLCBM).

AUTHOR(S)

Vineeth Tatineni, Patrick J. O’Shea, Yasmeen Rauf, Xuefei Jia, Erin S. Murphy, Samuel T. Chao, John H. Suh, David M. Peereboom, Manmeet S. Ahluwalia

ABSTRACT

2031


AUTHOR(S)


ABSTRACT

2032
Presentation and management of patients with brain metastases of primary melanoma, non-small cell lung cancer, and breast cancer origin.

AUTHOR(S)

ABSTRACT
2033

Outcomes of first, second, and third-generation anaplastic lymphoma kinase (ALK) inhibitors in non-small cell lung cancer brain metastases (NSCLCBM).

AUTHOR(S)
Vineeth Tatineni, Patrick J. O'Shea, Yasmeeen Rauf, Xuefei Jia, Erin S. Murphy, Samuel T. Chao, John H. Suh, David M. Peereboom, Manmeet S. Ahluwalia

ABSTRACT
2034

An investigation into the impact of next generation sequencing on the use of targeted treatments in glioblastoma.

AUTHOR(S)
Jordan John, Rimas V. Lukas, Priya Kumthekar

ABSTRACT
2035

Palliative care service utilization and advance care planning issues for adult glioblastoma patients: A systematic review.

AUTHOR(S)
Adela Wu, Gabriela R. Colon, Rebecca Aslakson, Erqi L. Pollom, Chirag B. Patel

ABSTRACT
2036

Phase 1 dose-escalation study of ACT001 in patients with recurrent glioblastoma and other advanced solid tumors.

AUTHOR(S)
Jason D. Lickliter, Ross Jennens, Charlotte R. Lemech, Ganessan Kichenadasse, Dongpo Cai, Steven Y. Su

ABSTRACT
2037
Efficacy finding cohort of a cancer peptide vaccine, TAS0313, in treating recurrent glioblastoma.

AUTHOR(S)
Yoshiki Arakawa, Yoshiko Okita, Yoshitaka Narita

ABSTRACT

A phase II study of anlotinib combined with STUPP regimen in the treatment of patients with newly diagnosed glioblastoma (GBM).

AUTHOR(S)
Peijing Li, Yuan yuan Y. Chen, Shuzhen Lai, Fagui Jiang, Xiaohui Liu, Changjuan Tao, Lei Wang, Guihong Liu, Jing Huang, Yiqiang Tang, Zhigang Liu, Guoping Shen, Chaoming Li, Tieming Xie, Fangxiao Lu

ABSTRACT

A phase I/II study to evaluate the safety and efficacy of a novel long-acting interleukin-7, NT-I7, for patients with newly diagnosed high-grade gliomas after chemoradiotherapy: The interim result of the phase I data.

AUTHOR(S)
Jian L. Campian, Jingqin Luo, Chai Avvaru, Ruth Katamba, Albert H. Kim, Gavin P. Dunn, Christopher Abraham, Puspanjali Bhatta, Se Hwan Yang, Jean Fan, Byung Ha Lee, Sunita Ranjitka, Ngocdiep T. Le, George Ansstas, Tanner M. Johanns, Milan G. Chhed, Jiayi Huang

ABSTRACT

PD-L1-R: A MR based surrogate for PD-L1 expression in Glioblastoma multiforme.

AUTHOR(S)
Francesco Sforazzini, Patrick Salome, Andreas Kudak, Matthias Ulrich, Laila König, Rolf Warta, Nina Bougatf, Juergen Debus, Christel Herold-Mende, Maximilian Knoll, Amir Abdollahi

ABSTRACT

Gene fusions in glioblastoma: Results of Gliocat project.

AUTHOR(S)
Ainhoa Hernandez Gonzalez, Anna Esteve-Codina, Cristina Carrato, Ana Munoz, Estela Pineda, Oscar Gallego Rubio, Oriol Arpi, Marta Gut, Maria Martinez Garcia, Raquel Lopez, Carlos Mesia, Sonia D. Barco Berron, Carolina Sanz, Sun Chen, Marta Domenech, Francesc Alameda, Carmen Balana

ABSTRACT
Improved risk stratification via integration of radiomics and dosimics features in patients with recurrent high-grade glioma undergoing carbon ion radiotherapy (CIRT).

**AUTHOR(S)**
Patrick Salome, Francesco Sforazzini, Andreas Kudak, Laila König, Philipp Kickingederer, Nina Bougatf, Wolfgang Wick, Oliver Jäkel, Juergen Debus, Maximilian Knoll, Amir Abdollahi

**ABSTRACT**

A phase I dose-escalation study to evaluate pharmacokinetics, safety and tolerability of ACT001 in patients with advanced glioma.

**AUTHOR(S)**
Yehui Shi, Guiying Bai, Peng Wang, Dongpo Cai, Yue Chen, Ping Wang

**ABSTRACT**

Pilot trial treating recurrent GBM patients with precision medicine regimens.

**AUTHOR(S)**

**ABSTRACT**

ATRX loss to impair glioma stem cell viability and self-renewal via proton radiotherapy induced necrosis.

**AUTHOR(S)**
Angel Garces, Lawrence Bronk, Krishna Bhat, David R. Grosshans

**ABSTRACT**

Evaluation of GM-CSF and AS01B adjuvants in a phase I/IIa trial of a therapeutic CMV vaccine (VBI-1901) against recurrent glioblastoma (GBM).

**AUTHOR(S)**
Patrick Y. Wen, David A. Reardon, Deborah A. Forst, Eudocia Q. Lee, Fabio M. Iwamoto, Francisco Diaz-Mitoma, David E. Anderson, Andrew B. Lassman
Targeted agents recommended by the CNS TAP tool compared to those selected by a tumor board in a molecularly-driven clinical trial in children and young adults with DIPG.

AUTHOR(S)
Holly Roberts, Karthik Ravi, Cassie Kline, Sabine Mueller, Carl J. Koschmann, Bernard Marini, Andrea Franson

A phase I/IIa study to evaluate the safety and efficacy of blood-brain barrier (BBB) opening with the SonoCloud-9 implantable ultrasound device in recurrent glioblastoma patients receiving IV carboplatin.

AUTHOR(S)

Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors.

AUTHOR(S)
Yazmin Odia, Ludimila Cavalcante, Howard Safran, Steven F. Powell, Pamela N. Munster, Wen Wee Ma, Benedito A. Carneiro, Bruno R. Bastos, Francis J. Giles, Solmaz Sahebjam

The clinical significance of telomerase reverse transcriptase (TERT) promoter mutations, telomere length and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status in newly diagnosed and recurrent IDH-wildtype glioblastoma (GBM) patients (PTS): A large mono-institutional study.

AUTHOR(S)
Giuseppe Lombardi, Silvia Giunco, Francesco Cavallin, Chiara Angelini, Mario Caccese, Giulia Cerretti, Pasquale De Bonis, Anita De Rossi, Vittorina Zagonel
ABSTRACT
2053

Resection and surgically targeted radiation therapy for locally recurrent GBM.

AUTHOR(S)
David Brachman, Peter Nakaji, Kris Smith, Theresa Thomas, Christopher Dardis, Dilini Pinnaduwage, Garrick Wallstrom, Leland Rogers, Mehee Choi, Emad Youssef

ABSTRACT
2054

Health-related quality of life for glioblastoma short and long-term survivors receiving treatment with TTfields.

AUTHOR(S)
Joshua D. Palmer, Po-Ya Chuang, Gordon Chavez, Bruce C. Wang, Christina Proescholdt

ABSTRACT
2055

Scalp-sparing radiation with concurrent temozolomide and tumor treating fields (SPARE) for patients with newly diagnosed glioblastoma.

AUTHOR(S)

ABSTRACT
2056

Phase 1 trial of drug resistant immunotherapy: A first-in-class combination of MGMT-modified γδ t cells and temozolomide chemotherapy in newly diagnosed glioblastoma.

AUTHOR(S)
Louis B. Nabors, Lawrence S. Lamb Jr., Melissa J. Beelen, Thriumaine Pillay, Mariska ter Haak, Samantha Youngblood, Louis Vaickus, Mina Lobbous

ABSTRACT
2057

Cost-effectiveness of concomitant and adjuvant temozolomide for glioblastoma patients with unmethylated O6-methylguanine-DNA methyltransferase promoter regions in the United States.
AUTHOR(S)
Manav D. Midha, Mark E. Votruba

ABSTRACT
2058

Comprehensive molecular pharmacodynamic assessment identifies response markers of intermediary metabolism associated with BPM 31510-IV treatment in advanced glioblastoma multiforme patients.

AUTHOR(S)

ABSTRACT
2059

Phase I study of ruxolitinib with radiation and temozolomide in patients with newly diagnosed grade III gliomas and glioblastoma.

AUTHOR(S)
Yasmeen Rauf, Rachel Hufsey, Kathy Robinson, John H. Suh, Samuel T. Chao, Erin S. Murphy, Jennifer S. Yu, David M. Peereboom, Manmeet S. Ahluwalia, Wei Wei

ABSTRACT
2060

Safety and feasibility of rhenium-186 nanoliposome ($^{186}$RNL) in recurrent glioma: The ReSPECT phase 1 trial.

AUTHOR(S)

ABSTRACT
2061

Autologous stem cell transplantation (ASCT) versus whole brain radiation (WBRT) as a consolidation therapy in primary CNS lymphoma (PCNSL): A nationwide analysis.

AUTHOR(S)

ABSTRACT
2062
Predictive value of lymphocyte immunophenotyping (LIP) in primary central nervous system lymphoma (PCNSL).

AUTHOR(S)
Axel Berthelot, Celine Boucard, Gregorio Petrirena, Chantal Campello, Olivier L. Chinot, Emeline Tabouret

ABSTRACT
2063

A phase II, open-label, single-arm trial of pembrolizumab for refractory atypical and anaplastic meningioma and hemangiopericytoma.

AUTHOR(S)
Shlomit Yust-Katz, Alexandra Amiel, Tali Siegal, Dror Limon

ABSTRACT
2064

LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma.

AUTHOR(S)
Andrew E. Sloan, Robin A. Buerki, Christopher Murphy, Andrea T. Kelly, Prakash Ambady, Michael Brown, Nicholas A. Butowski, Robert Cavaliere, William T. Curry, Annick Desjardins, Lisa Franklin, Henry S. Friedman, Matthias Gromeier, LeAnn Jackson, Lori Mixson, Shirley S. Ong, Dina Randazzo, Patrick Y. Wen, Garrett Nichols

ABSTRACT
TPS2065

BrainStorm: A brain metastases research platform to tackle the challenge of central nervous system (CNS) metastases in solid tumors (Oncodistinct 006).

AUTHOR(S)
Nuria Kotecki, Maria Alice B. Franzoi, Marianne Paesmans, Florian Clatot, Edith Borcoman, Anthony Goncalves, Philippe Barthelemy, Claire Cheymol, Jean-Pierre Delord, Andrea Gombos, Vincent Vanhaudenarde, Stephane Holbrechts, Francois P. Duhoux, Jean-Luc R. Canon, Lore Decoster, Hannelore denys, Caroline Duhem, Nadège Kindt, Ahmad Awada

ABSTRACT
TPS2066

A phase III multicenter randomized controlled trial of postsurgical stereotactic radiotherapy versus surgically targeted radiation therapy (STaRT) for the treatment of large (>2.5cm) newly diagnosed brain metastases: Trial in progress.

AUTHOR(S)
Jeffrey S. Weinberg, Mary Frances McAleer, Jason M. Johnson, Rajat Kudchadker, Jeffrey S. Wefel, Ying Yuan, Heather Y. Lin
The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: A phase 2 study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma.

AUTHOR(S)
Crescens D. Tiu, Sarah Derby, Noor M. Haris, Anna Stansfeld, Thomas Hundsberger, Patrick Roth, Fatima König, Joel R. Eisner, Malte Kleinschmidt, Stephanie Anderson, Felix Bachmann, Heidi A. Lane, Marc Engelhardt, Thomas Kaindl, Karine Litherland, Alexandru C. Stan, T. R. Jeffry Evans, Elizabeth R. Plummer, Juanita S. Lopez

Phase 2 trial of newly diagnosed high-grade glioma treated with concurrent radiation therapy, temozolomide, and BMX-001.

AUTHOR(S)
Katherine B. Peters, John L. Villano, Nicholas A. Butowski, Adam L. Cohen, Joe S. Mendez, Pierre Giglio, Chi Zhang, Shahzad Raza, Tresa McGranahan, Mina Lobbous, David MacLeod, Shayne Gad, Sara Penchev, David Silberstein, James Crapo

Safety and efficacy study of retifanlimab and epacadostat in combination with radiation and bevacizumab in patients with recurrent glioblastoma.

AUTHOR(S)
Jian L. Campian, Christopher Abraham, Jingqin Luo, Grayson Talcott, Ruth Katumba, Albert H. Kim, Gavin P. Dunn, George Ansstas, Tanner M. Johanns, Matthew A. Ciorda, Milan G. Chheda, Jiayi Huang

A phase 1/2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma.

AUTHOR(S)
Yazmin Odia, Samuel A. Goldlust, Minesh P. Mehta, Andrew B. Lassman, Howard Colman, Priya Kumthekar, Warren P. Mason, Rebecca A. Harrison, Nicholas A. Butowski, Vyshak Venur, Scott R. Plotkin, Michael Schulder, John A. Boockvar, J Paul Duic, Kai Li, Yang Liu, Sharon Tamir, Gregory Mundy, Sharon Shacham, Patrick Y. Wen
**First-in-human dose escalation and food effect study of oral ONC206 in adults with recurrent primary CNS neoplasms.**

**AUTHOR(S)**

**ABSTRACT**
TPS2072

**A multicenter observational study of cs-131 seeds embedded in a collagen carrier tile in intracranial brain neoplasms: Trial in progress.**

**AUTHOR(S)**

**ABSTRACT**
TPS2073

**GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.**

**AUTHOR(S)**

**ABSTRACT**
TPS2074

**Developmental Therapeutics—Immunotherapy**

**Back to Program**

Showing 160 Presentations

[https://meetinglibrary.asco.org/session/13618](https://meetinglibrary.asco.org/session/13618)
Early safety and efficacy from a phase I open-label clinical trial of CD137(4-1BB) agonistic antibody LVGN6051 as monotherapy and in combination with pembrolizumab.

**AUTHOR(S)**

**ABSTRACT**
2521

Activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab or panitumumab in patients with refractory solid tumors.

**AUTHOR(S)**
Elena Garralda, Gianluca Del Conte, Marina Macchini, Ignacio Matos, Konrad F. Klinghammer, Omar Saavedra Santa Gadea, Walter M. Fiedler, Christina C. Rolling, Maxim Kekenbo, Francesco Raspagliesi, Domenica Larusso, Isabelle ahrens-Fath, Beate Habel, Hans Baumeister, Alfredo Zurlo, Sebastian Ochsenreither

**ABSTRACT**
2522

Phase I study of LBL-007, a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody in patients with advanced solid tumors.

**AUTHOR(S)**
Yuankai Shi, Suxia Luo, Huan Zhou, Shengyu Zhou, Shan An, Zishu Wang, Sheng Yang, Ning Li, Xiaoli Li, Xinyi Yang

**ABSTRACT**
2523

Safety and tolerability results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab or panitumumab in patients with refractory solid tumors.

**AUTHOR(S)**
Sebastian Ochsenreither, Alfredo Zurlo, Elena Garralda, Ignacio Matos, Konrad F. Klinghammer, Gianluca Del Conte, Marina Macchini, Christina C. Rolling, Maxim Kekenbo, Omar Saavedra Santa Gadea, Francesco Raspagliesi, Domenica Larusso, Isabelle ahrens-Fath, Beate Habel, Hans Baumeister, Walter M. Fiedler

**ABSTRACT**
2524

Changes in T lymphocyte subsets in different tumors before and after radiotherapy: A meta-analysis.
AUTHOR(S)
Xiaoxia Zhu, Qin Wang, Shangbiao Li, Simiao Qiao, Zhihao Zheng, Xiaotong Duan

ABSTRACT
2525
A phase 1, open-label, dose escalation study of the safety and tolerability of T3011 in advanced cutaneous or subcutaneous malignancies.

AUTHOR(S)

ABSTRACT
2526
Safety and PK/PD of ALLO-647, an anti-CD52 antibody, with fludarabine (Flu)/cyclophosphamide (Cy) for lymphodepletion in the setting of allogeneic CAR-T cell therapy.

AUTHOR(S)

ABSTRACT
2527
Novel CoupledCAR technology for treating colorectal cancer.

AUTHOR(S)
Lei Xiao, Song Li, Chengfei Pu, Zhiyuan Cao, Xinyi Yang, Ning Li, Youli Luo, Haiyan Zhao, Hang Yang, Xi Huang, Xiaogang Shen, Xiwen Wang, Yongping Song, Junjie Mao, Pengfei Pang, Qun Hu, Zhao Wu, Victor Lu

ABSTRACT
2528

AUTHOR(S)

ABSTRACT
2529
CAR-T cells to deliver engineered peptide antigens and reprogram antigen specific T cell responses against solid tumors.

AUTHOR(S)
Daniel Y. Lee, Andy J. Minn, Lexus R. Johnson

ABSTRACT
A single-arm phase Ib study of autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)-CCICC-002.

AUTHOR(S)
Xiubao Ren, Li Zhou

ABSTRACT
A phase I-IIa study of genetically modified Tie-2 expressing monocytes in patients with glioblastoma multiforme (TEM-GBM Study).

AUTHOR(S)
Gaetano Finocchiaro, Bernhard Gentner, Francesca Farina, Alessia Capotondo, Marica Eoli, Elena Anghileri, Matteo G. Carabba, Valeria Cuccarini, Francesco Di Meco, Federico Legnani, Bianca Pollo, Maria Grazia Bruzzone, Marco Saini, Paolo Ferroli, Roberto Pallini, Alessandro Olivi, Stefania Mazzoleni, Carlo Russo, Luigi Naldini, Fabio Ciceri

ABSTRACT
In-depth immune and molecular profiling of melanoma patients receiving adoptive T-cell therapy reveals biomarkers of efficacy in ATATIL study.

AUTHOR(S)
Angela Orcurto, Johanna Chiffelle, Eleonora Ghisoni, David Barras, Isaac Crespo, Blanca Navarro Rodrigo, María Ochoa de Olza, Martina Imbimbo, Sylvie Rusakiewicz, Stephanie Tissot, Philippe O. Gannon, Urania Dafni, Stefan Zimmermann, Lana E. Kandalaft, Olivier Michielin, Michal Bassani-Sternberg, Denarda Dangaj, Lionel Trueb, Alexander Harari, George Coukos

ABSTRACT
PSMA targeted armored chimeric antigen receptor (CAR) T-cells in patients with advanced mCRPC: A phase I experience.

AUTHOR(S)
**A B S T R A C T**

2534

A single-arm phase Ib study of multiple target cytotoxic T-lymphocyte (MCTL) in combination with toripalimab as second-line therapy in advanced non-small cell lung cancer (NSCLC).

**AUTHOR(S)**

Xiubao Ren, Weihong Zhang

**A B S T R A C T**

2535

Initial results of a first-in-human, dose escalation study of a cell-based vaccine in HLA A*02+ patients (pts) with recurrent, locally advanced or metastatic HPV16+ solid tumors: SQZ-PBMC-HPV-101.

**AUTHOR(S)**

Antonio Jimeno, Joaquina C. Baranda, Monica M. Mita, Michael S. Gordon, Matthew H. Taylor, Wade T. Iams, Filip Janku, Ursula A. Matulonis, Howard Bernstein, Scott Loughhead, Martin Kornacker, Ricardo F. Zwirles, Oliver Rosen, Cathy Eng

**A B S T R A C T**

2536

Anakinra (AKR) prophylaxis (ppx) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) receiving orvacabtagene autoleucel (orva-cel).

**AUTHOR(S)**

Luciano J. Costa, Sham Mailankody, Paul Shaughnessy, Parameswaran Hari, Jonathan L. Kaufman, Sarah M. Larson, David Dingli, Kelvin Lee, Kristin Conte, Todd DeVries, Julia Piasecki, Meng Li, Ronald L. Dubowy, Myo Htut

**A B S T R A C T**

2537


**AUTHOR(S)**

Monzr Al Malki, Sumithira Vasu, Dipenkumar Modi, Miguel-Angel Perales, Donna Bui, Vineetha Edavana, Sojung Kim, Lauren Suarez, Mathias Oelke, Dan Bednářík, Robert D. Knight, Juan C. Varela
**Progression prediction model for solid tumors with clinical and immunological parameters.**

**AUTHOR(S)**

Aleksei V. Novik, Dmitrii V. Girdyuk, Tatyana L. Nekhaeva, Natalia V. Emelyanova, Anna Semenova, Gulfiya M. Teletaeva, Dilorom K. Latipova, Svetlana Protsenko, Irina A. Baldueva

**ABSTRACT**

Concordance of blood and tissue TMB from NGS testing in real-world settings and their ability to predict response to immunotherapy.

**AUTHOR(S)**

Emma Sturgill, Amanda Misch, Carissa Jones, Daniel Luckett, Xiaotong Fu, Suzanne F. Jones, Howard A. Burris III, David R. Spigel, Andrew J. McKenzie

**ABSTRACT**

Genomic immunotherapy (IO) biomarkers detected on comprehensive genomic profiling (CGP) of tissue and circulating tumor DNA (ctDNA).

**AUTHOR(S)**

Takayuki Yoshino, Hanna Tukachinsky, Jessica K. Lee, Ethan Sokol, Dean C. Pavlick, Aparna Aiyer, David Fabrizio, Jeffrey M. Venstrom, Saori Mishima, Yoshiaki Nakamura, Geoffrey R. Oxnard

**ABSTRACT**

Impact of circulating tumor DNA (ctDNA) detection on survival outcomes of patients (pts) treated with immune-checkpoint inhibitors (ICIs) in early clinical trials.

**AUTHOR(S)**

Vladimir Galvao, Ignacio Matos, Ana Moreno, Guzman Alonso, Irene Brana, Maria Villar, Omar Saavedra Santa Gadea, Honey K. Oberoi, Javier Ros, Roger Berche, Natassia Ann Wornham, Carlota Arenillas, Cristina Saura, Ana Oaknin, Enriqueta Felip, Eva Muñoz-Couselo, Elena Elez, Josep Tabernero, Rodrigo Toledo, Elena Garralda

**ABSTRACT**

Analysis of immune checkpoint blockade biomarkers in elderly patients using large-scale cancer genomics data.
ROSSIN ERBE, ZHEYU WANG, SHARON WU, JOANNE XIU, NEEHA ZAIDI, MARC E. LIPPMAN, CLAUDINE ISAACS, REVA K. BASHO, HEINZ-JOSEF LENZ, IGOR A. ASTSATUROV, JOHN MARSHALL, STEPHEN BAYLIN, ELIZABETH M. JAFFEE, EVANTHIA T. ROUSSOS TORRES, ASHANI WEERARATNA, HARIHARAN EASWARAN, ELANA J. FERTIG

ABSTRACT

2543

SER-ONCOVID: Seroconversion in solid-tumor cancer patients after COVID-19 diagnosis.

AUTHOR(S)

Anna Pous, Eudald Felip, Olatz Etxaniz, Ainhoa Hernandez Gonzalez, Sofia España, Margarita Romeo, David J. Pinato, Anna Esteve, Ricard Mesia

ABSTRACT

2544

Using the tumor microenvironment to identify predictors of immunotoxicity to checkpoint inhibitors.

AUTHOR(S)

William Alexander, Kristopher Attwood, Kayla Catalfamo, Grace K. Dy, Saby George, Marc S. Ernstoff, Yara Abdou

ABSTRACT

2545

A 4-chemokine signature to predict intermediate immunogenicity in homologous recombination repair deficient tumors.

AUTHOR(S)

Joan Miguel Romero, Yifan Wang, Alain Pacis, Robert E. Denroche, Gun Ho Jang, Barbara Grunwald, Steven Gallinger, George Zogopoulos

ABSTRACT

2546

First-in-human dose escalation of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies.

AUTHOR(S)

Justin C. Moser, Mark Voskoboynik, Nehal J. Lakhani, Michael Millward, Diwakar Davar, Wael A. Harb, Jing Yang, Gary Means, Kristi Manjarrez, Almudena Tercero, Hany Zayed, Jan Hillson, Christine Dela Cruz, Graciela N. Perez, Stanford L. Peng

ABSTRACT

2547
Phase 1A clinical trial of the first-in-class fascin inhibitor NP-G2-044 evaluating safety and anti-tumor activity in patients with advanced and metastatic solid tumors.

AUTHOR(S)
Vincent Chung, Komal L. Jhaveri, Daniel D. Von Hoff, Xin-Yun Huang, Edward G. Garmey, Jillian Zhang, Frank Y. Tsai

ABSTRACT
Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors.

AUTHOR(S)

ABSTRACT
Preliminary results of a first-in-human phase I study of IMM01, SIRPα Fc protein in patients with relapsed or refractory lymphoma.

AUTHOR(S)
Mingyuan Sun, Junyuan Qi, Weiwei Zheng, Lin Song, Bo Jiang, Zhenzhen Wang, Cheng Huang, Wenzhi Tian, Lugui Qiu

ABSTRACT
Results of a phase 1 study of SRF388, a first-in-human, first-in-class, high-affinity anti-IL-27 antibody in advanced solid tumors.

AUTHOR(S)

ABSTRACT
Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2.

**ABSTRACT**

2552

*Initial results from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel in patients with advanced solid tumors.*

**AUTHOR(S)**


**ABSTRACT**

2553

*Results of a phase 1 dose-escalation study of AMV564, a novel T-cell engager, alone and in combination with pembrolizumab in patients with relapsed/refractory solid tumors.*

**AUTHOR(S)**

Niharika B. Mettu, Alexander Starodub, Sarina Anne A. Piha-Paul, Raghad M. Abdul-Karim, Gabriel Tinoco, Michael R. Shafique, Victoria Smith, Christina Baccei, Patrick Y. Chun

**ABSTRACT**

2555

*A phase 1b, open-label, dose-escalation study to evaluate camidanlumab tesirine (Cami) as monotherapy in patients (pts) with advanced solid tumors.*

**AUTHOR(S)**

Igor Puzanov, Patricia LoRusso, Kyriakos P. Papadopoulos, Christopher T. Chen, Yvan LeBruchec, Xiaomin He, Thierry Cousin, Karin Havenith, Joseph Boni, Johanna C. Bendell

**ABSTRACT**

2556

*ItRECIST adapted efficacy assessment in solid tumors treated with intratumoral immunotherapy.*

**AUTHOR(S)**

Honey Kumar Oberoi, Xavier Serres-Créixams, Guzman Alonso, Ignacio Matos, Alberto Hernando-Calvo, Eva Muñoz-Couselo, Marc Diez, Iosune Baraibar, Maria Vieito, Omar Saavedra Santa Gadea, Vladimir Galvao, Gemma Mur-Bonet, Guillem Cunill-Macià, Mafalda Oliveira, Enriqueta Felip, Teresa Macarulla, Elena Elez, Josep Tabernero, Irene Brana, Elena Garralda
Targeting innate immunity with BXCL701 in combination with pembrolizumab in patients with advanced solid cancers: Phase 2 basket study.

AUTHOR(S)

ABSTRACT

GS-3583, a novel FLT3 agonist Fc fusion protein, to expand conventional dendritic cells in healthy volunteers.

AUTHOR(S)
Nishanthan Rajakumaraswamy, Anees Dauki, Michelle R. Kuhne, Torsten Trowe, Jing He, Christopher Clarke, Brian Carr, Angela Worth, Anshu Vashishta, Christian Schwabe, Ahmed A. Othman

ABSTRACT

Safety and efficacy of murine PVSRIPO plus anti-PD-1 immune checkpoint inhibitor (ICI) in a melanoma tumor model.

AUTHOR(S)
Lauren Neighbours, Zachary P. McKay, Matthias Gromeier, Garrett Nichols, Andrea T. Kelly, Daniel Corum, Michael Brown

ABSTRACT

Resetting the tumor microenvironment to favor anti-tumor immunity after local ablation.

AUTHOR(S)
Corrine A. Nief, Júlia Sroda Agudogo, Alana Gonzales, Rebecca A. Previs, Smita K. Nair, Nimmi Ramanujam

ABSTRACT

Phase 1 trial of the adenosine A2A receptor antagonist inupadenant (EOS-850): Update on tolerability, and antitumor activity potentially associated with the expression of the A2A receptor within the tumor.

AUTHOR(S)
Laurence Buisseret, Sylvie Rottey, Johann S. De Bono, Ariane Migeotte, Brant Delafontaine, Thubeena Manickavasagar, Chiara Martinoli, Noémie Wald, Maura Rossetti, Esha A. Gangolli, Erol Wiegert, Nicola McIntyre, Joanne J. Lager, Jean-Pascal H. Machiels

**ABSTRACT**

2562

Tumor-selective activity of XTX202, a protein-engineered IL-2, in mice without peripheral toxicities in nonhuman primates.

**AUTHOR(S)**


**ABSTRACT**

2563


**AUTHOR(S)**

Dominique Berton, Susana N. Banerjee, Giuseppe Curigliano, Sara Cresta, Hendrik-Tobias Arkenau, Cyril Abdeddaim, Rebecca S. Kristeleit, Andrés Redondo, Charles A. Leath III, Antonio Antón Torres, Wei Guo, Ellie Im, Thierry Andre

**ABSTRACT**

2564

Pembrolizumab in microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study.

**AUTHOR(S)**


**ABSTRACT**

2565

Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: A single-arm, multicenter, phase 2 study.

**AUTHOR(S)**

Shukui Qin, Jin Li, Haijun Zhong, Chuan Jin, Lili Chen, Xianglin Yuan, Qingxia Fan, Kehe Chen, Peiguo Cao, Jianjun Xiao, Da Jiang, Tao Zhang, Hongyu Zhang, Xicheng Wang, Wei Wang, Qingyu Wang

**ABSTRACT**
Multi-center phase 1 safety and efficacy study of nivolumab in renal transplant patients with metastatic malignancy.

AUTHOR(S)
John R. Zalcberg, Michael J. Boyer, Anne E. Taylor, Thean H. Tan, Bronwyn Hockley, Rob Carroll

ABSTRACT
Phase I dose escalation of KD033, a PDL1-IL15 bispecific molecule, in advanced solid tumors.

AUTHOR(S)
Jason J. Luke, Anthony J. Olszanski, Igor Puzanov, Dan Lu, Adrian Hackett, Stella Martomo, Jeegar Patel, Olivier Schueller, Alessandro Mora, Miranda Schlitt, Linghui Li

ABSTRACT
A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair deficient solid tumors.

AUTHOR(S)
Jian Li, Ye Xu, Aimin Zang, Yunong Gao, Quanli Gao, Yanqiao Zhang, Dong Wang, Jianming Xu, Ying Yuan, Haiping Jiang, Jieer Ying, Chunmei Shi, Yanhong Deng, Jing Wang, Tianshu Liu, Yi Huang, Zhezhen Li, Huanli Wang, Shou Liu, Lin Shen

ABSTRACT
Mega- and meta-analyses of fecal metagenomic studies in predicting response to immune checkpoint inhibitors.

AUTHOR(S)
Alya Heirali, Bo Chen, Matthew Wong, Pierre H. Schneeberger, Victor Rey, Anna Spreafico, Wei Xu, Bryan Coburn

ABSTRACT
Phase 2 study of retifanlimab (INCMGA00012) in patients (pts) with selected solid tumors (POD1UM-203).

AUTHOR(S)
Michele Maio, Michael Schenker, Jacques Medioni, Slawomir Mandziuk, Margarita Majem, Gwenaelle Gravis, Mark J. Cornfeld, Sulabha Ranganathan, Yubing Yao, Howard S. Yeh, Tibor Csösz
Efficacy of HX008 in high microsatellite instability/mismatch repair-deficient (MSI-H/dMMR) solid tumors: Results from a multicenter phase II open-label study.

AUTHOR(S)
Jing Huang, Yan Song, Suxia Luo, Xianli Yin, Enxiao Li, Hui Wang, Yifu He, Zhihui Liu, Qingxia Fan, Xinjun Liang Sr., Yongqian Shu, Yunpeng Liu, Nong Xu, Shu Zhang, Zhixiang Zhuang, Jingdong Zhang, Xiaoge Kou, Fen Wang, Xiaodong Zhu, Shengmian Li

Abstract
An exploratory study of nivolumab (nivo) with or without ipilimumab (ipi) according to the percentage of tumoral CD8 cells in advanced metastatic cancer.

AUTHOR(S)

Abstract
Assessment of cancer-specific microbiome signature of response to immune checkpoint inhibitors.

AUTHOR(S)
Michal Sarfaty, Christopher A. Desjardins, Paul Giardina, Kankana Bardhan, Swarna Pandian, Keith Halley, Elizabeth M. Halvorsen, Margaret K. Callahan, Michael A. Postow, Chung-Han Lee, Ritesh Kotecha, Daniel Kashani, Neha Ratna, Ashley M. Regazzi, Matthew R. Henn, Matthew D. Hellmann, Gopa Iyer, Christopher B. Ford, Jonathan U. Peled

Abstract
CheckMate 8KX: Phase 1/2 multitumor preliminary analyses of a subcutaneous formulation of nivolumab (± rHuPH20).

AUTHOR(S)
Sara Lonardi, Iwona Lugowska, Christopher G. Jackson, Anne O’Donnell, Rastilav Bahleda, Marcelo Garrido, Loes Latten-Jansen, Matias Chacon, Habte A. Yimer, Trixia Camacho, Srivani Konduri, Urvi Aras, Kinjal Sanghavi, Heather Vezina, Sonia Dolfi, Federica Alessi, Josè Trigo, Aitana Calvo
Final results of a phase I “RadVax” trial of hypofractionated radiation combined with pembrolizumab in patients with metastatic solid tumors.

AUTHOR(S)

ABSTRACT
2576

A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb) in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.

AUTHOR(S)
Vinod Ganju, Adam Cooper, Bo Gao, Kate Wilkinson

ABSTRACT
2577

Phase I/II study of nivolumab plus vorolanib in patients with thoracic malignancies: Interim efficacy of the SCLC and primary refractory NSCLC cohorts, and safety data across all cohorts.

AUTHOR(S)
Selina K. Wong, Jennifer G. Whisenant, Christine M. Bestvina, Lynne D. Berry, Taofeek K. Owonikoko, Rachel E. Sanborn, Philip E. Lammers, Badi E. El Osta, Suresh S. Ramalingam, Jennifer W. Carlisle, Conor E. Steuer, Hossein Borghaei, Giovanni Selvaggi, Yu Shyr, Heather A. Wakelee, Leora Horn, Katy Beckermann

ABSTRACT
2578

Phase Ib study of BI 836880 (VEGF/Ang2 nanobody) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with solid tumors.

AUTHOR(S)
Nicolas Girard, Martin Wermke, Fabrice Barlesi, Dong-Wan Kim, Francois Ghiringhelli, Jaafar Bennouna, Thierry Lesimple, Enriqueta Felip, David Berz, Jong-Seok Lee, Arnaud Jeanson, Celine Mascaux, Mark Voskoboynik, Piotr Serwatowski, Michael C. Burger, Harald T. Landsteiner, Victoria Chen, Girish Jayadeva, Juergen Alt, Bjoern Hackanson

ABSTRACT
2579
Phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.

AUTHOR(S)
Jermaine Coward, Afaf Abed, Adnan Nagrial, Ben Markman

ABSTRACT
Anlotinib enhanced penpulimab efficacy through remodeling of tumor vascular architecture and immune microenvironment in hPD-L1/hPD-1 humanized mouse model.

AUTHOR(S)
Yunlong Shan, Chongjin Zhong, Qi Ni, Mengying Zhang, Guangji Wang, Fang Zhou

ABSTRACT
Platform trial of ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients (pts) with previously treated advanced solid tumors: Combination with BI 836880, a VEGF/Ang2-blocking nanobody.

AUTHOR(S)
Maen A. Hussein, Ivor J. Percent, Johanna C. Bendell, Edward Arrowsmith, Hendrik-Tobias Arkenau, Quincy S. Chu, Aaron R. Hansen, Damijan Erzen, Sheng Qiu, Anthony Lucarelli, Susanna V. Ulahannan

ABSTRACT

AUTHOR(S)
Sophia Frentzas, Tarek Meniawy, Steven C. Kao, Ruihua Wang, Yunxia Zuo, Hao Zheng, Wei Tan

ABSTRACT
IFN-α, IFN-γ, IL-2 combined with TNF-α for predicting efficacy of PD-1 inhibitors combination therapy in patients with solid cancers.

AUTHOR(S)
A phase 1 dose-escalation study of a PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies.

AUTHOR(S)
Rachel E. Sanborn, Rodolfo E. Bordoni, Gini F. Fleming, Mustafa Khasraw, Thomas Hawthorne, Lawrence J. Thomas, Tracey Rawls, Diane C. Young, Philip Golden, Tibor Keler, Michael J. Yellin

The predictive values of loss-of-function variants in histone methyltransferases for response to immune checkpoint inhibitors in solid tumors.

AUTHOR(S)
Naixin Liang, Yanling Niu, Xin Zhang, Tonghui Ma

Association of KMT2C/D loss-of-function mutations with tumor infiltrating lymphocytes and response to immune checkpoint inhibitors in solid tumors.

AUTHOR(S)
Ruiqi Liu, Yanling Niu, Xin Zhang, Tonghui Ma

Risk of immunosuppression and hospitalization after checkpoint inhibitor therapy in patients with cancer and radiation therapy.

AUTHOR(S)
Kate E. Lee, David A. Bender, Catherine S. Spina, Brigham Hyde, Adam S. Faye, Simon Cheng

Phase Ia/Ib dose-escalation study of IBI110 (anti-LAG-3 mAb) as a single agent and in combination with sintilimab (anti-PD-1 mAb) in patients (pts) with advanced solid tumors.
A phase I trial evaluating NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with advanced cancers.

Overcoming resistance to anti-PD-1 with tumor agnostic NBTXR3: From bench to bed side.

A phase 1/2 study of intratumoral INT230-6 alone (IT-01) or in combination with pembrolizumab [KEYNOTE-A10] in adult subjects with locally advanced, unresectable and metastatic solid tumors refractory to therapy.

Nivolumab/ipilimumab primed immunotransplant in post-CAR-T and post-ASCT DLBCL.
Safety, pharmacokinetics, pharmacodynamics profiles and preliminary antitumor activity of phase 1b/2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: The phase 1b data report.

AUTHOR(S)
Aung Naing, Jean Fan, Byung Ha Lee, Debashree Basudhar, Shubham Pant, Marya F. Chaney, Cristina Laviada, Cynthia Rajan, Ngocdiep T. Le, Minal A. Barve

ABSTRACT
2594

Phase II trial of MEDI0457 and durvalumab for patients with recurrent/metastatic HPV-associated cancers.

AUTHOR(S)
Van K. Morris, Amir A. Jazaeri, Shannon N. Westin, Curtis A. Pettaway, Solly George, Ryan Huey, Michaela Onstad, Shi-Ming Tu, Jennifer Wang, Aaron Shafer, Benny Johnson, Lianchun Xiao, David J. Vining, Ming Guo, Ying Yuan, Michael M. Frumovitz

ABSTRACT
2595

Preliminary data from QUILT 3.055: A phase 2 multi-cohort study of N803 (IL-15 superagonist) in combination with checkpoint inhibitors (CPI).

AUTHOR(S)

ABSTRACT
2596

Evaluating the role of immune-checkpoint inhibitor (ICI) combinations in patients (pts) with unselected “cold” tumors enrolled in early clinical trials (CT).

AUTHOR(S)
Omar Saavedra Santa Gadea, Alberto Hernando-Calvo, Roger Berche, Maria Vieito, Irene Brana, Ignacio Matos, Guzman Alonso, Vladimir Galvao, Analia Azaro, Honey Kumar Oberoi, Natassia Ann Wornham, Javier Ros, Juan Francisco Grau Béjar, Carmen García, Teresa Macarulla, Jaume Capdevila, Elena Elez, Josep Tabernero, Rodrigo Dienstmann, Elena Garralda

ABSTRACT
2597

A pan-cancer analysis of MUC family genes as potential biomarkers for immune checkpoint therapy.

AUTHOR(S)
Yang Li, Qianqian Duan, Yuan Tan

**Abstract**

2598

Real-world pan-cancer landscape of frameshift mutations (FSM) and their role in predicting responses to immune checkpoint inhibitors (ICI) in patients (pts) with tumors with low tumor mutational burden (TMB).

**Authors**


**Abstract**

2599

Association of KMT2C mutations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.

**Authors**

Chunling Liu, Qianqian Duan, Qin Zhang

**Abstract**

2600

MSIFinder: A python package for detecting MSI status using random forest classifier.

**Authors**

Tao Zhou, Libin Chen, Jing Guo, Mengmeng Zhang, Huanhuan Liu, Yanrui Zhang, Huina Wang, Shanbo Cao, Haijun Wang, Feng Lou

**Abstract**

2601

A cancer organogram test as a guide for oncology treatments in SOLID tumors: An analysis of 628 tests in 419 patients.

**Authors**

Astrid Margossian, Madison Pollastro, Annie Richardson, Payel Chatterjee, Mia Lints, Danielle Peretti, Rachele Rosati, Lauren Appleyard, Grace Durenberger, G. A. Whitney, Hallie Swan, Shalini Pereira, Adam Diehl, Christopher J. Kemp, Barbara A. Goff, Kalyan Banda, William P. Harris, Elizabeth M. Swisher, Vijayakrishna K. Gadi, Carla Grandori

**Abstract**

2602
Relationship between DICER1 mutations and immunotherapy biomarkers in solid tumors.

AUTHORS
Jie Gao, Xia You, Taiyan Guo, Qin Zhang, Qianqian Duan, Chuang Qi

ABSTRACT
2603

YAP1 mutation as a novel predictor of response to anti-PD-1/PD-L1 treatment in pan-cancers.

AUTHORS
Wei-guo Xu, Jing Zhu, Lin Li, Dongsheng Chen, Qin Zhang, Qianqian Duan, Si Li, Mingzhe Xiao

ABSTRACT
2604

Pan-cancer analysis of CD274 (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression.

AUTHORS
Richard S. Huang, Brennan Decker, Karthikeyan Murugesan, Matthew Hiemenz, Douglas A. Mata, Gerald Li, James Creeden, Shakti H. Ramkissoon, Jeffrey S. Ross

ABSTRACT
2605

Investigating the various predictive values of POLE/POLD1 mutations for response to immune checkpoint inhibitors (ICIs) in different solid tumors.

AUTHORS
Yanling Niu, Tonghui Ma, Tao Li

ABSTRACT
2606

Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes predicts survival after immune checkpoint inhibitor therapy across multiple cancer types.

AUTHORS

ABSTRACT
Awareness and utilization of tumor mutation burden (TMB) as a biomarker for administration of immuno-oncology (I-O) therapeutics by practicing community oncologists in the United States (U.S.).

**AUTHORS**

Kristin M. Savill, Marjorie E. Zettler, Bruce A. Feinberg, Yolaine Jeune-Smith, Ajeet Gajra

**ABSTRACT**

Comprehensive genomic and transcriptomic profiling (CGTP) to predict pembrolizumab (P) benefit in patients (pts) with advanced solid tumors (STs).

**AUTHORS**

Dan Rhodes, Daniel H. Hovelson, Malek M. Safa, Mark E. Burkard, Eddy S. Yang, William J. Edenfield, Travis Reeder, Hana Vakil, Kat Kwiatkowski, Khalis Mitchell, Bryan Johnson, Scott A. Tomlins

**ABSTRACT**

YAP1 transcription factor expression to define subsets of cancers with T-cell inflamed phenotype in a pan-tumor analysis across 33 tumor types.

**AUTHORS**

Bhakti Dwivedi, Andrey Ivanov, Guojing Zhang, Fadlo R. Khuri, Suresh S. Ramalingam, Haian Fu, Gabriel Sica, Taofeek K. Owonikoko

**ABSTRACT**

Therapeutic effect of DDR pathway with different functional annotations for immune checkpoint inhibitor.

**AUTHORS**

Wei Nie, Hua Zhong, Fengcai Wen, Ding Zhang, Shiqing Chen, Baohui Han

**ABSTRACT**

First-in-human, phase I study of PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in biochemical relapse (BCR) and metastatic castration-resistant prostate cancer (mCRPC).
ABSTRACT
2612

Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors.

AUTHOR(S)
Maura L. Gillison, Mark M. Awad, Przemyslaw Twardowski, Ammar Sukari, Melissa L. Johnson, Mark N. Stein, Richard Hernandez, Jessica Price, Kevin J. Mancini, Mara Shainheit, Vijetha Vemulapalli, Jessica Flechtner, Thomas A. Davis, Roger B. Cohen

ABSTRACT
2613

Phase I trial to determine safety and immunogenicity of amplivant, a synthetic toll-like receptor 2 ligand, conjugated to two HPV16 E6 synthetic long peptides.

AUTHOR(S)
Frank M. Speetjens, Marij J. Welters, Marije Slingerland, Peggy de Vos van Steenwijk, Inge C. Roozen, Sanne Boekstijn, Nikki Loof, Gijs G. Zom, Rob Valentijn, Willem-Jan Krebber, Cornelis J. Melief, Dmitri V. Filippov, Hans Gelderblom, Sjoerd H. van der Burg, Ferry Ossendorp

ABSTRACT
2614

A phase 1b study of personalized neoantigen vaccine plus pembrolizumab in adults with advanced cancer.

AUTHOR(S)

ABSTRACT
2615

A phase 1 study of an off-the-shelf, multi-neoantigen vector (ADXS-503) in subjects with metastatic non-small cell lung cancer (NSCLC) progressing on pembrolizumab as last therapy.

AUTHOR(S)
Missak Haigentz, Suresh S. Ramalingam, Gregory J. Gerstner, Balazs Halmos, Neil Morganstein, Surya Vangala, Megan Parsi, Victor Kabala, Dinesh Simkhada, Cristiane Metran, ANDRES A. GUTIERREZ, Jonathan W. Goldman
A phase 1 open label trial of intravenous administration of MVA-BN-Brachyury vaccine in patients with advanced cancer.

AUTHOR(S)
Peter J. DeMaria, Katherine Lee-Wisdom, Ravi A. Madan, Fatima Karzai, Renee N. Donahue, Claudia Palena, Caroline Jochems, Charalampous Sioudas, Julius Strauss, Jennifer L. Marte, Jason Redman, Houssein Abdul Sater, Borys Korchin, Tatiana Adams, Guenter Silbernagl, Cesar Pico-Navarro, Jeffrey Schom, James L. Gulley, Marijo Bilusic

ABSTRACT
Long-term follow up of patients with mesothelioma treated with dendritic cell therapy in three phase I trials.

AUTHOR(S)
Daphne W. Dumoulin, Robin Cornelissen, Koen Bezemer, Sara Baart, Joachim Aerts

ABSTRACT
Final report and long-term outcomes: Phase I trial of a HER2 intracellular plasmid-based vaccine in HER2+ advanced stage breast cancer.

AUTHOR(S)
Mary L. Disis, Yushe Dang, Andrew L. Coveler, Doreen Higgins, Jennifer Childs, Lupe G. Salazar

ABSTRACT
A phase I clinical trial investigating the telomerase vaccine UV1 in combination with pembrolizumab in patients with advanced melanoma.

AUTHOR(S)
Yousef Zakharia, Steven O’Day, Wenche Rasch, Mohammed M. Milhem

ABSTRACT
Adverse effects of COVID-19 vaccination among cancer patients: Results from an Internet-based survey.

AUTHOR(S)
Brian Loew, Richard Tsai, John Hervey, Kathleen D. Hoffman, John Novack, Jennifer Johnson, Don S. Dizon, Stuart L. Goldberg
Risk factors for immune mediated adverse events with immune checkpoint inhibitors.

AUTHOR(S)
Ari Pelcovits, Hetal Mistry, Rani Chudasama, Sarah Andrea, Humera Khurshid

ABSTRACT
Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors.

AUTHOR(S)
Stéphane Champiat, Philippe A. Cassier, Nuria Kotecki, Iphigenie Korakis, Armelle Vinceneux, Christiane Jungels, Jon Blatchford, Mabrouk M. Elgadi, Nicole Clarke, Claudia Fromond, Nicolas Poirier, Berangere Vasseur, Aurelien Marabelle, Jean-Pierre Delord

ABSTRACT
A phase 1/2 open-label study of KY1044, an anti-ICOS antibody with dual mechanism of action, as single agent and in combination with atezolizumab, in adult patients with advanced malignancies.

AUTHOR(S)
Manish R. Patel, Aung Naing, Howard A. Burris III, Chia-Chi Lin, Giuseppe Curigliano, Fiona Thistlethwaite, Anna R. Minchom, Paolo A. Ascierto, Filippo G. De Braud, Michael Cecchini, Wouter Hanekom, Richard C. Sainson, Rosamund J. Wilson, Sonia Quaratino

ABSTRACT
Real world experience with standalone immunotherapy regimens: Immune-related adverse events, healthcare utilization and cost among patients with commercial or Medicare Advantage insurance.

AUTHOR(S)
Krishna S. Gunturu, Timothy Pham, Sonali Shambhu, Michael J. Fisch, John Barron, David J. Debono

ABSTRACT
KY1044 to target the ICOS pathways inducing intratumoral Treg depletion and agonism of effector T cells: Preliminary pharmacodynamic markers from a phase 1/2 multicenter trial.

AUTHOR(S)

ABSTRACT
2626

Association and prevalence of venous thromboembolism in cancer patients with COVID-19: A single healthcare system experience.

AUTHOR(S)
Aneesha Ananthula, Dat Tran, Katharine Thomas, Katie L. McQueen Amaker, Anh Nguyen, Soham Mahato, Brandon T. Thrash, Andrew G. Chapple, Suki Subbiah

ABSTRACT
2627

Priming immunotherapy with radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC) and head and neck squamous cell cancer (HNSCC): Interim analysis of phase II clinical trial.

AUTHOR(S)

ABSTRACT
2628

The Tim3-galectin-9 interactions in the tumor microenvironment of nasopharyngeal cancer.

AUTHOR(S)
Dora L. Kwong, Ngar-Woon Kam, Wai Chun Tse, Sing Hei Lok, George Tsao, Victor H. Lee

ABSTRACT
2629

Safety of AK117, an anti-CD47 monoclonal antibody, in patients with advanced or metastatic solid tumors in a phase I study.

AUTHOR(S)
Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors.

Comparison of checkpoint inhibitor treatment-related cutaneous adverse events in racial and ethnic minority and Caucasian cohorts at Memorial Sloan Kettering Cancer Center.

Proton pump inhibitor use (PPI) in patients treated with immune checkpoint inhibitors (ICI) for advanced cancer: Survival and prior therapy.

Initial findings of the first-in-human phase I study of AGEN2373, a conditionally active CD137 agonist antibody, in patients (pts) with advanced solid tumors.

Late immune-related adverse events with immune checkpoint inhibitors.
AUTHOR(S)

ABSTRACT
2635
Cardiovascular toxicity incidence following immune checkpoint inhibitors in randomized clinical trials: A systematic review and meta-analysis.

AUTHOR(S)
Camila B. Xavier, Carlos Diego H. Lopes, Guilherme Harada, Artur Katz, Denis L. Fontes Jardim

ABSTRACT
2636
Infections in cancer patients treated with immune checkpoint inhibitors: Data from randomized trials.

AUTHOR(S)
Cinzia Solinas, Anna Maria Morelli, Andrea Luciani, Antonio Ghidini, Fausto Petrelli

ABSTRACT
2637
Age affects the efficacy of immune checkpoint inhibitors in patients with advanced cancer.

AUTHOR(S)
Yongjie Wang, Ronghua Yang, Dong Wang, Donghua Zhao, Peng Li, Mengjun Li, Yinxue Qi, Ningning Luo, Yaqing Wu, Qin Zhang

ABSTRACT
2638
Improving tolerability of pembrolizumab with weight based dosing: A meta-analysis.

AUTHOR(S)
Nabeela K. Patail, Amna F. Sher, Shenhong Wu

ABSTRACT
2639
Pan-Canadian cohort of immune checkpoint inhibitor-induced insulin-dependent diabetes mellitus (CANDIED).
AUTHOR(S)
Thiago Pimentel Muniz, Daniel V. Araujo, Kerry J. Savage, Tina Cheng, Moumita Saha, Xinni Song, Sabrina Gill, Jose G. Monzon, Dejani Grenier, Sofia Genta, Anna Spreafico, David Hogg

ABSTRACT

Real-world outcomes of treatment with immune checkpoint inhibitors in unique patient cohorts: Elderly, non-caucasian race, poor performance status, obese, chronic viral infections, and autoimmune diseases.

AUTHOR(S)

ABSTRACT

Maintenance immunosuppressive therapy with resumption of immune checkpoint inhibitor treatment to reduce recurrence of immune-mediated colitis.

AUTHOR(S)
Hamzah Abu-Sbeih, Fangwen Zou, Barbara Dutra, Mehmet Altan, Jennifer L. McQuade, John A. Thompson, Anusha Thomas, Yinghong Wang

ABSTRACT

Outcomes of immune checkpoint inhibitor-mediated colitis: Multicenter cohort study.

AUTHOR(S)

ABSTRACT

Pancreatic volumes in immune checkpoint inhibitor-induced diabetes.

AUTHOR(S)
Rebecca Jeun, Sireesha Yedururi, Victor Lavis, Conor Best, Jeena Varghese, Ramona Dadu, Isabella C. Glitza, Sonali Thosani

ABSTRACT

203
Incidence of hepatitis associated with addition of immune checkpoint blockade to conventional solid tumor therapy: A meta-analysis of phase 3 randomized clinical trials.

AUTHOR(S)
Yu Fujiwara, Nobuyuki Horita, Ho Namkoong, Hirotaka Miyashita, Matthew Harrington, Matt D. Galsky

ABSTRACT
2645

A first-in-human, multicenter, open-label, phase 1 study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies.

AUTHOR(S)
Gustav J. Ullenag, Jeffrey Yachnin, Ana Carneiro, Emma Elison, Malin Carlsson, Charlotte A. Russell, Karin Enell Smith

ABSTRACT
2646

Consensus disease definitions for the spectrum of neurologic immune related adverse events.

AUTHOR(S)
Amanda C. Guidon, Leeann B. Burton, Bart K. Chwalisz, James M. Hillis, Teilo Schaller, Kerry L. Reynolds

ABSTRACT
2647

A risk stratification model for toxicities in phase 1 immuno-oncology (P1-IO) trials.

AUTHOR(S)
Alberto Hernando-Calvo, Abdulazeez Salawu, Marc Oliva Bernal, Daniel V. Araujo, Zhihui (Amy) Liu, Rachel Chen, Lillian L. Siu

ABSTRACT
2648

Prevalence of hyperprogressive disease (HPD) mutations and correlations to immune-related biomarkers in a large pan-cancer Chinese cohort.

AUTHOR(S)
Shengli Yang, Xinyi Liu, Ting Bei, Mengli Huang

ABSTRACT
2649
Pembrolizumab patient reported benefits: A perspective based on multiple tumors.

AUTHOR(S)
Elise Wu, Paivi H. Miskala, Mohd Kashif Siddiqui, Pankaj Rai, Eva Hajdukova, Nathalie Erpelding, Jacqueline Vanderpuye-Orgle

ABSTRACT
2650

Pseudoprogression and cancer immunotherapy: A seven year retrospective study of rate, temporal course, and predictive markers in an Irish tertiary referral center.

AUTHOR(S)
Kate McKendry, Fiona Desmond, Cian Ward, Austin G. Duffy

ABSTRACT
2651

Proton pump inhibitors and antibiotics impact on toxicities and clinical outcomes in cancer patients treated with immunotherapy.

AUTHOR(S)
Haniel a. Araujo, Camila M. Moniz, Oddone F. Braghiroli, Milena P. Mak, Lucas F. Uratani, Ricardo Dahmer Tiecher, Priscila M. Moraes, Ingrid Barbosa, Veridiana P. Camargo, Maria Ignez F. Braghiroli, Gilberto Castro Jr., Paulo M. Hoff, Maria Del Pilar Diz

ABSTRACT
2652

Impact of pharmacodynamic biomarkers in immuno-oncology (IO) phase 1 clinical trials.

AUTHOR(S)
Abdulazeez Salawu, Rachel Chen, Alberto Hernando-Calvo, Daniel V. Araujo, Marc Oliva Bernal, Zhihui (Amy) Liu, Lillian L. Siu

ABSTRACT
2653

Impact of multidisciplinary severe immunotherapy complication service on outcomes for cancer patients receiving immune checkpoint inhibition.

AUTHOR(S)

ABSTRACT
Patients with steroid-refractory toxicity following immune checkpoint inhibitors: Frequent hospitalizations and long duration of illness.

AUTHOR(S)
Mia Bothwell, Aaron Cheng, Leyre Zubiri, Meghan Mooradian, Yevgeniy R. Semenov, Gayle C. Blouin, Erica Tavares, Jennifer Hutchinson, Leila Rostamnjad, Monica Jackson, Kerry L. Reynolds

ABSTRACT

Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.

AUTHOR(S)
Keun Wook Lee, Young-Hyuck Im, Keun Seok Lee, Jae Y. Cho, Do-Youn Oh, Hyun Cheol C. Chung, Yee Chao, Li-Yuan Bai, Chia Jui Yen, In-Ho Kim, Sang Cheul Oh, Chia-Chi Lin, Jin Wang, Xin Wang, Huiyan Li, Yen-Yang Chen, Yoon-Koo Kang

ABSTRACT

SGNTGT-001: A phase 1 study of SEA-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies (trial in progress).

AUTHOR(S)
Elena Garralda, Rachel E. Sanborn, Anna R. Minchom, Diwakar Davar, Giuseppe Curigliano, Vincent Ribrag, Amitkumar Mehta, Francine M. Foss, Jasmine M. Zain, Andres Forero-Torres, Stephen M. Ansell

ABSTRACT


AUTHOR(S)
Ignacio Melero, Emiliano Calvo, Reinhard Dummer, Elena Garralda, Martin H. Schuler, Maria-Elisabeth Goebeler, Ralf C. Bargou, Tanja Gromke, Josep Tabernero, Egle Ramelyte, Maria De Miguel, Miguel F. Sanmamed, Maria E. Rodriguez-Ruiz, Petra Fettes, Kathrin Klar, Manfred Ruediger, Christine Schuberth-Wagner, Markus Haake, Joerg Wischhusen, Eugen Leo

ABSTRACT

A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC410 in subjects with advanced or metastatic solid tumors.
AUTHOR(S)

ABSTRACT
TPS2659

A phase 1, first in human study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors.

AUTHOR(S)
Joshua Bauml, Natalie S. Grover, Amy Ronczka, Daniel Cushing, Michael Klichinsky, Debora Barton, Elizabeth C. Dees

ABSTRACT
TPS2660

Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2).

AUTHOR(S)

ABSTRACT
TPS2661

A phase 1 study to evaluate chimeric antigen receptor (CAR) T cells incorporating a chlorotoxin tumor-targeting domain for patients with MMP2+ Recurrent or progressive glioblastoma (NCT04214392).

AUTHOR(S)
Behnam Badie, Michael E. Barish, Ammar Chaudhry, Massimo D’Apuzzo, Stephen J. Forman, Jana Portnow, Shirong (Sean) Wang, Julie A. Ressler, Jennifer Simpson, Julie Kilpatrick, Paige McNamara, Jamie Wagner, Suzette Blanchard, Dongrui Wang, Christine Brown

ABSTRACT
TPS2662

Phase I study of adoptive immunotherapy for advanced MUC1* positive breast cancer with autologous T cells engineered to express a chimeric antigen receptor, huMNC2-CAR44 specific for a cleaved form of MUC1 (MUC1*).
A phase 1 study of RTX-321, an engineered red blood cell as an artificial antigen-presenting cell expressing HLA-A*02 with the HPV-16 E7 peptide and 4-1BB ligand with membrane-bound IL-12 for the treatment of HPV 16-positive cancers.

AUTHOR(S)
Johanna C. Bendell, Alexander I. Spira, Ramez N. Eskander, Ezra E. Cohen, Geoffrey Kuesters, Christopher Plescia, Karen Campbell, Tiffany Chen, Omid Hamid

Identification of a microbiome signature predicting immune checkpoint inhibitor outcomes across multiple cancer types in the MITRE study.

AUTHOR(S)
Philippa G. Corrie, Sarah J. Welsh, Grant D. Stewart, Gary Doherty, Kevin Vervier, Anne Neville, Christine Parkinson, Kate Fife, Guy Faust, Kamalram T. Jayaparakash, Thomas R. Geldart, Ewan Brown, Matthew Wheeler, Jenny P. Nobes, David Bruce, Nikos Demiris, Katy M. Dalchau, David Adams, Mat Robinson, Trevor Lawley

Phase I/Ib study with INT-1B3, a novel LNP-formulated micro-RNA (miR-193a-3p mimic) therapeutic for patients with advanced solid cancer.

AUTHOR(S)
Nuria Kotecki, Frans Opdam, Debbie Rombrecht, Michiel Strijbos, Karlijn Kroon, Michel Janicot, Sanaz Yahyanejad, Bryony Telford, Marion van den Bosch, Farshid Alemdehy, Thijs de Gunst, Harm den Boer, Rogier M. Vos, Laurens van Pinxteren, Roel Schapveld

Phase 1/2 study of the novel SUMOylation inhibitor TAK-981 in adult patients (pts) with advanced or metastatic solid tumors or relapsed/refractory (RR) hematologic malignancies.

AUTHOR(S)
**TPS2667**

**Association of combined phase I/II study of a novel bicyclic peptide and MMAE conjugate BT8009 in patients with advanced malignancies with Nectin-4 expression.**

**AUTHOR(S)**

Meredith McKeen, Gerald S. Falchook, Johanna C. Bendell, Babar Bashir, Neil Palmisiano, Roshawn Watson, Mary-Anne McKenna, Carly Campbell, Dominic P. Smethurst, Phil Jeffrey, Julius Kirui, Hendrik-Tobias Arkenau, Elisa Fontana

**ABSTRACT**

**TPS2668**

**Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRAS\textsuperscript{G12C} inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101).**

**AUTHOR(S)**


**ABSTRACT**

**TPS2669**

**A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors.**

**AUTHOR(S)**


**ABSTRACT**

**TPS2670**

**Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors.**

**AUTHOR(S)**

Vivek Subbiah, Mark M. Awad, Adil Daud, Martin Gutierrez, Jessica D. McDermott, Sai-Hong Ignatius Ou, Tomoko Hirohashi, Kim Ingram, Colleen Oliver, Derek Smith, Lance Wollenberg, James L. Abbruzzese

**ABSTRACT**
Phase 1, first-in-human trial of JTX-8064, an anti-LILRB2/ILT4 monoclonal antibody, as monotherapy and in combination with anti-PD-1 in adult patients with advanced solid tumors (INNATE).

AUTHOR(S)

ABSTRACT

A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors.

AUTHOR(S)
Angela T. Alistar, Anthony B. El-Khoueiry, Devalingam Mahalingam, Monica M. Mita, Hwankyu Kang, Yeong-In Yang, Jiye Ahn, Jeongjun Kim, Baejung Choi, Yeejin Jeon, Chunwon Jung, Borami Jeon, Jaeseung Kim, Kiyean Nam

ABSTRACT

Phase 1 first-in-human study of ABBV-184 monotherapy in adult patients with previously treated acute myeloid leukemia or non-small cell lung cancer.

AUTHOR(S)

ABSTRACT

A phase I study of AK119, an anti-CD73 monoclonal antibody, in combination with AK104, an anti-PD-1/CTLA-4 bispecific antibody, in patients with advanced or metastatic solid tumors.

AUTHOR(S)
Ben Markman, Amy H. Hsieh, Jermaine Coward, Matteo S. Carlino, Sophia Frentzas, Xiaoping Jin, Baiyong Li, Zhongmin M. Wang, Kon Yew Kwek, Yu Xia

ABSTRACT
A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).

AUTHOR(S)

ABSTRACT
TPS2676

An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors.

AUTHOR(S)
Arvind Dasari, John S. Kauh, Christopher Tucci, Shivani Nanda, Marek K. Kania, Jennifer W. Carlisle, Andrew S. Paulson

ABSTRACT
TPS2677

Combination of atezolizumab and pirfenidone in second-line and beyond NSCLC: A phase I/II study.

AUTHOR(S)
Takefumi Komiya, Jun Zhang, Prakash C. Neupane, Kathan Mehta, Chao H. Huang

ABSTRACT
TPS2678


AUTHOR(S)

ABSTRACT
TPS2679

Personalized DNA neoantigen vaccine in combination with plasmid IL-12 and pembrolizumab for the treatment of patients with advanced hepatocellular carcinoma.

AUTHOR(S)
Phase I study investigating the safety of stereotactic body radiotherapy (SBRT) with anti-PD-1 and anti-IL-8 for the treatment of multiple metastases in advanced solid tumors.

AUTHOR(S)
Lilit Karapetyan, Adam C. Olson, William E. Gooding, Riyue Bao, Steven J. Chmura, Jason J. Luke

A phase 1 trial of FID-007, a novel nanoparticle paclitaxel formulation, in patients with solid tumors.

AUTHOR(S)
Jacob S. Thomas, Diane Habib, Diana L. Hanna, Irene Kang, Syma Iqbal, Jorge J. Nieva, Denice Tsao-Wei, Francisco Acosta, Ming Hsieh, Yilong Zhang, Anthony B. El-Khoueiry

Bosutinib in combination with pemetrexed in patients with selected metastatic solid tumors: A phase I study (NCT03023319).

AUTHOR(S)
Nagla F. Abdel Karim, Mahran Shoukier, Ihab Eldessouki, Ahmed Khaled, John Morris

**ABSTRACT**

3022

**Profiling 523 cancer associated genes in circulating tumor DNA of children with CNS tumors.**

**AUTHOR(S)**

Erin R. Bonner, Robin Harrington, Biswajit Das, Paul M. Williams, Chris A. Karlovich, Amanda Peach, D’Andra Howell, Maria Saeed, Javad Nazarian

**ABSTRACT**

3023

**Interleukin-1-beta concentration and neutrophil-lymphocyte ratio as possible predicting biomarkers of response to therapy with checkpoint inhibitors.**

**AUTHOR(S)**

Rashida Orlova, Natalia V. Zhukova, Anna Malkova, Ekaterina Kaledina, Anna Gubal, Vladimir Sharoyko

**ABSTRACT**

3024

**Genes copy number as a marker of low-invasive assessment of rectal tumors radiotherapy effectiveness.**

**AUTHOR(S)**


**ABSTRACT**

3025

**Liquid biopsy testing: Impact on treatment assignment and survival in a community-based oncology practice—A real-world experience.**

**AUTHOR(S)**


**ABSTRACT**

3027
Circulating tumor DNA as markers of dynamic recurrence risk and adjuvant chemotherapy benefit in resected non-small cell lung cancer.

AUTHOR(S)
Wei Guo, Fan Zhang, Fang Lv, Ying Ji, Yue Peng, Xiaoxi Chen, Hua Bao, Yang Xu, Yang Shao, Fengwei Tan, Qi Xue, Bin Qiu, Shugeng Gao

ABSTRACT

Plasma hPG<sub>80</sub> circulating prograstin levels in cancer patients in Nigeria: Prolevcan study.

AUTHOR(S)
Omolara A. Fatiregun, Dominique Joubert, Berengere Vire, Abigail A. Simon-Hart, Olaniyi A. Adekeye, Younes Mahi, Alexandre Prieur

ABSTRACT

Genetic predictor of severe sorafenib-induced diarrhea and hand-foot syndrome (HFS).

AUTHOR(S)

ABSTRACT

Tumor-educated platelets for breast cancer detection: Biological and technical insights.

AUTHOR(S)

ABSTRACT

Detection of prognostic cancer-specific circular RNA in plasma.

AUTHOR(S)
Jason Brown, Palak Shah, Josh Vo, Alex Tsodikov, Lena Kleyman, Xuhong Cao, Arul Chinnaian

ABSTRACT
Prognostic value of plasma hPG₈₀ (circulating progastrin), alone or in combination with Alpha-fetoprotein (AFP) in patients with hepatocellular carcinoma.

AUTHOR(S)
Alexandre Prieur, Eric Assenat, Marie Dupuy, Sarah Iltache, Berengere Vire, Julien Soulé, Pierre Liaud, Thierry Cousin, Younes Mahi, Dominique Joubert

ABSTRACT
Detection of any-stage cancer using plasma and urine glycosaminoglycans.

AUTHOR(S)
Francesco Gatto, Sinisa Bratulic, Ilaria Teresa Rita Cavarretta, Massimo Alfano, Francesca Maccari, Fabio Galeotti, Nicola Volpi, Per-Henrik Edqvist, Max Levin, Jan Nyman, Bengt Bergman, Andrea Salonia, Sven Lundstam, Ulrika Stierner, Henrik Kjölhede, Jens Nielsen

ABSTRACT
Dynamics of circulating tumor DNA in patients with advanced solid tumors treated with cediranib and olaparib.

AUTHOR(S)

ABSTRACT
Correlation between different levels of HER2 expression in Circulating Tumor Cells (cHER2 ratio) and metastatic behavior in stageIVaggressive breast cancer.

AUTHOR(S)
Paolo D’Amico, Carolina Reduzzi, Sara Gandini, Lorenzo Gerratana, Wenan Qiang, Qiang Zhang, Frederique St-Pierre, Youbin Zhang, Ami N. Shah, Andrew A. Davis, Saya Jacob, Elena Vagia, Firas H. Wehbe, Amir Behdad, Giuseppe Curigliano, Massimo Cristofanilli

ABSTRACT
Machine learning-based multiple cancer detections with circulating miRNA profiles in the blood.

AUTHOR(S)
Juntaro Matsuzaki, Yusuke Yamamoto, Ouyang Yi, Sandeep Ayyar, Ryo Miyajima, Yutaka Takeda, Timothy Nolan, Nobuhiro Kawai, Ken Kato, Nobuyuki Ota, Takahiro Ochiya
A single institution experience with droplet digital polymerase chain reaction (dd-PCR) liquid biopsy (LB) for therapeutic decision in advanced solid tumors.

AUTHOR(S)
Andre M. Murad, Juliana G. Carneiro, José C. Casali-da-Rocha

Hyper engorged cancer associated macrophage-like cells in circulation predict for multi-organ metastatic disease in solid tumors.

AUTHOR(S)

Blood-based tumor mutational burden from circulating tumor DNA (ctDNA) across advanced solid malignancies using a commercially available liquid biopsy assay.

AUTHOR(S)

Single cell RNA-sequence analysis to identify transcriptomic differences associated with treatment outcome and ethnicity in circulating tumor cells (CTCs) from patients (pts) with metastatic colorectal cancer (mCRC).

AUTHOR(S)
Francesca Battaglin, Yonatan Amzaleg, Masahiro Kozuka, Priya Jayachandran, Satoshi Matsusaka, Mitsuharu Hirai, Jingyuan Wang, Hiroyuki Arai, Natsuko Kawanishi, Shivani Soni, Wu Zhang, Min Yu, Heinz-Josef Lenz
Targeted ctDNA sequencing analysis reveals concurrent genomic alterations and its impact on TKI and immune checkpoint inhibitor therapy in advanced NSCLC from Asian population.

AUTHOR(S)
Wei Wu, Jing Shan Lim, Jonathan Poh, Trever G. Bivona

ABSTRACT
A dual target sequencing solution to assess genomic and epigenomic alterations in cell-free DNA with no sample splitting.

AUTHOR(S)
Grace Q. Zhao, Yun Bao, Heng Wang, Wanping Hu, John Coller, Shengrong Lin

ABSTRACT
Genome-wide 5hmC profiles to enable cancer detection and tissue of origin classification in breast, colorectal, lung, ovarian, and pancreatic cancers.

AUTHOR(S)

ABSTRACT
Multiomic, plasma-only ctDNA NGS assay for minimal residual disease (MRD) detection in solid tumors.

AUTHOR(S)
Jessica Kurata, Kristin S. Price, Kimberly Banks, Elena Zotenko, Dustin Hite, Donavan Cheng, Princy Parsana, Jin H. Ju, Tara Dinman, Zong Miao, AmirAli Talasaz

ABSTRACT
Addition of selpercatinib to overcome osimertinib resistance in non-small cell lung cancer (NSCLC) with acquired RET fusion detected in ctDNA at very low allele frequency.

AUTHOR(S)
Leeseul Kim, Young Kwang Chae, Chan Mi Jung, Alice D. Lee, Emma Yu
A B S T R A C T

Concordancy of immunocytochemistry profiling of circulating tumor cells with immunohistochemistry for analysis of therapeutically relevant biomarkers.

AUTHOR(S)

A B S T R A C T

Development of extracellular vesicles-based classifier for detection of early-stage bladder, ovarian, and pancreatic cancer.

AUTHOR(S)
Juan Pablo Hinestrosa, Razelle Kurzrock, Jean Lewis, Nick Schork, Ashish M. Kamat, Andrew M. Lowy, Ramez N. Eskander, Orlando Perrera, David Searson, Iryna Clark, Heath Balcer, Mark J. Adler, Scott M. Lippman, Rajaram Krishnan

A B S T R A C T

Dermatologic adverse events of brentuximab vedotin: Characteristics, management, and their relationship with dose regimen.

AUTHOR(S)
Yuna Oh, Alexander Bang, Nicholas Kurtansky, Niloufer Khan, Melissa Pulitzer, Sarah J. Noor

A B S T R A C T

A phase 1 study of TAK-164, an anti-guanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) cancers expressing GCC.

AUTHOR(S)

A B S T R A C T

Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in patients with advanced pancreatobiliary cancer.

**ABSTRACT**

RNA sequencing effectively identifies gene fusions undetected by DNA sequencing in lung adenocarcinomas.

**AUTHOR(S)**

Ruiying Zhao, Yuchen Han, Chan Xiang, Shengnan Chen, Jikai Zhao, Lianying Guo, Anbo Yu, Jinchen Shao, Lei Zhu, Yue Tian, Fan Yang, Lin Shao, Xuejing Li, Lu Zhang

**ABSTRACT**

Sputum supernatant as a viable alternative for liquid biopsy in advanced non-small cell lung cancer.

**AUTHOR(S)**

Chengzhi Zhou, Xiaohong Xie, Jianhui Wu, Bingpeng Guo, Yinyin Qin, Xinqing Lin, Ming Liu, Luting Qiu, Xiao Zou, Zhanhe Chen

**ABSTRACT**

Novel imaging biomarkers predict progression-free survival in stage 3 NSCLC treated with chemoradiation and durvalumab.

**AUTHOR(S)**

Khalid Jazieh, Mohammadhadi Khorrami, Anas M. Saad, Mohamed M. Gad, Vidya S. Viswanathan, Pingfu Fu, Prabhakar Rajiah, Anant Madabhushi, Nathan A. Pennell

**ABSTRACT**

Differences of US-FNA BSRTC class, postoperative pathology, and mutation landscape of thyroid nodules between China and other countries.

**AUTHOR(S)**

Yuntao Song, Jie Liu, Weiran Wang, Tonghui Ma

**ABSTRACT**

Circulating genetically abnormal cells combined with artificial intelligence for accurate and non-invasive early detection on NSCLC.
Prediction of adenocarcinoma among other subtypes of lung cancer from CT using deep learning.

Modeling cell-free DNA fragment size densities for non-invasive detection of cancer.

Advanced imaging to assess longitudinal vascular changes in brain metastases treated with checkpoint inhibition.

Genetic profiling across multiple cancer types using molecular prescreening comprehensive gene panels offered by clinical trials (CT).
Machine learning models to quantify HER2 for real-time tissue image analysis in prospective clinical trials.

**AUTHOR(S)**
Benjamin Glass, Michel E. Vandenbergh, Surya T. Chavali, Syed A. Javed, Marlon Rebelatto, Shamira Sridharan, Hunter Elliott, Sudha Rao, Michael Montalto, Murray Resnick, Ilan Wapinski, Andrew Beck, Craig Barker

**ABSTRACT**

3061

Comprehensive molecular profiling of advanced cancers in a real-world setting using an ultrasensitive amplicon-based next-generation sequencing (NGS) liquid biopsy assay.

**AUTHOR(S)**
Jonathan Poh, Kao Chin Ngeow, Michelle Pek, Daniel Tan, Jing Shan Lim, Yukti Choudhury

**ABSTRACT**

3062

Feasibility and clinical utility of cancer whole genome and transcriptome sequencing for pediatric and young adult solid tumors.

**AUTHOR(S)**
Neerav Shukla, Max Levine, Gunes Gundem, Barbara Spitzer, Jesus Gutierrez-Abril, Nancy Bouvier, Juan E. Arango Ossa, Juan Medina-Martinez, Emily Stockfisch, Tara O’Donohue, Ahmet Zehir, Agnes Viale, Shakeel Modak, Filemon S. Dela Cruz, Emily K. Slotkin, Matthias A. Karajannis, Julia L. Glade Bender, Michael F. Walsh, Andrew Kung, Elli Papaemmanuil

**ABSTRACT**

3063

Improving differential diagnosis of pulmonary large cell neuroendocrine carcinoma (LCNEC) and small cell lung cancer via a transcriptomic, biological pathway-based ridge regression model.

**AUTHOR(S)**
Jun Hong, Likun Hou, Wei Zhang, Zhengwei Dong, Zhan Huang, Wuzhou Yuan, Lei Zhang, Chunyan Wu

**ABSTRACT**

3065

Validation of FAPi PET biodistribution by immunohistochemistry in patients with solid cancers: A prospective exploratory study.

**AUTHOR(S)**
Safety profile and disease stabilization in late stage, heavily pretreated, solid tumor patients in a first-in-human (FIH) study of ATX-101, a drug targeting proliferating cell nuclear antigen (PCNA).

Association of low RKIP expression with poor prognosis in non-small cell lung cancer.

Mutational analysis of rare insertions and deletions in exon 18 and 19 of HER2 in Chinese patients with different cancer types.

A prespecified interim analysis of the PATHFINDER study: Performance of a multicancer early detection test in support of clinical implementation.

Performance of a targeted methylation-based multi-cancer early detection test by race/ethnicity.
AUTHOR(S)
Wai Hong Wilson Tang, Habte A. Yimer, Mohan K. Tummala, Spencer Shao, Gina G. Chung, Jessica M. Clement, Jingjing Gao, Earl Hubbell, Kathryn Kurtzman, Charles Swanton, Lewis R. Roberts

ABSTRACT
3071
Detection of cancer signal for over 50 AJCC cancer types with a multi-cancer early-detection test.

AUTHOR(S)
Habte A. Yimer, Wai Hong Wilson Tang, Mohan K. Tummala, Spencer Shao, Gina G. Chung, Fergus Couch, Jingjing Gao, Oliver Venn, Kathryn Kurtzman, Charles Swanton, Jessica M. Clement

ABSTRACT
3072
Preliminary efficacy from an ongoing phase 1 dose escalation study of seclidemstat (SP-2577) in patients (pts) with advanced solid tumors (AST).

AUTHOR(S)
Sant P. Chawla, Victoria S. Chua-Alcala, Jasgit C. Sachdev, David S. Wages, David D. Stenehjem, Daniela Y. Santiesteban, Nadeem Q. Mirza, Michael S. Gordon

ABSTRACT
3073
First-in-human phase I study of the bifunctional EGFR/TGFβ fusion protein BCA101 in patients with EGFR-driven advanced solid cancers.

AUTHOR(S)

ABSTRACT
3074
Phase 1 study of OKI-179, an oral class 1-selective depsipeptide HDAC inhibitor, in patients with advanced solid tumors: Final results.

AUTHOR(S)

ABSTRACT
3075
Patient-derived micro-organospheres recapitulate tumor microenvironment and heterogeneity for precision oncology.

AUTHOR(S)
Shengli Ding, Zhaohui Wang, Marcos N. Obando, Grecia R. Palomino, Tomer Rotstein, Ian Williamson, Shiaowen D. Hsu, Xiling Shen

ABSTRACT
3076

Phase Ia study of CBP-1008, a bi-specific ligand drug conjugate targeting FRα and TRPV6, in patients with advanced solid tumors.

AUTHOR(S)
Jifang Gong, Xichun Hu, Jian Zhang, Yiqun Du, Robert Huang, Yan Teng, Wei Tan, Lin Shen

ABSTRACT
3077


AUTHOR(S)

ABSTRACT
3078

Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors: Update from the ARROW trial.

AUTHOR(S)

ABSTRACT
3079

A phase 1/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in patients with advanced solid tumors.

AUTHOR(S)
Nashat Y. Gabrail, Erika P. Hamilton, Anthony D. Elias, Mothaffar F. Rimawi, Chao Li, Maria M. Corvez, Wei Li, Ying Feng, JiaoWei, Stephanie Greene, John Patterson, Qingping Zeng, Ai-Min Hui

ABSTRACT
First-time in-human study of VMD-928, an oral allosteric TrkA selective inhibitor targeting TrkA protein overexpression, in patients with solid tumors or lymphoma.

AUTHOR(S)
Vincent Chung, Ling Wang, Margaret S. Fletcher, Erminia Massarelli, Mihaela C. Cristea, Sailaja Kamaraju, Angela T. Alistar, Chao Feng, You Li, Roger L. Whiting, Giuseppe Giaccone, David S. Hong, Jay Wu

ABSTRACT
High-intensity focused ultrasound ablation for treatment of chemotherapy-induced thrombocytopenia and hypersplenism.

AUTHOR(S)
Min Yuan, Qing Xu, Zhongzheng Zhu, Wei Mao, Xianling Guo, Hui Wang, Hong Qian, Jianguo Wu

ABSTRACT
Phase 1 trial of a novel, first-in-class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in patients with advanced or recurrent treatment-refractory solid malignancies.

AUTHOR(S)
Carolyn Muller, Ursa A. Brown-Glaberman, Marya F. Chaney, Tina Garyantes, Patricia LoRusso, Jennifer L. McQuade, Alain C. Mita, Monica M. Mita, Christopher Natale, Marlene Orloff, Kyriakos P. Papadopoulos, Takami Sato, Emrullah Yilmaz, Jordi Rodon

ABSTRACT
A phase II study investigating biological effects of maintenance usage of hydroxychloroquine on Par-4 levels in patients with resected tumors.

AUTHOR(S)
Peng Wang, Ravshan Burikhanov, Heidi Weiss, Rani Jayswal, Susanne M. Arnold, John L. Villano, Vivek Rangnekar

ABSTRACT
Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A first-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an
inhibitor of allosteric \( ErbB \) mutations, in patients (pts) with advanced solid malignancies.

**AUTHOR(S)**


**ABSTRACT**

3086

A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U.

**AUTHOR(S)**


**ABSTRACT**

3087

Phase I trial of 5-aza-4’-thio-2’-deoxycytidine (Aza-TdC) in patients with advanced solid tumors.

**AUTHOR(S)**


**ABSTRACT**

3088

Evaluating clinical activity of MAPK targeted therapies (TT) in cancer patients (pts) with non-V600 BRAF mutations: A systematic scoping review and meta-analysis.

**AUTHOR(S)**

Matthew Dankner, Yifan Wang, Rouhi Fazelzad, Anna Spreafico, David W. Cescon, George Zogopoulos, April A. Rose

**ABSTRACT**

3089

Phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors.

**AUTHOR(S)**
Incidence of ERBB gene fusions (EGFR, ERBB2, ERBB4) across tumor types.

AUTHOR(S)
Laura Schubert, Andrew Elliott, Robert C. Doebele, Emil Lou, Hossein Borghaei, Michael J. Demeure, Razelle Kurzrock, Anh T. Le, Joshua E. Reuss, Sai-Hong I. Ou, David R. Braxton, Christian A. Thomas, Sourat Darabi, Wolfgang M. Korn, Wafik S. El-Deiry, Stephen V. Liu

Association of high gene expression levels of ARF6 with the immune microenvironment and prediction of poor outcomes.

AUTHOR(S)

Optimal dose selection in oncology biologics development: Need for a paradigm shift.

AUTHOR(S)
Rajendar K. Mittapalli, Kai H. Liao, Jason Williams, Rameshraja Palaparthy, Donghua Yin

Anticancer drugs associated with venous thromboembolic event: Analysis of the WHO pharmacovigilance database.

AUTHOR(S)
Angélique DA Silva, Joachim Alexandre, Damien Laneelle, Marion Sassier, Basile Chrétien, Sophie Fedrizzi, Florence Joly, George Emile, Laurent Bertoletti, Benoite Mery, Anne Flore Plane, Damien Legallois, Charles Dolladielle
Does oxaliplatin pharmacokinetics (PKs) explain associations between body composition and chemotherapy toxicity risk in older adults with gastrointestinal (GI) cancers?

**AUTHOR(S)**

Grant R. Williams, Mustafa Al-Obaidi, Joseph Rower, Christian Harmon, Chen Dai, Edward Acosta, Smith Giri, William Zamboni, Andrew T. Lucas, Shlomit S. Shachar, Olumide B. Gbolahan, Jeffrey A. Meyerhardt, Bette J. Caan, Smita Bhatia

**ABSTRACT**

3095

Pre-therapeutic dihydropyrimidimidine dehydrogenase (DPD) deficiency screening: Impact on fluoropyrimidine dose reduction at the second chemotherapy cycle and on early severe toxicity.

**AUTHOR(S)**

Côme De Metz, Benjamin Hennart, Marie-Cecile Le Deley, Pierre-Yves Cren, Christophe Desauw, Vincent Bourgeois, Fredrik Laestadius, Emilia Rad, Loïc Lebellec, Nicolas Penel, Aurelien Carnot

**ABSTRACT**

3096

Clinical pharmacokinetics of bdtx-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies in MasterKey-01 study.

**AUTHOR(S)**


**ABSTRACT**

3097

A phase I study of a TGF-β receptor I kinase inhibitor YL-13027 in patients with advanced solid tumors.

**AUTHOR(S)**

Jin Li, Tianshu Liu, Hanying Bao, Zusheng Xu, Yang Shu, Binghua Zheng

**ABSTRACT**

3098

A phase Ib study of the PI3Kδ inhibitor linperlisib in patients with advanced solid tumors.

**AUTHOR(S)**

Jin Li, Nong Xu, Tianshu Liu, Jianjin Huang, Yongmei Yin, Haibo Mou, Jun Zhang, Lihua Wu, Zong l. Liu, Hanying Bao, Zusheng Xu
ABSTRACT

Antibiotic use reduces efficacy of tyrosine kinase inhibitors in patients with advanced melanoma and non-small cell lung cancer.

AUTHOR(S)

Nadina Tinsley, Natalie Cook, Cong Zhou, Sharon H. Nahm, Samuel Rack, Grace C. Tan, Paul Lorigan, Fiona H. Blackhall

ABSTRACT

A phase I study of an IDO inhibitor (SHR9146) plus camrelizumab and in combination with/without apatinib in patients with advanced solid tumors: Safety and efficacy analysis.

AUTHOR(S)

Ying Cheng, Ying Liu, Jinhua Xu, Jing Zhu, Ying Wang, Ying Xin, Yanping Wang, Chunjiao Wu, Hongxia Cui, Xianhong Liu, Jixin Dai, Zili Li, XiangHua Zhang, Jing Zhang, Ben Zhang

ABSTRACT

Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors.

AUTHOR(S)

Ecaterina E. Dumbrava, Geoffrey Shapiro, Johanna C. Bendell, Timothy A. Yap, Rinath Jeselsohn, Denise M. Lepley, Sabrina Hurley, Kevin K. Lin, Michelle Liao, Jenn Habeck, Aaron Enke, Erika P. Hamilton

ABSTRACT

A phase Ib trial of ERK inhibition with ulixertinib combined with palbociclib in patients (Pts) with advanced solid tumors.

AUTHOR(S)

Alison L. Raybould, Brian Burgess, Clarissa Urban, Rashid Naim, Michael S. Lee, Autumn J. McRee

ABSTRACT


AUTHOR(S)
Inhibition of histone lysine demethylases with TACH101, a first-in-class pan-inhibitor of KDM4.

AUTHOR(S)
Chandtip Chandhasin, Sanghee Yoo, Joselyn Del Rosario, Young K. Chen, Jeffrey Stafford, Frank Perabo, Michael F. Clarke

WX390, a high-potent PI3K-mTOR dual inhibitor, first-in-human (FIH) phase I study in advanced relapsed or refractory solid tumor, and lymphoma.

AUTHOR(S)
Wenbo Tang, Ye Guo, Liqiong Xue, Wei Peng, Xiaoxiao Ge, Junli Xue, Wei Wei, Juncai Xu, Yongguo Li, Jin Li


AUTHOR(S)
Yong Man Kim, Kyun-Seop Bae, Nam Seok Baek, Kyungun Kim, Won Sik Lee, Eun-Jihn Roh, Chan-Young Ock, Sung-Bae Kim

Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer.

AUTHOR(S)

PARALLEL 303: Phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients (pts) with inoperable locally advanced or
metastatic gastric cancer that responded to platinum-based first-line (1L) chemotherapy.

AUTHOR(S)
Fortunato Ciardiello, Yung-Jue Bang, Johanna C. Bendell, Andres Cervantes, Mikhail Dvorkin, Charles D. Lopez, Jean-Philippe Metges, Antonio Sanchez, Mariona Calvo, Andrew Strickland, George Kannourakis, Kei Muro, Hisato Kawakami, Jia Wei, Christophe Borg, Song Mu, Kathy Zhang, Maggie Zhang, Lin Shen

ABSTRACT
3109

Biomarker results supporting selection of RP2D from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel in patients with advanced solid tumors.

AUTHOR(S)
Anneleen Daemen, Aleksandr Pankov, Shravani Barkund, Haiying Zhou, Maureen Duff, Ann Johnson, Rongda Xu, Pratik S. Multani, Edna Chow Maneval, Lori Friedman

ABSTRACT
3110

Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations.

AUTHOR(S)
Mark A. Dickson, Vinod Ravi, Kristen N. Ganjoo, Gopa Iyer

ABSTRACT
3111

Dosing, drug reduction, drug interruption, and drug discontinuation rates among U.S. FDA approved tyrosine kinase inhibitors.

AUTHOR(S)

ABSTRACT
3112

A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.

AUTHOR(S)
Seock-Ah Im, SeungHwan Lee, Keun Wook Lee, Youngjoo Lee, Joohyuk Sohn, Jee Hyun Kim, Young-Hyuck Im, Kyong Hwa Park, Do-Youn Oh, Min Hwan Kim, Yeon Hee Park, Tae Min Kim, Yoon Ji Choi, Chang-Seok Lee, Jiseon Park, Nam Seok Baek, MiKyung CHOI, John Kim, Eunyoung Yu, Yung-Jue Bang

**ABSTRACT**

3113

**Intra-patient comparison from larotrectinib clinical trials in TRK fusion cancer: An expanded dataset.**

**AUTHOR(S)**

David S. Hong, Antoine Italiano, Andrew Briggs, Jesus Garcia-Foncillas, Ulrik N. Lassen, Gilles Vassal, Shivaani Kummar, Cornelis M. van Tilburg, Karen N. Keating, John A. Reeves, Marc M. Fellous, Hendrik Nogai, Theodore W. Laetsch, Alexander E. Drilon

**ABSTRACT**

3114

**Phase I expansion study of the first-in-class monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL).**

**AUTHOR(S)**


**ABSTRACT**

3115

**The next-generation pan-RAF inhibitor, KIN-2787, is active in class II and class III BRAF mutant models.**

**AUTHOR(S)**

Aleksandra Franovic, Nichol Miller, Paul Severson, Toufike Kanouni, Noelito Timple, Ping Jiang, Eric Murphy, Eric Martin

**ABSTRACT**

3116

**Prognostic factors in RET dependent cancers treated with RET inhibitors in early phase clinical trials.**

**AUTHOR(S)**

Max Gordon, Jason Roszik, Maria E. Cabanillas, Mimi I. Hu, Naifa L. Busaidy, Steven I. Sherman, Ramona Dadu, Elizabeth G. Grubbs, Yasir Y. Elamin, Tina Cascone, Lauren A. Byers, George R. Blumenschein, Frank V. Fossella, Aung Naing, David S. Hong, John Heymach, Funda Meric-Bernstam, Vivek Subbiah

**ABSTRACT**

3117
Expression of end-binding protein 1 (EB1), a potential response-predictive biomarker for lisavanbulin, in glioblastoma and various other solid tumor types.

AUTHOR(S)

ABSTRACT
3118

TP53 and CHEK2 germline mutations in malignant solid tumors.

AUTHOR(S)
Zhiye Zhang, Yaqing Wu, Ningning Luo, Qin Zhang, Tianian Han, Xuesong Bu, Qin Shuai, Yingxue Qi

ABSTRACT
3119

A comprehensive landscape of BRCA1 versus BRCA2 associated molecular alterations and survival outcome across 35 cancer types.

AUTHOR(S)

ABSTRACT
3120

Analysis of the MOSAIC correlative cancer database integrating molecular cancer classification and tumor profiling to identify targeted treatment options for metastatic cancer.

AUTHOR(S)
Li Ma, Kai Treuner, Jenna Wong, David R. Spigel, Catherine A. Schnabel

ABSTRACT
3121

Temporal and spatial topography of cell proliferation in cancer.

AUTHOR(S)
Sheheryar K. Kabraji, Giorgio Gaglia, Danae Argyropoulou, Yang Dai, Shu Wang, Johann Bergholz, Shannon Coy, Jia-Ren Lin, Rinath Jeselsohn, Otto Metzger, Eric P. Winer, Deborah Dillon, Jean Zhao, Peter Sorger, Sandro Santagata

ABSTRACT
Multi-cancer detection and tissue of origin determination based on 5-hydroxymethylcytosine biomarkers in circulating cell-free DNA.

AUTHOR(S)
Zhou Zhang, Wenju Chang, Jiabin Cai, Yijiu Ren, Qiancheng You, Chang Zeng, Xiao-Long Cui, Zeliang Deng, Zeqiang Yu, Liang Zhang, Xiao Wang, Sen Sun, Brian C. Chiu, Chuan He, Dongdong Li, Chang Chen, Jianmin Xu, Jia Fan, Wei Zhang

ABSTRACT

Frequency of longitudinal changes in TP53 mutation status from gene sequencing of serial tumor biopsies from a large cohort of cancer patients.

AUTHOR(S)
D. Allen A. Annis, Dean C. Pavlick, Garrett M. Frampton, Lee A. Albacker, Vojislav M. Vukovic, Manuel Aivado

ABSTRACT

A comprehensive literature review and meta-analysis on prognostic value of BRCAm, HRRm and HRD+ across tumor types.

AUTHOR(S)
Changxia Shao, Andrew Marley, Huilin Tang, Jun Wan, Chelsey Miller, Madeline Brown, Yiqing Song, Jiali Han, Gboyega Adeboyeje

ABSTRACT

The value of defining molecular resistance in patients with progressive EGFR and ALK-driven lung cancer in a public system.

AUTHOR(S)
Carly C. Barron, Tracy Stockley, Jennifer H. Law, Muqdas Shabir, Roxanne Fernandes, Tong Zhang, Lisa W. Le, Ming S. Tsao, Suzanne Kamel-Reid, Prodipto Pal, Michael Cabanero, Joerg Schwock, Hyangmi Ko, Geoffrey Liu, Penelope A. Bradbury, Adrian G. Sacher, Frances A. Shepherd, Natasha B. Leighl, Kirstin Perdrizet

ABSTRACT

Landscape of KRAS\textsuperscript{G12C}, associated genomic alterations, and interrelation with immuno-oncology (IO) biomarkers.

AUTHOR(S)
Mohamed E. Salem, Sherif El-Refai, Wei Sha, Axel Grothey, Alberto Puccini, Thomas J. George, Jimmy J. Hwang, Laura W. Musselwhite, David King, Kunal C. Kadakia, Derek Raghavan, Eric Van Cutsem, Josep Tabernero, Jeanne Tie
The impact of clinical decision making in a molecular tumor board at a tertiary care center.

AUTHOR(S)
Meena Sadaps, Kathryn Denski, Ying Ni, Vicky Konig, Brandie Leach, Emily Mazzei, Pauline Funchain

The mutational landscape of the sensitivity of cancer to ionizing radiation.

AUTHOR(S)
Priyanka Gopal, Brian Yard, Aaron Petty, Jessica Castrillon, Jyoti D. Patel, Mohamed E. Abazeed

Clinically advanced pelvic squamous cell carcinomas (pSCC) in men and women: A comprehensive genomic profiling (CGP) study.

AUTHOR(S)

Partitioning of cancer therapeutics in nuclear condensates.

AUTHOR(S)
Isaac Klein, Ann Boija, Lena Afeyan, Susana Hawken, Mengyang Fan, Dylan Taatjes, Arup Chakraborty, Phillip Sharp, Young Tae Chang, Anthony Hyman, Nathanael Gray, Richard Young

The genomic landscape of gene fusions across solid tumors and clinical outcome of targeted therapies: A real-world retrospective analysis.

AUTHOR(S)
Yumeng Zhang, Bindiya G. Patel, Todd C. Knepper, Dung-Tsa Chen, Jhanelle E. Gray, James K. Hicks

AUTHOR(S)
Rozana Abdul Rahman, Neethu Billy Graham Mariam, Hitesh Mistry, Sreeja Aruketty, Matt Church, Aidi Adamson-Raieste, Julie-Anne Scott, Fiona Thistlethwaite, Matthew Krebs, Louise Carter, Donna M. Graham, Natalie Cook

ABSTRACT
3133

A phase Ib trial of alpelisib and weekly cisplatin in patients with solid tumor malignancies.

AUTHOR(S)
Erica S. Tsang, Rahul R. Aggarwal, Mallika S. Dhawan, Romain Pacaud, Delaire Fattah, Scott Thomas, Jennifer A. Grabowsky, Pamela N. Munster

ABSTRACT
3134

Cancer and COVID-19: A proposed mechanism with therapeutic interventions.

AUTHOR(S)
Yan Leyfman, Nancy Emmanuel, Aleksey Tentler, Jared Cappelli, Timothy K. Erick, Pushpa Sharma, Chandler H. Park

ABSTRACT
3135

Genome-wide cfDNA fragmentation in patients with cancer and other diseases.

AUTHOR(S)
Jacob Carey, Sian Jones, Alessandro Leal, Bryan Chesnick, Denise Butler, Michael Rongione, Robert B. Scharpf, Julia S. Johansen, Victor E. Velculescu, Nicholas C. Dracopoli

ABSTRACT
3136

Outcomes of active cancer patients with COVID-19 infection treated with COVID-19 neutralizing monoclonal antibodies.

AUTHOR(S)
Justin Shaya, Aaron Lee, Angelo Cabal, Rana R. McKay

ABSTRACT
3137

Patients with advanced solid cancers treated with ERK inhibitors exhibit pseudo-progression in lymphatic nodes.
AUTHOR(S)


ABSTRACT

3138

Germline polymorphisms in genes maintaining replication fork to predict the efficacy of oxaliplatin and irinotecan in metastatic colorectal cancer (mCRC) patients enrolled in MAVERICC trial.

AUTHOR(S)

Hiroyuki Arai, Yi Xiao, Jingyuan Wang, Francesca Battaglin, Natsuko Kawanishi, Priya Jayachandran, Shivani Soni, Zhang Wu, Christoph Mancao, Bodour Salhia, Shannon M. Mumenthaler, Joshua Millstein, Heinz-Josef Lenz

ABSTRACT

3139

Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT2): Challenges and Opportunities in Conducting an MD Anderson Randomized Study in Precision Oncology.

AUTHOR(S)


ABSTRACT

3140

A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring HER2 amplification (JUPITER trial).

AUTHOR(S)

Ryo Kudo, Toshio Kubo, Yukiko Mori, Yohei Harada, Hidekazu Shirota, Hideyuki Hayashi, Masayuki Kano, Yasushi Shimizu, Eri Ishibashi, Hirotoshi Akita, Hisahiro Matsubara, Hiroshi Nishihara, Chikashi Ishioka, Naoko Sueoka-Aragane, Manabu Muto, Shinichi Toyooka, Ukihide Tateishi, Akihiro Hirakawa, Satoshi Miyake, Sadakatsu Ikeda

ABSTRACT

TPS3141

A phase 1b, open-label, single-arm study of cofetuzumab pelidotin (a PTK7-targeting antibody-drug conjugate) in patients with PTK7-expressing, recurrent non-small cell lung cancer (NSCLC).

AUTHOR(S)
ABSTRACT

TPS3142

TCF-001 TRACK (Target Rare Cancer Knowledge): A national patient-centric precision oncology trial for rare cancers.

AUTHOR(S)

Vivek Subbiah, Roman Groisberg, Catherine Skefos, James M. Cleary, Ishwaria M. Subbiah, Jim Palma, Mary Oster, Steven W. Young, Julia A. Elvin, Jason K. Sicklick, Sarah Gaffey, Ashley Ward, Brian M. Alexander, J. Jack Lee, Pradip De, Shumei Kato, Razelle Kurzrock

ABSTRACT

TPS3143

A phase 1 study of SGN-B6A, an antibody-drug conjugate targeting integrin beta-6, in patients with advanced solid tumors (SGNB6A-001, Trial in Progress).

AUTHOR(S)

Amita Patnaik, Emiliano Calvo, Sarina Anne A. Piha-Paul, Antoine Hollebecque, Vladimir Galvao, Juanita S. Lopez, Fadi S. Braiteh, Rachel E. Sanborn, Peigen Zhou, Natalya N. Nazarenko, Afshin Dowlati

ABSTRACT

TPS3144

Phase I trial of acoustic cluster therapy (ACT) with chemotherapy in patients with liver metastases of gastrointestinal origin (ACTIVATE study).

AUTHOR(S)

Udai Banerji, Crescens D. Tiu, Andra Curcean, Sumita Gurung, Mark O’Leary, Nigel Bush, Spiros Kotopoulis, Andrew Healey, Svein Kvåle, Hilary Hilary McElwaine-Johnn, Jeff Bamber, Robert Miller, Per Sontum, Sarah Arbe-Barnes, Nina Tunariu

ABSTRACT

TPS3145

First-in-human phase 1 trial (DRAGON) of SRK-181, a potential first-in-class selective latent TGFβ1 inhibitor, alone or in combination with anti-PD-(L)1 treatment in patients with advanced solid tumors.

AUTHOR(S)

Timothy A. Yap, Minal A. Barve, Justin F. Gainor, Colin D. Weekes, Bruno Bockorny, Yawen Ju, Ryan Faucette, Sanela Bilic, Si Tuen Lee-Hoeftich, Guochen Song, Yung Chyung, Michelle Legler, Lu Gan, Johanna C. Bendell

ABSTRACT

TPS3146
Phase 1b dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GS-3583, a FLT3 agonist Fc fusion protein, in patients with advanced solid tumors.

AUTHOR(S)
Joshua Brody, John A. Thompson, Anthony W. Tolcher, Michelle R. Kuhne, Xi (Rochelle) Huang, Ellen Kwan, Michael Petrarca, Anees Dauki, Indrajeet Singh, Nishanthan Rajakumaraswamy, Shivaani Kummar

ABSTRACT
TPS3147

Phase 1 and phase 2a, first-in-human (FIH) study, of DRP-104, a broad glutamine antagonist, in adult patients with advanced solid tumors.

AUTHOR(S)
Melissa L. Johnson, Deborah B. Doroshow, Tanguy Y. Seiwert, Michael K. Gibson, Vamsidhar Velcheti, Aaron E. Lisberg, Shetal A. Patel, Matthias Scheffler, Francois Lafleur, Margaret H. Dugan, Sunil Sharma

ABSTRACT
TPS3149

Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: PALOMA, an open-label, multicenter, dose escalation phase 1b study.

AUTHOR(S)
Matthew Krebs, Melissa L. Johnson, Byoung Chul Cho, Keunchil Park, Nahor Haddish-Berhane, Donna Zemlickis, Anna Mitselos, Francis Meacle, Roland E. Knoblauch, Peter Hellemans, Anna R. Minchom

ABSTRACT
TPS3150

SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (trial in progress).

AUTHOR(S)

ABSTRACT
TPS3151

Trial in progress: Phase 1a/b study of PF-07284890 (brain-penetrant BRAF inhibitor) with/without binimetinib in patients with BRAF V600-mutant solid tumors.

AUTHOR(S)

ABSTRACT

TPS3152


AUTHOR(S)


ABSTRACT

TPS3153

Tumor-agnostic precision immuno-oncology and somatic targeting rationale for you (TAPISTRY): A novel platform umbrella trial.

AUTHOR(S)

Alexander E. Drilon, Haiying Liu, Felice Wu, David Chen, Timothy R. Wilson, Brian P. Simmons, Fabrice Barlesi

ABSTRACT

TPS3154

Alpha-T: An innovative decentralized (home-based) phase 2 trial of alectinib in ALK-positive (ALK+) solid tumors in a histology-agnostic setting.

AUTHOR(S)


ABSTRACT

TPS3155

A phase 1/2 study with open-label, dose escalation phase followed by single-arm expansion at the maximum tolerated dose to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 injection alone and in combination with cetuximab in adults with advanced solid tumors and head and neck cancer.

AUTHOR(S)


ABSTRACT
TPS3156

**Trial in progress: A phase 1-2 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors.**

**AUTHOR(S)**
Dae Ho Lee, Aflah Roohullah, Byoung Chul Cho, Charlotte R. Lemech, Paul L. de Souza, Michael Millward, Jun Young Choi, Kyung Eui Park, Minseon Lee, YeongMun Kim, YOUNGKEE Shin, Ji-Youn Han

**ABSTRACT**

TPS3157

**First-in-man phase I clinical trial evaluating TTI-101, an orally bioavailable, small molecule inhibitor of STAT3, in patients with advanced solid tumors.**

**AUTHOR(S)**
Apostolia M. Tsimberidou, Sofia de Achaval, Imran Alibhai, Ahmed O. Kaseb

**ABSTRACT**

TPS3158

**A multicenter open-label phase 1 study evaluating the safety and tolerability of HMPL-306 in patients with locally advanced or metastatic solid tumors with IDH mutations.**

**AUTHOR(S)**
Filip Janku, John S. Kauh, Christopher Tucci, Zhao Yang, Marek K. Kania, Olatunji B. Alese

**ABSTRACT**

TPS3159

**EPIK-P2: A prospective phase 2, double-blind, randomized, placebo-controlled study of alpelisib in pediatric and adult patients (Pts) with PIK3CA-related overgrowth spectrum (PROS).**

**AUTHOR(S)**
Guillaume Canaud, Juan Carlos López Gutiérrez, Adrienne M. Hammill, Lisa Weibel, Ghislaine Vincent, Séverine Niglis, Michaela Paul, Denise M. Adams

**ABSTRACT**

TPS3160

**Phase 1/2 study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies.**

**AUTHOR(S)**
A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of solid tumors harboring specific HER2-activating mutations (DESTINY-PanTumor01).

AUTHOR(S)
Bob T. Li, Funda Meric-Bernstam, Soham D. Puvvada, Jacqui Rowbottom, Darren Jolliffe, Mark Gustavson, Ariadna Mendoza-Naranjo

ABSTRACT
TPS3162

HPV-mediated anal squamous cell carcinoma and precancerous lesions in HIV positive patients.

AUTHOR(S)
Omar Bushara, Brian Finkelmen, Sam Weinberg, Katrina Krogh, Aparna Kalyan, Guang-Yu Yang

ABSTRACT
3520

Final analysis of dose-finding and single-arm confirmatory study (phase I/II study) of definitive chemoradiotherapy (dCRT) with S-1/mitomycin-C (MMC) in patients (pts) with clinical (c) Stage II/III squamous cell carcinoma of the anal canal (SCCA): JCOG0903.

AUTHOR(S)
Yoshinori Ito, Tetsuya Hamaguchi, Atsuo Takashima, Junki Mizusawa, Yasuhiro Shimada, Manabu Shiozawa, Takeshi Kodaira, Masayuki Ohue, Makoto Kinouchi, Kohei Murata, Gen Iinuma, Fumihiko Fujita, Hirohisa Miura, Fumio Ishida, Yoshihisa Saida, Takahisa Matsuda, Hiroshi Katayama, Haruhiko Fukuda, Yukihide Kanemitsu

**ABSTRACT**

3521

Association between cancer stem cell marker ALDH1 and clinical and morphological factors of colorectal cancer prognosis.

**AUTHOR(S)**

Elena A. Dzhenkova, Inna A. Novikova, Oleg I. Kit, Elena Y. Zlatnik, Elena P. Ulianova, Anastasia O. Sitkovskaya, Oksana G. Shulgina, Yuriy A. Gevorkyan, Natalya V. Soldatkina, Vladimir E. Kolesnikov, Maksim K. Aleksandrovich, Andrey V. Dashkov, Sergey I. Poluektov, Dmitry O. Kaymakchi, Ellada A. Mirzoyan, Vladislav K. Pavlov, Maksim A. Vereshchak, Oksana V. Katelnitskaya, Dmitriy A. Savchenko, Roman E. Tolmakh

**ABSTRACT**

3522

Circulating tumor DNA-based genomic profiling of small bowel adenocarcinoma.

**AUTHOR(S)**

Pat Gulhati, Karan Pandya, Hiba I. Dada, Christopher R. Cogle, Jason S. Starr, Sujith R. Kalmadi, Fadi S. Braiteh, Leylah Drusbosky

**ABSTRACT**

3523

Association of HER2 expression with pathologic features and prognosis in stage II and III colon cancer.

**AUTHOR(S)**

Zehua Wu, Huabin Hu, Yanhong Deng

**ABSTRACT**

3524

Clinical utility of stool-based SDC2 methylation test for the detection and screening of colorectal cancer in a Chinese population.

**AUTHOR(S)**

Yanmei Liu, Weiguo Yin, Lei Peng, Xianshu Wang, Hongzhi Zou, Haibo Zhou

**ABSTRACT**

3525
Patient-reported quality of life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: Interim results of the TALLISUR study.

AUTHOR(S)
Meinolf Karthaus, Albrecht Kretzschmar, Stefan Fuxius, Jorge Riera Knorrenschild, Florian Kaiser, Rolf Mahlberg, Manfred Welslau, Henning Pelz, Volker Heinemann

ABSTRACT
3526

Globo H expression in metastatic colorectal cancer (CRC).

AUTHOR(S)

ABSTRACT
3527

Use of circulating tumor DNA in colorectal cancer patients to assess tumor burden and response to therapy: An observational study.

AUTHOR(S)
Erin L. Symonds, Susanne K. Pedersen, Bernita H. Yeo, Hiba Al Najji, Susan E. Byrne, Amitesh C. Roy, Graeme P. Young

ABSTRACT
3528

Profiling plasma angiogenesis factors after use of biologics in metastatic colorectal cancer (mCRC): Update results from GI-SCREEN CRC Ukit study.

AUTHOR(S)
Yu Sunakawa, Satoshi Yuki, Manabu Shiozawa, Toshiki Masuishi, Tomohiro Nishina, Hisateru Yasui, Takashi Ohta, Naoki Takahashi, Hironaga Satake, Akiyoshi Kanazawa, Masahiro Goto, Hideaki Bando, Hiroya Taniguchi, Yoshinaga Okugawa, Kentaro Yamazaki, Hiromichi Ebi, Yukiko Abe, Shogo Nomura, Chiharu Asano, Takayuki Yoshino

ABSTRACT
3529

The role of HPSE in BRAF V600E-mutant colorectal cancer.

AUTHOR(S)
Mengling Liu, Xiaojing Xu, Ke Peng, Pengcong Hou, Qing Liu, Yiyi Yu, Tianshu Liu

ABSTRACT
The impact of colorectal cancer screening on incidence and stage IV disease in the Netherlands.

AUTHOR(S)

ABSTRACT

Resectability, conversion and resections rates, and outcomes in RAS&BRAF wildtype (wt), RAS mutant (mt) and BRAFmt metastatic colorectal cancer (mCRC) subgroups in the prospective Finnish RAXO-study.

AUTHOR(S)

ABSTRACT

A model combing an immune-related genes signature and an extracellular matrix-related genes signature in predicting prognosis of left- and right-sided colon cancer.

AUTHOR(S)
Min-Er Zhong, Du Cai, Dejun Fan, Wei Wang, Cheng-Hang Li, Ze-Ping Huang, Qiqi Zhu, Min-Yi Lv, Chuling Hu, Xiaojian Wu, Feng Gao

ABSTRACT

Automated computed tomography (CT)-derived skeletal muscle mass determination as a significant prognostic factor in colorectal cancer patients using deep neural network model.

AUTHOR(S)
Dongjin Seo, Han Sang Kim, Yu Rang Park

ABSTRACT
Genetic variants involved in the cGAS-STING pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and TRIBE trials.

AUTHOR(S)
Jingyuan Wang, Yi Xiao, Fotios Loupakis, Sebastian Stintzing, Hiroyuki Arai, Francesca Battaglin, Natsuko Kawanishi, Priya Jayachandran, Shivani Soni, Wu Zhang, Christoph Mancao, Chiara Cremolini, Volker Heinemann, Alfredo Falcone, Joshua Millstein, Heinz-Josef Lenz

ABSTRACT
Multimodal circulating tumor DNA (ctDNA) colorectal neoplasia detection assay for asymptomatic and early-stage colorectal cancer (CRC).

AUTHOR(S)
Jeeyun Lee, Hee C. Kim, Seung Tae Kim, Yupeng He, Paul Sample, Yoshiaki Nakamura, Victoria M. Raymond, Ariel Jaimovich, AmirAli Talasaz

ABSTRACT
Comprehensive characterization of neurotransmitters and neuronal signaling (NT) pathway alterations in colorectal cancer (CRC).

AUTHOR(S)

ABSTRACT
KMT2C as a positive predictor for treatment of immune checkpoint inhibitor and correlation with immune infiltrates in colorectal cancer (CRC).

AUTHOR(S)
Ling Zhang, Jianping Song, Yiting Wang, Yaoxu Chen

ABSTRACT
Multi-omics analysis to reveal the role of gut microbiome-associated serum metabolites in the detection of colorectal cancer and adenoma.

AUTHOR(S)
Feng Chen, Xudong Dai, Wei Cui
ABSTRACT

3539

Serial circulating tumor DNA analysis to assess recurrence risk, benefit of adjuvant therapy, growth rate and early relapse detection in stage III colorectal cancer patients.

AUTHOR(S)

Tenna V V. Henriksen, Noelia Tarazona, Amanda Frydendahl, Thomas Reinert, Juan Antonio Carbonell-Asins, Shruti Sharma, Derrick Renner, Desamparados Roda, Marisol Huerta, Susana Roselló, Käre A. Gotschalck, Lene H. Iversen, Uffe S. Løve, Ole Thorlacius-Ussing, Himanshu Sethi, Alexey Aleshin, Andres Cervantes, Claus L. Andersen

ABSTRACT

3540

The effect of primary tumor location on second- or later-line treatment with anti-EGFR antibodies in patients with metastatic colorectal cancer: A single-center cohort study.

AUTHOR(S)

Anita Archwamety, Naravat Poungvarin, Charuwan Akewanlop, Krittiya Korphaisarn

ABSTRACT

3541

Multi-omics characterization of left-right colorectal cancer.

AUTHOR(S)


ABSTRACT

3542

Genome-wide analysis indicating cancer associated fibroblast (CAF) impacts on colorectal cancer (CRC) prognosis via immunosuppression.

AUTHOR(S)

Yu-feng Chen, Xiaojian Wu, Feng Gao

ABSTRACT

3543

NTRK fusion positive colorectal cancer as a unique subset of CRC with high tumor mutation burden and microsatellite instability.

AUTHOR(S)
A panel of DNA methylation markers for the classification of consensus molecular subtypes 2 and 3 in patients with colorectal cancer.

Inge van Den Berg, Marcel Smid, Robert R. Coebergh van den Braak, Mark A. van de Wiel, Carolien H. Van Deurzen, Vanja de Weerd, John W. Martens, Jan N. IJzermans, Saskia M. Wilting

Clinical performance of methylation-based liquid biopsy test COLVERA after optimization of test interpretation rules.

Zivjena Vucetic, Naima Loayza, Susanne K. Pedersen, Missy Tuck, Lawrence C. LaPointe

Effect of Medicaid expansion on incidence of early-onset colorectal cancer incidence among Hispanics.

Shafia Rahman, Riya J. Patel, Jianyou Liu, Ana Acuna-Villaorduna, Mimi Kim, Sanjay Goel

PMC: A more precise classifier of POLE mutations to identify candidates for immune therapy.

Fadl Zeineddine, Benjamin Garmezy, Timothy A. Yap, John Paul Y. Shen

Are current family-history based colorectal cancer screening guidelines adequate for early detection and potential prevention of young-onset cases?

ABSTRACT
3549

A nationwide analysis of outcomes and healthcare utilization in HIV versus non-HIV patients with colon cancer.

AUTHOR(S)
Syed Ali A. Sherazi, Ikechukwu Achebe, Yaseen Alkaddoumi, Jennifer C. Asotibe, Bashar Attar, Shweta Gupta, Michael R. Mullane

ABSTRACT
3550

Investigating intra-tumor microbes, blood microbes, and CEA for development of non-invasive biomarkers in colorectal cancer.

AUTHOR(S)
Pannaga G. Malalur, Xiaokui Mo, Rebecca Hoyd, John L. Hays, David P. Carbone, Daniel Spakowicz

ABSTRACT
3551

Consensus molecular subtypes and RAS status as biomarker of treatment intensity with fluoropyrimidine, bevacizumab, and irinotecan in metastatic colorectal cancer (XELAVIRI, AIO KRK 0110).

AUTHOR(S)

ABSTRACT
3552

FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases: The PARLIM trial (AIO KRK 0314).

AUTHOR(S)

ABSTRACT
3553
Impact of a metastatic site on circulating tumor DNA (ctDNA) analysis in patients (pts) with metastatic colorectal cancer (mCRC).

AUTHOR(S)


ABSTRACT

Pertuzumab plus trastuzumab and real-world standard of care (SOC) for patients (pts) with treatment refractory metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) confirmed by tumor tissue or ctDNA analysis (TRIUMPH, EPOC1602).

AUTHOR(S)


ABSTRACT

Repeat sequential oxaliplatin-based chemotherapy (FLOX) and nivolumab versus FLOX alone as first-line treatment of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Initial results from the randomized METIMMOX study.

AUTHOR(S)

Anne H. Ree, Hanne Hamre, Christian Kersten, Eva Hofsvi, Marianne G. Guren, Halfdan Sorbye, Christin Johansen, Anne Negård, Kjersti Flatmark, Sebastian Meltzer

ABSTRACT

Impact of BRAF mutations on prognosis and immunotherapy response in microsatellite instability/mismatch repair deficient metastatic colorectal cancer: A systematic review and meta-analysis.

AUTHOR(S)

Robin Park, Laércio Lopes da Silva, Sunggon Lee, Anwaar Saeed

ABSTRACT
Phase II study of panitumumab monotherapy in chemotherapy-naïve frail or elderly patients with unresectable, RAS wild type colorectal cancer: OGSG 1602, survival update data.

AUTHOR(S)

Shingo Noura, Takeshi Kato, Tetsuji Terazawa, Masahiro Goto, Katsuya Ohta, Hironaga Satake, Yoshinori Kagawa, Hisato Kawakami, Hiroko Hasegawa, Kazuhiro Yanagihara, Tatsushi Shingai, Ken Nakata, Masahito Kotaka, Masayuki Hiraki, Ken Konishi, Shiro Nakae, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, Taroh Satoh

ABSTRACT

Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + Imprime PGG (Imprime) + bevacizumab (bev) vs regorafenib (rego) in MORPHEUS: Microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).

AUTHOR(S)

Marwan Fakih, James M. Cleary, Yong Sang Hong, Tae-You Kim, Rachael A. Safyan, Simon Allen, Lorna Bailey, Edward Cha, Christelle Lenain, Danny Lu, Jochen Schulze, Colby S. Shemesh, Stefan Zimmermann

ABSTRACT

Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).

AUTHOR(S)


ABSTRACT

Concurrent BRAFV600E and BRCA mutations in microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Prevalence and case series of mCRC (pts) with prolonged overall survival (OS).

AUTHOR(S)

Timothy L. Cannon, Jamie Randall, Ethan Sokol, Sonja Alexander, Raymond C. Wadlow, Daniel Barnett, Danny Rayes, John F. Deeken, Halla Nimeiri, Kimberly McGregor

ABSTRACT
Increased neutrophil infiltration and lower prevalence of tumor mutation burden and microsatellite instability are hallmarks of RAS mutant colorectal cancers.

AUTHOR(S)

ABSTRACT
3563
LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.

AUTHOR(S)

ABSTRACT
3564
Circulating tumor derived cell-free DNA (ctDNA) to predict recurrence of metastatic colorectal cancer (mCRC) following curative intent surgery or radiation.

AUTHOR(S)

ABSTRACT
3565
RAMucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic colorectal cancer: Safety results from the phase IIb part of the RAMTAS phase II/III trial of the German AIO (AIO-KRK-0316).

AUTHOR(S)

ABSTRACT
3566
Neoadjuvant chemotherapy improves colon cancer survival in resectable metastatic colon cancer: A real world NCDB data analysis.

AUTHOR(S)
Saurabh Parasramka, Aasems Jacob, Quan Chen, Bin Huang, Zhonglin Hao

ABSTRACT
3567

Influence of dietary insulin scores on survival in patients with metastatic colorectal cancer (mCRC): Findings from CALGB (Alliance) 80405.

AUTHOR(S)
Katherine DiNardo, Chao Ma, Fang-Shu Ou, Chen Yuan, Brendan J. Guercio, Vicente Morales-Oyarvide, Erin Van Blarigan, Donna Niedzwiecki, I-Wen Chang, Heinz-Josef Lenz, Charles D. Blanke, Alan P. Venook, Robert J. Mayer, Charles S. Fuchs, Federico Innocenti, Andrew B. Nixon, Richard M. Goldberg, Eileen M. O’Reilly, Jeffrey A. Meyerhardt, Kimmie Ng

ABSTRACT
3568

Exploratory biomarker findings from cohort 2 of MODUL: An adaptable, phase 2, signal-seeking trial of fluoropyrimidine + bevacizumab ± atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer.

AUTHOR(S)
Josep Tabernero, Axel Grothey, Dirk Arnold, Michel Ducreux, Peter J. O’Dwyer, Maurizio Perdicchio, Alexander Abbas, Meghna Das Thakur, Natsumi Irahara, Anila Tahir, Hans-Joachim Schmoll, Eric Van Cutsem

ABSTRACT
3570

Treatment responses and disease dynamics in patients with untreated metastatic colorectal cancer receiving bevacizumab-based sequential versus combination chemotherapy: Analysis of a phase 3 trial (AIO KRK0110, XELAVIRI study).

AUTHOR(S)

ABSTRACT
3571

Serial circulating tumor DNA (ctDNA) monitoring in metastatic colorectal cancer (mCRC) reveals dynamic profile of actionable alterations.
AUTHOR(S)


ABSTRACT

3572

Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer.

AUTHOR(S)

Tae Won Kim, Keun Wook Lee, Joong Bae Ahn, Jin Lee, Jiyeon Ryu, Bitna Oh, Chan-Young Ock, Sunjin Hwang, Ki Baik Hahm, Seong-Jin Kim, Young Suk Park

ABSTRACT

3573

Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan.

AUTHOR(S)

Emma C. Hulshof, Mirjam de With, Femke M. de Man, Geert-Jan Creemers, Birgit A. Deiman, Jesse J. Swen, Saskia Houterman, Stijn L. Koolen, Marjan Laven, Saskia Luelmo, Ron H. van Schaik, Henk-jan Guchelaar, Ron H. Mathijsse, Hans Gelderblom, Maarten J. Deenen

ABSTRACT

3574

Characteristics of patients (pts) and prognostic factors across treatment lines (TL) in metastatic colorectal cancer (mCRC): An analysis from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.

AUTHOR(S)


ABSTRACT

3575

Liquid biopsy-driven anti-EGFR rechallenge in patients with metastatic colorectal cancer.

AUTHOR(S)

Stefano Mariani, Marco Puzzoni, Nicole Liscia, Valentino Impera, Andrea Pretta, Simona Tolu, Anna Grazia Pireddu, Mara Persano, Francesca Musio, Clelia Donisi, Giovanna Pinna, Eleonora Lai, Laura Demurtas, Pina Ziranu, Valeria Pusceddu, Marina Pisano, Grazia Palomba, Milena Casula, Giuseppe Palmieri, Mario Scartozzi
ABSTRACT

3577

Final results from the CAVE (cetuximab rechallenge plus avelumab) mCRC phase II trial: Skin toxicity as a predictor of clinical activity.

AUTHOR(S)
Giulia Martini, Stefania Napolitano, Vincenzo Famiglietti, Filippo G. De Braud, Marinella Terminiello, Carola Borrelli, Pietro Paolo Vitiello, Antonio Avallone, Nicola Normanno, Evaristo Maiello, Alfredo Falcone, Giuseppe Santabarbara, Carmine Pinto, Daniele Santini, Alessandra Di Liello, Daniela Renato, Lucia Esposito, Francesca Marrone, Teresa Troiani, Davide Ciardiello

ABSTRACT

3578

Circulating tumor DNA and circumferential resection margin as key prognostic indicators for survival in rectal cancer.

AUTHOR(S)
Mia Shepherdson, Erin L. Symonds, Susan Byrne, Kirsten Gormly, Christos S. Karapetis, Sina Vatandoust, Graeme P. Young, Amitesh C. Roy

ABSTRACT

3579

Parameters associated with outcomes in pretreated MSI/dMMR metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI): Subgroup analysis of a prospective cohort.

AUTHOR(S)
Raphael Colle, Marine Cachanado, Alexandra Rousseau, Magali Svrcek, Yves Menu, Romain Cohen, Thierry Andre

ABSTRACT

3580

The role of PP2A variants to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and TRIBE trials.

AUTHOR(S)
Jingyuan Wang, Joshua Millstein, Fotios Loupakis, Sebastian Stintzing, Hiroyuki Arai, Francesca Battaglin, Natsuko Kawanishi, Priya Jayachandran, Shivani Soni, Wu Zhang, Christoph Mancao, Chiara Cremolini, Volker Heinemann, Alfredo Falcone, Heinz-Josef Lenz

ABSTRACT

3581

The prognostic impact of RAS and TP53 mutation according to primary tumor location in colorectal liver metastases.
AUTHOR(S)
Yongjun Cha, Bun Kim, Seung Jae Roh, Moon Ki Choi, Dong Woon Lee, Sung-Sik Han, Seong Hoon Kim, Sang-Jae Park, Ji Yeon Baek, Sung Chan Park, Hee Jin Chang, Jae Hwan Oh

ABSTRACT
3582
Overall survival (OS) with encorafenib (enco) + cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC).

AUTHOR(S)

ABSTRACT
3583
A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.

AUTHOR(S)
Elena Garralda, Ammar Sukari, Nehal J. Lakhani, Amita Patnaik, Yanyan Lou, Seock-Ah Im, Talia Golan, Ravit Geva, Martin Wermke, Maria De Miguel, John Palcza, Sujata Jha, Marya F. Chaney, Jane A. Healy, Gerald S. Falchook

ABSTRACT
3584
Differential impact of different TP53 gain-of-function mutations on overall survival of patients with metastatic colorectal cancer: Results from a large integrated healthcare system.

AUTHOR(S)

ABSTRACT
3585
Mucinous colorectal cancer: Disease characteristics, treatment outcomes and the impact of metastasectomy.

AUTHOR(S)
ABSTRACT

Young-onset colorectal cancer treatment side effects: Infertility, sexual dysfunction, and quality-of-life outcomes.

AUTHOR(S)
Laura D. Porter, Ronit Yarden, Kim L. Newcomer, Negeen Fathi

ABSTRACT

Dietary fat in relation to overall and progression-free survival among patients (pts) with advanced or metastatic colorectal cancer (CRC): Data from CALGB 80405 (Alliance).

AUTHOR(S)
Erin Van Blarigan, Chao Ma, Fang-Shu Ou, Alan P. Venook, Kimmie Ng, Donna Niedzwiecki, Edward L. Giovannucci, Heinz-Josef Lenz, Federico Innocenti, James E. Shaw, Blase N. Polite, Howard S. Hochster, Richard M. Goldberg, Robert J. Mayer, Eileen M. O’Reilly, Charles S. Fuchs, Jeffrey A. Meyerhardt

ABSTRACT

Assessment of HER2 (ERBB2) amplification (HER2amp) using blood-based circulating tumor DNA (ctDNA) next generation sequencing (NGS) and correlation with tissue-based testing in metastatic colorectal cancer (mCRC).

AUTHOR(S)

ABSTRACT

XELOX or mFOLFOX6 chemotherapy combined with resection of primary lesion versus chemotherapy alone for colon cancer with unresectable metastases: A randomized clinical trial.

AUTHOR(S)
Weijian Guo, Xinxiang Li, Mingzhu Huang, Ya’nan Yang, Qingguo Li, Chenchen Wang, Lei Liang, Xiaodong Zhu, Wen Zhang, Zhiyu Chen, Wenhua Li, Xiaowei Zhang, Xiaoying Zhao, Lixin Qiu, Qirong Geng, Xuedan Sheng
Association of plasma adiponectin with tumor infiltrating lymphocytes and survival in patients with stage III colon cancer (NCCTG N0147; Alliance).

AUTHOR(S)

ABSTRACT
3591

Young-onset colorectal: Emotional and psychosocial effects on patients, survivors, and caregivers.

AUTHOR(S)
Laura D. Porter, Ronit Yarden, Kim L. Newcomer

ABSTRACT
3592

Doublet (FOLFOX or FOLFIRI) versus triplet (FOLFOXIRI) backbone chemotherapy regimen as first-line treatment of metastatic colorectal cancer: A meta-analysis and systematic review.

AUTHOR(S)
Vishal Jindal, Ruby Gupta, Kamal K. Sahu, Mandeep Singh Rahi, Michael J. Stender, Ishmael A. Jaiyesimi

ABSTRACT
3593

A novel clinical tool to estimate risk of false negative KRAS mutation in circulating tumor DNA testing.

AUTHOR(S)
Stefania Napolitano, Ryan Sun, Aparna R. Parikh, Jason Henry, Christine M. Parseghian, Jason Willis, Kanwal P. Raghav, Van K. Morris II, Arvind Dasari, Michael J. Overman, Rajyalakshmi Luthra, Ryan B. Corcoran, Scott Kopetz

ABSTRACT
3594

Impact of time to treatment initiation on real-world (RW) outcomes in metastatic colorectal cancer (mCRC) in the United States.

AUTHOR(S)
Olumide B. Gbolahan, Darryl A. Outlaw, Neda Hashemi, Ravi K. Paluri, Grant R. Williams

ABSTRACT
358
Real-world survival outcomes associated with completion of adjuvant chemotherapy for stage III colon cancer.

AUTHOR(S)
Jemma M. Boyle, Angela Kuryba, Thomas E. Cowling, Jan van der Meulen, Nicola S. Fearnhead, Kate Walker, Michael Braun, Ajay Aggarwal

ABSTRACT
Clinicopathological and molecular characteristics of early-onset stage III colon adenocarcinoma: An analysis of 25 studies with 35,713 patients in the Adjuvant Colon Cancer End Points (ACCENT) database.

AUTHOR(S)

ABSTRACT
Clinical efficacy and safety of early adjuvant chemotherapy for stage III colon cancer: Short-term outcomes of a multicenter, randomized, open-label, phase 3 trial.

AUTHOR(S)
Jun Seok Park, Soo Yeun Park, Gyu-Seog Choi, Hye Jin Kim, Jong Gwang Kim, Byung Woog Kang, In Kyu Lee, Yoon Suk Lee, Sohyun Kim, Seong Kyu Baek, Gyung Mo Son, Ki Beom Bae, Ji Yeon Kim, Kyung-ha Lee

ABSTRACT
Patient-specific meta-analysis of 3 validation studies of the 12-gene colon cancer recurrence score assay for recurrence risk assessment after surgery with or without 5FU and oxaliplatin.

AUTHOR(S)
Greg Yothers, Alan P. Venook, Takeharu Yamanaka, Yan Lin, Michael Crager, Calvin Y. Chao, Frederick L. Baehner, Takayuki Yoshino

ABSTRACT
Prognostic value of baseline and early changes of circulating-free (cf) and circulating tumor (ct) DNA in the neoadjuvant (NA) setting of early stage colon cancer (CC).

**AUTHOR(S)**
Giacomo Bregni, Chiara Senti, Caroline Vandeputte, Elena Acedo Reina, Paraskevas Gkolfakis, Jean-Luc Van Laethem, Philippe Vergauwe, Marc Van Den Eynde, Jos Janssens, Gauthier Demolin, Stephane Holbrechts, Marylene Clausse, Thierry De Grez, Lionel A. D'Hondt, Karen P. Geboes, Tatiana Besse-Hammer, Francoise Rothe, Patrick Flamen, Alain Hendlisz, Francesco Sclafani

**ABSTRACT**
3600

Association of suboptimal lymph node yield with inferior survival in resected stage 1 colon cancer patients.

**AUTHOR(S)**

**ABSTRACT**
3601

Phase I study of transarterial chemoembolization of lung metastases.

**AUTHOR(S)**
Franz E. Boas, Nancy E. Kemeny, Constantinos T. Sofocleous, Randy Yeh, Vanessa R. Thompson, Meier Hsu, Chaya S. Moskowitz, Etay Ziv, Hooman Yarmohammadi, Achiude Bendet, Stephen B. Solomon

**ABSTRACT**
3602

Long-term outcome of a phase III trial on neoadjuvant chemoradiation with capecitabine and irinotecan in patients with locally advanced rectal cancer: Updated results of the CinClare trial.

**AUTHOR(S)**
Ji Zhu, Xinchen Sun, Anwen Liu, Yaqun Zhu, Tao Zhang, Luying Liu, Jianhui Jia, Shisheng Tan, Junxin Wu, Xin Wang, Juying Zhou, Jialin Yang, Chen Zhang, Hongyan Zhang, Xujia He, Gang Cai, Wei Zhang, Sanjun Cai, Zhen Zhang

**ABSTRACT**
3603

Impact of radiotherapy for local control in T3 N0 rectal cancer managed with total mesorectal excision: A systematic review and meta-analysis.

**AUTHOR(S)**
Jesus C. Fabregas, Andrew Bang, Michael Tjong, Michael Kucharczyk
H101 treatment of hepatic metastasis of colorectal cancer with recombinant human adenovirus 5 injection: A phase I clinical trial-TROJAN 021.

AUTHOR(S)
Yang He, Jianhua Chen, Zhongzheng Zhu, Song Gao, Hui Wang, Wei Mao, Hong Qian, Weixing Liu, Xianling Guo, Huanlong Qing, Qing Xu

Accurate early-stage colorectal cancer detection through analysis of cell-free circulating tumor DNA (ctDNA) methylation patterns.

AUTHOR(S)
James M. Kinross, Pol Canal-Noguer, Marko Chersicola, Primož Knap, Marko Bitenc, Alexandre Perera-Lluna, Michael H. Roehrl, Kristi Kruusmaa

A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study first-stage.

AUTHOR(S)
Stefano Tamberi, Elisa Grassi, Jody Corbelli, Giorgio Papiani, Maria a. Barbera, Chiara Zingaretti, Chiara Carli Moretti, Isacco Montroni, Elisabetta Petracci, Dora Caruso, Sofia Nosseir, Oriana Nanni, Giovanni Luca Frassineti, Maria Di Bartolomeo, Marina Marzola, Andrea Bonetti, Fabio Gelsomino, Carmine Pinto, Davide Tassinari, Giampaolo Ugolini

Minimal residual disease by circulating tumor DNA analysis for colorectal cancer patients receiving radical surgery: An initial report from CIRCULATE-Japan.

AUTHOR(S)
Pharmacologic ascorbate enhances the therapeutic index of ATM-inhibitor based chemoradiation for colorectal cancer.

AUTHOR(S)

ABSTRACT
Evaluating longitudinal toxicity of cetuximab in patients with metastatic colorectal cancer (mCRC): A pooled analysis from 1,302 patients in the ARCAD database.

AUTHOR(S)

ABSTRACT
Influence of preoperative chemoradiation on tumor-infiltrating lymphocytes in locally advanced rectal cancer: The STAR-01 cohort.

AUTHOR(S)
Francesca Negri, Letizia Gnetti, Lorena Bottarelli, Nicoletta Campanini, Maria Emanuela Negru, Francesca Bergamo, Salvatore Siena, Michela Frisinghelli, Marija Petric, Germana Chiaulon, Valeria Smiroldo, Domenico C. Corsi, Giulia A. Vita, Enrico M. Silini, Cinzia Azzoni, Federica Gaiani, Luigi Laghi, Gian Luigi de'Angelis, Luca Boni, Carlo Aschele

ABSTRACT
Impact of the COVID-19 pandemic in treating gastrointestinal (GI) cancer patients receiving systemic anticancer treatment (SACT): The Guy’s Cancer Centre experience.

AUTHOR(S)
Jose Roca, Ailsa Sita-Lumsden, Eirini Tsotra, Charalampos Gousis, Beth Russell, Charlotte Moss, Victoria Harris, Kasia Owczarczyk, Julien De Naurois, Nicholas R. Maisey, Sarah Ngan, Debashis Sarker, Kiruthikah Thillai, Vasiliki Michalarea, Asad Qureshi, Imran Petkar, Anne S. Rigg, Mieke Van Hemelrijck, Paul J. Ross, Saoirse Dolly

ABSTRACT

262
Multi-omics longitudinal analyses in stages I to III CRC patients: Surveillance liquid biopsy test to predict early recurrence and enable risk-stratified postoperative CRC management.

AUTHOR(S)
Xuanhui Liu, Yani Zhang, Xiurui Zhu, Sheeno P. Thyparambil, Wei-Li Liao, Xiao-bin Zheng, Jin You, Ashiq Masood, Zhen Li, Gabriel Yang, Xiaoming Yao, Shiying Hao, Robert Heaton, James Schilling, Karl G. Sylvester, Jiayu Liao, Feng Gao, Ping Lan, Xuefeng Ling, Xiaojian Wu

ABSTRACT
A randomized phase III study of immune checkpoint inhibition with chemotherapy in treatment-naive metastatic anal cancer patients: A trial of the ECOG-ACRIN cancer research group (EA2176).

AUTHOR(S)

ABSTRACT
Total neoadjuvant treatment versus standard chemoradiation to increase the sphincter preservation rate for distal locally advanced rectal cancer (TESS).

AUTHOR(S)
Weiwei Xiao, Xiaojun Wu, Peiqiang Cai, YeZhong Zhuang, Xiaozhong Wang, Shoumin Bai, Qiaoxuan Wang, Yijing Ye, Qing Liu, Min Liu, Shuang Liu, ZhiFan Zeng, Zhi-Zhong Pan, Yuanhong Gao, Gong Chen

ABSTRACT
TPS3615

PERSPECTIVE: Tepotinib + cetuximab in patients (pts) with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to MET amplification (METamp).

AUTHOR(S)
Tanios S. Bekaii-Saab, Eric Van Cutsem, Antonio Cubillo, Caroline Petorin-Lesens, Nuria Rodriguez-Salas, Kanwal P. Raghav, Olivier Dupuis, Carlos López-López, Christophe Tournigand, Nicolas Isambert, Khalid Abubaker, Karl-Maria Schumacher, Karin Berghoff, Soetkin Vlassak, Gordon Otto, Josep Taberner
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610.

AUTHOR(S)

ABSTRACT
TPS3618

BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAF^{V600E}) metastatic colorectal cancer (mCRC).

AUTHOR(S)

ABSTRACT
TPS3619

Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).

AUTHOR(S)
Kanwal P. Raghav, Takayuki Yoshino, Rosine Guimbaud, Ian Chau, Marc Van Den Eynde, Joan Maurel, Jeanne Tie, Tae Won Kim, Kun-Huei Yeh, Daniel Barrios, Kojiro Kobayashi, Emarjola Bako, Mehreteab Aregay, Gerold Meinhardt, Salvatore Siena

ABSTRACT
TPS3620

JCOG1805 (PanDRa-BD study): A randomized controlled study of adjuvant chemotherapy for stage II colorectal cancer patients at high-risk of developing recurrence according to T-stage and three selected pathological factors (Pn, DR, and BD).

AUTHOR(S)
Megumi Ishiguro, Hideki Ueno, Atsuo Takashima, Junki Mizusawa, Keita Sasaki, Hiroshi Katayama, Tetsuya Hamaguchi, Shunsuke Tsukamoto, Yukihide Kanemitsu

ABSTRACT
Phase II/III study of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

AUTHOR(S)
Van K. Morris, Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal, Patrick M. Boland, Dustin A. Deming, Aaron J. Scott, Howard J. Lim, Norman Wolmark, Thomas J. George

ABSTRACT
Neoadjuvant chemoradiotherapy with sequential ipilimumab and nivolumab in rectal cancer (CHINOREC): A prospective randomized, open-label, multicenter, phase II clinical trial.

AUTHOR(S)
Johannes Laengle, Irene Kuehrer, Dietmar Pils, Julijan Kabiljo, Judith Stift, Friedrich Herbst, Bernhard Dauser, Matthias Monschein, Peter Razek, Stefanie Haegele, Wolfgang Huller, Reinhold Fuegger, Hans Geinitz, Andreas L. Petzer, Clemens Bitterman, Friedrich Laengle, Dietmar Tamandl, Joachim Widder, Rainer Schmid, Michael Bergmann

ABSTRACT
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Back to Program

Showing 151 Presentations

https://meetinglibrary.asco.org/session/13627

The prognostic value of tumor markers in patients (pts) with resectable gastric cancer (GC) receiving perioperative therapy in the CRITICS trial.

AUTHOR(S)
Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the advanced gastric cancer expansion cohort.

AUTHOR(S)
Kensei Yamaguchi, Satoru Iwasa, Motohiro Hirao, Takashi Oshima, Kazuaki Harada, Yasuyoshi Sato, Akihito Kawazoe, Kan Yonemori, Kazuhiro Nishikawa, Nozomu Machida, Yoshito Komatsu, Takuya Suzuki, Shiori Okumura, Reiko Nagai, Takao Takase, Kohei Shitara

Neoadjuvant nivolumab monotherapy in patients with resectable gastric cancer: Preliminary results from a multicenter study.

AUTHOR(S)
Shuji Takiguchi, Kohei Shitara, Noriaki Takiguchi, Seiji Ito, Mitsugu Kochi, Hidehito Horinouchi, Takahiro Kinoshita, Kei Muro, Takaki Yoshikawa, Hirotaka Hasegawa, Hiroyoshi Nishikawa, Yasuhiro Kodera

A phase II study of chemoselection with docetaxel, cisplatin, and 5-fluorouracil as a strategy for organ preservation in patients with resectable esophageal cancer (CROC trial).

AUTHOR(S)

Camrelizumab plus chemotherapy as neoadjuvant therapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, open-label, single-arm, phase 2 study.

AUTHOR(S)
Jingpei Li, Jun Liu, Zhuoyi Li, Fei Cui, Yuan Zeng, Wenhua Liang, Hengrui Liang, Wei Wang, Ke Xu, Weipeng Cai, JunHui Fu, Jianxing He
Nivolumab and ipilimumab for second-line therapy in elderly patients with advanced esophageal squamous cell cancer: Safety interim analysis of the RAMONA trial.

AUTHOR(S)
Nicolai Hartel, Nadja M. Meindl-Beinker, Martin Maenz, Wolfgang Hiegl, Johannes Betge, Ralf D. Hofheinz, Arndt Vogel, Stefan Angermeier, Claus Bolling, Maike de Wit, Ralf Jakobs, Meinolf Karthaus, Gertraud Stocker, Peter C. Thuss-Patience, Matthias P. Ebert

ABSTRACT

LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort.

AUTHOR(S)

ABSTRACT

Frequency of homologous recombination-related (HRR) genes mutations in gastric cancer.

AUTHOR(S)
Wei Wang, Wang Huaiming, Yuhong Chen, Huanhuan Liu, Yanrui Zhang, Xiayuan Liang, Yun Zhang, Feng Lou, Shanbo Cao, Huina Wang

ABSTRACT

ENSURE: An international multicenter study exploring whether surveillance after esophageal cancer surgery impacts oncological and quality-of-life outcomes.

AUTHOR(S)

ABSTRACT

Circulating tumor DNA (ctDNA) analysis by low-coverage whole genome sequencing (lcWGS) of resectable esophageal adenocarcinoma (rEAC) patients.
DNA and RNA sequencing analysis revealed alterations of *ANK3*, *PKHD1* and olfactory transduction as potential biomarker of three-year survival in gastric cancer.

The prognosis of gastric adenocarcinoma depends on the crosstalk between immune profiles and tumor genomic alterations.

Camrelizumab combined with FLOFOX as neoadjuvant therapy for resectable locally advanced gastric and gastroesophageal junction adenocarcinoma: Updated results of efficacy and safety.

Randomized phase II study comparing docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma who are refractory to fluoropyrimidine and platinum-based chemotherapy: OGS1201.
ABSTRACT

Real-world data (RWD) reveals benefit for adjuvant chemotherapy with docetaxel, oxaliplatin and fluorouracil/leucovorin (FLOT) is limited to those with tumour regression grade (TRG) ≥3 in oesophago-gastric cancer (OGC).

AUTHOR(S)
Brindley S. Hapuarachi, Rebecca Lee, Adeel Khan, Laura Woodhouse, Valentinos Kounnis, Fiona Britton, Jessica Coyle, Kathleen Connors, Neethu Billy Graham Mariam, Jamie Weaver, Tom Waddell, Richard Hubner, Konstantinos Kamposioras, Wasat Mansoor

ABSTRACT

SHARED: Efficacy and safety of sintilimab in combination with concurrent chemoradiotherapy (cCRT) in patients with locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma.

AUTHOR(S)
Jia Wei, Xiaofeng Lu, Qin Liu, Yao Fu, Song Liu, Ju Yang, Meng Wang, Liming Zheng, Yang Yang, Xiangshan Fan, Yang Zhao, Wenxian Guan, Baorui Liu

ABSTRACT

Final survival results from a multicenter, randomized phase II trial of intravenous paclitaxel plus FOLFOX (ivPOF) and/or intraperitoneal paclitaxel plus FOLFOX (ipPOF) versus mFOLFOX6 as first-line treatment of advanced gastric cancer (AGC): SYLT/FNF 004.

AUTHOR(S)
Shen Zhao, Rongbo Lin, Nan-Feng Fan, Yigui Chen, Xiaofeng Li, Peicheng Lin, Wujin Chen, Wenzheng Fang, Jinfeng Zhu, Hui Li, Jie Liu

ABSTRACT

Immunogenomic features of pathologic response to neoadjuvant immune checkpoint blockade in esophageal cancer.

AUTHOR(S)
A multicenter phase II study of S-1 plus ramucirumab as first-line treatment in elderly patients with advanced/recurrent gastric cancer (KSCC1701).

AUTHOR(S)
Hiroo Katsuya, Koichi Suyama, Kazuma Kobayashi, Naoki Izawa, Yoshikazu Uenosono, Qingjiang Hu, Tetsuya Kusumoto, Hajime Otsu, Hiroyuki Orita, Hirofumi Kawanaka, Kazunori Shibao, Satoshi Koga, Mototsugu Shimokawa, Akitaka Makiyama, Hiroshi Saeki, Eiji Oki, Hideo Baba, Masaki Mori

ABSTRACT
Survival analysis by tumor response from real-world data in advanced gastric cancer treated with nivolumab: The DELIVER trial (JACCRO GC-08).

AUTHOR(S)

ABSTRACT
ERBB2 copy number (CN) as a quantitative biomarker for real-world (RW) outcomes to anti-HER2 therapy in advanced gastroesophageal adenocarcinoma (adv GEA).

AUTHOR(S)
Samuel J. Klempner, Liangliang Zhang, Ryon Graf, Russell Madison, Jeremy Snider, Cheryl D. Cho-Phan, Emily Castellanos, Gerald Li, Halla Nimeiri, Garrett M. Frampton, Geoffrey R. Oxnard, Jeffrey M. Venstrom, Kimberly McGregor, Alexa B. Schrock

ABSTRACT
Phase II trial of perioperative chemotherapy + avelumab in locally advanced gastroesophageal adenocarcinoma: Preliminary results.

AUTHOR(S)

ABSTRACT
Neoadjuvant camrelizumab combined with chemotherapy and apatinib for locally advanced thoracic esophageal squamous cell carcinoma (ESCC): A single-arm, open-label, phase Ib study.

AUTHOR(S)
Zhen Wang

ABSTRACT

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).

AUTHOR(S)

ABSTRACT


AUTHOR(S)
Zhigang Li, Yubei Sun, Feng Ye, Dong Ma, Xianli Yin, Wu Zhuang, Xianglin Yuan, Shukui Qin, Yiping Zhang, Kangsheng Gu, Kuaile Zhao, Juxiang Xiao, Ying Cheng, Yuxian Bai, Suxia Luo, Liwei Wang, Cailian Wang, Yi Cui, Lingling Mei, Lin Shen

ABSTRACT

Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma.

AUTHOR(S)
Hongli Li, Jingyu Deng, Shaohua Ge, Fenglin Zang, Le Zhang, Peng Ren, Baogui Wang, Fuliang Cao, Ting Deng, Rui Liu, Tao Ning, Yuchong Yang, Ming Bai, Xia Wang, Zhi Ji, Jingjing Duan, Yong Liu, Dejun Zhou, Han Liang, Yi Ba

ABSTRACT
The sequence of chemotherapy and anti-PD-1 antibody influence the efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell cancer: A phase II study.

AUTHOR(S)
Lingdi Zhao, Wenqun Xing, Yonghao Yang, Yong Zhang, Baozhen Ma, Xiaomin Fu, Guanghui Liang, Yiman Shang, Zibing WANG, Hongwei Lin, Quanli Gao

ABSTRACT

Risk factors for recurrence in each pattern after curative gastrectomy for pStage II/III gastric cancer: An exploratory analysis of a randomized controlled trial (JCOG1001).

AUTHOR(S)
Tetsuro Toriumi, Masanori Terashima, Junki Mizusawa, Yuya Sato, Yukinori Kurokawa, Shuji Takiguchi, Yuichiro Doki, Yasuyuki Kawachi, Hisashi Shinhara, Yasuhiro Choda, Seiji Ito, Takaki Yoshikawa, Takeshi Sano, Mitsuru Sasako

ABSTRACT

Risk factors of metachronous peritoneal carcinomatosis after potentially curative gastric cancer resection in the CRITICS trial.

AUTHOR(S)
Irene A. Caspers, Karolina Sikorska, Astrid E. Slagter, Elma Meershoek – Klein Kranenbarg, Cornelis J. Van De Velde, Pehr A. Lind, Marianne Nordsmark, Edwin P. Jansen, Marcel Verheij, Johanna W. van Sandick, Annemieke Cats, Nicole C. van Grieken

ABSTRACT


AUTHOR(S)
Bang Wool Eom, Hong Man Yoon, Young-Woo Kim, Jae Seok Min, Ji Yeong An, Hoon Hur, Young-Joon Lee, Gyu Seok Cho, Young-Kyu Park, Mi Ran Jung, Ji-Ho Park, Woo Jin Hyung, Sang-Ho Jeong, Myeong-Cherl Kook, Mira Han, Byung-Ho Nam, Keun Won Ryu

ABSTRACT

Apatinib in combination with docetaxel and S1 chemotherapy in the first-line treatment of metastatic gastric cancer.
AUTHOR(S)
Ling Xia, Yu Gao, Jun Gong, Jing Dai, Jin Peng, Lilin He, Weidong Chen, Wei Gong, Lei Yang, Wang Wen-bo, Huangang Jiang, Hui Xu, Qing-Yun Wang, Han Wu, You Wang, Lu Wu, Fuxiang Zhou

ABSTRACT
4055
Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSG-ST19-16).

AUTHOR(S)
Dae Young Zang, Hye Sook Han, Bum Jun Kim, Hee-Jung Jee, Young Ju Suh, Hyonggin An, Ji-Hye Byun, Dong Sook Kim, Se Hoon Park, Sun Y. Rha, Do-Youn Oh, Jong Gwang Kim, Woo Kyun Bae, In-Ho Kim, Sun Jin Sym, So Yeon Oh, Hyeong Su Kim, Keun Wook Lee, Min-Hee Ryu

ABSTRACT
4056
Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) versus chemotherapy in patients with advanced gastric cancer from the DESTINY-Gastric01 trial.

AUTHOR(S)
David Cella, Michelle D. Hackshaw, Gerard T. Vondeling, Lee Bennett, Diana Garbinsky, Kaku Saito, Masahiro Sugihara, Yung-Jue Bang, Kensei Yamaguchi, Kohei Shitara

ABSTRACT
4057
Early predictors of benefit to dual anti-PD1/HER2 inhibition: Biomarker analysis from phase 2 trial of pembrolizumab/trastuzumab in HER2-positive metastatic esophagogastric (mEG) cancer.

AUTHOR(S)

ABSTRACT
4058
A phase II study of neoadjuvant immunotherapy combined with chemotherapy (camrelizumab plus albumin paclitaxel and carboplatin) in resectable thoracic esophageal squamous cell cancer (NICE study): Interim results.

AUTHOR(S)
Zhigang Li, Jun Liu, Ming Zhang, Jinchen Shao, Yang Yang, Hongxuan Li, Zhichao Liu, Renquans Zhang, Bentong Yu, Hezhong Chen

**ABSTRACT**

4060

A prospective, phase II, single-arm study of neoadjuvant/conversion therapy with camrelizumab, apatinib, S-1 ± oxaliplatin for locally advanced cT4a/bN+ gastric cancer.

**AUTHOR(S)**

Song Li, Wenbin Yu, Fei Xie, Zhimin Liu, Weiwei Lv, Duanbo Shi, Dexin Yu, Meng Wei, Jiaqian Wang, Yongtian Zhao, Cheng Chen, Zhikun Zhao, Jing Gao, Lei Sheng, Lian Liu

**ABSTRACT**

4061

Efficacy and safety of KN046 plus paclitaxel/cisplatin as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

**AUTHOR(S)**

Jianming Xu, Rongrui Liu, Yanqiao Zhang, Nong Xu, Qingxia Fan, Shegan Gao, Hongming Pan, Mingquan Cai, Dong Yan, Qianqian Liang, Qiong Wu, Baohong Guo, Yakun Qi, Ting Xu

**ABSTRACT**

4062

Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer (HER-RAM study).

**AUTHOR(S)**

Sun Y. Rha, Chang Gon Kim, Minkyu Jung, Hyo Song Kim, Choong-kun Lee, Hei-Cheul Jeung, Dong-Hoe Koo, Woo Kyun Bae, Dae Young Zang, Hyunki Kim, Hyun Cheol C. Chung

**ABSTRACT**

4063

A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of a safety run-in—A trial of the ECOG-ACRIN Cancer Research Group (EA2174).

**AUTHOR(S)**

**ABSTRACT**

4064

Intraperitoneal aerosolized nanoparticle albumin based paclitaxel (NAB-PTX) for irresectable peritoneal metastases: A first in human phase I study.

**AUTHOR(S)**

Wim Ceelen, Louis Sandra, Leen Van de Sande, Martin Graversen, An Vermeulen, Dries Reynders, Sarah Cosyns, Anne Hoorens, Wouter Willaert

**ABSTRACT**

4065

Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N+C) versus (C) from CheckMate 649.

**AUTHOR(S)**

Lucjan Wyrwicz, Elena Elimova, Steven I. Blum, Hong Xiao, Eric Davenport, Jinyi Wang, Shannon Hunter, Mingshun Li, Kaoru Kondo, Markus H. Moehler

**ABSTRACT**

4066

Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery in esophageal or gastro-esophageal carcinoma.

**AUTHOR(S)**


**ABSTRACT**

4067

Imaging HER2-positive metastatic esophagogastric cancer with $^{89}$Zr-trastuzumab PET and $^{18}$F-FDG PET.

**AUTHOR(S)**

Melissa A. Lumish, Steven B. Maron, Viktoriya Paroder, Steven Philemond, Joseph A. O’Donoghue, Heiko Schöder, Jason S. Lewis, Yelena Y. Janjigian, Neeta Pandit-Taskar

**ABSTRACT**
Final results from ClarIDHy, a global, phase 3, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.

AUTHOR(S)
Ghassan K. Abou-Alfa, Teresa Macarulla, Milind M. Javle, Robin Kate Kelley, Sam J. Lubner, Jorge Adeva, James M. Cleary, Daniel V. Catenacci, Mitesh J. Borad, John A. Bridgewater, William P. Harris, Adrian G. Murphy, Do-Youk Oh, Jonathan R. Whisenant, Christina X. Chamberlain, Liewen Jiang, Camelia Gliser, Shuchi S. Pandya, Juan W. Valle, Andrew X. Zhu

ABSTRACT

Adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis.

AUTHOR(S)

ABSTRACT

IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor).

AUTHOR(S)

ABSTRACT

Pembrolizumab (pembro) versus placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (AHCC) previously treated with sorafenib: Updated data from the randomized, phase 3 KEYNOTE-240 study.

AUTHOR(S)
**ABSTRACT**

**4072**

**IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.**

**AUTHOR(S)**


**ABSTRACT**

**4073**

**Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase 2 KEYNOTE-224 study.**

**AUTHOR(S)**


**ABSTRACT**

**4074**

**A phase Ib study of anlotinib plus TQB2450 as second-line therapy for advanced biliary tract adenocarcinoma.**

**AUTHOR(S)**

Yongkun Sun, Aiping Zhou, Wen Zhang, Zhichao Jiang, Wang Qu

**ABSTRACT**

**4075**

**Update on overall survival (OS) of RESCUE: An open-label, phase 2 trial of camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (HCC).**

**AUTHOR(S)**

Yun Zhang, Jianming Xu, Jie Shen, Shanzhi Gu, Lihua Wu, Jian Wu, Guoliang Shao, Yanqiao Zhang, Li Xu, Tao Yin, Jingfeng Liu, Zhenggang Ren, Jianping Xiong, Xianhai Mao, Ling Zhang, Jiayin Yang, Lequon Li, Xiaoming Chen, Zhiming Wang, Quanren Wang

**ABSTRACT**

**4076**
A randomized, double-blinded, phase III study of icaritin versus huachashu as the first-line therapy in biomarker-enriched HBV-related advanced hepatocellular carcinoma with poor conditions: Interim analysis result.

AUTHOR(S)
Yan Sun, Shukui Qin, Wei Li, Yabing Guo, Ying Zhang, Lingzhan Meng, Yuping Sun, Hongbo Ji, Yueyin Pan, Xiufeng Liu, Bin Hu, Yongqian Shu, Yi Li, Zhiqiang Meng, Kangsheng Gu, Hong Guo, Gang Chen, Bin Ye, Kun Meng

ABSTRACT
4077
Updated results of a phase 1b study of regorafenib (REG) 80 mg/day or 120 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).

AUTHOR(S)
Anthony B. El-Khoueiry, Richard D. Kim, William P. Harris, Max W. Sung, Dirk Waldschmidt, Roniel Cabrera, Vittorio Luigi Garosi, Hong Zebger-Gong, Barbara J. Brennan, Ying A. Wang, Udo Mueller, Tatiane C. Ishida, Peter R. Galle

ABSTRACT
4078
Association of cell-free DNA dominant clone allele frequency with poor outcomes in advanced biliary cancers treated with platinum-based chemotherapy.

AUTHOR(S)

ABSTRACT
4079
Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study.

AUTHOR(S)

ABSTRACT
4080
Preliminary results of molecular screening for FGFR alterations (alts) in the RAGNAR histology-agnostic study with the FGFR-inhibitor (FGFRi) erdafitinib.

AUTHOR(S)
Preliminary efficacy and safety of perioperative treatment of camrelizumab combined with apatinib in resectable hepatocellular carcinoma (HCC): A prospective phase II study.

AUTHOR(S)
Yongxiang Xia, Ping Wang, Liyong Pu, Xiaofeng Qian, Feng Cheng, Ke Wang, Chuanyong Zhang, Donghua Li, Xiangcheng Li, Feng Zhang, Jie Zhao, Si Li, Wenjing Xi, Xuehao Wang

A phase II trial of lenvatinib plus toripalimab and hepatic arterial infusion chemotherapy as a first-line treatment for advanced hepatocellular carcinoma (LTHAIC study).

AUTHOR(S)
MinKe He, Shi Ming, Zhicheng Lai, QiJiong Li

Exploratory circulating biomarker analyses: lenvatinib + pembrolizumab (L + P) in a phase 1b trial in unresectable hepatocellular carcinoma (uHCC).

AUTHOR(S)
Andrew X. Zhu, Josep M Llovet, Masahiro Kobayashi, Masafumi Ikeda, Marc Pracht, Max W. Sung, Ari D. Baron, Masatoshi Kudo, Tim Meyer, Takuji Okusaka, Hiromitsu Kumada, Shuichi Kaneko, Taisuke Hoshi, Kenichi Saito, Shuyu D. Li, Yasuhiro Funahashi, Yukinori Minoshima, Leonid Dubrovsky, Richard S. Finn

Treatment-related toxicity and improved outcomes with immune checkpoint inhibitors in patients with hepatocellular carcinoma.

AUTHOR(S)

AUTHOR(S)
Ghassan K. Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina M. Vaccaro, Davide Melisi, Raed M. Al-Rajabi, Andrew S. Paulson, Mitesh J. Borad, David H. Gallinson, Adrian G. Murphy, Do-Youn Oh, Efrat Dotan, Daniel Catenacci, Eric Van Cutsem, Christine F. Lihou, Huiling Zhen, Luis Félix, Arndt Vogel

ABSTRACT

T-cell receptor pharmacodynamics associated with survival and response to tremelimumab (T) in combination with durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).

AUTHOR(S)
Patricia McCoon, Young S. Lee, Robin Kate Kelley, Violeta B. Guthrie, Song Wu, Stephanie A. Bien, Alejandra Negro, Philip He, John Kurland, Fernanda Pilataxi, Steven Ching, Ghassan K. Abou-Alfa

ABSTRACT

Phase I trial of fourth-generation chimeric antigen receptor T-cells targeting glypican-3 for advanced hepatocellular carcinoma.

AUTHOR(S)
Weijia Fang, Qihan Fu, Qingwei Zhao, Yi Zheng, Lulu Liu, Zonghai Li, Xiaomeng Dai, Huamao Wang, Xudong Zhu, Peng Zhao, Meihua Lin, Hangyu Zhang, Jun Xiao, Jian Liu, Zhou Tong, Zhen Wang, Tingbo Liang

ABSTRACT

Natural history of patients (pts) with advanced cholangiocarcinoma (CCA) with FGFR2 gene fusion/rearrangement or wild-type (WT) FGFR2.

AUTHOR(S)
Rachna T. Shroff, Jessica Rearden, Ai Li, Susan Moran, Stacie P. Shepherd, Angela Lamarca

ABSTRACT

Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC).
Relationship between *Helicobacter pylori* and development of hepatocellular carcinoma: A systematic review and meta-analysis.

**AUTHOR(S)**
Samragnyi Madala, Kira MacDougall, Balarama K. Surapaneni, Robin Park, Anup Kasi, Mohit Girotra

A multi-center randomized controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF trial): Analysis of overall survival.

**AUTHOR(S)**
Masatoshi Kudo, Kiyoshi Hasegawa, Yoshikuni Kawaguchi, Tadatoshi Takayama, Namiki Izumi, Naoki Yamanaka, Mitsuo Shimada, Masahumi Inomata, Shuichi Kaneko, Hideo Baba, Kazuhiko Koike, Masao Omata, Masatoshi Makuuchi, Yutaka Matsuyama, Norihiro Kokudo

Gemox chemotherapy in combination with anti-PD1 antibody toripalimab and lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial.

**AUTHOR(S)**
Zhou Jian, Jia Fan, Guo-Ming Shi, Xiao-Yong Huang, Dong Wu, Guo-Huan Yang, Yuan Ji, Yi Chen, Fei Liang, Jia-Cheng Lu, Ning-Ling Ge, Hui-Chuan Sun, Xiao-Wu Huang, Shuang-Jian Qiu, Yi-Feng He, Xin-Rong Yang, Yang Xu, Qiang Gao, Jian Sun
An armored GPC3-directed CAR-T for refractory or relapsed hepatocellular carcinoma in China: A phase I trial.

AUTHOR(S)
Zhongwei Zhao, Wenyuan Guo, Shiji Fang, Shaohua Song, Jingjing Song, Fei Teng, Liyun Zheng, Jianting Mao, Hao Guo, Wang Huajing, Xiaofeng Feng, Xiaowen He, Guoshan Ding, Jiansong Ji

ABSTRACT

Regomune: A phase II study of regorafenib + avelumab in solid tumors—Results of the biliary tract cancer (BTC) cohort.

AUTHOR(S)
Sophie Cousin, Carine A. Belleria, Jean Philippe Guégan, Thibault Mazard, Carlos A. Gomez-Roca, Jean Philippe Metges, Coralie Cantarel, Antoine Adenis, Iphigenie Korakis, Pierre-guillaume Pourreau, Mariella spalato-Ceruso, Kevin Bourcier, Michèle Kind, Isabelle Soubeyran, Alban Bessede, Antoine Italiano

ABSTRACT

FOENIX-CCA2 quality of life data for futibatinib-treated intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions/rearrangements.

AUTHOR(S)
Juan W. Valle, Antoine Hollebecque, Junji Furuse, Lipika Goyal, Funda Meric-Bernstam, Robert S. Epstein, Tehseen Salimi, Volker Wacheck, Mei Liu, Karim A. Benhadji, John A. Bridgewater

ABSTRACT

The cost effectiveness of lenvatinib versus atezolizumab and bevacizumab or sorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in Canada.

AUTHOR(S)
David Trueman, Yifeng Liu, Marc Geadah, Nicholas Hon, Suthakar Sabapathy, Laveena Kamboj, Huimin Li, Melanie Lucero, Genevieve Meier

ABSTRACT

Lenvatinib plus toripalimab as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-arm, phase 2 trial.

AUTHOR(S)
Zhou Jian, Jia Fan, Guo-Ming Shi, Xiao-Yong Huang, Dong Wu, Fei Liang, Guo-Huan Yang, Jia-Cheng Lu, Yi Chen, Ning-Ling Ge, Yuan Ji, YY Hou, Hui-Chuan Sun, Shuang-Jian Qiu, Qing-Hai Ye, Xiao-Wu Huang, Ying-Hong Shi, Qiang Gao, Xin-Rong Yang, Xiao-Ying Wang

ABSTRACT

4099

Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.

AUTHOR(S)

Philipp K. Haber, Miguel Torres-Martin, Jean-Francois Dufour, Chris Verslype, Jens Marquardt, Peter R. Galle, Arndt Vogel, Tim Meyer, Ismail Labgaa, Lewis R. Roberts, Beatriz Minguez, Vincenzo Mazzaferro, Fabian Finkelmeier, Tobias Müller, Moritz Schmelzle, Richard S. Finn, Swan Thung, Augusto Villanueva, Daniela Sia, Josep M Llovet

ABSTRACT

4100

Phase 2 study of AK104 (PD-1/CTLA-4 bispecific antibody) plus lenvatinib as first-line treatment of unresectable hepatocellular carcinoma.

AUTHOR(S)

Li Bai, Meili Sun, Aibing Xu, Yuxian Bai, Jian Wu, Guoliang Shao, Lijie Song, Xiaoping Jin, Weifeng Song, Baiyong Li, Yu Xia, Shunchang Jiao

ABSTRACT

4101

Comparative effectiveness of sorafenib, lenvatinib, and nivolumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis treated at VA Medical Centers.

AUTHOR(S)

William J. Chapin, Wei-Ting Hwang, Thomas B. Karasic, Anne Marie McCarthy, David E. Kaplan

ABSTRACT

4102

Tumor-informed assessment of circulating tumor DNA and its incorporation into practice for patients with hepatobiliary cancers.

AUTHOR(S)


ABSTRACT

4103
Does adjuvant chemoradiation benefit patients with lymph node-positive biliary tract cancer? A secondary analysis of SWOG S0809.

AUTHOR(S)
Sepideh Gholami, Mai T. Duong, David P. Horowitz, Katherine A. Guthrie, Edgar Ben-Josef, Anthony B. El-Khoueiry, Charles D. Blanke, Philip A. Philip, Syed A. Ahmad, Flavio G. Rocha

ABSTRACT
4104

ARID1A mutation to predict disease progression during first-line chemotherapy in biliary tract cancer patients.

AUTHOR(S)
Sung Hwan Lee, Jaekyung Cheon, Seoyoung Lee, Hye Jin Choi, Beodeul Kang, Hyeon-Su Im, Chan Kim, Sung Hoon Choi, Choong-kun Lee, Hongjae Chon

ABSTRACT
4105

Clinical outcomes analysis of TP53-mutated advanced and metastatic biliary tract cancers.

AUTHOR(S)
Sunyoung S. Lee, Hop S. Tran Cao, Ching-Wei D. Tzeng, Zeyad Metwalli, Eugene J. Koay, Ethan B. Ludmir, Yun Shin Chun, Stephen G. Chun, Milind M. Javle

ABSTRACT
4106

Impact of cell density in lymphocyte-rich areas in the tumor microenvironment on prognosis and gene expression landscape in hepatocellular carcinoma.

AUTHOR(S)
Jeonghyuk Park, Kyungdoc Kim, Hong-Seok Lee, Guhyun Kang, Kyu-Hwan Jung, Ahmed O. Kaseb, Sunyoung S. Lee

ABSTRACT
4107

Should all pancreatic neuroendocrine tumors (PNET) over 1 cm be resected?

AUTHOR(S)
Diana Hsu, Sidney Le, Alex Chang, Austin Spitzer, George Kazantsev, Peter D. Peng, CK Chang, Thach-Giao Truong

ABSTRACT
4108
Validation of a clinical score (CS) for patients (pts) with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177 dotatate.

AUTHOR(S)
Satya Das, Aman Chauhan, Liping Du, Katharine Thomas, Aasems Jacob, Aimee Schad, Shikha Jain, Aaron Jessop, Chirayu Shah, David Eisner, Dana B. Cardin, Kristen K. Ciombor, Laura W. Goff, Marques Bradshaw, Dominique Delbeke, Martin P. Sandler, Jordan Berlin, Robert A. Ramirez

ABSTRACT
The safety and efficacy of PEN-221 somatostatin analog (SSA)-DM1 conjugate in patients (PTS) with advanced GI mid-gut neuroendocrine tumor (NET): Phase 2 results.

AUTHOR(S)

ABSTRACT
Subgroup analysis by Ki-67 and baseline CgA of the randomized, placebo-controlled phase 3 study of surufatinib in advanced well-differentiated pancreatic neuroendocrine tumors (SANET-p).

AUTHOR(S)
Xianjun Yu, Jianming Xu, Lin Shen, Chunmei Bai, Jie Li, Zhiwei Zhou, Zhiping Li, Enxiao Li, Xianglin Yuan, Yihebali Chi, Yongmei Yin, Wenhui Lou, Nong Xu, Yuxian Bai, Tao Zhang, Dianrong Xiu, Xiwen Wang, Sha Guan, Qian Xu, Weiguo Su

ABSTRACT
Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors.

AUTHOR(S)
Plasma biomarker study of lenvatinib in gastroenteropancreatic neuroendocrine tumors reveals Ang2 and FGF2 as predictors of treatment response: Results from the international phase II TALENT trial (GETNE 1509).

AUTHOR(S)
Jaume Capdevila, Gabriela Jimenez-Valerio, Alba Martinez, Jorge Hernando, Toni Ibrahim, Nicola Fazio, Carlos Lopez, Alex Teule, Juan W. Valle, Salvatore Tafuto, Ana B. Custodio, Nicholas S. Reed, Markus Raderer, Enrique Grande, Rocio Garcia-Carbonero, Paula Jiménez-Fonseca, Vicente Alonso, Oriol Casanovas

ABSTRACT
4113

Interim analysis results of surufatinib in U.S. patients with neuroendocrine tumors (NETs).

AUTHOR(S)
Andrew S. Paulson, Daneng Li, Max W. Sung, Christopher Tucci, John S. Kauh, Shivani Nanda, Marek K. Kania, Arvind Dasari

ABSTRACT
4114

Phase I study of autolytic immunotherapy of metastatic neuroendocrine tumors using intralesional rose bengal disodium.

AUTHOR(S)
Timothy J. Price, Gabby Cehic, Eric A. Wachter, Ian D. Kirkwood, Jessica Reid, Ruben Sebbon, Anas Alawawdeh, Mark McGregor, Dominic Rodrigues, Susan Neuhaus, Guy Maddern

ABSTRACT
4115

Efficacy and safety of $^{177}$Lu-DOTATATE in patients (pts) with advanced pancreatic neuroendocrine tumors (pNETs): Data from the NETTER-R international, retrospective registry.

AUTHOR(S)
Dominique Clement, Shaunak Navalkissoor, Rajaventhan Srirajaskanthan, Frédéric Courbon, Lawrence Dierickx, Amy Eccles, Valerie Lewington, Mercedes Mitjavila, Juan Carlos Percovich, Benoît Lequoy, Bellei He, Ilya Folitar, John Ramage

ABSTRACT
4116

Phase I dose-escalation study of AlphaMedix for targeted-alpha-emitter therapy of PRRT-naive neuroendocrine patients.

AUTHOR(S)
Clinical impact of pathogenic germline variants in pancreatic cancer: Results from a multicenter prospective universal genetic testing study.

AUTHOR(S)

Modified FOLFIRINOX versus S-1 as second-line chemotherapy in patients with gemcitabine-failed metastatic pancreatic cancer: A randomized phase III trial (MPACA-3).

AUTHOR(S)
Se-Il Go, Sang-Cheol Lee, Woo Kyun Bae, Dae Young Zang, Hyun Woo Lee, Joung Soon Jang, Jun Ho Ji, Jung Hoon Kim, Sanggon Park, Sun Jin Sym, Yaewon Yang, So Yeon Jeon, Sung Yong Oh, Jung Hun Kang

A phase I/IIa trial of the RNA oligonucleotide STNM01 by EUS-FNI to investigate the safety and efficacy in patients with first-line refractory, unresectable pancreatic cancer.

AUTHOR(S)
Takayoshi Tsuchiya, Toshio Fujisawa, Motohiko Kato, Masafumi Mizuide, Yuichi Torisu, Makoto Nishimura, Takashi Kurosawa, Ko Tomishina, Kazuki Takakura, Hiromu Kutsumi, Yoko Matsuda, Tomio Arai, Hideyuki Saya, Shomei Ryozawa, Hiroyuki Isayama, Takao Ito, Naohisa Yahagi

Genomic profiling of KRAS wide-type pancreatic ductal adenocarcinomas identifies targetable genetic alterations.

AUTHOR(S)
Deng Wei, Xiaomo Li, Xinsheng Zhang, Tonghui Ma, Rong Liu
Baseline level and early on-treatment clearance of circulating mutant KRAS in metastatic pancreatic ductal adenocarcinoma treated with chemotherapy with or without immunotherapy.

AUTHOR(S)

ABSTRACT
4122

Gemcitabine plus nab-paclitaxel versus gemcitabine alone in elderly patients aged 76 years or older with unresectable pancreatic cancer: A propensity score-matched multicenter prospective observational study.

AUTHOR(S)
Satoshi Kobayashi, Motoko Suzuki, Makoto Ueno, Yuta Maruki, Junji Furuse, Akiko Todaka, Masato Ozaka, Kunihiro Tsuji, Kazuhiko Shioji, Keitaro Doi, Yasushi Kojima, Hidetaka Tsumura, Kazunari Tanaka, Hajime Higuchi, Ken Kawabe, Takeharu Yamanaka, Hiroshi Ishii

ABSTRACT
4123

Genomic alterations for novel targeted therapies in pancreatobiliary cancers from real-world data.

AUTHOR(S)
Kumiko Umemoto, Hiroyuki Yamamoto, Ritsuko Oikawa, Hiroyuki Takeda, Ayako Doi, Yoshiki Horie, Takashi Ogura, Takuro Mizukami, Naoki Izawa, Jay A. Moore, Ethan Sokol, Yu Sunakawa

ABSTRACT
4124

Alternating gemcitabine/nab-paclitaxel (GA) and 5-FU/leucovorin/irinotecan (FOLFIRI) as first-line treatment for de novo metastatic pancreatic cancer (MPC): Safety and effect.

AUTHOR(S)
Brett A. Schroeder, Margaret T. Mandelson, Vincent J. Picozzi

ABSTRACT
4125

Impact of G-CSF during neoadjuvant therapy on outcomes of operable pancreatic cancer.
SBP-101, a polyamine metabolic inhibitor, administered in combination with gemcitabine and nab-paclitaxel, shows signals of efficacy as first-line treatment for subjects with metastatic pancreatic ductal adenocarcinoma.

Randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.

Fecal microbiome composition in pancreatic cancer cachexia and response to nutrition support.

Circulating cell free tumor DNA detection as a prognostic tool in advanced pancreatic cancer.
Body composition measurements and overall survival in patients with resectable pancreatic adenocarcinoma receiving neoadjuvant chemotherapy: Analysis from SWOG S1505.

AUTHOR(S)
Davendra Sohal, Mai T. Duong, Robert Boutin, Leon Lenchik, Jiyoon Kim, Namita Gandhi, Muhammad S. Beg, Andrea Wang-Gillam, James L. Wade III, Katherine A. Guthrie, Elena G. Chiorean, Syed A. Ahmad, Andrew M. Lowy, Howard S. Hochster, Philip A. Philip, Victor T. Chang

ABSTRACT

The fear of cancer progression and recurrence in patients with pancreatic cancer.

AUTHOR(S)
Esther N. Pijnappel, Willemieke P. Dijkstra, Mirjam A. Sprangers, Simone Augustinus, Lonneke V. van de Poll-Franse, Judith de Vos-Geelen, Hjalmar van Santvoort, Ignace H. de Hingh, I. Q. Molenaar, Olivier R. Busch, Marc G. Besselink, Johanna Wilmink, Hanneke W. Van Laarhoven

ABSTRACT

Local and systemic recurrence following total neoadjuvant therapy (TNT) and resection for borderline resectable and locally advanced pancreatic adenocarcinoma: Long-term follow up from two phase II studies.

AUTHOR(S)
Grace E. Ryan, Janet E. Murphy, Christine A. Ulysse, Beow Y. Yeap, Jennifer Y. Wo, Colin D. Weekes, Jeffrey W. Clark, Jill N. Allen, Lawrence S. Blaszkowsky, Ryan D. Nipp, Lorraine C. Drapek, Aparna R. Parikh, Christine Bolton, Jacob Maruna, Cristina R. Ferrone, Motaz Qadan, Keith D. Lillemoe, David P. Ryan, Carlos Fernandez Del-Castillo, Theodore S. Hong

ABSTRACT

A phase 2 study of cyclophosphamide (CY), GVAX, pembrolizumab (Pembro), and stereotactic body radiation (SBRT) in patients (pts) with locally advanced pancreas cancer (LAPC).

AUTHOR(S)
Valerie Lee, Ding Ding, Christina Rodriguez, Beth Onners, Amol Narang, Jeffrey Meyer, Joseph M. Herman, Amy Hacker-Prietz, Richard A. Burkhart, William Burns, Jin He, Ana De Jesus-Acosta, Rachel B. Klein, Dan Laheru, Dung T. Le, Amy Ryan, Elizabeth Sugar, Lei Zheng

ABSTRACT
Predictive value of germline ATM mutations in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D) and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).

AUTHOR(S)

ABSTRACT
4135

Impact of KRAS alterations in pancreatic ductal adenocarcinoma (PDAC).

AUTHOR(S)
Maahum Mehdi, Mandana Kamgar, Ben George, Aniko Szabo, Kaitlin Annunzio, Bradley W. Taylor, Aditya V. Shreenivas, Sakti Chakrabarti, James P. Thomas, Susan Tsai, Kathleen K. Christians, Douglas B. Evans, Callisia Clarke, William A. Hall, Beth Erickson, Gulraiz Ahmed, Bicky Thapa

ABSTRACT
4136

Impact of the COVID-19 pandemic on care delivery and outcomes for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).

AUTHOR(S)
Ravi K. Paluri, Paul Cockrum, Ashley A. Laursen, Joseph L. Gaeta, Shu Wang, Andy Surinach

ABSTRACT
4137

Efficacy and safety of KN046 plus nab-paclitaxel/gemcitabine as first-line treatment for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).

AUTHOR(S)
Gang Jin, Shiwei Guo, Yanqiao Zhang, Yue Ma, Xiaodong Guo, Xiaocui Zhou, Qin Yu

ABSTRACT
4138

A phase II trial combining tumor-targeting TP53 gene therapy with gemcitabine/nab-paclitaxel as a second-line treatment for metastatic pancreatic cancer.

AUTHOR(S)
Genetic and immune divergence in pancreatic cancer lesions at the time of metastatic relapse compared to primary tumor.

AUTHOR(S)
Bereket Gebregziabher, Derek A. Oldridge, Emma E. Furth, Michael D. Feldman, Andrew J. Rech, Robert H. Vonderheide

Identification of pancreatic adenocarcinoma molecular subtypes on histology slides using deep learning models.

AUTHOR(S)

Impact of KRAS mutational status on outcomes in patients with pancreatic cancer (PDAC).

AUTHOR(S)
Lucy X. Ma, Gun Ho Jang, Amy Zhang, Robert E. Denroche, Anna Dodd, Stephanie Ramotar, Shawn Hutchinson, Yifan Wang, Mustapha Tehfe, Ravi Ramjeesingh, James J. Biagi, Bernard Lam, Julie Wilson, Faiyaz Notta, Sandra Fischer, Robert C. Grant, George Zogopoulos, Steven Gallinger, Jennifer J. Knox, Grainne M. O’Kane

TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma.

AUTHOR(S)
Nai-Jung Chiang, Yan-Shen Shan, Li-Yuan Bai, Chung-Pin Li, Jen-Shi Chen, Shih-Hung Yang, Yung-Chia Kuo, Yee Chao, Yao-yu Hsieh, Hsiang-fong Kao, Chin-Fu Hsiao, Li-Tzong Chen
Treatment with pembrolizumab in combination with the oncolytic virus pelareorep promotes anti-tumor immunity in patients with advanced pancreatic adenocarcinoma.

AUTHOR(S)
Devalingam Mahalingam, Siqi Chen, Ping Xie, Aparna Kalyan, Sheetal M. Kircher, Masha Kocherginsky, Jiahui Xu, Victoria Maurer, Pedro A. Viveiros, Elena Vagia, Grey A. Wilkinson, Matthew C. Coffey, Mary F. Mulcahy, Al B. Benson III, Bin Zhang

ABSTRACT
4144

Association of total neoadjuvant therapy with major pathologic response and survival in localized pancreatic cancer: A multi-institutional analysis of 504 patients.

AUTHOR(S)

ABSTRACT
4145

Prognostic and predictive factors in patients treated with ramucirumab (RAM) with advanced hepatocellular carcinoma (aHCC) and elevated alpha-fetoprotein (AFP): Results from two phase III trials.

AUTHOR(S)
Josep M. Llovet, Amit G. Singal, Augusto Villanueva, Richard S. Finn, Masatoshi Kudo, Peter R. Galle, Chunxiao Wang, Ryan C. Widau, Elena Gonzalez Gugel, Andrew X. Zhu

ABSTRACT
4146

Prognostic impact of pSTAT3 on overall survival (OS) in gastrointestinal (GI) cancers: Data from 3 phase 3, randomized controlled trials (RCTs).

AUTHOR(S)
Emily Brooks, Claudia Lebedinsky, Tanios S. Bekaii-Saab, Manish A. Shah, Derek J. Jonker, Kamesh Kuchimanchi, Ewa Wybieralska, Marilyn Fontaine, Cindy Oh, Suha Sari, Emma Foos, Bo Xu, Matthew Hitron

ABSTRACT
4147
Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part B (pembrolizumab + chemotherapy).

AUTHOR(S)
Jennifer A. Chan, Nitya P. Raj, Rahul R. Aggarwal, Susan Calabrese, April DeMore, Mallika S. Dhawan, Delaire Fattah, Lawrence Fong, Jennifer Grabowsky, Thomas A. Hope, Kanti P. Kolli, Pamela N. Munster, Kimberly Perez, Diane L. Reidy, Sofia Von Fedak, Li Zhang, Emily K. Bergsland

ABSTRACT
Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma: The phase III “PREVENT” trial of the AIO /CAOG /ACO.

AUTHOR(S)
Thorsten O. Goetze, Pompiliu Piso, Sylvie Lorenzen, Ulli S. Bankstahl, Marcin Ostrzyzek, Claudia Pauligk, Timursah Habibzade, Daniel Reim, Wolf O. Bechstein, Alfred Königsrainer, Stefan P. Möng, Beate Rau, Matthias Schwarzbach, Salah-Eddin Al-Batran

ABSTRACT
AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1).

AUTHOR(S)
Rui-hua Xu, Sung-Bae Kim, David Tougeron, Yunxia Zuo, Haiyuan Yang, Juan Zhang, Jingwen Shi, Eric Van Cutsem

ABSTRACT
MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer—A randomized, double-blind, placebo-controlled, phase 3 study.

AUTHOR(S)
Yelena Y. Janjigian, Eric Van Cutsem, Kei Muro, Zev A. Wainberg, Salah-Eddin Al-Batran, Woo Jin Hyung, Daniela Molena, Brent Evans, Dario Ruscica, Scott H. Robbins, Alejandra Negro, Josep Tabernero
Phase II trial of docetaxel and ramucirumab combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer (HGCSG1903).

AUTHOR(S)
Rika Saito, Yasuyuki Kawamoto, Satoshi Yuki, Susumu Sogabe, Masayoshi Dazai, Ayumu Hosokawa, Kentaro Sawada, Atsushi Sato, Michio Nakamura, Kazuteru Hatanaka, Atsushi Ishiguro, Osamu Muto, Yoshiaki Shindo, Yasushi Tsuji, Miki Tateyama, Akira Ueda, Takahide Sasaki, Masaki Katagiri, Naoya Sakamoto, Yoshito Komatsu

ABSTRACT
TPS4152


AUTHOR(S)
Tae Yong Kim, Jee Sun Yoon, Ah-Rong Nam, Ju-Hee Bang, Kyoung Seok Oh, Hye-Rim Seo, Jae-Min Kim, Do-Youn Oh

ABSTRACT
TPS4153

TGF-β and PD-L1 inhibition combined with definitive chemoradiotherapy in esophageal squamous cell carcinoma: A phase II clinical trial (NCT04595149).

AUTHOR(S)

ABSTRACT
TPS4154

MONEO: A phase II study of avelumab (Av) plus FLOT in the peri-operative treatment for patients (pts) with resectable gastric or gastroesophageal junction cancer (GC).

AUTHOR(S)

ABSTRACT
TPS4155

EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—An open-label randomized controlled phase II study.
TPS4156

A phase II study of short course FOLFOX chemotherapy with either nivolumab (Nivo) or Nivo plus radiation in the first line treatment of metastatic or unresectable gastroesophageal (GEA) cancers.

AUTHOR(S)
Elizabeth C. Smyth, Ellen Peeters, Maren Kristina Knoedler, Anne Giraut, Anna D. Wagner, Markus H. Moehler, Nicole C. van Grieken, Magnus Nilsson, Murielle E. Mauer, Florian Lordick

ABSTRACT

A multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin with or without CPI-613 as first-line therapy for patients with advanced unresectable biliary tract cancer (BiLT-04).

AUTHOR(S)
Rutika Mehta, Sarbajit Mukherjee, Kelsey Klute, Haeseong Park, Uqba Khan, Sahrish Khan, Carina Puello, Sabrina Machado, Paul J. Christos, Nicholas J. Sanfilippo, Manish A. Shah

ABSTRACT

The IMMULAB trial: A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early stage hepatocellular carcinoma (HCC).

AUTHOR(S)
Arndt Vogel, Thorsten O. Goetze, Guido Hausner, Michael Geißler, Gabriele M. Siegler, Ludwig Fischer von Weikersthal, Angelika M. Kestler, Matthias Kleiß, Tobias Müller, Andreas Teufel, Jens Marquardt, Maria A. Gonzalez-Carmona, Daniel W. Mueller, Regina Eickhoff, Enrico N. de Toni, Oliver Waidmann, Salah-Eddin Al-Batran

ABSTRACT

Camrelizumab plus apatinib combined with TACE and cryoablation in the first-line treatment of advanced hepatocellular carcinoma.

AUTHOR(S)
Wenge Xing, Zhi Guo
ABSTRACT

TPS4160


AUTHOR(S)

Choong-kun Lee, Jaekyung Cheon, Hong Jae Chon, Min Hwan Kim, Jin Won Kim, Myung Ah Lee, Hyung Soon Park, Myoung Joo Kang, Joung-Soon Jang, Hye Jin Choi

ABSTRACT

TPS4161

REPLACEMENT trial in progress: Combination therapy with atezolizumab plus bevacizumab for TACE unsuitable patients with beyond up-to-seven criteria in intermediate stage hepatocellular carcinoma: A phase II study.

AUTHOR(S)

Kazuomi Ueshima, Masatoshi Kudo, Takeharu Yamanaka, Hiroshi Aikata, Tatsuya Yamashita, Masafumi Ikeda, Ryosuke Tateishi, Michihisa Moriguchi, Atsushi Hiraoka, Kaoru Tsuchiya, Sadahisa Ogasawara, Satoshi Mochida, Shiro Miyayama, Kiyoshi Hasegawa, Kenichi Yoshimura, Tetsuo Takehara

ABSTRACT

TPS4162

CaboRISE: A phase II study evaluating reduced starting dose and dose escalation of cabozantinib as second-line therapy for advanced HCC in patients with compensated liver cirrhosis.

AUTHOR(S)

Jorg Trojan, Stefan Pluntke, Florian van Boemmel, Ursula Ehmer, Thorsten O. Goetze, Lutz Jacobasch, Daniel Pink, Christina Kopp, Sarah Lehnerts, Johanna Riedel, Oliver Waidmann, Fabian Finkelmeier, Michael Geißler

ABSTRACT

TPS4163

Phase III study of NUC-1031 + cisplatin versus gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).

AUTHOR(S)

Jennifer J. Knox, Mairead G. McNamara, Lipika Goyal, David Cosgrove, Christoph Springfield, Katrin M. Sjoquist, Joon Oh Park, Helena Verdaguer, Chiara Braconi, Paul J. Ross, Do-Youn Oh, Aimery De Gramont, John R. Zalcberg, Daniel H. Palmer, Juan W. Valle

ABSTRACT

TPS4164

AUTHOR(S)

ABSTRACT
TPS4165


AUTHOR(S)
Jee Sun Yoon, Jin Won Kim, Ji-Won Kim, Tae-Yong Kim, Ah-Rong Nam, Ju-Hee Bang, Hye-Rim Seo, Jae-Min Kim, Kyoung Seok Oh, Peter G. Mortimer, Simon Smith, Do-Youn Oh

ABSTRACT
TPS4166

Assessing safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumors (NETs): The phase II LOLA trial.

AUTHOR(S)
Francesca Corti, Vito Amoroso, Davide Campana, Maria Pia Brizzi, Francesco Panzuto, Ivana Puliafito, Natalie Prinzi, Massimo Milione, Monica Niger, Maria Antista, Alessandra Raimondi, Federica Morano, Michele Prisciandaro, Teresa Beninato, Filippo Pagani, Giovanni Randon, Iolanda Pulice, Maria Di Bartolomeo, Filippo G. De Braud, Sara Pusceddu

ABSTRACT
TPS4167

Biologically optimized schedule of gemcitabine and nab-paclitaxel regimen in metastatic pancreatic adenocarcinoma.

AUTHOR(S)

ABSTRACT
TPS4168

Camrelizumab combined with ablation and chemotherapy for pancreatic cancer with liver metastases: A single-arm, phase II, prospective clinical study.
AUTHOR(S)
Zhiwei Li, Qingwei Li, Zhigang Ma, Yue Ma, Dan Su, Changjie Lou, Guangyu Wang, Chao Liu, Yanqiao Zhang

ABSTRACT
TPS4169


AUTHOR(S)
Sherise C. Rogers, Brian H. Ramnaraign, Kathryn Hitchcock, Steven J. Hughes, Ji-Hyun Lee, Z. H. Fan, Carmen J. Allegra, Jose Trevino, Ahmad El-Far, Anita A. Turk, Karen B. Russell, David L. DeRemer, Thomas J. George

ABSTRACT
TPS4170

Total neoadjuvant FOLFIRINOX or gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2): A nationwide multicenter randomized controlled trial.

AUTHOR(S)
Quisette Janssen, Jacob L. van Dam, Marc G. Besselink, Marjolein Y. Homs, Geertjan van Tienhoven, Johanna W. Wilmink, Bas Groot Koerkamp

ABSTRACT
TPS4171

Australasian Gastro-Intestinal Trials Group (AGITG) MASTERPLAN: Randomized phase II study of modified neoadjuvant FOLFIRINOX alone or in combination with stereotactic radiotherapy (SBRT) for patients with high-risk and locally advanced pancreatic cancer.

AUTHOR(S)
Andrew Oar, Andrew Kneebone, Mark Lee, David Goldstein, Katrin M. Sjoquist, Hien Le, Julie Chu, Andrew Barbour, Leily Gholamrezaei, James F. Lynam, Andrej Bece, Sandra Bahamad, Sonia Yip, David Espinoza, Lorraine A. Chotrill, Alisha Moore, Dominique Lee, Quoc Nam Nguyen, Jaswinder Samra, No Firstname Jan. Mumford@Tics.Com.Au

ABSTRACT
TPS4172

Phase II study of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-
paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).

**AUTHOR(S)**

Peter Grell, Chia-Chi Lin, Michele Milella, Cheng E. Chee, Shivan Sivakumar, Katriina J. Peltola, Geraldine Bostel, Dragana Jankovic, Maria-Athina Altzerinakou, Claire Fabre, Armando Santoro

**ABSTRACT**

TPS4173

Trial in progress: Open-label, randomized, comparative phase 2/3 study of combination immunotherapy plus standard-of-care chemotherapy and SBRT versus standard-of-care chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer.

**AUTHOR(S)**

Tara E. Seery, Chaitali S. Nangia, Leonard S. Sender, Sandeep K. Reddy, Patrick Soon-Shiong

**ABSTRACT**

TPS4174

GRECO-2: A randomized, phase 2 study of stereotactic body radiation therapy (SBRT) in combination with GC4711 in the treatment of unresectable or borderline resectable nonmetastatic pancreatic cancer (PC).

**AUTHOR(S)**

Sarah E. Hoffe, Dae W. Kim, James Costello, Mkenge P. Malafa, Todd A. Aguilera, Muhammad S. Beg, Parag Parikh, Joseph M. Herman, Jon Holmlund, Kara Terry, Elizabeth C. Moser

**ABSTRACT**

TPS4175

A phase II open-label study of cpi-613 in combination with modified (m)FOLFIRINOX in patients with locally advanced pancreatic cancer.

**AUTHOR(S)**


**ABSTRACT**

TPS4176
Safety and efficacy of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression in the phase Ib/II FORT-2 study.

**AUTHOR(S)**

**ABSTRACT**
4521

**Phase I/II study to evaluate the efficacy of TAS0313, a cancer peptide vaccine, combined with pembrolizumab for locally advanced or metastatic urothelial carcinoma.**

**AUTHOR(S)**
Ryuji Matsumoto, Junji Yonese, Takashi Kawahara, Hideaki Miyake, Nobuaki Matsubara, Hiroji Uemura, Masatoshi Eto, Haruhito Azuma, Wataru Obara, Akito Terai, Satoshi Fukasawa, Shigetaka Suekane, Hiroyuki Nishiyama

**ABSTRACT**
4522

**Circulating tumor cell-driven use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer.**

**AUTHOR(S)**
Nick Beije, Ingeborg E. de Kruijff, Joep de Jong, Sjoerd O. Klaver, Peter de Vries, Rens Jacobs, Diederik M. Somford, Ed te Slaa, Toine van der Heijden, Johannes A. Wiljes, Laurent Fossier, Egbert Boeve, John van der Hoeven, Harm H. van Melick, Carl J. Wijburg, John W. Martens, Ronald De Wit, Jaco Kraan, Stefan Sleijfer, Joost L. Boormans

**ABSTRACT**
4523

**Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2.**

**AUTHOR(S)**
Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100.

Authors:

Abstract
Large cell neuroendocrine carcinoma of the urothelial tract (LNEC): The MSKCC experience.

Authors:

Abstract
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance.

Authors:
Srikala S. Sridhar, Thomas Powles, Yohann Loriot, Miguel A. Climent Durán, Shilpa Gupta, Norihiro Tsuchiya, Aristotelis Bamias, Andrea Ardizzoni, Anders Ullén, Bo Huang, Nuno M. Costa, Robert J. Laliberte, Alessandra Di Pietro, Cora N. Sternberg, Petros Grivas

Abstract
Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC).

**ABSTRACT

Effect of Bacillus Calmette-Guerin (BCG) exposure on severity of COVID-19 infection: A COVID-19 and Cancer Consortium (CCC19) study.**

**AUTHOR(S)**


**ABSTRACT

Fibroblast growth factor receptor alteration (FGFRα) status and progression outcomes of patients with advanced or metastatic urothelial cancer (mUC).**

**AUTHOR(S)**

Sarah Fleming, Dina Gifkins, Waleed Shalaby, Jianjun Gao, Philip Rosenberg, Christopher Gaj, Albert Crawford, Grace L. Lu-Yao, Vittorio Maio, Arlene O. Siefker-Radtke

**ABSTRACT

Safety evaluation of combined PD-1+CTLA4 inhibition concurrently to chemoradiotherapy (CRT) in localized muscle invasive bladder carcinoma (MIBC).**

**AUTHOR(S)**

Ben-Max de Ruiter, Jons W. van Hattum, Theo M. De Reijke, Jorg R. Oddens, Maarten C. Hulshof, Adriaan D. Bins

**ABSTRACT

Pembrolizumab (pembro) versus investigator’s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial.**

**AUTHOR(S)**

Joaquim Bellmunt, Andrea Necchi, Ronald De Wit, Jae-Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel A. Climent Durán, Daniel P. Petrylak, Toni K. Choueiri, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stephane Culiné, Cora N. Sternberg, Jin Zhi Xu, Blanca Homet Moreno, James L. Godwin, Dean F. Bajorin, David J. Vaughn, Yves Fradet

**ABSTRACT**
Stool microbiota profiling of patients with muscle invasive bladder cancer receiving neoadjuvant pembrolizumab.

**AUTHOR(S)**
Filippo Pederzoli, Irene Locatelli, Michela Riba, Marco Bandini, Daniele Raggi, Laura Marandino, Elisa Alchera, Patrizia Giannatempo, Paolo Provero, Dejan Lazarevic, Roberta Lucianò, Andrea Gallina, Alberto Briganti, Francesco Montorsi, Andrea Salonia, Andrea Necchi, Massimo Alfano

**ABSTRACT**

**4533**

RC48-ADC combined with toripalimab, an anti-PD-1 monoclonal antibody (Ab), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase Ib/II study.

**AUTHOR(S)**
Li Zhou, Huayan Xu, Xieqiao Yan, Zhihong Chi, Chuanliang Cui, Lu Si, Bixia Tang, Lili Mao, Bin Lian, Xuan Wang, Siming Li, Xue Bai, Jun Guo, Xinan Sheng

**ABSTRACT**

**4534**

Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who receive second-line immunotherapy.

**AUTHOR(S)**
Benjamin Miron, Elizabeth A. Handorf, Kevin Zarrabi, Matthew R. Zibelman, Pooja Ghatalia, Fern Anari, Elizabeth R. Plimack, Daniel M. Geynisman

**ABSTRACT**

**4535**

Use of neoadjuvant chemotherapy in elderly patients with muscle invasive bladder cancer: A population-based study, 2006 to 2017.

**AUTHOR(S)**
Natasza Posielski, Nathan Jung, Hannah Koenig, On Ho, John P. Flores, Christopher Porter

**ABSTRACT**

**4536**

Response and outcomes to immune checkpoint inhibitors (ICI) in advanced urothelial cancer (aUC) based on prior intravesical BCG.

**AUTHOR(S)**

ABSTRACT

4537

Real-world treatment patterns and clinical outcomes among patients with metastatic urothelial carcinoma.

AUTHOR(S)

Daniel M. Geynisman, Edward Broughton, Hasan Alhasani, Yi Hao, Ying Zhang, Brian Stwalley, Trong K. Le, Stephen Huo

ABSTRACT

4538

Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy.

AUTHOR(S)


ABSTRACT

4539

Impact of recurrence on health-related quality of life in patients at high risk of recurrence after radical surgery for muscle-invasive urothelial carcinoma (MIUC): Results from the phase 3 CheckMate 274 trial.

AUTHOR(S)

Matt D. Galsky, Johannes A. Witjes, Jürgen Gschwend, Julia Braverman, Edward Broughton, Federico Nasroulah, Hasan Alhasani, Mario Maira-Arce, Xiaomei Ye, Ling Shi, Melissa Hamilton, Dean F. Bajorin

ABSTRACT

4540

Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).

AUTHOR(S)

Genomic predictors of response to PD-1 axis inhibitors in metastatic urothelial cancer (mUC) patients using machine learning analysis of tissue comprehensive genomic profiling (CGP).

AUTHOR(S)

ABSTRACT
Survival outcomes in patients receiving immune checkpoint inhibitor (ICI) for metastatic small cell urothelial cancer (SCUC).

AUTHOR(S)
Omar Alhalabi, Nathaniel Wilson, Neema Navai, Matthew T. Campbell, Amishi Y. Shah, Jianjun Gao, Paul G. Corn, Ana Aparicio, Bogdan Czerniak, Charles Guo, Christopher Logothetis, Nizar M. Tannir, Seungtaek Choi, Arlene G. Siefker-Radtke

ABSTRACT
Phase I/II trial of pembrolizumab and cabozantinib in the treatment of metastatic renal cell carcinoma (mRCC).

AUTHOR(S)
Elizabeth R. Kessler, Junxiao Hu, Geetika Srivastava, Douglas J. Kemme, Praveena Iruku, Vishal Rana, Steven R. Schuster, Mali Amirault, Eryn Callihan, Thomas W. Flaig, Elaine T. Lam

ABSTRACT
Health care disparities and barriers to palliative care among metastatic renal cell carcinoma patients: An NCDB analysis.

AUTHOR(S)
Janvi Wadiwala, Mausam Patel, Chenghui Li, Sanjay Maraboyina, Ahmed Safar, Thomas Kim

ABSTRACT
TIVO-3: Durability of response and updated overall survival of tivozanib versus sorafenib in metastatic renal cell carcinoma (mRCC).

AUTHOR(S)
Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).

AUTHOR(S)

Association of C-reactive protein (CRP) with efficacy of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): Long-term follow-up results from JAVELIN Renal 101.

AUTHOR(S)
Yoshihiko Tomita, James Larkin, Balaji Venugopal, John B. Haanen, Hiro-Omi Kanayama, Masatoshi Eto, Marc-Oliver Grimm, Yosuke Fujii, Yoshiko Umeyama, Mariangela Mariani, Alessandra Di Pietro, Toni K. Choueiri

Association between neutrophil-to-eosinophil ratio (NER) and efficacy outcomes in the JAVELIN Renal 101 study.

AUTHOR(S)
Matthew D. Tucker, Martin H. Voss, Toni K. Choueiri, Mehmet A. Bilen, Marc-Oliver Grimm, Paul D. Nathan, Christian K. Kollmannsberger, Yoshihiko Tomita, Bo Huang, Despina Thomaidou, Mariangela Mariani, Alessandra Di Pietro, Brian I. Rini

Camrelizumab plus famitinib for advanced renal cell carcinoma or unresectable urothelial carcinoma: Updated results from a phase II trial.

AUTHOR(S)
Yuan-Yuan Qu, Qing Zou, Hongqian Guo, Nianzeng Xing, Zhongquan Sun, Weiqing Han, Hong Luo, Shujie Xia, Xuepei Zhang, Chaohong He, Hai liang Zhang, Jinling Cai, Xiao Zhang, Quanren Wang, Dingwei Ye

AUTHOR(S)
Kevin Zarrabi, Elizabeth A. Handorf, Benjamin Miron, Matthew R. Zibelman, Fern Anari, Pooja Ghatlia, Elizabeth R. Plimack, Daniel M. Geynisman

ABSTRACT
The impact of antibiotic (Ab) exposure on clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or VEGF targeted therapy (VEGF-TT).

AUTHOR(S)

ABSTRACT
Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial.

AUTHOR(S)

ABSTRACT
Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).

AUTHOR(S)

ABSTRACT
Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).

AUTHOR(S)

ABSTRACT
Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlukafusp α in combination with atezolizumab ± bevacizumab in patients with unresectable advanced/ metastatic renal cell carcinoma (RCC) (NCT03063762).

AUTHOR(S)

ABSTRACT
Treatment outcomes in renal cell carcinoma patients with metastases to the pancreas and other sites.

AUTHOR(S)

ABSTRACT
Programmed death ligand-1 (PD-L1) expression in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in NIVES study.

AUTHOR(S)
Cristina Masini, Gabriele Carlinfante, Cinzia Iotti, Ugo De Giorgi, Roberto S. Bellia, Sebastian Buti, Francesco Salaroli, Ilaria Zampiva, Renzo Mazzarotto, Claudia Mucciariini, Maria Giuseppa Vitale, Alessio Bruni, Giuseppe Procopio, Stefania Kinspergher, Valentina Vanoni, Franco Nole, Franco Morelli, Susanne Baier, Consuelo Buttiglier, Carmine Pinto

ABSTRACT
An FDA-pooled analysis of frontline combination treatment benefits by risk groups in metastatic renal cell carcinoma (mRCC).

AUTHOR(S)

ABSTRACT

Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (LEN) + pembrolizumab (PEMRO) and sunitinib (SUN) treatment arms.

AUTHOR(S)

ABSTRACT

Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC).

AUTHOR(S)

ABSTRACT

Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) + everolimus (EVE) versus sunitinib (SUN) treatment arms.

AUTHOR(S)

ABSTRACT
Association of baseline neutrophil-to-eosinophil ratio (NER) and neutrophil-to-lymphocyte ratio (NLR) with response to combination immunotherapy (IO) with ipilimumab plus nivolumab (ipi/nivo) in patients with metastatic renal cell carcinoma (mRCC).

AUTHOR(S)

ABSTRACT
4563
Phase II trial of stereotactic ablative radiation (SAbR) for oligoprogressive kidney cancer.

AUTHOR(S)
Raquibul Hannan, Michael Christensen, Aurelie Garant, Hans J. Hammers, Waddah Arafat, Kevin D. Courtney, Isaac A. Bowman, Suzanne Cole, David Sher, Chul Ahn, Robert D. Timmerman, James Brugarolas

ABSTRACT
4564
Ipilimumab + nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: Part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma.

AUTHOR(S)
Craig Gedye, David W. Pook, Laurence E. Krieger, Carole A. Harris, Jeffrey C. Goh, Ganessan Kichenadasse, Howard Gurney, Craig Underhill, Francis Parnis, Anthony M. Joshua, Tom Ferguson, Felicia Roncolato, Michelle L. Harrison, Stephen Begbie, Michelle F. Morris, Elizabeth J. Hovey, Mathew George, Prashanth Prithviraj, Emma Link, Ian D. Davis

ABSTRACT
4565
Survival trends of men and women with metastatic clear cell renal cell carcinoma.

AUTHOR(S)
Claud Grigg, Sally Trufan, Peter E. Clark, Stephen B. Riggs, Jason Zhu, Justin T. Matulay, Derek Raghavan, Earle F. Burgess

ABSTRACT
4566
Temporal characteristics of treatment-emergent adverse events and dose modifications with tivozanib and sorafenib in the phase 3 TIVO-3 study of relapsed or refractory mRCC.

AUTHOR(S)
Sumanta K. Pal, David F. McDermott, Bernard Escudier, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael B. Atkins, Michael N. Needle, Brian I. Rini

ABSTRACT

Immune checkpoint inhibitors (ICI) in advanced sarcomatoid renal cell carcinoma (sRCC): A multicenter study.

AUTHOR(S)
Dharmesh Gopalakrishnan, Katharine Collier, Joseph J. Park, Jacob P. Zaemes, Elaine T. Lam, Sabah Alaklabi, Ellen Jaeger, Rahul A. Parikh, Pedro C. Barata, Eric Kauffman, Michael B. Atkins, Ajai S. Alva, Yuanquan Yang, Saby George

ABSTRACT

A phase 2 single-arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune checkpoint inhibitor: The BREAKPOINT trial (MeetUro trial 03-NCT03463681).

AUTHOR(S)
Giuseppe Procopio, Melanie Claps, Chiara Pircher, Luca Porcu, Pierangela Sepe, Valentina Guadalupi, Ugo De Giorgi, Cristian Lolli, Marco Maruzzo, Franco Nole, Roberto Iacovelli, Cristina Masini, Cinzia Baldessari, Laura Doni, Antonio Cusmai, Angela Gernone, Sarah Scaglieri, Sandro Pignata, Filippo G. De Braud, Elena Verzoni

ABSTRACT


AUTHOR(S)
Maryam Soleimani, Marisa Thi, Neetu Saxena, Bernhard J. Egl, Daniel J. Khalaf, Kim N. Chi, Christian K. Kollmannsberger, Lucia Nappi

ABSTRACT
A phase 2 prospective trial of cabozantinib as first-line treatment for metastatic collecting ducts renal cell carcinoma: The BONSAI trial (Meeturo 2) clinical trial information—NCT03354884.

AUTHOR(S)
Giuseppe Procopio, Pierangela Sepe, Sebastiano Buti, Melanie Claps, Maurizio Colecchia, Loris De Cecco, Devecchi Andrea, Matteo Dugo, Chiara Gargiuli, Patrizia Giannatempo, Valentina Guadalupi, Luigi Mariani, Arianna Ottini, Marialuisa Sensi, Filippo G. De Braud, Elena Verzoni

ABSTRACT


AUTHOR(S)
Mark Farha, Randy Vince, Srinivas Nallandhighal, Judith Stangl-Kremser, Steven Goldenthal, Daniel Triner, Todd M. Morgan, Ganesh S. Palapattu, Aaron M. Udager, Simpa S. Salami

ABSTRACT

Dynamic changes of the immune infiltrate after neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx).

AUTHOR(S)
Axel Bex, Yasmin Abu-Ghanem, Johannes V. Van Thienen, Niels Graafland, Brunolf Lagerveld, Patricia Zondervan, Harrie Beerlage, Jeroen van Moorselaar, Mark Kockx, Pieter-Jan Van Dam, Bernadett Szabados, Christian U. Blank, Thomas Powles, John B. Haanen

ABSTRACT

Efficacy of avelumab + axitinib (A + Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.

AUTHOR(S)
John B. Haanen, James Larkin, Toni K. Choueiri, Laurence Albiges, Brian I. Rini, Michael B. Atkins, Manuela Schmiderer, Konstantin Penkov, Despina Thomaidou, Jing Wang, Mariangela Mariani, Alessandra Di Pietro, Robert J. Motzer

ABSTRACT
Association with immune checkpoint inhibitor efficacy of a 27-gene classifier in renal cell cancer.

AUTHOR(S)

ABSTRACT

Efficacy of nivolumab/ipilimumab in patients with initial or late progression with nivolumab: Updated analysis of a tailored approach in advanced renal cell carcinoma (TITAN-RCC).

AUTHOR(S)
Marc-Oliver Grimm, Emilio Esteban, Philippe Barthélémy, Manuela Schmidinger, Jonas Busch, Begoña P. Valderrama, Marc Schmitz, Ulrike Schumacher, Gustavo B. Baretton, Ignacio Duran, Guillermo de Velasco, Frank Priou, Pablo Maroto-Rey, Giovanni Schinzari, Laurence Albiges

ABSTRACT

Retrospective study for the characterization of COVID-19 in renal cancer (COVID-REN) patients treated with antiangiogenics or immunotherapy and outcome comparison with non-infected cases.

AUTHOR(S)
Jesus G. Donas, Guillermo de Velasco, Teresa Alonso Gordoa, Jesús Chamorro, Diana Rosero, Olatz Etxaniz, Jose L. Perez-Gracia, Alvaro Pinto, Ignacio Duran, Diego Cacho, María Barba, Monica Yagüe, Pablo Borrega, Martín Lázaro, Laura Rodriguez, María Laura L. Villalobos Leon, Lourdes García Sanchez, Xavier García del Muro, M. Andres Cuellar, Juan Francisco Rodriguez-Moreno

ABSTRACT


AUTHOR(S)
Bradley A. McGregor, Daniel M. Geynisman, Mauricio Burotto, Camillo Porta, Cristina Suarez Rodriguez, Maria T. Bourlon, Pedro C. Barata, Shuchi Gulati, Brian Stwalley, Viviana Del Tejo, Ella X. Du, Aozhou Wu, Andi Chin, Keith A. Betts, Stephen Huo, Toni K. Choueiri

ABSTRACT
Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results from the 2020 Global Patient Survey from 41 countries.

AUTHOR(S)
Rachel H. Giles, Deb Maskens, Robin Martinez, Karin Kastrati, Carlos Castro, Juan Carlo Julian Mauro, Robert Bick, Malcolm Packer, Daniel Y. Heng, James Larkin, Axel Bex, Eric Jonasch, Sara J. Maclellan, Michael A. Jewett

ABSTRACT
4579

Outcomes with novel combinations in non-clear cell renal cell carcinoma(nccRCC): ORACLE study.

AUTHOR(S)

ABSTRACT
4580

Disease-free survival as a predictor of overall survival in localized renal cell carcinoma (RCC) following first nephrectomy.

AUTHOR(S)
Naomi B. Haas, Yan Song, Jaqueline Willemann Rogerio, Su Zhang, Oluwakayode Adejoro, Christopher Carley, Jingjing Zhu, Rituparna Bhattacharya, James Signorovitch, Murali Sundaram

ABSTRACT
4581

Role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC).

AUTHOR(S)

ABSTRACT
4582

Effect of high-dose corticosteroid use on efficacy of immune checkpoint inhibitors in patients with renal cell carcinoma (RCC).

AUTHOR(S)
Chris Labaki, Sarah A. Alaiwi, Andrew L. Schmidt, Talal El Zarif, Ziad Bakouny, Pier Vitale Nuzzo, Wenzin Xu, David A. Braun, Bradley A. McGregor, Toni K. Choueiri
**ABSTRACT**

4583

An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009).

**AUTHOR(S)**

Xinan Sheng, Zhisong He, Weiqing Han, Ai-Ping Zhou, Hong Luo, Yanxia Shi, Changlu Hu, Ziling Liu, Hongqian Guo, Xin Yao, Benkang Shi, Jiyan Liu, Zhigang Ji, Jianming Guo, Yi Hu, Shi Ying Yu, Guohua Yu, Jianming Ying, Jianmin Fang, Jun Guo

**ABSTRACT**

4584

Circulating tumor DNA (ctDNA) in patients with advanced adrenocortical carcinoma.

**AUTHOR(S)**

Bassel Nazha, Hiba I. Dada, Leylah Drusbosky, Jacqueline T. Brown, Deepak Ravindranathan, Bradley C. Carthon, Omer Kucuk, Viraj A. Master, Mehmet A. Bilen

**ABSTRACT**

4585

A phase 3, multicenter, randomized study evaluating the efficacy of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy in participants with muscle-invasive urothelial carcinoma of the bladder.

**AUTHOR(S)**

Stephen B. Williams, Christopher Cutie, Kirk A. Keegan, Bradley Raybold, Milin Acharya, Wei Zhu, Xiang Li, Lang A. O'Dondi, Neil Beeharry, Daniel E. Spratt

**ABSTRACT**

TPS4586

KEYNOTE-B15/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC).

**AUTHOR(S)**

Christopher J. Hoimes, Jens Bedke, Yohann Loriot, Hiroyuki Nishiyama, Xiao Fang, Ritesh S. Kataria, Blanca Homet Moreno, Matt D. Galsky

**ABSTRACT**

TPS4587
Consolidative radiotherapy for metastatic urothelial bladder cancer patients without progression and with no more than three residual metastatic lesions following first line systemic therapy: A prospective randomized comparative phase II trial (BLAD RAD01/GETUG-AFU V07).

AUTHOR(S)

ABSTRACT
TPS4588

AUREA study: Atezolizumab (Atezo) combined with split-dose gemcitabine plus cisplatin (s-GC) in locally advanced or metastatic urothelial cancer (LA/mUC): A SOGUG study.

AUTHOR(S)
Alfonso Gomez De Liano Lista, Georgia Anguera, Emilio Esteban, Ovidio Fernandez Calvo, Iciar Garcia-Carbonero, Xavier Garcia del Muro, Iria González Maeso, David Lorente-Estelles, Esther Martínez Ortega, Alvaro Pinto, Javier Puente, Guillermo de Velasco

ABSTRACT
TPS4589

EA8185: Phase 2 study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node positive urothelial carcinoma (INSPIRE)—An ECOG-ACRIN and NRG Collaboration.

AUTHOR(S)

ABSTRACT
TPS4590

A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study.

AUTHOR(S)

ABSTRACT
TPS4591
Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) (CaNI) for advanced renal cell carcinoma with variant histology (aRCCVH).

AUTHOR(S)
Bradley A. McGregor, Wanling Xie, Mehmet A. Bilen, David A. Braun, Wenxin Xu, Praful Ravi, Elisabeth I. Heath, David F. McDermott, Rana R. McKay, Hans J. Hammers, Toni K. Choueiri

ABSTRACT
TPS4592
A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL/Alliance A031801).

AUTHOR(S)

ABSTRACT
TPS4593
A phase 1b/2 umbrella study of investigational immune and targeted combination therapies as first-line therapy for patients with advanced renal cell carcinoma (RCC).

AUTHOR(S)

ABSTRACT
TPS4594
KEYNOTE-B61: Open-label phase 2 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC).

AUTHOR(S)
Chung-Han Lee, Chenxiang Li, Rodolfo F. Perini, Daniela Hoehn, Laurence Albiges

ABSTRACT
TPS4595

AUTHOR(S)
ABSTRACT

TPS4596

A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).

AUTHOR(S)

Marit Ahrens, Bernard Escudier, John B. Haanen, Ekaterini Boleti, Marine Gross Goupil, Marc-Oliver Grimm, Sylvie Negrier, Philippe Barthelemy, Gwenaelle Gravis, Philipp Ivanyi, Jens Bedke, Daniel Castellano, Andrej Panic, Begona Mellado, Pablo Maroto-Rey, Sylvie Rottey, Stefanie Zschaebitz, Dorothee Deckbar, Arndt Hartmann, Lothar Bergmann

ABSTRACT

TPS4597

Cyto-KIK: A phase II trial of cytoreductive surgery in kidney cancer plus immunotherapy (nivolumab) and targeted kinase inhibition (cabozantinib).

AUTHOR(S)

Karie Runcie, Eric A. Singer, Moshe C. Ornstein, Christopher B. Anderson, Matthew Dallos, Jessica Hawley, Emerson A. Lim, Charles G. Drake, Benjamin Izar, Hiram A. Shaish, Mark N. Stein

ABSTRACT

TPS4598

A phase I study of bintrafusp alfa (M7824) and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in adults with metastatic non-prostate genitourinary malignancies.

AUTHOR(S)


ABSTRACT

TPS4599
Concordance of DNA damage repair (DDR) gene mutations in paired primary and metastatic prostate cancer (PC) samples.

**AUTHOR(S)**

**ABSTRACT**
5020

Copy number profiles of primary tumors for risk stratification of advanced prostate cancer: A biomarker study embedded in the multicenter STAMPEDE trial.

**AUTHOR(S)**
Emily Grist, Marina Parry, Stefanie Friedrich, Christopher D. Brawley, Larissa Mendes, Sharanpreet Lall, Leila Zakka, Sara Santos Vidal, Nafisah B. Atako, Malissa Richmond, Sofeya Ishaq, Alex Hoyle, Adnan Ali, Noel W. Clarke, Nicholas D. James, Mahesh K. Parmar, Daniel Berney, Paolo Cremaschi, Louise C. Brown, Gerhardt Attard

**ABSTRACT**
5021

Characterization of findings on prostate cancer tumor sequencing that should prompt consideration for germline testing.

**AUTHOR(S)**
Hong Truong, Kelsey Breen, Yelena Kemel, Andrew T. Lenis, Peter Reisz, Nicole Benfante, Behfar Ehdai, Karim A. Touijer, Vincent P. Laudone, Peter T. Scardino, James A. Eastham, Vijai Joseph, Ozge Birsoy, Diana Mandelker, Zsòfia K. Stadler, Kenneth Offit, Michael J. Morris, Wassim Abida, Mark E. Robson, Maria I. Carlo

**ABSTRACT**
5022

PSMA-targeted imaging with $^{18}$F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.

**AUTHOR(S)**

Frederic Pouliot, Michael A. Gorin, Steven P. Rowe, Lawrence Saperstein, David Josephson, Peter R. Carroll, Jeffrey Y. Wong, Austin R. Pantel, Steve Y. Cho, Kenneth L. Gage, Morand Pier, Andrei Iagaru, Janet H. Pollard, Vivien Wong, Jessica Jensen, Nancy Stambler, Michael J. Morris, Barry A. Siegel

**ABSTRACT**

5023

**Evaluation of PSA progression after initiation of enzalutamide or abiraterone: Real-world data on metastatic castration-resistant prostate cancer (mCRPC).**

**AUTHOR(S)**


**ABSTRACT**

5024

**Factors associated with use of medications for anxiety and depression in testicular cancer survivors after cisplatin-based chemotherapy.**

**AUTHOR(S)**


**ABSTRACT**

5025

**Adjuvant chemotherapy with CAV/IE for malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): An institutional analysis from Indiana University.**

**AUTHOR(S)**

Cynthia Wei, Clint Cary, Timothy A. Masterson, Richard Foster, Ryan Ashkar, Nabil Adra, Nasser H. Hanna, Lawrence H. Einhorn

**ABSTRACT**

5026

**Clinical utility of FDG PET-CT in stage 1 and advanced testicular seminoma.**

**AUTHOR(S)**

Ciara Conduit, Michael S. Hofman, Jeremy H. Lewin, Guy C. Toner, Ben Tran

**ABSTRACT**

5027
Efficacy of TIP (paclitaxel, ifosfamide and cisplatin) as salvage chemotherapy for relapsed germ cell cancer patients stratified by the modified International Prognostic Factors Study Group (IPFSG) score: The Northern Ireland (NI) Experience.

AUTHOR(S)
Adam Uprichard, Julie-Anne Scott, James McAleer, Judith Carser, Olabode Oladipo

ABSTRACT
5028
Outcomes of patients with germ cell tumors diagnosed with stage I disease who subsequently received high dose chemotherapy (HDCT) with peripheral stem cell transplant (PBSCT) following failure of initial therapy for metastatic disease: The Indiana University experience.

AUTHOR(S)
Stephen B. Benzinger, Ryan Ashkar, Rafat Abonour, Mohammad I. Abu Zaid, Nabil Adra, Lawrence H. Einhorn, Nasser H. Hanna

ABSTRACT
5029
Very late recurrence in germ cell tumor of the testis: Lessons and implications.

AUTHOR(S)

ABSTRACT
5030
First-in-human study of TAS3681, an oral androgen receptor (AR) antagonist with AR and AR splice variant (AR-SV) downregulation activity, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to abiraterone (ABI) and/or enzalutamide (ENZ) and chemotherapy (CT).

AUTHOR(S)
Johann S. De Bono, Natalie Cook, Evan Y. Yu, Primo "Lucky" N. Lara Jr., Judy S. Wang, Yoshihiko Yamasaki, Ikuo Yamamiya, Ping Gao, Elizabeth M. Calleja, Dana E. Rathkopf

ABSTRACT
5031
Survival of veterans treated with enzalutamide and abiraterone in advanced prostate cancer.
AUTHOR(S)

Martin W. Schoen, Kenneth R. Carson, Suhong Luo, Seth Eisen, Melissa A. Reimers, Bettina F. Drake, Charles L. Bennett, Eric M. Knoche, Yan Yan, Kristen M. Sanfilippo

ABSTRACT

5032

A methodology for the extraction and analysis of real-world radiographic and electronic medical record data to reconstruct treatment arms of historical prostate cancer clinical trials.

AUTHOR(S)

William D. Lindsay, Christopher A. Ahern, Aaron Kamauu, Robert Wilder, Karen Chagin, Timmothy Taps

ABSTRACT

5033

A phase 2 study of berzosertib (M6620) in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.

AUTHOR(S)


ABSTRACT

5034

Cortisol as biomarker for CYP17 inhibition in mCRPC patients treated with abiraterone acetate.

AUTHOR(S)

Maaike Bruin, Merel van Nuland, Bart Jacobs, Andre M. Bergman, Hilde Rosing, Jos H. Beijnen, Alwin Huitema

ABSTRACT

5035

Biomarker analysis of phase (Ph) IB trial of radium-223 (Rad) and niraparib (Nira) in patients (Pts) with metastatic castrate-resistant prostate cancer (mCRPC) (NiraRad).

AUTHOR(S)

Eddy S. Yang, Benjamin Leiby, Guru P. Sonpavde, David J. Einstein, Zachary L. Quinn, Russell Z. Szmulewitz, A. O. Sartor, William K. Kelly

ABSTRACT
Analysis of two poor prognosis subgroups in ACIS evaluating apalutamide + abiraterone acetate plus prednisone (APA + AAP) versus placebo (PBO) + AAP in metastatic castration-resistant prostate cancer (mCRPC).

AUTHOR(S)
Fred Saad, Eleni Efstathiou, Gerhardt Attard, Thomas W. Flaig, Fabio Franke, Oscar Goodman Jr., Stephane Oudard, Thomas Steuber, Hiroyoshi Suzuki, Christopher M. Pieczonka, Francis Parnis, Daphne Wu, Kesav Yeruva, Peter De Porre, Sabine Brookman-May, Susan Li, Jinhui Li, Suneel Mundle, Sharon A. McCarthy, Dana E. Rathkopf

ABSTRACT
5036

Complementary detection of genomic alterations in metastatic castration-resistant prostate cancer (mCRPC) from CheckMate 9KD through analyses of tumor tissue and plasma DNA.

AUTHOR(S)
Mark Sausen, Jonathan F. Baden, Natallia Kalinava, Xuya Wang, Jun Li, Esperanza Anguiano, Keziban Unsal-Kacmaz, Megan Wind-Rotolo, Katie Quinn, George Green

ABSTRACT
5037

ARC-6: A phase 1b/2, open-label, randomized platform study to evaluate efficacy and safety of etrumadenant (AB928)-based treatment combinations in patients with metastatic castrate-resistant prostate cancer (mCRPC).

AUTHOR(S)
Sumit K. Subudhi, Johanna C. Bendell, Michael A. Carducci, Lisa M. Kopp, Jennifer Scott, Michele M. Grady, Olivia Gardner, David R. Wise

ABSTRACT
5038

Differential responses to taxanes and PARP inhibitors (PARPi) in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer (mCRPC) patients (pts).

AUTHOR(S)

ABSTRACT
5040
Molecular, immunologic, and clinicodemographic landscape of MYC-amplified (MYCamp) advanced prostate cancer (PCa).

AUTHOR(S)
Brandon A. Mahal, Liangliang Zhang, Mohamed Alshalalfa, Ryon Graf, Hanna Tukachinsky, Richard S. Huang, Kimberly McGregor, Alexa B. Schrock, Jeffrey M. Venstrom

ABSTRACT
5041

Pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Updated analyses after one additional year of follow-up from cohorts 4 and 5 of the KEYNOTE-199 study.

AUTHOR(S)

ABSTRACT
5042

A phase (Ph) 1b/2 study of ribociclib (R) in combination with docetaxel (D) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC).

AUTHOR(S)
Ivan de Kouchkovsky, Arpit Rao, Benedito A. Carneiro, Li Zhang, Catriona Lewis, Audrey Phone, Eric J. Small, Terence W. Friedlander, Lawrence Fong, Pamela Paris, Charles J. Ryan, Russell Z. Szmulewitz, Rahul R. Aggarwal

ABSTRACT
5043

CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC).

AUTHOR(S)
Russell K. Pachynski, Margitta Retz, Jeffrey C. Goh, Mauricio Burotto, Gwenaelle Gravis, Daniel Castellano, Aude Flechon, Stefanie Zschaebitz, David R. Shaffer, Juan Carlos Vazquez Limon, Marc-Oliver Grimm, Steven L. McCune, Neha P. Amin, Jia Li, Xuya Wang, Keziban Unsai-Kacmaz, Fred Saad, Daniel P. Petrylak, Karim Fizazi

ABSTRACT
5044

The impact of prior radiation therapy on outcome in a phase 2 trial combining sipuleucel-T (SipT) and ipilimumab (Ipi) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).
AUTHOR(S)

Li Zhang, Meenal Sinha, Sumit K. Subudhi, Brandon Chen, Jaqueline Marquez, Eric Liu, Kathryn Allaire, Alexander Cheung, Sharon Ng, Christopher Nguyen, Terence W. Friedlander, Rahul R. Aggarwal, Matthew Spitzer, James P. Allison, Eric J. Small, Padmanee Sharma, Lawrence Fong

ABSTRACT

ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC).

AUTHOR(S)


ABSTRACT

Talazoparib (TALA), an oral poly (ADP-ribose) polymerase (PARP) inhibitor for men with metastatic castration-resistant prostate cancer (mCRPC) and DNA damage response (DDR) alterations: Detailed safety analyses from TALAPRO-1 trial.

AUTHOR(S)

Niven Mehra, Karim Fizazi, Johann S. De Bono, Philippe Barthélémy, Tanya B. Dorff, Adam P. Stirling, Jean-Pascal H. Machiels, Davide Bimbatti, Deepak Kilari, Herlinde Dumez, Consuelo Buttigliero, Inge M. van Oort, Elena Castro, Hsiang-Chun Chen, Nicola Di Santo, Liza L. DeAnnuntis, Cynthia G. Healy, Giorgio V. Scagliotti

ABSTRACT

Association of plasma tumor DNA (ptDNA) with increased risk of venous thromboembolism (VTE) in metastatic castration resistant prostate cancer patients (mCRPC).

AUTHOR(S)

Vincenza Conteduca, Emanuela Scarpi, Daniel Wetterskog, Fabio Ferroni, Alice Rossi, Alessandro Romanel, Giorgia Gurioli, Sara Bleve, Caterina Gianni, Nicole Brighi, Giuseppe Schepisi, Cristian Lolli, Pietro Cortesi, Domenico Barone, Francesca Demichelis, Giovanni Paganelli, Himisha Beltran, Gerhardt Attard, Ugo De Giorgi

ABSTRACT

5048
Circulating tumor DNA fraction (ctDNA%) to independently predict for clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

**AUTHOR(S)**
Corinne Maurice-Dror, Nicolette Fonseca, Cameron Herberts, William Fan, Alexander W. Wyatt, Kim N. Chi

**ABSTRACT**
5049

**Title:** An open-label, pharmacokinetic study to determine the bioavailability, safety and tolerability of single dose oral docetaxel (Oradoxel) in metastatic prostate cancer (mPC) patients treated with IV docetaxel.

**AUTHOR(S)**
Christopher G. Jackson, Yen-chuan Ou, Meng En, Tsu-Yi Chao, Noelyn A. Hung, David Wang, David Cutler, Douglas Kramer, Jay Zhi, Wing Kai Chan, Min-Fun R. Kwan, Tak Hung

**ABSTRACT**
5050

Indirect treatment comparison of the efficacy of olaparib 300 mg tablets BID and cabazitaxel 25 mg/m² every 3 weeks plus daily prednisolone and granulocyte colony-stimulating factor in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

**AUTHOR(S)**
Tim Reason, Charles McCrea, Robert Hettle, Sameer Ghate, Christian H. Poehlein, David Olmos

**ABSTRACT**
5051

A phase II study evaluating the efficacy of enzalutamide and the role of ARv7 in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with visceral disease.

**AUTHOR(S)**
Pierangela Sepe, Giuseppe Procopio, Umberto Basso, Orazio Caffo, Vera Cappelletti, Melanie Claps, Ugo De Giorgi, Lucia Fratino, Valentina Guadalupi, Patrizia Miodini, Bruno Perrucci, Alessia Mennitto, Daniele Santini, Francesco Spina, Arianna Ottini, Filippo G. De Braud, Elena Verzoni

**ABSTRACT**
5052
Immunogenic priming with $^{177}$Lu-PSMA-617 plus pembrolizumab in metastatic castration resistant prostate cancer (mCRPC): A phase 1b study.

**AUTHOR(S)**


**ABSTRACT**

Using real-world outcomes to evaluate the predictive power of tissue-assessed genomic biomarkers for taxane versus novel hormonal therapy (NHT) outcomes in metastatic castration-resistant prostate cancer (mCRPC).

**AUTHOR(S)**

Ryon Graf, Virginia Fisher, Ole Gjoerup, Alexa B. Schrock, Russell Madison, Samantha Morley, Lei Zhong, Geoffrey R. Oxnard, Jeffrey M. Venstrom, Amado J. Zurita

**ABSTRACT**

Long-term adverse events (AE) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT).

**AUTHOR(S)**

Michael Sun, Charlene Thomas, Benedict Ho, Muhammad Junaid Niaz, Ana M. Molina, Cora N. Sternberg, David M. Nanus, Neil H. Bander, Scott T. Tagawa

**ABSTRACT**

VERU-111, an oral cytoskeleton disruptor, to treat men with metastatic castration-resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent.

**AUTHOR(S)**

Mark C. Markowski, Ronald F. Tutrone, Mario A. Eisenberger, Christopher M. Pieczonka, Robert H. Getzenberg, Domingo Rodriguez, K. G. Barnette, Mitchell S. Steiner, Daniel Saltzstein, Emmanuel S. Antonarakis

**ABSTRACT**

Radiographic progression-free survival as a surrogate endpoint of overall survival in men with metastatic castrate-resistant prostate cancer.
Differences in the tumor genomic landscape between African Americans (AA) and Caucasians (CA) advanced prostate cancer (aPC) patients (pts) by comprehensive genomic profiling (CGP) of cell-free DNA (cfDNA).

Author(s)

First results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC).

Author(s)
Kim van der Zande, Vincent van der Noort, Milou Busard, Paul Hamberg, Suzan Ras - van Spijk, Jeantine De Feijter, Vincent O. Dezentjé, Metin Tascilar, Danny Houtsma, Aart Beeker, Diederik ten Oever, Irma M. Oving, Wilbert Zwart, Andre M. Bergman

TROP-2 co-expression with androgen receptor splice variants as a new therapeutic target in prostate cancer.

Author(s)
Charlotte Stahlfeld, Jamie Sperger, Susan F. Slovin, Scott T. Tagawa, Christos Kyriakopoulos, Manish Kohli, Liewei Wang, Scott Dehm, Joshua M. Lang


Author(s)
Matthew R. Cooperberg, Paul Brendel, Daniel J. Lee, Rahul Doraiswami, Hariesh Rajasekar, Danil V. Makarov, William Meeks, Raymond Fang, Matthew T. Roe, Jeremy B. Shelton
Genomic landscape of \textit{MSH6}-mutated clinically advanced castrate-resistant prostate cancer (mCRPC).

\textbf{AUTHOR(S)}


\textbf{ABSTRACT}

Association of ATM mutations in metastatic prostate cancer with differential genomic alteration profiles from homologous recombination deficient and proficient tumors.

\textbf{AUTHOR(S)}

Charles J. Ryan, Julie E. McGrath, Joanne Xiu, Justin Hwang, Chadi Nabhan, Andre L. De Souza, Pedro C. Barata, Shuchi Gulati, Shuanzeng Wei, Jaime R. Merchán, Arpit Rao, Daniel M. Geynisman, Inas Abuali, Wolfgang M. Korn, Elisabeth I. Heath

\textbf{ABSTRACT}

\textbf{PSMA-PET/CT Registry for Recurrent Prostate Cancer (PREP): Initial findings from a single center.}

\textbf{AUTHOR(S)}

Anil Kapoor, Katherine Zukotynski, Camilla Tajzler, Jen Hoogenes, Edward Matsumoto, Michael Uy, Glenn Bauman, Ur Metser, Antonio Finelli, Maylynn Ding, Bobby Shayegan

\textbf{ABSTRACT}

Single-lesion PSMA protein expression and response to Lu-177 PSMA therapy in patients with castration-resistant prostate cancer.

\textbf{AUTHOR(S)}

Judith Stangl-Kremser, Sazan Rasul, Jeffrey J. Tosoian, Simpa Salami, Alexander Zaslavsky, Aaron M. Udager, Peter Mazal, Renate Kain, Eva Comperat, Carmen Pozo Salido, Christina Steinbach, Melanie Hassler-Di Fratta, Gero Kramer, Shahrokh Shariat, Ganesh S. Palapattu

\textbf{ABSTRACT}

Interim PSMA PET/CT for response evaluation during LuPSMA treatment in mCRPC (INTERIM PET): An explorative, multicenter study.
AUTHOR(S)

ABSTRACT

5066

Impact of androgen deprivation therapy on mortality of prostate cancer patients with COVID-19: A propensity score-based analysis.

AUTHOR(S)
Mateus B. Duarte, Frederico Leal, Juliana L. Argenton, Jose B. Carvalheira

ABSTRACT

5067

Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

AUTHOR(S)
Neeraj Agarwal, Simon Chowdhury, Anders Bjartell, Byung Ha Chung, Andrea J. Pereira de Santana Gomes, Robert Given, Álvaro Juárez, Axel S. Merseburger, Mustafa Ozguroglu, Hirotsgu Uemura, Dingwei Ye, Sabine Brookman-May, Suneel Mundle, Sharon A. McCarthy, Florence Lefresne, Shiva Dibaj, Katherine B. Bevans, Kim N. Chi

ABSTRACT

5068

Association of androgen receptor signature and RB1, PTEN, TP53 gene expression with clinical outcome in metastatic hormone-sensitive prostate cancer treated with docetaxel and androgen deprivation therapy.

AUTHOR(S)

ABSTRACT

5069

The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES.

AUTHOR(S)
Andrew J. Armstrong, Taro Iguchi, Arun Azad, Arnauld Villers, Boris Alekseev, Daniel P. Petrylak, Russell Z. Szmulewitz, Antonio Alcaraz, Neal D. Shore, Jeffrey Holzbeierlein, Francisco Gomez-Veiga, Brad Rosbrook, Fabian Zohren, Gabriel P. Haas, Georgia Gourgioti, Nader N. El-Chaar, Arnulf Stenzl

ABSTRACT

5071

Real-world first-line (1L) treatment patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database.

AUTHOR(S)

Umang Swami, Agnes Hong, Nader N. El-Chaar, David Nimke, Krishnan Ramaswamy, Elizabeth J. Bell, Rickard Sandin, Neeraj Agarwal

ABSTRACT

5072

Real-world utilization of advanced therapies and racial disparity among patients with metastatic castration-sensitive prostate cancer (mCSPC): A Medicare database analysis.

AUTHOR(S)

Stephen J. Freedland, Neeraj Agarwal, Krishnan Ramaswamy, Rickard Sandin, Dave Russell, Agnes Hong, Hongbo Yang, Wei Gao, Kaitlin Hagan, Daniel J. George

ABSTRACT

5073

Real-world treatment patterns among patients diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) in community oncology settings.

AUTHOR(S)

Daniel J. George, Neeraj Agarwal, Jennifer R. Rider, Benjamin Li, Rohan Shirali, Rickard Sandin, Agnes Hong, Dave Russell, Krishnan Ramaswamy, Stephen J. Freedland

ABSTRACT

5074

Impact of age on efficacy and safety of relugolix: A subgroup analysis from the randomized, phase 3 hero study versus leuprolide in men with advanced prostate cancer.

AUTHOR(S)

Michael Cookson, Neal D. Shore, Daniel J. George, Hideyuki Akaza, Daniel Saltzstein, Ronald F. Tutrone, Alberto Bossi, Bruce Brown, Bryan Selby, Sophia Lu, Jacqueline M. Walling, Bertrand F. TOMBAL, Fred Saad

ABSTRACT
Proliferation index and survival in men with prostate cancer starting long-term androgen deprivation therapy in the STAMPEDE clinical trial.

AUTHOR(S)
Larissa Mendes, Christopher D. Brawley, Emily Grist, Adnan Ali, Sara Santos Vidal, Marina Parry, Sharanpreet Lall, Nafisah B. Atako, Sofeya Ishaq, Malissa Richmond, Aine Haran, Alex Hoyle, Leila Zakka, Christopher Sweeney, Noel W. Clarke, Mahesh K. Parmar, Nicholas D. James, Louise C. Brown, Daniel Berney, Gerhardt Attard

ABSTRACT
Correlation of baseline circulating tumor cells (CTC) and associated genomic profile with survival outcomes in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a real-world cohort.

AUTHOR(S)
Umang Swami, Taylor R. McFarland, Benjamin Haaland, Adam Kessel, Roberto Nussenzveig, Nicolas Sayegh, Andrew W. Hahn, Nityam Rathi, Deepika Sirohi, John Esther, Haoran Li, Manish Kohli, Benjamin L. Maughan, Amir Goldkorn, Neeraj Agarwal

ABSTRACT

AUTHOR(S)
Juliano J. Cerci, Stefano Fanti

ABSTRACT
Darolutamide (DARO) tolerability from extended follow up and treatment response in the phase 3 ARAMIS trial.

AUTHOR(S)
Karim Fizazi, Neal D. Shore, Matthew R. Smith, Teuvo Tammela, Christopher M. Pieczonka, Jeanny B. Aragon-Ching, David Morris, Marie-Aude Le Berre, Shankar Srinivasan, Oana Petrenciuc, Christian Zurth, Iris Kuss

ABSTRACT
A phase II randomized controlled trial of exercise on biochemical progression in men with prostate cancer on active surveillance.
AUTHOR(S)
Dong-Woo Kang, Adrian S. Fairey, Normand G. Boulé, Catherine J. Field, Stephanie A. Wharton, Kerry S. Courneya

ABSTRACT
5080
Active surveillance of postradical prostatectomy biochemical recurrence: Long-term assessment of outcomes.

AUTHOR(S)
Tom E. Ahlering, Erica Huang, Linda M. Huynh, Huang Wei Su

ABSTRACT
5081
The somatic mutation landscape of germline CHEK2-altered prostate cancer.

AUTHOR(S)
Emily Nizialek, Tamara L. Lotan, William B. Isaacs, Srinivasan Yegnasubramanian, Channing J. Paller, Emmanuel S. Antonarakis

ABSTRACT
5084

AUTHOR(S)
Andrew J. Armstrong, Michael S. Gordon, Melissa A. Reimers, Alex Sedkov, Kate Lipford, Juliana Snavely-Merhaut, Sonia Kumar, Sylvie M. Guichard, Neal Shore

ABSTRACT
TPS5085
CYCLONE 1: A phase 2 study of abemaciclib in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a novel hormonal agent and taxane-based chemotherapy.

AUTHOR(S)
Neeraj Agarwal, Stephane Oudard, Josep M. Piulats, Michael T. Schweizer, Aude Flechon, Teresa Alonso Gordoa, Karim Nacerddine, Andrew Lithio, Erica L. Johnston, Matthew R. Smith

ABSTRACT
TPS5086
Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using $^{177}$Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH).

**AUTHOR(S)**

**ABSTRACT**

TPS5087

Safety and efficacy of AMG 160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration-resistant prostate cancer (mCRPC).

**AUTHOR(S)**

**ABSTRACT**

TPS5088

TALAPRO-2: A phase 3 randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo in patients with new metastatic castration-resistant prostate cancer (mCRPC).

**AUTHOR(S)**

**ABSTRACT**

TPS5089

A phase 1/2a, open-label, multicenter study of intramuscular (IM) abiraterone decanoate (PRL-02) depot in patients with advanced prostate cancer (NCT04729114).

**AUTHOR(S)**
Tim Warneke, Michael R. Kurman, Robert Dreicer, Daniel J. George, Neal Shore, William D. Figg, Robert Schotzinger, William R. Moore

**ABSTRACT**

TPS5090
A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.

AUTHOR(S)
Michael J. Morris, Ronald De Wit, Nicholas J. Vogelzang, Scott T. Tagawa, Celestia S. Higano, Paul Hamberg

ABSTRACT
TPS5091

TNB585.001: A multicenter, phase 1, open-label, dose-escalation and expansion study of tnb-585, a bispecific T-cell engager targeting PSMA in subjects with metastatic castrate resistant prostate cancer.

AUTHOR(S)
Ben Buelow, Pranjali Dalvi, Kevin Dang, Ashwin Patel, Kiran Johal, Duy Pham, Shailee Panchal, Yvonne Liu, Lawrence Fong, A. O. Sartor, Meredith McKean, Ute Schellenberger, Suhasini Iyer

ABSTRACT
TPS5092

Radium-223 (Ra-223) versus novel antihormone therapy (NAH) for progressive metastatic castration-resistant prostate cancer (mCRPC) after 1 line of NAH: RADIANT, an international phase 4, randomized, open-label study.

AUTHOR(S)
Karim Fizazi, Aránzazu González del Alba, Özgür-oğlu Mustafa, Iwona A. Skoneczna, Heiko Krissel, Deise Uema, Huanyu Chen, Volker J. Wagner, Martin Boegemann

ABSTRACT
TPS5093

Phase I study of CCW702, a bispecific small molecule-antibody conjugate targeting PSMA and CD3 in patients with metastatic castration-resistant prostate cancer (mCRPC).

AUTHOR(S)
Mark C. Markowski, Deepak Kilari, Mario A. Eisenberger, Rana R. McKay, Robert Dreicer, Mohit Trikha, Elisabeth I. Heath, Jing Li, Pamela D. Garzone, Travis S. Young

ABSTRACT
TPS5094

Open label phase II trial of cabozantinib (cabo) in patients with metastatic castrate resistant prostate cancer (mCRPC) and known amplifications or
activating mutations in gene targets who have received prior anti-androgen therapy.

**AUTHOR(S)**

Jones T. Nauseef, Sharon Singh, Angela Tan, Amie Patel, Brian D. Robinson, Francesca Khani, Charles G. Drake, Emerson A. Lim, Mark N. Stein, Elisabeth I. Heath, Himisha Beltran, Ana M. Molina, Bishoy M. Faltas, Karla V. Ballman, Cora N. Sternberg, Scott T. Tagawa, David M. Nanus

**ABSTRACT**

TPS5095

A phase I/II study of bintrafusp alfa and NHS-IL12 in combination with docetaxel in adults with metastatic castration sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC).

**AUTHOR(S)**

Mohammad O. Atiq, Marijo Bilusic, Fatima Karzai, Lisa M. Cordes, Julius Strauss, Houssein Abdul Sater, Jason Redman, Charalampos S. Floudas, James W. Hodg, Sofia Gameiro, William D. Figg, Jeffrey Schlom, William L. Dahut, James L. Gulley, Ravi A. Madan

**ABSTRACT**

TPS5096

Identifying androgen receptor (AR) and genomic characteristics that define populations of patients with mHSPC who benefit from early PARP inhibition therapy with talazoparib.

**AUTHOR(S)**

Saro Kasparian, Leanne Burnham, Rick Kittles, Zj Sun, Fornati Bedell, Justin Tran, Min Li, Tanya B. Dorff

**ABSTRACT**

TPS5097

Phase III study of local or systemic therapy INtensification DIrected by PET in prostate CAncer patients with post-prostaTEctomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.

**AUTHOR(S)**


**ABSTRACT**

TPS5098

The fluciclovine (FACBC) PET/CT site-directed therapy of oligometastatic prostate cancer (Flu-BLAST-PC) trial.
AUTHOR(S)

ABSTRACT
TPS5099

Phase 1b study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune-oncology therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).

AUTHOR(S)
Rahul R. Aggarwal, Ana Aparicio, Axel Heidenreich, Shahneen K. Sandhu, Yiran Zhang, Mark Salvati, Aditya Shetty, Nooshin Hashemi Sadraei

ABSTRACT
TPS5100

Gynecologic Cancer

Back to Program

Showing 84 Presentations

https://meetinglibrary.asco.org/session/13636

Parametrial evaluation in cervical cancer by magnetic resonance imaging and clinical examination: Analysis of data from the prospective Leipzig School MMR study.

AUTHOR(S)
Benjamin Wolf, Paulina Sodeikat, Massimiliano Lia, Mireille Martin, Lars-Christian Horn, Michael Höckel, Bahriye Aktas

ABSTRACT
5525
Discovery and validation of novel methylated DNA markers of cervical cancer.

AUTHOR(S)

ABSTRACT
5526

A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium.

AUTHOR(S)
Camille C. Jackson, Leigh Cantrell, Britt K. Erickson, Kathleen N. Moore, Linda R. Duska, Debra L. Richardson, Lisa M. Landrum, Laura L. Holman, Joan L. Walker, Robert S. Mannel, Katherine M. Moxley, Lurdes Queimado, Kai Ding, Andrew Cohoon, Sara Vesely, Lauren E. Dockery

ABSTRACT
5527

Defective mismatch repair associated mutational signatures, a prognostic and predictive biomarker in endometrial cancer.

AUTHOR(S)
Yifan E. Chang, Naomi N. Adjei, Wafa Khadraoui, Gary Altwerger

ABSTRACT
5528

Differentiated activity profile for the PD-1 inhibitor balstilimab.

AUTHOR(S)
Cailin Joyce, Dhan Chand, Benjamin Duckless, Manuel Hidalgo, Joseph E. Grossman, Remigiusz Kaleta, David M. O’Malley

ABSTRACT
5529

Differential benefit from fractionated dose-dense first-line chemotherapy for epithelial ovarian cancer (EOC) according to KELIM-evaluated tumor primary chemosensitivity: Exploratory analyses of ICON-8 trial.

AUTHOR(S)
Benoit You, Andrew Clamp, Adrian D. Cook, Iain A. McNeish, Olivier Colomban

ABSTRACT
5530
An international, multicenter, real-world analysis of epithelial ovarian cancer treatment and outcomes.

AUTHOR(S)
Geoff Hall, Sue Cheeseman, Bethany Levick, Eun Ji Nam, Subin Lim, Jean-Marc Classe, Elodie Martin, Paul Kubelac, Patriciu Achimas-Cadariu, Joana Savva-Bordalo, Marina Borges, Sven Becker, Shabnam Shaid, Nicolas Niklas, Mariana Guergova-Kuras

ABSTRACT
5531

Metronomic cyclophosphamide and bevacizumab for the treatment of recurrent gynecologic carcinosarcoma: A multi-institution, retrospective study.

AUTHOR(S)
Sara Bouberhan, Jill S. Hyde, McKenzie Foxall, Richard T. Penson, Rebecca C. Arend

ABSTRACT
5532

Anlotinib plus pemetrexed as a further treatment for patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study.

AUTHOR(S)
Jueming Chen, Wei Wei, Lie Zheng, Han Li, Yanling Feng, Ting Wan, Jiaqi Qiu, Xingyu Jiang, Ying Xiong, Min Zheng, Jundong Li, He Huang, Libing Song, Jihong Liu, Yanna Zhang

ABSTRACT
5533

Efficacy of niraparib maintenance therapy in Chinese women with platinum-sensitive recurrent ovarian cancer with and without secondary cytoreductive surgery: Results from the NORA trial.

AUTHOR(S)
Lingying Wu, Xiaohua Wu, Jianqing Zhu, Rutie Yin, Jiaxin Yang, Jihong Liu, Jing Wang, Ziling Liu, Yunong Gao, Danbo Wang, Ge Lou, Hongying Yang, Qi Zhou, Beihua Kong, Yi Huang, Lipai Chen, Guiling Li, Ruifang An, Tao Tan, Juan Dong

ABSTRACT
5534


AUTHOR(S)
Jing Wang, Xiaohua Wu, Jianqing Zhu, Rutie Yin, Jiaxin Yang, Qidan Huang, Lingying Wu, Ziling Liu, Yunong Gao, Danbo Wang, Ge Lou, Hongying Yang, Qi Zhou, Beihua Kong, Yi Huang, Lipai Chen, Guiling Li, Ruifang An, Tao Tan, Juan Dong

**ABSTRACT**

5535

Association of homologous recombination deficiency in ovarian cancer with neoantigen load and expression of immune checkpoints.

**AUTHOR(S)**

Kathleen Fenerty, Charlene M. Fares, Gottfried E. Konecny

**ABSTRACT**

5536

Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer (HGOC).

**AUTHOR(S)**

Tanya Kwan, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew P. Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew R. Clamp, Giovanni Scambia, Alexandra Leary, Robert W. Holloway, Margarita Amenedo, Peter C. Fong, Jeffrey C. Goh, David M. O'Malley, Lara Maloney, Sandra Goble, Jonathan A. Ledermann, Robert L. Coleman

**ABSTRACT**

5537

LIO-1: Lucitanib + nivolumab in patients with advanced solid tumors—Updated phase 1b results and initial experience in phase 2 ovarian cancer cohort.

**AUTHOR(S)**

Erika P. Hamilton, Camille C. Jackson, Ramez N. Eskander, Floor J. Backes, Vicky Makker, Fernanda Musa, Alexander Olawaiye, Jill Aldredge, Bhavana Pothuri, Angeles A. Secord, Nicole Concin, Antonio Gonzalez Martin, Jowell Go, Kenton Wride, Denise M. Lepley, Teresa Cameron, Manish R. Patel

**ABSTRACT**

5538

Underutilization of germline BRCA testing in commercially-insured women diagnosed with ovarian cancer.

**AUTHOR(S)**

Stephanie Cham, Alexi A. Wright

**ABSTRACT**

5539
Postoperative adjuvant dose-dense chemotherapy with bevacizumab and maintenance bevacizumab after neoadjuvant chemotherapy for advanced ovarian cancer: A phase II AGOG/TGOG trial.

AUTHOR(S)
Wei-Chun Chen, Hung-Hseuh Chou, Lan-Yan Yang, Huei-Jean Huang, Wei-Yang Chang, Hao Lin, Ren-Chin Wu, Min-Yu Chen, J. Timothy Qiu, Kuan-Gen Huang, Angel Chao, Ting-Chang Chang, Chyong-Huey Lai

ABSTRACT

5540

Patient self-reporting of tolerability using PRO-CTCAE: A randomized double-blind placebo controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in women with platinum resistant epithelial ovarian cancer.

AUTHOR(S)
Ainhoa Madariaga, Sandra A. Mitchell, Tyler Pittman, Lisa Wang, Valerie Bowering, Nisan Kavak, Judy Quintos, Karen Chang, Janelle Ramsahai, Katherine Karakasis, Stephen Welch, Neesha C. Dhani, Stephanie Lheureux, Amit M. Oza

ABSTRACT

5541

A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in patients (Pts) with selected fRα-positive solid tumors: Results in the ovarian cancer (EC) cohort.

AUTHOR(S)
Mihaela C. Cristea, Nora H. Ruel, Paul H. Frankel, Timothy W. Synold, Daphne B. Stewart, Edward W. Wang, Alex Jung, Sharon Wilczynski, Michael Tran, Gottfried E. Konecny, Melissa Eng, Lindsay Kilpatrick, Yi-Jen Chen, Scott Glaser, Thanh H. Dellinger, Amy Hakim, Stephen Lee, Robert Morgan, Ernest S. Han

ABSTRACT

5542

The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma.

AUTHOR(S)
Rachel Soyoun Kim, Janet Malcolmson, Xuan Li, Marcus Bernardini, Liat F. Hogen, Taymaa May

ABSTRACT

5543
Nanoanalysis of plasma volatile organic compounds using novel DNA-decorated carbon nanotube vapor sensors to noninvasively distinguish ovarian and pancreatic cancer from benign and control samples.

AUTHOR(S)
A. T. Charlie Johnson, Christopher Kehayias, Erica L. Carpenter, Jody Piltz-Seymour, Janos L. Tanyi, Cindy Otto, Young E. Lee, Taylor A. Black, Stephanie S. Yee, George Preti

ABSTRACT
Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION primary analysis.

AUTHOR(S)
Andres Poveda, Stephanie Lheureux, Nicoletta Colombo, David Cibula, Kristina Lindemann, Johanne I. Weberpals, Maria Bjurberg, Ana Oaknin, Magdalena Sikorska, Antonio Gonzalez Martin, Radoslaw Madry, Maria J. Rubio, Jonathan A. Ledermann, Richard Davidson, Christopher Blakeley, James Bennett, Jessica Brown, Alan Barnicle, Erik Skof

ABSTRACT
Feasibility of an adapted schedule of carboplatin plus paclitaxel in elderly women with advanced ovarian cancer: A retrospective cohort.

AUTHOR(S)
Benjamin Nicaise, Soraya Mebarki, Mathilde Gisselbrecht, Elisabeth Ashton, Henri Azais Sr., Meriem Koual, Anne-Sophie Bats, Laure Fournier, Marie-Aude Le Frère - Belda, Jacques Medioni, Elena Paillaud, Stephane Oudard, Nicolas Delanoy

ABSTRACT
Stage I Sertoli-Leydig cell tumors: An interim report from the International PPB/DICER1 & OTST Registry.

AUTHOR(S)
Alexander Nelson, Anne Harris, Dave Watson, Sean R. Pyper, Nathan Hall, Junne Kamihara, Douglas R. Stewart, Louis P. Dehner, D. Ashley Hill, Yoav H. Messinger, Lindsay L. Frazier, Deborah F. Billmire, Dominik T. Schneider, Kris Ann P. Schultz

ABSTRACT
Circulating tumor DNA as a noninvasive marker of resectability in ovarian carcinomas.

AUTHOR(S)
Health-related quality of life (QoL) in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD), a multicenter single-arm phase II clinical trial (ROLANDO, GEICO-1601).

AUTHOR(S)
José Alejandro Perez-Fidalgo, Alfonso Cortés Salgado, Yolanda García, María Iglesias, Uriel Bohn Sarmiento, Elisa Calvo García, Luis Manso Sánchez, Ana Santaballa, Ana Oaknin, Andrés Redondo, María J. Rubio, Antonio González-Martín

Phase 1 dose-escalation study of STRO-002, an antifolate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced, progressive platinum-resistant/refractory epithelial ovarian cancer (EOC).

AUTHOR(S)

Serum-based assay for adnexal mass risk of ovarian malignancy.

AUTHOR(S)
Daniel Ure, Rowan Bullock, Gary Altwerger, Elena Ratner, Lesley Northrop

Disparities in ovarian cancer treatment and overall survival according to race: An update.

AUTHOR(S)
Deanna Huffman, Thejus T. Jayakrishnan, Karthik Shankar, Chelsea Peterson, Rodney E. Wegner
Next generation sequencing in ovarian cancer patients: Does personalized medicine improve oncological outcomes?

AUTHOR(S)
Tamar Safra, Dov Hershkovizh, Eliya Shachar, Lyri Adar, Miriam R. Brezis, Yuval Raviv, Lee Galmor, Shira Peleg Hasson

ABSTRACT
5553

Symptom identification and management in epithelial ovarian cancer.

AUTHOR(S)
Ashley D. Hickman, Kathryn J. Ruddy, Deirdre R. Pachman, Kristin Fischer, Parvez Rahman, Krista M. Goergen, Minji Lee, Andrea L. Cheville, Andrea E. Wahner Hendrickson

ABSTRACT
5554

Association of the Khorana Score with development of venous thromboembolism in ovarian cancer.

AUTHOR(S)
Ellen Marcus, Dennis Y. Kuo, Nicole S. Nevadunsky, Gregory M. Gressel

ABSTRACT
5555

Does aggressive surgery only benefit patients with less advanced ovarian cancer?

AUTHOR(S)
Shinichi Tate, Kyoko Nishikimi, Ayumu Matsuoka, Satoyo Otsuka, Makio Shozu

ABSTRACT
5556

Anlotinib in combination with TQB2450 in patients with recurrent ovarian cancer (ACTION): A multicenter, single-arm, open-label, phase Ib trial.

AUTHOR(S)
Chunyan Lan, Jing Zhao, Fan Yang, Rong Li, Yu Huang, Jing Wang, Weihong Zhao, Li Zhang, Chang Liu, Xuehan Bi, Haihong Jin, Jin Meng, Xin Huang

ABSTRACT
5557
Improving the prediction of surgical outcome at secondary cytoreduction in patients with ovarian cancer: Results from retrospective part of HELP-ER study NOGGO TR2/ENGOT OV47-TR.

AUTHOR(S)
Ioana Braicu, Wanja Nikolai Kassuhn, Hagen Kulbe, Pauline Wimberger, Cagatay Taskiran, Klaus Pietzner, Alexander Mustea, Robert Armbrust, J.P. P. Grabowski, Felix Schmidt, Ali Ayhan, Carmen R. Beteta, Christina Fotopoulou, Jalid Sehouli

ABSTRACT
5558

Real-life data of niraparib maintenance treatment in patients with recurrent platinum-sensitive ovarian cancer.

AUTHOR(S)
Bente Vilming, Jørgen Fallås-Dahl, Anne-Gry Bentzen, Vibeke Anett Ingebrigtsen, Elisabeth Berge Nilsen, Ingvild Vistad, Anne Dørum, Olesya Solheim, Line Bjørge, Guro Aune, Kristina Lindemann

ABSTRACT
5560

Role of CD10 expression in endometriosis-associated mesenchymal stem cells on the progression of endometriosis-associated carcinoma.

AUTHOR(S)
Huda Atiya, Taylor Orellana, Lan G. Coffman

ABSTRACT
5561

Outcomes of ovarian cancer patients treated with platinum or non-platinum based chemotherapy after PARP inhibitor maintenance.

AUTHOR(S)
Ralyynn Brann, Kevin M. Kremer, Matthew Carlson, Salvatore LoCoco, Jayanthi S. Lea, David S. Miller, Jessica Lee

ABSTRACT
5563


AUTHOR(S)
Sara Nasser, Christina Fotopoulou, Murat Guktekin, Desislava Dimitrova, Philippe Morice, Jalid Sehouli

ABSTRACT
Selinexor in combination with weekly paclitaxel in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multiarm phase 1b study.

**AUTHOR(S)**

**ABSTRACT**

Phase 1b study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma.

**AUTHOR(S)**
Katherine C. Fuh, Michael A. Bookman, Robert L. Coleman, Thomas J. Herzog, Premal H. Thaker, Joyce F. Liu, Michelle W. Lane, Reshma A. Rangwala, Gail McIntyre, Bradley J. Monk, Kathleen N. Moore

**ABSTRACT**

Assessment of predictive biomarker prevalence in molecularly defined adult-type ovarian granulosa cell tumors.

**AUTHOR(S)**
Robert T. Hillman, Douglas I. Lin, David M. Gershenson

**ABSTRACT**

Correlation of HRD status with clinical and survival outcomes in patients with advanced-stage ovarian cancer.

**AUTHOR(S)**
Travis T. Sims, Anil K. Sood, Shannon N. Westin, Bryan M. Fellman, Jenna Unke, Kelly M. Rangel, Tyler Hilton, Nicole D. Fleming

**ABSTRACT**

Final results of phase 1 evaluation of the safety and clinical activity of sapanisertib in combination with serabelisib and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer.

**AUTHOR(S)**
Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician’s choice (TPC).

AUTHOR(S)
Domenica Lorusso, Nicoletta Colombo, Antonio Casado Herraez, Alessandro Santin, Emeline Colomba, David S. Miller, Keiichi Fujiwara, Sandro Pignata, Sally E. Baron-Hay, Isabelle L. Ray-Coquard, Ronnie Shapira-Frommer, Yong Man Kim, Mary McCormack, Steven Bird, Vimalanand S. Prabhu, Allison Martin Nguyen, Qi Zhao, Lea Dutta, Vicky Makker

Race-related disparities in patterns of uterine cancer recurrence.

AUTHOR(S)
Camilla Dagum, Nicole Vilardo, Gregory M. Gressel

Phase II trial assessing niraparib with or without dostarlimab (anti-PD-1) in recurrent endometrial carcinoma.

AUTHOR(S)
Ainhoa Madariaga, Swati Garg, Nairi Tchrakian, Neesha C. Dhani, Waldo Jimenez, Stephen Welch, Helen Mackay, Josee-Lyne Ethier, Lucy Gilbert, Angela Rodriguez, Lucy Chan, Valerie Bowering, Blaise Clarke, Tracy Stockley, Xuan Li, Lisa Wang, Smitha Udagani, Amit M. Oza, Stephanie Lheureux

Evaluating the role of aromatase inhibitors (AIs) in the treatment of endometrial stromal sarcomas (ESS).

AUTHOR(S)
Fionnuala Crowley, Karen A. Cadoo, Sarah Chiang, Jennifer J. Mueller, Martee L. Hensley, Roisin E. O’Cearbhaill
Open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel to assess safety and efficacy in patients with advanced or metastatic endometrial cancer.

AUTHOR(S)

ABSTRACT
5576

High prevalence of actionable germline variants in unselected endometrial cancer (EC) patients.

AUTHOR(S)
Monica Levine, Rachel Pearlman, Heather Hampel, Casey Cosgrove, David E. Cohn, Alexis Chassen, Adrian Suarez, Steven E. Waggoner, Caroline Billingsley, Kimberly E. Resnick, Steve Andrews, Sareena Singh, Eric Jenison, Aine E. Clements, Robert Neff, Paul J. Goodfellow

ABSTRACT
5577


AUTHOR(S)
Fangjian Guo, Lyuba Levine, Abbey Berenson

ABSTRACT
5578

Exploring molecular profiles and survival in hormone receptor-positive uterine serous carcinoma.

AUTHOR(S)
Amaranta Craig, Annelise M. Wilhite, Sharon Wu, Joanne Xiu, Gina Mantia-Smaldone, Enrique Hernandez, Jubilee Brown, Nathaniel L. Jones

ABSTRACT
5579

HER2 in uterine serous carcinoma: Testing platforms and implications for targeted therapy.

AUTHOR(S)
**ABSTRACT**

5580

**Treatment patterns and outcomes among patients with microsatellite stable (MSS) advanced endometrial cancer in the United States: Endometrial Cancer Health Outcomes (ECHO) retrospective chart review Study.**

**AUTHOR(S)**

Shelby Corman, Sneha Kelkar, Shardu Odak, Jingchuan Zhang, Vimalanand S. Prabhu, Nifasha Rusibamayila, Cynthia Macahilig, Linda R. Duska

5581

**Molecular determinants of response to immune-oncology therapy in uterine carcinosarcoma.**

**AUTHOR(S)**

Annelise M. Wilhite, Sharon Wu, Joanne Xiu, Britt K. Erickson, Rodney P. Rocconi, Jubilee Brown, Thomas J. Herzog, Robert W. Holloway, John Wallbillich, Ira S. Winer, Matthew A. Powell, Wolfgang M. Korn, Nathaniel L. Jones

5582

**Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial.**

**AUTHOR(S)**

Wei Wei, Xiaohua Ban, Fan Yang, Yongwen Huang, Jibin Li, Ya Qiu, Xiaqin Cheng, Jundong Li, Min Zheng

5583

**Tumor-associated immune cells and progression-free survival in advanced endometrial cancer (EC), results from the PHAEDRA trial (ANZGOG 1601).**

**AUTHOR(S)**

Deborah Smith, Kristy Robledo, Sonia Yip, Michelle Cummins, Peey-Sei Kok, Yeh Chen Lee, Michael Friedlander, Sally E. Baron-Hay, Catherine M. Shannon, Jermaine Coward, Philip J. Beale, Geraldine Goss, Tarek Meniawy, Janine M. Lombard, Amanda B. Spurdle, John Andrews, Martin R. Stockler, Linda R. Mileshkin, Yoland C. Antill

5584

**Computational features of TIL architecture are differentially prognostic of uterine cancer between African and Caucasian American women.**
Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced endometrial carcinoma.

Exploring molecular profiles of uterine carcinosarcoma with alterations in the chromatin remodeling pathway.

Association of the presence of estrogen and progesterone receptors in uterine carcinosarcoma with improved survival and increased immunogenicity.

Use of Khorana score to predict VTE in patients undergoing chemotherapy for uterine cancer.
Immune-response markers and actual response to immune-oncology therapy in uterine serous carcinoma.

AUTHOR(S)
Nathaniel L. Jones, Sharon Wu, Joanne Xiu, Amaranta Craig, Gina Mantia-Smaldone, Enrique Hernandez, Rodney P. Rocconi, Jubilee Brown, Thomas J. Herzog, Robert W. Holloway, Wolfgang M. Korn, Matthew A. Powell, Annelise M. Wilhite

ABSTRACT
Metabolic and bariatric surgery among endometrial cancer survivors: Are we missing an opportunity to help?

AUTHOR(S)
Justin Gray, Ajay A. Myneni, Lorin M. Towle-Miller, Iman Simmonds, Matthew Burnstein, Steven Schwartzberg, Aaron B. Hoffman, Emese Zsiros, Katia Noyes

ABSTRACT
Photodynamic therapy for preinvasive vaginal cancer.

AUTHOR(S)
Viktoria A. Ivanova, Ekaterina V. Verenikina, Vera P. Nikitina, Oksana E. Zhenilo, Anna Y. Ardzha

ABSTRACT
Does time to completion of radiation treatment in locally advanced vulvar cancer impact survival?

AUTHOR(S)
Nancy T. Nguyen, Xiao Zhao, Matthew Ponzini, Machelle Wilson, Gary S. Leiserowitz, Rebecca A. Brooks

ABSTRACT
Potential impact of HPV vaccine on incidence of high-grade vulvar, vaginal, and anal precancers among females and males aged 15 to 39 years, United States 2000 to 2017.

AUTHOR(S)
Mona Saraiya, Virginia Senkomago

ABSTRACT
AdvantIG-202: A phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer.

AUTHOR(S)
Lingying Wu, Peng-Hui Wang, Sheng-Yen Hsiao, Chih-Long Chang, Hee Seung Kim, Jung-Yun Lee, Sang-Young Ryu, Yunxia Zuo, Xiyan Mu, Yujuan Gao, Silu Yang, Jae-Kwan Lee

ABSTRACT
TPS5595

Tisotumab vedotin versus investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG 3057, trial in progress).

AUTHOR(S)

ABSTRACT
TPS5596

Immunotherapy in combination with PARP inhibition in advanced cervical cancer patients functionally competent or deficient for the Fanconi anemia repair pathway.

AUTHOR(S)
John P. Diaz, Wenrui Duan, Eric Schroeder, Zuanel Diaz, Nicholas Lambrou, Troy A. Gatcliffe, Thomas Morrissey, Miguel A. Villalona-Calero

ABSTRACT
TPS5597

ENGOT-ov54/Swiss-GO-2/MATAO including LOGOS (Low-Grade Ovarian cancer Substudy): MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer—A randomized, double-blinded, placebo-controlled, multicenter phase III Trial.

AUTHOR(S)
Viola A. Heinzelmann-Schwarz, Christian Kurzeder, Seraina Schmid, Natalie Gabriel, Andreas Mueller, Mathias K. Fehr, Christian Marth, Andreas Du Bois, Maximillian Klar

ABSTRACT
TPS5598

AUTHOR(S)

ABSTRACT
TPS5599

Trial in progress: A phase 1, multicenter, open-label, dose-exploration and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG650 in subjects with advanced solid tumors.

AUTHOR(S)

ABSTRACT
TPS5600

A randomized phase III, two-arm trial of paclitaxel, carboplatin, and maintenance letrozole versus letrozole monotherapy in patients with stage II-IV, primary low-grade serous carcinoma of the ovary or peritoneum.

AUTHOR(S)
Amanda Nickles Fader, Lilian T. Gien, Austin Miller, Al Covens, David M. Gershenson

ABSTRACT
TPS5601

A phase I/II, multicenter, open-label study of REGN5668 (mucin [MUC]16 x CD28 bispecific antibody [bsAb]) with cemiplimab (programmed death [PD]-1 Ab) or REGN4018 (MUC16 x CD3 bsAb) in recurrent ovarian cancer (rOVCA).

AUTHOR(S)
Ira S. Winer, Anthony F. Shields, Oladapo O. Yeku, Joyce F. Liu, Mary J. Peterman, Suk-Young Yoo, Israel Lowy, N. Alice Yam-Dang, Priscila H. Goncalves, Glenn Kroog

ABSTRACT
TPS5602
ENGOT-ov60/GOG3052/RAMP 201: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).

AUTHOR(S)

ABSTRACT
TPS5603

ROCSAN trial (GINECO-EN203b/ENGOT-EN8): A multicentric randomized phase II/III evaluating dostarlimab in combination with niraparib versus niraparib alone compared to chemotherapy in the treatment of endometrial/ovarian carcinosarcoma after at least one line of platinum based chemotherapy.

AUTHOR(S)
Isabelle L. Ray-Coquard, Alexandra Leary, Frédéric Bigot, Laure Montane, Michel Fabbro, Anne-Claire Hardy-Bessard, Frederic Selle, Camille Chakiba, Alain Lortholary, Dominique Berton, Valérie Chevalier-Evain, Magali Provansal, Laurence Gladieff, Marie-Christine Kaminsky, Sandro Pignata, Elena I. Braicu, Christophe Caux, Marc-Henri Stern, Audrey Bellesoeur, Elsa Kalbacher

ABSTRACT
TPS5604


AUTHOR(S)
Katherine C. Fuh, Thomas J. Herzog, Kathleen N. Moore, Tashanna K. Myers, BJ Rimel, Joyce F. Liu, Angeles A. Secord, Erika P. Hamilton, Thomas J. Reid, Sharyn N. Lewin, Mary M. Mullen, Kathryn A. Mills, Randy Anderson, Reshma A. Rangwala

ABSTRACT
TPS5605


AUTHOR(S)
Angeles A. Secord, Sunil Gupta, Cathy Reddick, Jyoti Chauhan, Sarah Gill, John O. Schorge, Michael Gold, Devansu Tewari, Christopher A. Breed, Patricia S. Braly, Dennis Y. Kuo, Susan C. Modesitt, Robert W. Holloway

ABSTRACT
TPS5606

**Uplift (ENGOT-ov67): A pivotal cohort to evaluate XMT-1536 (upifitamab rilsodotin), a NaPi2b-directed antibody drug conjugate for platinum-resistant ovarian cancer.**

**AUTHOR(S)**

**ABSTRACT**

**TPS5607**

**ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer.**

**AUTHOR(S)**

**ABSTRACT**

**TPS5608**

**A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient (MMR-P) recurrent or persistent endometrial cancer (EC).**

**AUTHOR(S)**

**ABSTRACT**

**TPS5609**

**SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.**

**AUTHOR(S)**

**ABSTRACT**
TPS5610

A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) endometrial cancer (EC).

AUTHOR(S)

ABSTRACT

ADAGIO: A phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma.

AUTHOR(S)
Joyce F. Liu, Nicoletta Colombo, Amit M. Oza, Ana Oaknin, Lydia Gaba, Jean-Sebastien Frenel, Nicole Nevadunsky, Victoria de Giorgio-Miller, Pingping Ni, Dana C. Ghiorgiu

ABSTRACT

TPS5612

Head and Neck Cancer

Back to Program

Showing 74 Presentations

https://meetinglibrary.asco.org/session/13639

Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck (SCCHN).

AUTHOR(S)
Byoung Chul Cho, Amaury Daste, Alain Ravaud, Sébastien Salas, Nicolas Isambert, Edward F. McClay, Ahmad Awada, Christian Borel, Christoph Helwig, P. A. Rolfe, Laureen S. Ojalvo, James L. Gulley, Nicolas Penel

**ABSTRACT**

6020

The association of skeletal muscle mass and cisplatin pharmacokinetics in head and neck cancer patients: The prospective PLATISMA study.

**AUTHOR(S)**

Laura Molenaar-Kuijsten, Najiba Chargi, Lot Devriese, Remco de Bree, Alwin Huitema

**ABSTRACT**

6021

Anlotinib in radioiodine-refractory differentiated thyroid carcinoma: A subanalysis based on ALTER01032 study for patients with poor baseline characteristics.

**AUTHOR(S)**

Yihebali Chi, Ming Gao, Yuan Zhang, Feng Shi, Ying Cheng, Zhuming Guo, Minghua Ge, Jianwu Qin, Jiewu Zhang, Zhendong Li, Xiaohong Zhou, Rui Huang, Xiaohong Chen, Hui Liu, Ruochuan Cheng, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Pingzhang Tang

**ABSTRACT**

6022

Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: An open-label single-arm, phase II trial.

**AUTHOR(S)**

Mingyuan Chen, Yijun Hua, Rui You, Zhi-Qiang Wang, Peiyu Huang, Mei Lin, Yan-Feng Ouyang

**ABSTRACT**

6023

Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA Study): A phase II study with biomarker analysis.

**AUTHOR(S)**

Hsiang-fong Kao, Bin-Chi Liao, Yen-Lin Huang, Huai-Cheng Huang, Chun-Nan Chen, Tseng-Cheng Chen, Yuan-Jing Hong, Ching-Yi Chan, Ruey-Long Hong

**ABSTRACT**

6024
A phase 2 study of liposomal irinotecan with 5-fluorouracil and leucovorin in squamous cell carcinoma of head and neck or esophagus after prior platinum-based chemotherapy or chemoradiotherapy.

AUTHORS
Li-Yuan Bai, Muh-Hwa Yang, Nai-Jung Chiang, Shang-Yin Wu, Chen-Yuan Lin, Ming-Yu Lien, Jia-Hong Chen, Mu-Hsin Chang, Ching-Yun Hsieh, Ruey-Long Hong, Hsiang-fong Kao, Ren-Hua Ye, Shang-Hung Chen, Chin-Fu Hsiao, Li-Tzong Chen, Tsang-Wu Liu

ABSTRACT
Preliminary results of the efficacy and safety of all-trans retinoic acid combined with low-dose apatinib in the treatment of patients with recurrent/metastatic adenoid cystic carcinoma of the head and neck.

AUTHORS
Lulu Ye, Lin Zhang, Rongrong Li, Guopei Zhu

ABSTRACT
Mathematical predication models to optimize post-treatment surveillance in HPV-associated oropharyngeal cancer.

AUTHORS

ABSTRACT
Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma.

AUTHORS
Irene Brana, Martin Forster, Antonio Lopez-Pousa, Bernard Doger, Patricia Roxburgh, Pawan Bajaj, Daniela Urueta Portillo, Vanesa Quiroga, Matthew Krebs, Christian Mueller, Frederic Triebel

ABSTRACT
Update on safety and efficacy of a phase 1/2 of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN).
Expansion cohort validation of a clinical predictive model for head and neck cancer survival in patients treated with immune checkpoint inhibitors.

Adjuvant nivolumab following salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy: A single-arm phase II multi-institutional study.

A phase III multicenter randomized clinical trail to compare cisplatin plus fluorouracil with or without docetaxel as the first-line induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Long-term outcomes update.

Effect of neoadjuvant systemic therapy given during window trials on quality metrics in resectable head and neck squamous cell carcinoma.
Phase II trial of combined durvalumab plus tremelimumab with proton therapy to boost the abscopal effect for recurrent or metastatic head and neck squamous cell carcinoma.

AUTHOR(S)
Hana Kim, Myung-Ju Ahn, Dongryul Oh, Sehhoon Park, Hyun Ae Jung, Se-Hoon Lee, Keunchil Park, Yong Chan Ahn

Maintenance intervention to improve survival in patients with metastatic nasopharyngeal carcinoma who benefit from first-line treatment: A prospective multicenter randomized controlled clinical study.

AUTHOR(S)
Ying Lu, Haixin Huang, Hui Yang, Xiaohua Hu, Xianbing Feng, Changjie Huang

Final analysis of a phase 1b, randomized, multicenter study of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) combination for the treatment (Tx) of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): MASTERKEY-232.

AUTHOR(S)
Kevin J. Harrington, Anthony Kong, Nicolas Mach, Jason A. Chesney, Beatriz Castelo, Danny Rischin, Ezra E. Cohen, Hoi-Shen Radcliffe, Burak Gumuscu, Wendy Snyder, Lillian L. Siu

Interim analysis of IMMUNEBOOST-HPV: A multicenter, randomized, open label, phase II study evaluating the feasibility, and tolerance of neoadjuvant nivolumab in high-risk HPV driven oropharynx cancer.

AUTHOR(S)
Haitham Mirghani, Caroline Even, Alicia Larive, Jerome Fayette, Karen Benezery, Florian Ciatot, Lionnel Geoffrois, Yungan Tao, France Nguyen, Emmanuelle Fabiano, Sarah Kreps, Eve Marie Neidhardt, Florence Garic, Anne Auperin, Pierre Blanchard
Use of cetuximab added to weekly chemotherapy to improve progression-free survival in patients with recurrent metastatic head and neck squamous cell carcinoma after progression on immune checkpoint inhibitors.

AUTHOR(S)
Majd Issa, Brett Klamer, Vidhya Karivedu, Priyanka Bhateja, Georgios Laliotis, Khaled Dibs, Nikol Mladkova, Xueliang J. Pan, Matthew O. Old, Mauricio Gamez, John C. Grecula, Sachin R. Jhawar, Darrion L. Mitchell, Sujith Baliga, Ricardo Carrau, James W. Rocco, Dukagjin Blakaj, Marcelo R. Bonomi

ABSTRACT
6038

Adjuvant toripalimab or combined with S-1 in recurrent, previously irradiated head and neck squamous cell carcinoma treated with salvage surgery: A phase II clinical trial (The RePASS study).

AUTHOR(S)
Shengjin Dou, Rongrong Li, Lin Zhang, Wen Jiang, Lulu Ye, Guopei Zhu

ABSTRACT
6039

Update and external validation of a multivariable prediction model for tube feeding dependency for at least four weeks during chemoradiotherapy for head and neck cancer.

AUTHOR(S)

ABSTRACT
6040


AUTHOR(S)
Fangjian Guo, Mihyun Chang, Abbey Berenson

ABSTRACT
6041

Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer in elderly or frail patients.
AUTHOR(S)
Rebecca Forman, Aarti K. Bhatia, Barbara Burtness

ABSTRACT

6042

Palbociclib (P) in patients (pts) with head and neck cancer (HNC) with CDKN2A loss or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

AUTHOR(S)

ABSTRACT

6043

Capecitabine maintenance therapy after induction chemotherapy in newly diagnosed metastatic nasopharyngeal carcinoma: An open-label, randomized, controlled, phase III trial.

AUTHOR(S)
Guo-Ying Liu, Wang-Zhong Li, De-Shen Wang, Hu Liang, Xing Lv, Yan-Fang Ye, Chong Zhao, Liang-Ru Ke, Mengyun Qiang, Xun Cao, Shu-Hui Lv, Nian Lu, Wei-Xin Bei, Zhuocheng Cai, Xi Chen, Jun-Zhi Xie, Chixiong Liang, Xiang Guo, Weixiong Xia, Xiang Yanqun

ABSTRACT

6044

Evaluation of radiomics as a predictor of tumor hypoxia and response to anti-PD-1 mab treatment (IO) in recurrent/metastatic HNSCC patients (R/M).

AUTHOR(S)
Dan P. Zandberg, Serafettin Zenkin, Murat AK, Priyadarshini Mamindla, Vishal Peddagangireddy, Ashley V. Menk, Greg Delgoffe, Maria A. Velez, Angen Liu, Heath D. Skinner, Robert L. Ferris, Rivka R. Colen

ABSTRACT

6045

Refining TNM-8 M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma.

AUTHOR(S)
Sik-Kwan Chan, Cheng Lin, Shao Hui Huang, Tin Ching Chau, Qiaojuan Guo, Brian O’Sullivan, Ka-On Lam, Sze Chun Chau, Ann S. Chan, Chi-Chung Tong, Varut Vardhanabhuti, Dora L. Kwong, Tsz Him So, Sherry C. Ng, To Wai Leung, Mai-Yee Luk, Anne W. Lee, Cheuk-Wai Choi, Jianji Pan, Victor H. Lee
Outcomes and prediction of lethal recurrence after transoral robotic surgery for HPV+ head and neck cancer.

AUTHOR(S)

Ultra-sensitive detection and quantification of HPV DNA in the plasma of patients with oropharyngeal squamous cell carcinoma (OPSCC) enrolled in the OPTIMA 2 treatment de-escalation trial.

AUTHOR(S)

The impact of tumor infiltrating lymphocytes (TILs) on disease progression in human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma.

AUTHOR(S)
Linda X. Yin, Michael Rivera, Joaquin J. Garcia, Kathleen Bartemes, Derrick B. Lewis, Christine M. Lohse, David Routman, Daniel J. Ma, Eric J. Moore, Kathryn M. Van Abel


AUTHOR(S)
Min Kang, Shaomin Lin, Haisheng Zhu, Sihui Liao, Haixin Huang, Bin Yu, Hongqian Wang, Meilin Liu, Jinxian Zhu, Guang Huang, Tingting Zhang, Zhendong Yang, Pingting Zhou, Ziyuan Zhou, Yutao Qin, Zhuxin Wei, Qinghua Du, Changhong Zhao, Mingjun Shen, Rensheng Wang
Phase I study of functionalized hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients.

AUTHOR(S)

Christophe Le Tourneau, Valentin Calugaru, Zoltan Takacsi-Nagy, Xavier Liem, Zsuzsanna Papai, Jacek Fijuth, Victor Moreno, Jordi Giralt, Sébastien Salas, Gilles Poissonnet, Emiliano Calvo, Bernard Doger, Olivier Choussy, Xavier Mirabel, Samar Krhili, Katell Bernois, Nicolas Fakhry, Stéphanie Wong-Hee-Kam, Edith Borcoman, Caroline Hoffmann

ABSTRACT

Inductive camrelizumab and apatinib for patients with locally advanced and resectable oral squamous cell carcinoma: A single-arm trial (Icemelting trial).

AUTHOR(S)

Lai-Ping Zhong, Wu-tong Ju, Rong-hui Xia, Qi Zhu, Guopei Zhu, Shengjin Dou, Jiang Li, Min-jun Dong

ABSTRACT

Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck.

AUTHOR(S)


ABSTRACT

Transoral robotic surgery for human papillomavirus-associated oropharynx squamous cell carcinoma: Recurrence and survival in the Veterans Affairs health system.

AUTHOR(S)


ABSTRACT

Survival outcomes in primary head and neck adult sarcoma: A systematic review and meta-analysis.

AUTHOR(S)
Sondos Zayed, Cindy Lin, Gabriel Boldt, Pencilla Lang, Nancy Read, Varagur Venkatesan, Jinka Sathya, Fung Kevin, Danielle MacNeil, Adrian Mendez, John Yoo, Andrew Warner, Anthony C. Nichols, David A. Palma

**ABSTRACT**

6055

**A phase II study of PRV111 nanoengineered cisplatin patch as a neoadjuvant therapy for early-stage oral squamous cell carcinoma (OSCC).**

**AUTHOR(S)**

Nishant Agrawal, Evgeny Izumchenko, Kenneth Hodge, Simon Young, James C. Melville, Jonathan Shum, Dhafer Alsuwied, Vlad Sandulache, Michael Harris, Aaron Manzi, Manijeh Goldberg

**ABSTRACT**

6056

**Impact of comprehensive geriatric assessment (CGA) in the treatment decision and outcome of older patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC).**

**AUTHOR(S)**

Sandra Llop Serna, Clara Ejarque Martinez, Jesús Brenes Castro, Macarena Honorato, M. Esther Vilajosana Altamis, Mireia Melero, Oriol Bermejo, Victoria Gomez Garcia, Marta Fulla, Montse Goma, Isabel Linares, Alicia Lozano, Miren Taberna, Ricard Mesia, Maria Plana, Maite Antonio Rebollo, Marc Oliva Bernal

**ABSTRACT**

6057

**Survival (OS) and progression-free survival (PFS) results after induction chemotherapy (IC) followed by de-escalated chemoradiotherapy (RDCRT) for locally advanced (LA) HPV positive oropharynx cancer (HPVOPC).**

**AUTHOR(S)**


**ABSTRACT**

6058

**Prospective manipulation of the gut microbiome with Microbial Ecosystem Therapeutic 4 (MET4) in locoregionally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC) undergoing primary chemoradiation (ROMA2).**

**AUTHOR(S)**

Postoperative PET/CT for detection of early recurrence (ER) after surgery for squamous cell carcinomas (SCC) of the oral cavity (OC).

AUTHOR(S)


AUTHOR(S)
Pau Guillen Sentis, Carmen Castillo Manzano, Beatriz Quirós, Francisca Morey Cortes, Sara Tous, Maria Plana, Jesús Brenes Castro, Alicia Lozano, Isabel Linares, M. Esther Vilajosana Altamis, Victoria Gomez Garcia, Maria Labori Trias, Montse Goma, Antonio Mari Roig, Oriol Bermejo, Jordi Tornero Salto, Miren Taberna, Laia Alemany, Ricard Mesia, Marc Oliva Bernal

Quality of life analysis of HPV-positive oropharyngeal cancer patients in a randomized trial of reduced-dose (rdCRT) versus standard (sdCRT) chemoradiotherapy: Five-year follow-up.

AUTHOR(S)

Evaluating a clinically validated circulating tumor HPV DNA assay in saliva as a proximal biomarker in HPV+ oropharyngeal squamous cell carcinoma.

AUTHOR(S)
Sophie P. Gerndt, Ricardo J. Ramirez, Benjamin M. Wahle, Charlotte Kuperwasser, Alicia Gunning, Aadel A. Chaudhuri, Jose P. Zevallos
Quantitative immunofluorescence and mRNA analysis of immune-related biomarker groups in matched paired tumor samples from OPHELIA window study in head and neck squamous cell carcinoma (HNSCC).

AUTHOR(S)
Amanda Psyrri, Myrto Moutafi, Georgia-Angeliki Kolliou, George Papaxoinis, Niki Gavrielatou, Panagiota Economopoulou, Ioannis Kotsantis, Maria Gkotzamanidou, Maria Anastasiou, Dimitrios G. Pectasides, Aileen Fernandez, Vesal Yaghoobi, Saba Shafi, Ioannis Vathiotis, Thazin Nwe Aung, Stavros Gkolfinopoulos, Periklis Foukas, George Fountzilas, David L. Rimm

ABSTRACT
6064

Cisplatin and capecitabine induction chemotherapy in nasopharyngeal carcinoma.

AUTHOR(S)
Zhiyuan Xu, Li Yang, Victor H. Lee, Anne W. Lee

ABSTRACT
6065

The SINTART 1 study: A phase II trial of induction chemotherapy (IC), surgery, photon-, proton-and carbon ion-based radiotherapy (RT) integration in locally advanced operable sinonasal epithelial tumors patients (pts).

AUTHOR(S)
Carlo Resteghini, Paolo Castelnuovo, Piero Nicolai, Ester Orlandi, Paolo Bossi, Barbara Vischioni, Alberto Schreiber, Nicola Alessandro Iacovelli, Paolo Battaglia, Davide Mattavelli, Nadia Facchinetti, Simone Gambazza, Giuseppina Calareso, Marco Ravanelli, Carla Facco, Tiziana Tartaro, Andrea Pietro Spongini, Fabio Pagella, Luigi Mariani, Lisa F. Licitra

ABSTRACT
6066

Comparative assessment of the eighth and seventh AJCC staging edition prognostic performance of patients with p16 positive oropharynx cancer.

AUTHOR(S)
Felippe Lazar Neto, Luana G. Sousa, Faye M. Johnson, J. Jack Lee, Steven J. Frank, Amy C. Moreno, Kristina Dahlstrom, Renata Ferrarotto

ABSTRACT
6067

Pathologic and radiographic responses in a window of opportunity for durvalumab plus metformin trial for squamous cell carcinoma of the head and neck (HNSCC).
AUTHOR(S)
Joseph M. Curry, Angela Alnemri, Brian Swendseid, Uche Nwagu, David M. Cognetti, Voichita C. Bar-Ad, Adam Luginbuhl, Rita S. Axelrod, Diana Whitaker-Menezes, Larry Harshyne, Andrew South, My G. Mahoney, Alban Linnenbach, Athanassios Argiris, Ulrich Rodek, Ubaldo Martinez-Outschoorn, Jennifer M. Johnson

ABSTRACT
6068

The efficacy and safety of anlotinib in neoadjuvant treatment in locally advanced thyroid cancer: A single-arm phase II clinical trial.

AUTHOR(S)
Naisi Huang, Guohua Sun, Yulong Wang, Jiaying Chen, Qing Guan, Zhongwu Lu, Jun Xiang, Wenjun Wei, Ben Ma, Qinghai Ji, Yu Wang

ABSTRACT
6069

Planned drug holiday in a cohort study exploring the effect of lenvatinib on differentiated thyroid cancer.

AUTHOR(S)
Makoto Tahara, Hiroshi Takami, Yasuhiro Ito, Takahiro Okamoto, Iwao Sugitani, Kiminori Sugino, Shunji Takahashi, Hiroshi Takeyama, Hidemitsu Tsutsui, Hisato Hara, Ayako Mitsuma, Hiroyuki Yamashita, Yasuo Ohashi, Tsuneo Imai

ABSTRACT
6070

Predictive and prognostic biomarker identification in a large cohort of androgen receptor-positive salivary duct carcinoma patients scheduled for combined androgen blockade.

AUTHOR(S)
Gerben Lassche, Yuichiro Tada, Carla M. Van Herpen, Marianne A. Jonker, Diederick Keizer, Wim Verhaegh, Toshitaka Nagao, Takashi Saotome, Hideaki Hirai, Natsuki Saigusa, Adriana C. van Engen - van Grunsven, Jack A. Schalken, Chihiro Fushimi, Gerald W. Verhaegh

ABSTRACT
6071

Clinical disease course and survival outcomes following disease recurrence in adenoid cystic carcinoma (ACC) with NOTCH signaling pathway activation.

AUTHOR(S)
Brindley S. Hapuarachi, Laura Feeney, Sam Rack, Helen Adderley, David Morgan, Guy Betts, Russell Walker, Rami Rauch, Elad Herz, Kevin J. Harrington, Robert Metcalf

ABSTRACT
Selpercatinib efficacy and safety in patients with RET-altered thyroid cancer: A clinical trial update.

AUTHOR(S)
Eric J. Sherman, Lori J. Wirth, Manisha H. Shah, Maria E. Cabanillas, Bruce Robinson, Janessa J. Laskin, Matthias Kroiss, Vivek Subbiah, Alexander E. Drilon, Jennifer Wright, Victoria Soldatenkova, Pearl P. French, Antoine Italiano, Daniela Weiler

ABSTRACT
Efficacy of selpercatinib after prior systemic therapy in patients with RET mutant medullary thyroid cancer.

AUTHOR(S)
Lori J. Wirth, Eric J. Sherman, Daniela Weiler, Maria E. Cabanillas, Bruce Robinson, Antoine Italiano, Janessa J. Laskin, Vivek Subbiah, Alexander E. Drilon, Victoria Soldatenkova, Pearl P. French, Jennifer Wright, Matthias Kroiss, Manisha H. Shah

ABSTRACT
Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head and neck (H&N) cancer.

AUTHOR(S)
Daniel Osei-Fofie, Julie Wetter, Greg A. Landers, Peter A. Kraus, Shawgi Sukumaran, Hui Mun, Brian N. Stein, Victoria J. Bray, Bomi Framroze, Jeffrey Gelfand, Paul Y. Song, Andries Lategan, Mikaela Dimitriu, Stephen T. Sonis

ABSTRACT
Randomized phase II study of sorafenib with or without everolimus in patients with radioactive iodine refractory Hürthle cell thyroid cancer (HCC) (Alliance A091302/ ITOG 1706).

AUTHOR(S)
Eric J. Sherman, Nathan R. Foster, Yungpo B. Su, Ardaman Shergill, Alan L. Ho, Bhavana Konda, Ronald A. Ghossein, Ian Ganly, Gary K. Schwartz

ABSTRACT
Radiomics-based prediction of response to multikinase inhibitors in radiiodine-refractory differentiated thyroid cancer patients.
A pooled analysis of response to selective RET inhibitors among patients with medullary thyroid cancer with M918T versus non-M918T RET mutations.

Trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing salivary duct carcinoma: Subgroup analysis of two phase 1 studies.

Patient-reported outcomes (PROs) from a phase II trial of pembrolizumab for HPV-associated papilloma patients with laryngeal, tracheal and/or pulmonary involvement.

Molecular profiling and targeted agents in recurrent, metastatic salivary gland tumor (R/M SGT) patients (pts) treated at two academic centers.
Benefits of pembrolizumab in progressive radioactive iodine refractory thyroid cancer: Results of the AcSé Pembrolizumab Study from Unicancer.

**AUTHOR(S)**
Sophie Lebouleux, Yann Godbert, Nicolas Penel, Segolene Hescot, Christelle De La Fouchardiere, Marie Blonski, Livia Lamartina, Sophie Cousin, Christine Do Cao, Julien Hadoux, Clotilde Simon, Natalie Hoog Labouret, Sylvie Chevret, Christophe Massard

**ABSTRACT**

**NTRK, RET, BRAF, and ALK fusions in thyroid fine-needle aspirates (FNAs).**

**AUTHOR(S)**
Lori J. Wirth, Mimi I. Hu, Steven G. Waguespack, Chrysooula Dosiou, Paul Ladenson, Masha J. Livhits, Peter M. Sadow, Jeffrey Krane, Brendan C. Stack, Mark Zafereo, Syed Z. Ali, Steven P. Weitzman, Yangyang Hao, Joshua Babiarz, Giulia Kennedy, Richard Kloos

**ABSTRACT**

**Treatment patterns and systemic therapy outcomes for patients with salivary duct carcinoma and adenocarcinoma NOS.**

**AUTHOR(S)**
Luana G. Sousa, Kaiwen Wang, Danice Torman, Bailee Binks, Clark Andersen, Whitney E. Lewis, Melvin Rivera, Diana Kaya, Adel K. El-Naggar, Ehab Y. Hanna, Bita Esmaeli, Steven J. Frank, Diana Bell, Bonnie S. Glisson, Jordi Rodon Ahnert, Funda Meric-Bernstam, J. Jack Lee, Renata Ferrarotto

**ABSTRACT**

**Encorafenib and binimetinib with or without nivolumab in treating patients with metastatic radioiodine refractory BRAF V600 mutant thyroid cancer.**

**AUTHOR(S)**
Matthew H. Taylor, Rom S. Leidner, Richard B. Bell, Bernard Fox, Hong Xiao, Marcus Couey, Andrew Baker, George Morris, Lessli Rushforth

**ABSTRACT**

**Phase II multicenter randomized trial to assess the efficacy and safety of first line nivolumab in combination with paclitaxel in subjects with R/M HNSCC unable for cisplatin-based chemotherapy (NIVOTAX): A TTCC study.**
AUTHOR(S)

ABSTRACT

TPS6086

The AIM-HN Study: A pivotal study evaluating the efficacy of tipifarnib in patients with recurrent or metastatic head and neck squamous cell carcinoma with HRAS mutations.

AUTHOR(S)
Robert I. Haddad, Douglas Adkins, Lisa F. Licitra, Justine Y. Bruce, Maura L. Gillison, Myung-Ju Ahn, Ching-Yun Hsieh, Hung-Ming Wang, Amanda Psyrri, Jean-Pascal H. Machiels, Binaifer Balsara, Mollie Leoni, Kevin J. Harrington, Nabil F. Saba, Alan L. Ho

ABSTRACT

TPS6087

CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001 + pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma.

AUTHOR(S)

ABSTRACT

TPS6089

The BURAN study of buparlisib (AN2025) in combination with paclitaxel compared to paclitaxel alone, in patients with recurrent or metastatic head and neck squamous cell carcinoma.

AUTHOR(S)
Denis Soulieres, Sandrine J. Faivre, Kevin Dreyer, Lisa F. Licitra

ABSTRACT

TPS6090

TrilynX: A phase 3 trial of xevinapant and concurrent chemoradiation for locally advanced head and neck cancer.

AUTHOR(S)
Jean Bourhis, Barbara Burtness, Lisa F. Licitra, Christopher Nutting, Jonathan D. Schoenfeld, Rafik Ait Sarkouh, Florilene Bouisset, Heidi Nauwelaerts, Yulia Urfer, Claudio Zanna, Ezra E. Cohen
ABSTRACT

TPS6091

First-in-human phase I/II trial of PRGN-2009 vaccine as monotherapy or with bintrafusp alfa in patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-associated cancers (HPVC) and as neoadjuvant/induction therapy in locoregionally advanced (LA) HPV oropharyngeal (OP) and sinonasal (SN) squamous cell cancer (SCC).

AUTHOR(S)

Charalampos S. Floudas, Julius Strauss, Clint Allen, Nyall R. London Jr., Renee N. Donahue, Caroline Jochems, Seth M. Steinberg, Lisa M. Cordes, Sheri McMahon, Jenn Marte, Houssein Abdul Sater, Jason Redman, Fatima Karzai, Marijo Bilusic, Ravi A. Madan, Douglas E. Brough, Amy Lankford, Jeffrey Schlom, James L. Gulley

ABSTRACT

TPS6092

NRG Oncology HN006: Randomized phase II/III trial of sentinel lymph node biopsy versus elective neck dissection for early-stage oral cavity cancer.

AUTHOR(S)


ABSTRACT

TPS6093

Trial in progress: A phase I/II trial of novel MDM2 inhibitor alrizomadlin (APG-115), with or without platinum chemotherapy, in patients with p53 wild-type salivary gland carcinoma.

AUTHOR(S)

Paul Swiecicki, Yuefen Tang, Alexander T. Pearson, Jameel Muzaffar, Mary J. Fidler, Robert Winkler, Tommy Fu, Mingyu Li, Mohammad Ahmad, Dajun Yang, Yifan Zhai

ABSTRACT

TPS6094
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Effect of geriatric assessment (GA) and genetic profiling on overall survival (OS) of older adults with acute myeloid leukemia (AML).

**AUTHOR(S)**

**ABSTRACT**
7021


**AUTHOR(S)**

**ABSTRACT**
7022

Updated results from DIAMOND-01 (CLI24-001) trial: A phase I/II study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in acute myeloid leukemia.

**AUTHOR(S)**

**ABSTRACT**
7023
Molecular annotation of extramedullary acute myeloid leukemia to identify prevalence of targetable mutations.

**AUTHOR(S)**

Somedeb Ball, Todd C. Knepper, Yehuda E. Deutsch, Chirag K. Bhagat, Justin M. Watts, Terrence J. Bradley, Wassim Samra, Onyee Chan, Mohammad O. Hussaini, Kendra L. Sweet, Chetasi Talati, Eric Padron, Rami S. Komrokji, Jeffrey E. Lancet, David A. Sallman

**ABSTRACT**

7024

Contemporary outcomes for adults with AML requiring ICU admission.

**AUTHOR(S)**

Danielle Hammond, Koji Sasaki, Alexis Geppner, Fadi Haddad, Shehab Mohamed, Daniel Rivera, Maria Siddiqui, Yasmin Alwash, Jorge Ramos Perez, Kiyomi Morita, Kunhwa Kim, Sherry Pierce, Cristina Gutierrez, Naveen Pemmaraju, Gautam Borthakur, Courtney D. Dinardo, Farhad Ravandi, Guillermo Garcia-Manero, Hagop M. Kantarjian, Tapan M. Kadia

**ABSTRACT**

7025

Preliminary results of V-FAST, a phase 1b master trial to investigate CPX-351 combined with targeted agents in newly diagnosed AML.

**AUTHOR(S)**

Vinod Pullarkat, Mark J. Levis, Gabriel N. Mannis, Stephen A. Strickland, Tara L. Lin, Stefan Faderl, Divya Chakravarthy, Vijayalakshmi Chandrasekaran, Ronald Cheung, Harry P. Erba

**ABSTRACT**

7026

Cellworks Omics Biology Model (CBM) to predict therapy response and identify biomarkers for all-trans retinoic acid (ATRA) benefit as addition to induction chemotherapy in adults with acute myeloid leukemia (AML).

**AUTHOR(S)**


**ABSTRACT**

7027

Clinical utility of whole genome sequencing in hematological neoplasms.

**AUTHOR(S)**

AUTHOR(S)
Sanjeev K. Gupta, Sameer Bakhshi, Ritu Gupta, Preity Sharma, Deepam Pushpam, Ranjit K. Sahoo, Atul Sharma

TP53/NPM1-mutated acute myeloid leukemia as a molecularly distinct disease entity.

AUTHOR(S)
Frank J. Scarpa, Madhuri Paul, Rachel Daringer, Wendy A. Wolfson, Fernando Lopez Diaz, Sally Agersborg, Vincent A. Funari, Lawrence M. Weiss, Forrest Blocker

Predictors of clinical trial enrollment and impact on outcome in children and adolescents with acute lymphoblastic leukemia: A population based study.

AUTHOR(S)
Paul J. Gibson, Uma H. Athale, Vicky R. Breakey, Nicole Mittmann, Mylene Bassal, Mariana Silva, Serina Patel, Veda Zabih, Petros Pechlivanoglou, Jason D. Pole, Sumit Gupta


AUTHOR(S)
Hermioni L. Amonoo, Carlisle E. Topping, Madison A. Clay, Thomas W. LeBlanc, Joseph A. Greer, Stephanie Lee, Jennifer Temel, Areej El-Jawahri
Outcomes with COVID-19 in hematopoietic stem cell transplant and cellular therapy patients.

AUTHOR(S)

ABSTRACT
7033

Characterizing advance care planning, palliative care utilization, and location of end-of-life for adult allogeneic hematopoietic stem cell transplant recipients.

AUTHOR(S)
Stephanie Hoffman, Pavan Reddy, John M. Magenau, Attaphol Pawarode, Brian Parkin, Sarah M. Anand, Monalisa Ghosh, John J. Maciejewski, Darren P. King, Mary Riwes

ABSTRACT
7034

Early results of phase 1 study of JSP191, an anti-CD117 monoclonal antibody, with non-myeloablative conditioning in older adults with MRD-positive MDS/AML undergoing allogeneic hematopoietic cell transplantation.

AUTHOR(S)
Lori S. Muffly, Michelle Chin, Hye-Sook Kwon, Cara Lieber, Steven Smith, Robert Sikorski, Judith Shizuru, Wendy Pang, Andrew S. Artz

ABSTRACT
7035

Phase 1 trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox combined with rituximab for relapsed/refractory hairy cell leukemia.

AUTHOR(S)
Robert J. Kreitman, Maryalice Stetler-Stevenson, Constance Yuan, Hao-Wei Wang, Hong Zhou, Mark Raffeld, Liqiang Xi, Evgeny Arons, Julie Feurtado, Lacey James-Echenique, Raul Braylan, Katherine R. Calvo, Irina Maric, Alina Dulau, Ira Pastan

ABSTRACT
7036

The effect of body mass index on efficacy and safety of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia.

AUTHOR(S)
Novel application of Kaplan-Meier methods to model tolerance for nonadherence to imatinib in patients with chronic myeloid leukemia (CML) in the ADAGIO study.

AUTHOR(S)
Mavis Obeng-Kusi, Karen MacDonald, Marie-Anne van Lierde, Ivo Abraham

Outcomes before and after dose reduction in patients with newly diagnosed chronic myeloid leukemia receiving bosutinib or imatinib.

AUTHOR(S)
Michael W. Deininger, Tim H. Brümmendorf, Dragana Milojkovic, Francisco Cervantes, Françoise Huguet, Andrea Viqueira, Eric Leip, Simon Purcell, Jorge E. Cortes

Health-related quality of life (HRQoL) in patients (pts) with myelodysplastic syndromes (MDS) in the Connect Myeloid Disease Registry.

AUTHOR(S)

Comparison of dose modification strategies to address expected hematologic toxicities in treatment-naïve higher-risk (HR) MDS patients treated with venetoclax + azacitidine.

AUTHOR(S)
Jacqueline S. Garcia, Andrew Wei, Uma Borate, Chun Y. Fong, Maria R. Baer, Daniel Nowak, Pierre Peterlin, Joseph G. Jurcic, Meagan Jacoby, Uwe Platzbecker, Olatoyosi Odenike, Ilona Cunningham, Ying Zhou, David Hoffman, Kiran Naqvi, Steve Kye, Guillermo Garcia-Manero
Model-based analysis to support dose selection of pevonedistat (PEV) combined with azacitidine (AZA) in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML).

AUTHOR(S)
Xiaofei Zhou, Diane R. Mould, Dan Zhao, Mikkael A. Sekeres, Lionel Adès, Ronan T. Swords, Hiroshi Handa, Robert J. Fram, Douglas V. Faller, Olga Tsukurov, Neeraj Gupta

ABSTRACT
7042
Predictors of hypomethylating agent discontinuation among patients with higher-risk myelodysplastic syndromes.

AUTHOR(S)
Amer M. Zeidan, Namita Joshi, Hrishikesh Kale, Wei-Jhih Wang, Shelby Corman, Kala Hill, Tehseen Salimi, Robert S. Epstein

ABSTRACT
7043
Using tissue microarray to detect inflammasome signaling components that contribute to the pathogenesis of myelodysplastic syndrome.

AUTHOR(S)
Tony Kurian, Kathy L. McGraw, Sanjay Bridgelall, Rohit Sharma, Jeffrey E. Lancet, Rami S. Komrokji, Seongseok Yun, Ling Zhang

ABSTRACT
7044
Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A systematic review and meta-analysis.

AUTHOR(S)
Jan Philipp Bewersdorf, Amar Sheth, Shaurey Vetsa, Alyssa Grimshaw, Smith Giri, Nikolai A. Podoltsev, Lohith Gowda, Roni Tamari, Martin S. Tallman, Raajit Rampal, Amer M. Zeidan, Maximilian Stahl

ABSTRACT
7045
Association of transfusion independence with improved overall survival in myelofibrosis patients receiving momelotinib.

AUTHOR(S)

**ABSTRACT**

7046

Clinical characteristics, treatment patterns, and overall survival of real-world patients with idiopathic multicentric Castleman disease.

**AUTHOR(S)**


**ABSTRACT**

7048

Phenotypes and prognostic factors in adults with Langerhans cell histiocytosis.

**AUTHOR(S)**


**ABSTRACT**

7049

BRAF\textsuperscript{V600E} frequency and impact on outcomes in adults with langerhans cell histiocytosis.

**AUTHOR(S)**


**ABSTRACT**

7050

A phase 4 study to evaluate outpatient blinatumomab in patients with minimal/measurable residual disease (MRD) positivity (+) of B-cell precursor acute lymphoblastic leukemia (BCP-ALL).

**AUTHOR(S)**


**ABSTRACT**

TPS7051
V2 Trial: A phase I study of venetoclax and CPX-351 for young patients with relapsed/refractory acute leukemia.

AUTHOR(S)

ABSTRACT
TPS7052

A prospective phase I/IIa trial to evaluate the safety and efficacy of GTA002, an off-the-shelf, ex vivo-cultured allogeneic NK cell preparation in patients with acute myeloid leukemia in complete morphological remission who have measurable residual disease.

AUTHOR(S)

ABSTRACT
TPS7053

Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-naïve higher-risk myelodysplastic syndromes.

AUTHOR(S)
Amer M. Zeidan, Jacqueline S. Garcia, Pierre Fenaux, Uwe Platzbecker, Yasushi Miyazaki, Zhi-Jian Xiao, Ying Zhou, Kiran Naqvi, Steve Kye, Guillermo Garcia-Manero

ABSTRACT
TPS7054

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): The phase 3, randomized, ENHANCE study.

AUTHOR(S)
Guillermo Garcia-Manero, Naval G. Daver, Jin Xu, Mark Chao, Trisha Chung, Anderson Tan, Vivian Wang, Andrew Wei, Paresh Vyas, David A. Sallman

ABSTRACT
TPS7055

IMerge: A phase 3 study to evaluate imetelstat in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndromes that are relapsed/refractory to erythropoiesis-stimulating agent treatment.
AUTHOR(S)
Uwe Platzbecker, Rami S. Komrokji, Pierre Fenaux, Amer M. Zeidan, Mikkael A. Sekeres, Michael R. Savona, Yazan Madanat, Laurie J. Sherman, Souria Dougherty, Libo Sun, Fei Huang, Ying Wan, Aleksandra Rizo, Tymara Berry, Faye Feller, Valeria Santini

ABSTRACT
TPS7056

BOREAS: A global phase 3 study of KRT-232, a first-in-class murine double minute 2 (MDM2) inhibitor in TP53WT relapsed/refractory (R/R) myelofibrosis (MF).

AUTHOR(S)

ABSTRACT
TPS7057


AUTHOR(S)
Abdulraheem Yacoub, Susan Erickson-Viitanen, Feng Zhou, Albert Assad

ABSTRACT
TPS7058

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Showing 55 Presentations

https://meetinglibrary.asco.org/session/13647
Effect of time to relapse on overall survival (OS) in Mantle cell lymphoma (MCL) patients (pts) following frontline high-dose therapy and autologous hematopoietic cell transplantation (autoHCT).

AUTHOR(S)

Peter A. Riedell, Mehdi Hamadani, Kwang W. Ahn, Carlos Litovich, Mohamed Kharfan-Dabaja, Alex F. Herrera, Craig S. Sauter, Sonali M. Smith

ABSTRACT

7521

Progression-free survival at 24 months as a landmark after autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma.

AUTHOR(S)


ABSTRACT

7522

Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.

AUTHOR(S)

Paul M. Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Jan A. Burger, Peter Hillmen, Steve E. Coutre, Stephen Devereux, Sebastian Grosicki, Helen McCarthy, Jianyong Li, David Simpson, Fritz C. Offner, Carol Moreno, Sandra Dai, Anita Szoke, James P. Dean, Thomas J. Kipps, Paolo Ghia

ABSTRACT

7523


AUTHOR(S)

Neda AlRawashdh, Ali McBride, Daniel O. Persky, Joann Sweasy, Brian Erstad, Ivo Abraham

ABSTRACT

7524

Updated results of the selective Bruton tyrosine kinase (BTK) inhibitor TG-1701, as monotherapy and in combination with ublituximab and umbralisib (U2) in patients (pts) with B-cell malignancies.

AUTHOR(S)
Identification of genetic markers associated with ibrutinib-related cardiovascular toxicity.

AUTHORS
Issam Hamadeh, Ryan Jacobs, Bei Hu, Tamara K. Moyo, Amy Soni, Steven I. Park, Jai N. Patel, Nury Steuerwald, Nilanjan Ghosh


AUTHORS
Nirav Antao, Abhishek R. Chilkulwar, Suhong Luo, Kenneth R. Carson, Kristen M. Sanfilippo, Martin W. Schoen

Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 Echelon-1 study.

AUTHORS

A phase II study of penpulimab, an anti-PD-1 antibody, in patients with relapsed or refractory classic Hodgkin lymphoma (cHL).

AUTHORS
Yuqin Song, Keshu Zhou, Chuan Jin, Zhengzi Qian, Ming Hou, Lei Fan, Fei Li, Kaiyang Ding, Hui Zhou, Xiaoling Li, Bing Chen, Xiuhua Sun, Xianmin Song, Ming Jiang, Qingyuan Zhang, Xiaoping Jin, Zhongmin M. Wang, Bajyong Li, Yu Xia, Jun Zhu
Salvage therapies in transplant-eligible relapsed classic Hodgkin lymphoma, are novel regimens better?

AUTHOR(S)

ABSTRACT
7530

A phase Ib study of a PI3Kδ inhibitor Linperlisib in patients with relapsed or refractory peripheral T-cell lymphoma.

AUTHOR(S)
Jie Jin, Hong Cen, Keshu Zhou, Xiaohong Xu, Fei Li, Tao Wu, Haiyan Yang, Zheng Wang, Zhiming Li, Lugui Qiu, Hanying Bao, Zusheng Xu, Yang Shu

ABSTRACT
7531

CD19 CAR T-cell product type independently impacts CRS and ICANS severity in patients with aggressive NHL.

AUTHOR(S)

ABSTRACT
7532

Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma.

AUTHOR(S)
Niloufer Khan, Farhad Khimani, Andrei R. Shustov, Mazyar Shadman, Jia Ruan, Alison J. Moskowitz, David J. Straus, Anita Kumar, Craig S. Sauter, Andrew D. Zelenetz, Ariela Noy, Gunjan L. Shah, Matthew J. Matasar, Pamela Drullinsky, Audrey M. Hamilton, Esther N. Drill, Koen Van Besien, Sergio Giralt, Steven M. Horwitz, Parastoo Dahi

ABSTRACT
7533

Polatuzumab vedotin + obinutuzumab + venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Primary analysis of a phase 1b/2 trial.
AUTHOR(S)
Rajat Bannerji, Sam Yuen, Tycel Phillips, Christopher Arthur, Iris Isufi, Paula Marlton, John F. Seymour, Paolo Corradini, Annalia Molinari, Giuseppe Gritti, Robert Emmons, Jamie Hirata, Lisa Musick, Sourish Saha, Brandon Croft, Christopher Flowers

ABSTRACT
7534

Comparative efficacy of tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).

AUTHOR(S)
Stephen J. Schuster, Jie Zhang, Hongbo Yang, Abhijit Agarwal, Wenxi Tang, Marcela Martinez-Prieto, Vamsi Bollu, Qiufei Ma, David Kuzan, Richard T. Maziarz, Marie J. Kersten

ABSTRACT
7535

Favorable tumor immune microenvironment (TME) and robust chimeric antigen receptor (CAR) T-cell expansion may overcome tumor burden (TB) and promote durable efficacy with axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL).

AUTHOR(S)
Justin Chou, Vicki Plaks, Soumya Poddar, Zixing Wang, Frederick L. Locke, Sattva S. Neelapu, David B. Miklos, Caron A. Jacobson, Philippe Armand, Zahid Bashir, Jérôme Galon, John M. Rossi, Adrian Bot

ABSTRACT
7536

Combination of sintilimab, anlotinib and pegasparagase "sandwich" with radiotherapy in localized natural killer/T cell lymphoma: A multicenter, phase 2 study.

AUTHOR(S)
Zhiming Li, Peng Sun, Yu Wang, Hang Yang, Yajun Li, Hui Zhou, Haiyan Yang, Liqun Zou

ABSTRACT
7537

Safety and efficacy of VIP152, a CDK9 inhibitor, in patients with double-hit lymphoma (DHL).

AUTHOR(S)
Victor Moreno, Raul Cordoba, Daniel Morillo, Jennifer R. Diamond, Ahmed M. Hamdy, Raquel Izumi, Claudia Merz, Oliver Boix, Isabelle Genvresse, Grzegorz S. Nowakowski
Lenalidomide plus rituximab in patients with rituximab-resistant indolent B-cell and mantle cell lymphomas: 10-year follow-up.

**AUTHOR(S)**
Aditi Gupta, Stephen J. Schuster, Jakub Svoboda, Sunita Nasta, Ellen Napier, Kristy Walsh, Elise A. Chong

First-MIND: A phase Ib, open-label, randomized study to assess safety of tafasitamab (tafa) or tafa + lenalidomide (LEN) in addition to R-CHOP in patients with newly diagnosed DLBCL.

**AUTHOR(S)**
David Belada, Katerina Kopeckova, Juan M. Bergua, Marc André, Ernesto Perez Persona, Petra Pichler, Pia Klöpfert, Bettina Brackertz, Emanuel Lohrmann, Anirban Lahiry, Neha Shah, Wolfram Brugger, John M. Burke, Grzegorz S. Nowakowski

Preliminary results of a phase I trial of FT516, an off-the-shelf natural killer (NK) cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line expressing high-affinity, non-cleavable CD16 (hnCD16), in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).

**AUTHOR(S)**

Survival trends of older adult patients with diffuse large B-cell lymphoma: A National Cancer Database analysis.

**AUTHOR(S)**
CNS relapse in DLBCL patients below 60 years treated with R-ACVBP, R-CHOEP, or R-CHOP: A joint analysis of LYSA and GLA/DSHNHL.

AUTHOR(S)

Catherine Thieblemont, Bettina Altmann, Olivier Casanasovas, Fabian Frontzek, Franck Morschhauser, Lucie Oberic, Viola Poeschel, Olivier Fitoussi, Loic Renaud, Georg Lenz, Nicolas Mounier, Andreas Rosenwald, German Ott, Thierry Molina, Marie Parrens, Loic Chartier, Marita Ziepert, Herve Tilly, Norbert Schmitz

ABSTRACT

Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma (R/R iNHL): Primary analysis of a phase 2 trial from LYSA.

AUTHOR(S)

Charles Herbaux, Herve Ghesquieres, Reda Bouabdallah, Stephanie Guidez, Emmanuel Gyan, Remi Gressin, Nadine Morineau, Loic Ysebaert, Steven Le Gouill, Camille Laurent, Herve Tilly, Roch Houot, Gandhi Damaj, David Silbon, Pierre Feugier, Catherine Thieblemont, Corinne Haioun, Karine Tarte, Franck Morschhauser, Guillaume Cartron

ABSTRACT

Obinutuzumab short-duration infusion (SDI) in previously untreated advanced follicular lymphoma: Results from the end of induction analysis of the phase IV GAZELLE study.

AUTHOR(S)

Miguel Angel A. Canales Albendea, Thomas A. Buchholz, Koji Izutsu, Takayuki Ishikawa, Laura M. Fogliatto, Ekaterina Vorozheikina, Dirk Klingbiel, Sunny Pokala, Monique Tomiczek, Joana Parreira, Kai Hübel

ABSTRACT

Duration of response to loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma by demographic and clinical characteristics: Subgroup analyses from LOTIS 2.

AUTHOR(S)

Paolo Caimi, Weiyun Z. Ai, Juan P. Alderuccio, Kirit Ardeshna, Mehdi Hamadani, Brian T. Hess, Brad S. Kahl, John A. Radford, Melhem M. Solh, Anastasios Stathis, Pier L. Zinzani, Jay M. Feingold, David Ungar, Yajuan Qin, Shui He, Carmelo Carlo-Stella

ABSTRACT
Outcomes with KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24).

AUTHOR(S)
Michael Wang, Javier Munoz, Andre Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John Timmerman, Houston Holmes, Samantha Jaglowski, Ian Flinn, Peter A. McSweeney, David B. Miklos, Marie J. Kersten, Krimo Bouabdallah, Max S. Topp, Rhine Shen, Ioana Kloos, Weimin Peng, Xiang Fang, Patrick M. Reagan

ABSTRACT

Updated outcomes with axicabtagene ciloleucel (axi-cel) retreatment (reTx) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) in ZUMA-5.

AUTHOR(S)
Julio C. Chavez, Caron A. Jacobson, Alison Sehgal, Sattva S. Neelapu, David G. Maloney, Gilles A. Salles, Basem M. William, Yin Yang, Lovely Goyal, Justin Chou, Vicki Plaks, Mauro P. Avanzi

ABSTRACT

NVG-111, a novel ROR1xCD3 bispecific antibody for non-Hodgkin lymphoma.

AUTHOR(S)
David Granger, Satyen Gohil, Alessandro Barbarulo, Annalisa Baccaro, Vincent Muczynski, Kerry Chester, Fiona Germaeschewski, Toby Batten, Kathryn Brown, Sarah Cook, Kieran O’Donovan, Parag Jasani, Amit C. Nathwani, Peter Phillips

ABSTRACT

Efficacy and safety of the PI3Kδ inhibitor zandelisib (ME-401) on an intermittent schedule (IS) in patients with relapsed/refractory follicular lymphoma (FL) with progression of disease within 24 months of first-line chemoimmunotherapy (POD24).

AUTHOR(S)

ABSTRACT
Long-term follow-up results of a phase II study of dose-adjusted (DA)-EPOCH-R with high-dose methotrexate (HD-MTX) for newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL).

**AUTHOR(S)**
Kana Miyazaki, Rika Sakai, Noriko Iwaki, Go Yamamoto, Tomomi Yamada, Yuki Nishimura, Satoshi Tamaru, Naoko Asano, Kohta Miyawaki, Koji Izutsu, Tomohiro Kinoshita, Ritsuro Suzuki, Koichi Ohshima, Koji Kato, Naoyuki Katayama, Motoko Yamaguchi

**ABSTRACT**
7551

Real-world evidence of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) in the United States (US).

**AUTHOR(S)**
Caron A. Jacobson, Frederick L. Locke, Zhen-Huan Hu, Tanya Siddiqi, Sairah Ahmed, Armin Ghabadi, David B. Miklos, Yi Lin, Miguel-Angel Perales, Matthew A. Lunning, Megan Herr, Brian T. Hill, Siddhartha Ganguly, Hua Dong, Sarah Nikiforow, Jing Xie, Hairong Xu, Michele Hooper, Jun Kawashima, Marcelo C. Pasquini

**ABSTRACT**
7552

Initial results of the combination of PI3Kδ inhibitor zandelisib (ME-401) and the BTK inhibitor zanubrutinib in patients (pts) with relapsed or refractory (R/R) B-cell malignancies.

**AUTHOR(S)**

**ABSTRACT**
7553

Outpatient practice pattern and remote patient monitoring for axicabtagene ciloleucel CAR-T therapy in patients with aggressive lymphoma.

**AUTHOR(S)**
Radhika Bansal, Jonas Paludo, Adam Holland, Spychalla Megan, McClanahan Alli, Matthew Hathcock, Hassan Alkhateeb, David Dingli, Yucai Wang, Saad Kenderian, Shaji Kumar, Mithun V. Shah, Siddiqui Mustaqueem, Rahma M. Warsame, Jose C. Villasboas, Nabila N. Bennani, Patrick B. Johnston, Stephen M. Ansell, Tuflia C. Haddad, Yi Lin

**ABSTRACT**
7554

Vaccine titers in lymphoma patients receiving chimeric antigen receptor T-cell therapy.
AUTHOR(S)
Radhika Bansal, Paschalis Vergidis, Pritish Tosh, John W. Wilson, Matthew Hathcock, N. Nora Bennani, Jonas Paludo, Jose C. Villasboas, Yucai Wang, Stephen M. Ansell, Patrick B. Johnston, Catherine M. Freeman, Yi Lin

ABSTRACT
7555

Phase 1/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).

AUTHOR(S)

ABSTRACT
7556

Survival outcomes, treatment toxicity, and healthcare utilization in older adults with aggressive non-Hodgkin lymphoma (NHL).

AUTHOR(S)

ABSTRACT
7557

Prognostic role of lymphocyte to monocyte ratio in patients treated with CAR-T for aggressive lymphoma.

AUTHOR(S)
Henan Zhang, Radhika Bansal, Kodi Peterson Martinez, Matthew Hathcock, Zuoyi Shao, Gabriele McCoy, Anatilde Gonzalez-Guerrico, N. Nora Bennani, Jonas Paludo, Yucai Wang, Patrick Johnston, Stephen M. Ansell, Saad Kenderian, Luis F. Porrata, Jose C. Villasboas, Yi Lin

ABSTRACT
7558


AUTHOR(S)
Jorge J. Castillo, Keri Yang, Rongzhe Liu, Yu Wang, Aileen Cohen, Todd M. Zimmerman, Qian Zhao, Xin Gao, Boxiong Tang

ABSTRACT
Immune priming with nivolumab followed by nivolumab and rituximab in first-line treatment of follicular lymphoma: The phase 2 1st FLOR study.

AUTHOR(S)
Eliza A. Hawkes, Sze Ting Lee, Geoff Chong, Michael Gilbertson, Andrew Grigg, Leonid Churilov, Tineke Fancourt, Colm Keane, David Ritchie, Rachel Koldej, Rishu Agarwal, Kate Manos, Charmaine Smith, Kristen Houdyk, Joanne Hawking, Allison Barraclough

ABSTRACT

Treatment free remission (TFR) and overall response rate (ORR) results in patients with relapsed/refractory Waldenstrom's macroglobulinemia (WM) treated with CLR 131.

AUTHOR(S)
Sikander Ailawadhi, Asher Alban A. Chanan-Khan, Jennifer L. Peterson, Jarrod Longcor, Katherine Oliver, Matthew F. Brown, John Friend, Damian J. Green

ABSTRACT

A novel index using inflammatory markers improves the diagnosis of hemophagocytic lymphohistiocytosis in patients with hematologic malignancies.

AUTHOR(S)
Adi Zoref Lorenz, Jun Murakami, Liron Hofstetter, Swaminathan P. Iyer, Ahmed Alotaibi, Shehab Mohamed, Peter G. Miller, Elad Guber, Shiri Weinstein, Joanne Yacobovich, Sarah Nikiforow, Benjamin L. Ebert, Oren Pasvolsky, Pia Raanani, Arnon Nagler, Nancy Berliner, Naval G. Daver, Martin Ellis, Michael Jordan

ABSTRACT


AUTHOR(S)
Elise A. Chong, Daniel E. Tsai, Mitchell E. Hughes, Mary Ann C. Lim, Behdad D. Besharatian, Yvonne El Kassiss, Roy Bloom, Deepa Jagadeesh

ABSTRACT

Phased variants improve DLBCL minimal residual disease detection at the end of therapy.
IL-1 receptor antagonist for prevention of severe immune effector cell-associated neurotoxicity syndrome.

Randomized, phase III study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): EVOLVE CLL/SLL study (SWOG S1925, NCT#04269902).

A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).

Phase 3 trial (GCT3013-05) of epcoritamab versus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
AUTHOR(S)
Catherine Thieblemont, Michael Roost Clausen, Anna Sureda Balari, Pier L. Zinzani, Christopher Fox, Su Young Kim, Signe Diness Vindeloev, Pieternella Lugtenburg

ABSTRACT
TPS7569

A phase 1 dose escalation and cohort expansion study of the safety and efficacy of allogeneic CRISPR-Cas9-engineered T cells (CTX110) in patients (Pts) with relapsed or refractory (R/R) B-cell malignancies (CARBON).

AUTHOR(S)

ABSTRACT
TPS7570

Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Trials in Progress).

AUTHOR(S)
Nancy L. Bartlett, Christopher A. Yasenchak, Khaleel K. Ashraf, William N. Harwin, Robert B. Sims, Grzegorz S. Nowakowski

ABSTRACT
TPS7571

ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL).

AUTHOR(S)
Laurie H. Sehn, Brad S. Kahl, Matthew J. Matasar, Georg Lenz, Koji Izutsu, Weili Zhao, Lin Tao, Roser Calvo, Pier L. Zinzani

ABSTRACT
TPS7572

Coastal: A phase 3 study of the PI3Kδ inhibitor zandelisib with rituximab (R) versus immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL).

AUTHOR(S)
Wojciech Jurczak, Pier L. Zinzani, David Cunningham, Sharon Yavrom, Wenying Huang, Igor Gorbachevsky, Vincent Ribrag

AUTHOR(S)
Mehdi Hamadani, Yuliya Linhares, Mitul Gandhi, Michael Chung, Helena Adamis, David Ungar, Carmelo Carlo-Stella

A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

AUTHOR(S)
Mark Hertzberg, Matthew Ku, Olivier Catalani, Betsy Althaus, Stephen Simko, Gareth P. Gregory

Randomized, double-blind, placebo-controlled phase 3 study of ibrutinib plus rituximab in patients with previously untreated marginal zone lymphoma (MZL).

AUTHOR(S)
Ariela Noy, Stephanie Hughes, Erin Biggar, Matthew Bogdan

Hematologic Malignancies—Plasma Cell Dyscrasia

Showing 35 Presentations

https://meetinglibrary.asco.org/session/13651
High-dose lenalidomide and melphalan as conditioning for autologous stem cell transplantation in relapsed or refractory multiple myeloma.

AUTHOR(S)
Adriana C. Rossi, Jorge Monge, Ruben Niesvizky, Jing Mei Hsu, Tsi porah Shore, Koen Van Besien, Roger Pearse, Tomer Mark, David Jayabal an, Sebastian A. Mayer

ABSTRACT
8021

Improved outcomes with maintenance therapy after salvage autologous hematopoietic cell transplantation (AHCT) in multiple myeloma: A CIBMTR study.

AUTHOR(S)
Oren Pasvolsky, Raphael Fraser, Noel Estrada-Merly, Moshe Yeshurun, Uri Rozovski, Liat Shargian-Alon, Shaji Kumar, Nina Shah, Muzaffar H. Qazilbash, Anita D’Souza

ABSTRACT
8022

Phase 2 study of MGTA-145 + plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma.

AUTHOR(S)

ABSTRACT
8023

Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma.

AUTHOR(S)

ABSTRACT
8024

The clinical study of anti-BCMA CAR-T with single-domain antibody as antigen binding domain.
AUTHOR(S)

Lu Han, Quanli Gao, Keshu Zhou, Jian Zhou, Qing-Song Yin, Baijun Fang, Xing-Hu Zhu, Jishuai Zhang, Chaolemeng Bao, Yongping Song

ABSTRACT

8025

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.

AUTHOR(S)

Thierry Facon, Philippe Moreau, Thomas G. Martin, Ivan Spicka, Albert Oriol, Youngil Koh, Andrew Lim, Gabor Mikala, Laura Rosiñol, Münci Yağcı, Michele Cavo, Kwee Yong, Marie-Laure Risse, Gaëlle Asset, Sandrine Schwab, Gracia Martinez

ABSTRACT

8026

Effects of weekly selinexor, bortezomib, dexamethasone (XVd) versus standard twice weekly bortezomib and dexamethasone (Vd) on RAS-mutated previously treated multiple myeloma (MM).

AUTHOR(S)

Christopher J. Walker, Shirong Li, Yi Chai, Jatin J. Shah, Sharon Shacham, Suzanne Lentzsch, Yosef Landesman

ABSTRACT

8027

Incidence, mitigation, and management of neurologic adverse events in patients with multiple myeloma (MM) treated with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-2.

AUTHOR(S)

Hermann Einsele, Samir S. Parekh, Deepu Madduri, Bianca Santomasso, Jaime Gállego Pérez De Larraya, Niels W. van de Donk, Bertrand Arnulf, Maria-Victoria Mateos, Kevin C. De Braganca, Helen Varsos, Marlene Carrasco-Alfonso, Muhammad Akram, Nikoletta Lendvai, Carolyn C. Jackson, Yunsi Olyslager, Enrique Zudaire, Claire Li, Dong Geng, Andrzej J. Jakubowiak, Adam D. Cohen

ABSTRACT

8028

Personalized, ctDNA analysis to detect minimal residual disease and identify patients at high risk of relapse with multiple myeloma.

AUTHOR(S)

Binod Dhakal, Shruti Sharma, Svetlana Shchegrova, Minu Maninder, Meenakshi Malhotra, Himanshu Sethi, Bernhard Zimmermann, Paul R. Billings, Alexey Aleshin, Parameswaran Hari
ABSTRACT
8029

Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma.

AUTHOR(S)

ABSTRACT
8030

Assessing financial difficulty in patients with multiple myeloma: Preliminary results of ALLIANCE A231602CD.

AUTHOR(S)
Rena M. Conti, Shaylene McCue, Travis Dockter, Bruce D. Rapkin, Stacie Dusetzina, Antonia V. Bennett, Gabriela Gracia, Michelle E. Johnson, Sarah A. Martin, George J. Chang, Paul G. Richardson, Robert J. Behrens, Elisa S. Weiss

ABSTRACT
8031

5-Hydroxymethylcytosines in circulating cell-free DNA and overall survival in patients with multiple myeloma.

AUTHOR(S)
Brian C. Chiu, Zhou Zhang, Benjamin A. Derman, Jason Karpus, Spencer Langerman, Chang Zeng, Parveen Bhatti, Andrzej J. Jakubowiak, Chuan He, Wei Zhang

ABSTRACT
8032

Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (belamaf).

AUTHOR(S)
Evangelos Terpos, Ashraf Badros, Rakesh Popat, Paula Rodriguez-Otero, Asim Farooq, Bennie Jeng, Simona Degli Esposti, Eric Lewis, Ira Gupta, Joanna Opalinska, Antonio Palumbo, Suzanne Trudel
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma according to prior lines of treatment and refractory status: IKEMA subgroup analysis.

AUTHOR(S)

ABSTRACT
Daratumumab (DARA) maintenance therapy following DARA + cyclophosphamide, bortezomib, and dexamethasone (CyBorD) induction therapy in multiple myeloma (MM): End-of-study analysis of LYRA.

AUTHOR(S)
Robert M. Rifkin, Jason M. Melear, Edward Faber, William I. Bensinger, John M. Burke, Mohit Narang, Don A. Stevens, Kathleen Gray, Yana Lutska, Padma Bobba, Keqin Qi, Ming Qi, Thomas S. Lin, Habte A. Yimer

ABSTRACT
Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study.

AUTHOR(S)
Salomon Manier, Ankit J. Kansagra, Larry D. Anderson, Jr, Jesus G. Berdeja, Sundar Jagannath, Yi Lin, Sagar Lonial, Nina Shah, Noopur S. Raje, David S. Siegel, Albert Oriol, Anna Truppel-Hartmann, Everton Rowe, Payal Patel, Amit Agarwal, Timothy B. Campbell, Paula Rodríguez-Otero, Nikhil C. Munshi

ABSTRACT
ANCHOR (OP-104): Melflufen plus dexamethasone (dex) and bortezomib (BTZ) in relapsed/refractory multiple myeloma (RRMM)—Optimal dose, updated efficacy and safety results.

AUTHOR(S)
Roman Hajek, Luděk Pour, Miquel Granell, Vladimir Maisnar, Paul G. Richardson, Stefan Norin, Malin Sydvander, Jakob Obermüller, Enrique M. Ocio

ABSTRACT
Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.

AUTHOR(S)
Cristina Gasparetto, Gary J. Schiller, Sascha Tuchman, Natalie S. Callander, Muhamed Baljevic, Suzanne Lentzsch, Adriana C. Rossi, Rami Kotb, Darrell White, Nizar J. Bahlis, Christine Chen, Heather J. Sutherland, Sumit Madan, Richard LeBlanc, Michael Sebag, Christopher P. Venner, Noa Biran, Dane Van Domelen, Brea Lipe

ABSTRACT
Phase Ib trial of vactosertib in combination with pomalidomide in relapsed multiple myeloma: A corticosteroid-free approach by targeting TGF-β signaling pathway.

AUTHOR(S)
Ehsan Malek, Sunjin Hwang, Paolo F. Caimi, Leland L. Metheny, Benjamin K. Tomlinson, Brenda W. Cooper, Kirsten M. Boughan, Folashade Otegbeye, Molly Gallogly, James J. Driscoll, Marcos J. De Lima

ABSTRACT
Using mobile wearables to establish sleep bioprofiles in newly diagnosed multiple myeloma (MM) patients.

AUTHOR(S)

ABSTRACT
LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma (RRMM) receiving ≥3 prior lines of therapy.

AUTHOR(S)

ABSTRACT
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.
AUTHOR(S)
Ivan Spicka, Philippe Moreau, Thomas G. Martin, Thierry Facon, Gracia Martinez, Albert Oriol, Youngil Koh, Andrew Lim, Gabor Mikala, Laura Rosiñol, Münci Yaşıcı, Michele Cavo, Marie-Laure Risse, Gaëlle Asset, Sandrine Macé, Helgi Van De Velde, Kwee Yong

ABSTRACT
8042
Ixazomib (IXA), carfilzomib (CAR), elotuzumab (ELO) or daratumumab (DAR) with lenalidomide and dexamethasone (LEN+DEX) versus LEN+DEX only in relapsed/refractory multiple myeloma (R/R MM): A comparative cost-effectiveness analysis.

AUTHOR(S)
Mavis Obeng-Kusi, Daniel Arku, Neda AlRawashdh, Briana Choi, Nimer S. Alkhatib, Ali McBride, Ivo Abraham

ABSTRACT
8043
ISB 1342: A first-in-class CD38 T cell engager for the treatment of relapsed refractory multiple myeloma.

AUTHOR(S)
Marie-Agnès Doucey, Blandine Pouleau, Carole Estoppey, Cian Stutz, Amelie Croset, Amélie Laurendon, Thierry Monney, Mégane Pluess, Christelle Ries-Fecourt, Julie Macoin, Riccardo Turrini, Perrine Suere, M.Lamine Mbow, Emilie Nallet, Adam Drake, Mario Perro, Stanislas Blein

ABSTRACT
8044
Comparison of outcomes with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 versus real-world standard of care (RW SOC) for patients (pts) with triple-class exposed relapsed/refractory multiple myeloma (RRMM).

AUTHOR(S)
Thomas G. Martin, Amrita Y. Krishnan, Kwee Yong, Katja Weisel, Maneesha Mehra, Sandhya Nair, Keqin Qi, Anil Londhe, Joris Diels, Concetta Crivera, Carolyn C. Jackson, Yunsi Olyslager, Martin Vogel, Jordan M. Schecter, Arnob Banerjee, Satish Valluri, Saad Z. Usmani, Jesus G. Berdeja, Sundar Jagannath

ABSTRACT
8045
Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO.
Evangelos Terpos, Meletios A. Dimopoulos, Mario Boccadoro, Sosana Delimpasi, Meral Beksaç, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris Symeonidis, Jelena Bila, Albert Oriol, Maria-Victoria Mateos, Hermann Einsele, Ioannis Orfanidis, Katharine S. Gries, John Fastenau, Tobias Kampfenkel, Yanping Qiu, Himal Amin, Pieter Sonneveld

**ABSTRACT**

8046

**Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.**

**AUTHOR(S)**


**ABSTRACT**

8047

**Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies.**

**AUTHOR(S)**

Paula Rodríguez-Otero, Maria-Victoria Mateos, Albert Oriol, Alessandra Larocca, Joan Blade, Michele Cavo, Xavier Leleu, Omar Nadeem, John W. Hiemenz, Hani Hassoun, Cyrille Touzeau, Adrian Alegre, Agne Paner, Christopher Maisel, Amitabha Mazumder, Anastasios Raptis, Marcus Thuresson, Johan Harmenberg, Olof Harlin, Paul G. Richardson

**ABSTRACT**

8048

**Prognostic impact of depth of response in Waldenström macroglobulinemia patients treated with fixed duration chemoimmunotherapy.**

**AUTHOR(S)**


**ABSTRACT**

8049

**An animal model of MGUS/SMM to investigate the role of cellular senescence in progression to MM.**

**AUTHOR(S)**

Hengwei Zhang, Omar S. Aljitawi, Lianping X. Zhang, Thomas Conley, Frank C. Passero, Brea Lipe

**ABSTRACT**

8050
LIGHTHOUSE (OP-108): A phase 3 study of melflufen in combination with dexamethasone (dex) and daratumumab (dara) versus dara in relapsed/refractory multiple myeloma (RRMM) patients (pts).

AUTHOR(S)
Maria-Victoria Mateos, Luděk Pour, Enrique M. Ocio, Pieter Sonneveld, Catarina Jansson Blixt, Kajsa Larsson, Linda Palmér, Paul G. Richardson

ABSTRACT
TPS8051

ECOG-ACRIN EAA181: Effective quadruplet utilization after treatment evaluation (EQUATE)—a randomized phase 3 trial for newly diagnosed multiple myeloma (NDMM) not intended for early autologous transplantation.

AUTHOR(S)
Shaji Kumar, Zihan Wei, Michael A. Thompson, Bradley Snyder, Matthias Weiss, Lynne I. Wagner, Lale Kostakoglu, S. V. Rajkumar

ABSTRACT
TPS8052

KarMMa-4: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma.

AUTHOR(S)
Saad Z. Usmani, Jesus G. Berdeja, Anna Truppel-Hartmann, Yizhou Fei, Honeylet Wortman-Vayn, Suresh Shelat, Steven Novick, Nina Shah

ABSTRACT
TPS8053

Subcutaneous daratumumab (DARA SC) plus lenalidomide versus lenalidomide alone as maintenance therapy in patients (pts) with newly diagnosed multiple myeloma (NDMM) who are minimal residual disease (MRD) positive after frontline autologous stem cell transplant (ASCT): The phase 3 AURIGA study.

AUTHOR(S)
Nina Shah, Sharmila Patel, Huiling Pei, Ming Qi, Maria Krevvata, Thomas S. Lin, Vipin Khare

ABSTRACT
TPS8054
A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand.

Author(s)
Hang Quach, Masa Lasica, David Routledge, Anna Kalff, Andrew Lim, Michael Low, Jane A. Estell, M Hasib Sidiqi, Philip Campbell, Richard W. Eek, Hock C. Lai, Georgia J. McCaughan, James D’Rozario, Peter Browlett, Rajeev Rajagopal, Jessica Heenan, Nicholas E. Murphy, William Renwick, Georgina Huan, Peter Mollee

Abstract

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Showing 69 Presentations

https://meetinglibrary.asco.org/session/13657

Updated overall survival (OS) and exploratory analysis from the randomized, phase II EVAN study of erlotinib (E) versus vinorelbine plus cisplatin (NP) as adjuvant therapy in Chinese patients with stage IIIA EGFR+ NSCLC.

Author(s)
Dongsheng Yue, Shi-Dong Xu, Qun Wang, Xiaofei Li, Yi Shen, Heng Zhao, Chun Chen, Weimin Mao, Wei Liu, Junfeng Liu, Lan-Jun Zhang, Haitao Ma, Qiang Li, Yue Yang, Yongyu Liu, Haiquan Chen, Zhenfa Zhang, Bin Zhang, Fuyu Gong, Changli Wang

Abstract
8520

Different exposure duration of adjuvant icotinib in stage II-IIIA non-small cell lung cancer patients with positive EGFR mutation (ICOMPARE study): A randomized, open-label phase 2 study.

Author(s)
**ABSTRACT**

8521

**Two-year follow-up of single PD-1 blockade in neoadjuvant resectable NSCLC.**

**AUTHOR(S)**

Shugeng Gao, Ning Li, Shunyu Gao, Qi Xue, Shuhang Wang, Fang Lv, Liang Zhao, Fan Zhang, Ziran Zhao, Kai Su, Fengwei Tan, Yun Ling, Zhijie Wang, Wei Tang, Jianming Ying, Ning Wu, Jie Wang, Jie He

**ABSTRACT**

8522

**Statewide rates of adjuvant checkpoint inhibitor use after definitive chemoradiation for stage III non-small cell lung cancer.**

**AUTHOR(S)**

Alex K. Bryant, Huiying Yin, Matthew J. Schipper, Peter A. Paximadis, Thomas P. Boike, Derek P. Bergsma, Benjamin Movsas, Munther I. Ajlouni, Robert T. Dess, Melissa A. Mietzel, Randi Kendrick, Merita Seferi, Michael M. Dominello, Martha Matuszak, Reshma Jagsi, James Hayman, Lori J. Pierce, Shruti Jolly

**ABSTRACT**

8523

**Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR mutant lung adenocarcinoma (NEOS).**

**AUTHOR(S)**

Chao Lyu, Wentao Fang, Haitao Ma, Jia Wang, Wenjie Jiao, Rui Wang, Nan Wu, Shi-Dong Xu, Yue Yang

**ABSTRACT**

8524

**Cost evaluation of adjunctive osimertinib use in resected epidermal growth factor receptor-positive non-small cell lung cancer.**

**AUTHOR(S)**

Briana Choi, Neda AlRawashd, Ali McBride, Ivo Abraham

**ABSTRACT**

8525

**Minimal residual disease (MRD) in patients with resected stage I NSCLC: Results of the prospective adjuvant IFCT-0703 trial.**

**AUTHOR(S)**
Modeling the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer patients.

AUTHOR(S)
Christopher Lemmon, Emily C. Zabor, Nathan A. Pennell

Driver mutations to predict for poorer outcomes in non-small cell lung cancer patients treated with concurrent chemoradiation and consolidation durvalumab.

AUTHOR(S)
Yufei Liu, Zhe Zhang, Waree Rinsurongkawong, Xiuning Le, Carl M. Gay, Matthew S. Ning, John Heymach, Jianjun Zhang, Steven H. Lin

Natural history of curatively resected stage IB-III A EGFR mutation (+) NSCLC: Clinicopathologic and molecular prognostic factors (ROOT-EGFR-ADJ).

AUTHOR(S)
Hyun Ae Jung, Yeong Jeong Jeon, Jhingook Kim, Sehhoon Park, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park

Molecular characteristics of EGFR exon 19 deletion subtypes in NSCLC patients.

AUTHOR(S)
Weiquan Gu, Zhongyu Lu, Shulin Shi, Juan Ma, Guanghua Lu, Wanglong Deng, Ran Ding, Fanfeng Bu

Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients (p): SOLID study.

AUTHOR(S)

**ABSTRACT**

8531

**Association of high level of plasma tissue factor activity with venous thromboembolism and early death in lung cancers.**

**AUTHOR(S)**

Helene Doubre, Isabelle Monnet, Reza Azarian, Philippe Girard, Guy Meyer, Julie Trichereau, Philippe Devillier, Patrick Van Dreden, Louis-Jean Couderc, Christos Chouaid, Marc Vasse

**ABSTRACT**

8532

**Noninvasive identification of emergent mutations following cytotoxic therapy for lung cancer.**

**AUTHOR(S)**

Everett J. Moding, Angela B. Hui, Yonina R. Murciano-Goroff, Barzin Nabet, Andre Schultz, Yawei Qiao, Bob T. Li, Steven H. Lin, Ash A. Alizadeh, Maximilian Diehn

**ABSTRACT**

8533

**Sequential monitoring of PD-L1 on circulating stromal cells in blood predicts PFS in NSCLC patients undergoing immunotherapy after definitive chemoradiation.**

**AUTHOR(S)**

Daniel L. Adams, Alexander Augustyn, Jianzhong He, Yawei Qiao, Ting Xu, Zhongxing X. Liao, Kirby J. Gardner, Jillian Moran, Chau-Mei Tang, Steven H. Lin

**ABSTRACT**

8534

**Genomic and immunologic characterization of large-cell neuroendocrine carcinoma of the lung.**

**AUTHOR(S)**

Chul Kim, Julie E. McGrath, Joanne Xiu, Misako Nagasaka, Patrick C. Ma, Jorge J. Nieva, Gilberto Lopes, Hossein Borghaei, Chukwuemeka Ikpeazu Sr., Taofeek K. Owonikoko, Michael J. Demeure, Antoinette J. Wozniak, Chadi Nabhan, Wolfgang M. Korn, Stephen V. Liu

**ABSTRACT**

8535
Deep learning to predict subtypes of poorly differentiated lung cancer from biopsy whole slide images.

AUTHOR(S)
Gouji Toyokawa, Fahdi Kanavati, Seiya Momosaki, Kengo Tateishi, Hiroaki Takeoka, Masaki Okamoto, Koji Yamazaki, Sadanori Takeo, Osamu Iizuka, Masayuki Tsuneki

ABSTRACT
A new model using artificial intelligence to predict recurrence after surgical resection of stage I-II non-small cell lung cancer.

AUTHOR(S)

ABSTRACT
Surgical outcomes for early-stage non-small cell lung cancer at facilities with stereotactic body radiation therapy programs.

AUTHOR(S)

ABSTRACT
Prognostic value of SUVmax on FDG-PET/CT before and after stereotactic body radiotherapy (SBRT) on recurrence and survival in early-stage non-small cell lung cancer (NSCLC).

AUTHOR(S)
Saarang Deshpande, Tarun K. Podder, Yuxia Zhang, Yiran Zheng, William Grubb, Michael Kharouta, Philip A. Linden, Tithi Biswas

ABSTRACT
Multiomics analysis reveals high-immune infiltration in tumor-adjacent lung tissues affects the prognosis of stage I NSCLC.

AUTHOR(S)
Lisa Ying, Dan Su, Zhang Chunliu, Yiping Tian, Jing Bai, Canming Wang, Jianfei Fang, Andrew Futreal, Jianjun Zhang

ABSTRACT
Phase II trial of toripalimab plus chemotherapy as neoadjuvant treatment in resectable stage III non-small cell lung cancer (NeoTPD01 Study).

AUTHOR(S)
Zerui Zhao, Si Chen, Han Qi, Chao-Pin Yang, Yao-Bin Lin, Jie-Tian Jin, Shan-Shan Lian, Yi-Zhi Wang, Hui Yu, Long Hao

ABSTRACT

Impact of genomic aberrations and additional therapies on survival outcomes of patients with operable non-small cell lung cancer (NSCLC) from the NEOSTAR study.

AUTHOR(S)

ABSTRACT

PIT-2: A multicenter phase II trial of S-1 plus cisplatin with concurrent radiotherapy followed by surgery in stage IIIA (N2) lung squamous cell carcinoma.

AUTHOR(S)
Kazuya Takamochi, Masahiro Tsuboi, Morihito Okada, Seiji Niho, Satoshi Ishikura, Shunsuke Oyamada, Takuhiro Yamaguchi, Fumihiro Tanaka, Ichiro Yoshino, Masanori Tsuchida, Satoshi Shiono, Hiroyuki Oizumi, Norihiro Okumura, Tomohiro Haruki, Kenji Suzuki

ABSTRACT


AUTHOR(S)
Aina Pons, Paulo De Sousa, Chiara Proli, Sarah Ann Booth, Abigail Palmares, Maria Leung, Abdullah Alshammari, Dimitrios Vlastos, Hilgardt Raubenheimer, Anant Patel, Mohan Devbhandari, Eric K. Lim

ABSTRACT

The efficacy of PD-1 antibody sintilimab on ground glass opacity lesions in patients with early-stage multiple primary lung cancer (CCTC-1901, NCT04026841).
Bo Cheng, Caichen Li, Yi Zhao, Jianxing He

**ABSTRACT**

8545

**Doubling of median overall survival in a nationwide cohort of Veterans with stage III non-small cell lung cancer in the durvalumab era.**

**AUTHOR(S)**

Kamya Sankar, Alex K. Bryant, Michael Green, Nithya Ramnath

**ABSTRACT**

8546

**Elderly patients with unresectable stage 3 NSCLC treated with definitive chemoradiation with or without durvalumab: Safety and outcomes.**

**AUTHOR(S)**

Malcolm I. Ryan, Jessica Weiss, Aline F. Fares, Ming S. Tsao, Geoffrey Liu, Penelope A. Bradbury, Natasha B. Leighl, Frances A. Shepherd, Adrian G. Sacher, Sally C. Lau

**ABSTRACT**

8547

**NRG-RTOG 1106/ACRIN 6697: A phase IIR trial of standard versus adaptive (mid-treatment PET-based) chemoradiotherapy for stage III NSCLC—Results and comparison to NRG-RTOG 0617 (non-personalized RT dose escalation).**

**AUTHOR(S)**

Feng-Ming S. Kong, Chen Hu, Randall Ten Haken, Ying Xiao, Martha Matuszak, Vera Hirsh, Daniel A. Pryma, Barry A. Siegel, Daphna Y. Gelblum, James Hayman, Clifford G. Robinson, Billy W. Loo, Gregory M. Videtic, Sergio Faria, Catherine Ferguson, Neal E. Dunlap, Vijayananda Kundapur, Rebecca Paulus, Jeffrey D. Bradley, Mitchell Machtay

**ABSTRACT**

8548

**The impact of Percepta Genomic Sequencing Classifier (GSC) on clinical decision making in patients with a high-risk lung nodule.**

**AUTHOR(S)**

Sonali Sethi, Scott Oh, Alexander Chen, Christina Bellinger, Lori Lofaro, Jennifer Tom, Marla Johnson, Jing Huang, Sangeeta M. Bhorade, Giulia Kennedy

**ABSTRACT**

8549
Patients with early-stage (T1-2N0) adenosquamous lung cancer have worse long-term survival compared to patients with early-stage lung adenocarcinoma or squamous cell histology.

Author(s)
Larisa Shagabayeva, Patel B. Heer, Chi-Fu J. Yang, Michael Lanuti

Abstract
8550

Early candidate nasal swab classifiers developed using machine learning and whole transcriptome sequencing may improve early lung cancer detection.

Author(s)
Peter J. Mazzone, Carla Lamb, Kimberly M. Rieger-Christ, Chakravarthy B. Reddy, Jianghan Qu, Shuyang Wu, Jie Ding, Duncan Whitney, Daniel G. Pankratz, Joshua Babiarz, Lori Lofaro, P. S. Walsh, Jonathon Wilde, Sangeeta M. Bhorade, Jing Huang, Giulia Kennedy, Avrum Spira

Abstract
8551

A comparative analysis of mortality between black and white stage III non–small cell lung cancer patients in the United States.

Author(s)
Elizabeth B. Elimimian, Rafael Arteta-Bulos, Hong Liang, Nadeem Bilani, Leah Elson, Diana Saravia, Evan W. Alley

Abstract
8552

Early detection of lung cancer with an incidental lung nodule program (ILNP).

Author(s)
Matthew Smeltzer, Wei Liao, Meghan Meadows-Taylor, Nicholas Faris, Carrie Fehnel, Jordan Goss, Sara C. Williams, Olawale Akinbobola, Alicia Pacheco, Amanda Epperson, Joy Luttrell, Denise McCoy, Keith Tokin, Rob Optican, Jeffrey Wright, Edward T. Robbins, Shailesh Satpute, Parker Harris, Meredith Ray, Raymond U. Osarogiagbon

Abstract
8553

Radical surgery in malignant pleural mesothelioma (MPM): An analysis of SEER database.

Author(s)
Qian Wang, Yaning Zhang, Meng Ru, Changchuan Jiang, Jessica Tran, Juan P. Wisnivesky, Rajwanth Veluswamy

Abstract
Comprehensive molecular profiling of pleural mesothelioma according to histologic subtype.

AUTHOR(S)

ABSTRACT
Improved survival among patients with malignant pleural mesotheliomas who develop immune-related adverse events on immunotherapy.

AUTHOR(S)
Michael Offin, Jacklynn V. Egger, Caroline G. McCarthy, Vasilisa Rudneva, Jason Beattie, Michelle S. Ginsberg, Jennifer L. Sauter, Andreas Rimner, Valerie W. Rusch, Prasad S. Adusumilli, Marjorie G. Zauderer

ABSTRACT
Comprehensive genomic profiling of malignant peritoneal mesothelioma (MPeM) reveals key genomic alterations (GAs) distinct from malignant pleural mesothelioma (MPM).

AUTHOR(S)
Lynne O. Chapman, Michael J. Overman, Annelies Willett, Mark Knaff, Szu-Chin Fu, Anais Malpica, Christopher Scally, Paul F. Mansfield, Aurelio A. Matamoros Jr., Ajaykumar Morani, Scott E. Woodman, Boris Sepesi, Reza J. Mehran, Cara L. Haymaker, Gauri R. Varadhachary, Anne S. Tsao, Keith Fournier, Kanwal P. Raghav

ABSTRACT
A phase II trial of abemaciclib in patients with p16INK4A negative, relapsed mesothelioma.

AUTHOR(S)
Dean A. Fennell, Amy King, Seid Mohammed, Amy Branson, Alastair Greystoke, Sam Moody, Margaret Hutka, Alan G. Dawson, Liz Darlison, Molly Scotland, Vina Bhundia, Amrita Bajaj, Bruno Morgan, Adrian Nicholson, Cassandra Brookes, Aarti Gaba, Peter Wells-Jordan, Catherine J. Richards, Anne Thomas

ABSTRACT
Genomic landscape of malignant mesothelioma by site and histology.
AUTHOR(S)
Elio Adib, Elie Akl, Amin Nassar, Talal El Zarif, Sarah Abou Alaiwi, David J. Kwiatkowski

ABSTRACT
8559

Efficacy and safety analysis of anlotinib combined with etoposide plus cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (SCLC): The final results from a phase II single-arm trial.

AUTHOR(S)
Tiandong Kong, Lu Chen, Fangfang Duan, Xiaoxia Hou, Liuyan Wang, Hanli Zhou, Lanrong Wang, Shanshan Hu, Danna Liu

ABSTRACT
8560

Real-world evidence of cancer immunotherapy (CIT) combination treatment in first-line (1L) extensive-stage small cell lung cancer (ES-SCLC).

AUTHOR(S)
Eric S. Nadler, Anupama Vasudevan, Kalatu Davies, Yunfei Wang, Ann Johnson, Sarika Ogale

ABSTRACT
8561

The clinical efficacy of olaparib monotherapy or combination with ceralasertib (AZD6738) in relapsed small cell lung cancer.

AUTHOR(S)

ABSTRACT
8562


AUTHOR(S)

ABSTRACT
8563
Circulating tumor DNA (ctDNA) mutations may predict treatment response in extensive-stage small cell lung cancer (ES-SCLC) treated with talazoparib and temozolomide (TMZ).

AUTHOR(S)

ABSTRACT
8564

Cisplatin versus carboplatin for the treatment of limited-stage small cell lung cancer (LS-SCLC).

AUTHOR(S)
Ibrahim Azar, Adam Austin, Seongho Kim, Hyejeong Jang, Malini Surapaneni, Daniel Kurtz, Omid Yazdanpanah, Amit Chopra, Syed Mehdi, Hirva Mamdani

ABSTRACT
8565

Application value of plasma exosomal long RNA in SCLC diagnosis and prognosis.

AUTHOR(S)
Chang Liu, Jialei Wang, Shenglin Huang, Hui Yu, Zhengfei Zhu, Min Fan

ABSTRACT
8566

Imfirst: A phase IIIb, safety, single arm study of carboplatin (CB) or cisplatin (CP) plus etoposide (ET) with atezolizumab (ATZ) in patients with untreated extensive-stage small cell lung cancer (ES-SCLC) in Spain—Primary safety results of the induction phase.

AUTHOR(S)
Maria Rosario García Campelo, Manuel Domine, Javier De Castro, Alberto Moreno, Santiago Ponce Aix, Edurne Arriola, Enric Carcereny, Margarita Majem, Gerardo Huidobro Vence, Emilio Esteban, Jose Fuentes Pradera, Bartomeu Massuti, Ana Laura Ortega, Guillot Mónica, Juan F. Cordoba, Natalia Fernandez, Ruben Alonso, Leonardo Crama, Natalia Lerones, Manuel Cobo

ABSTRACT
8567

Penpulimab plus anlotinib as second-line treatment for the small cell lung cancer after failure of platinum-based systemic chemotherapy.

AUTHOR(S)
Changgong Zhang, Sheng Yang, Jianhua Chen, Huijuan Wu, Jun Wang, Yingping Li, Liying Gao, Zhongyao Jia, Yan Sun, Jun Zhao, Xin L. Mu, Chunmei Bai, Rui Wang, Kaijiang Wu, Qiang Liu, Xiaoping Jin, Xiaowen Tan, Yuankai Shi

**ABSTRACT**

8568

Chemoimmunotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC) in patients with an Eastern Cooperative Group (ECOG) performance status (PS) of two or greater.

**AUTHOR(S)**

Daniel Almquist, Blake Langlais, Nathan Y. Yu, Terence T. Sio, Panos Savvides, Ping Yang, Steven E. Schild, Aaron S. Mansfield, Vinicius Ernani

**ABSTRACT**

8569


**AUTHOR(S)**


**ABSTRACT**

8570

A randomized phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small cell lung cancer (JCOG1201/TORG1528).

**AUTHOR(S)**

Tsuneo Shimokawa, Yuki Misumi, Hiroaki Okamoto, Yukio Hosomi, Isamu Okamoto, Hiroshi Tanaka, Shinji Atagi, Toyoaki Hida, Koichi Goto, Hiroaki Akamatsu, Kaoru Kubota, Kazuhiko Nakagawa, Hidehito Horinouchi, Masahiko Ando, Ryunosuke Machida, Junko Eba, Tomoko Kataoka, Yuichiro Ohe

**ABSTRACT**

8571

Combination of quantitative features from H&E biopsies and CT scans predicts response to chemotherapy and overall survival in small cell lung cancer (SCLC).

**AUTHOR(S)**

Cristian Barrera, Mohammadhadi Khorrami, Prantesh Jain, Pingfu Fu, Kate Butler, Abdullah Osme, Paula Toro, Vidya S. Viswanathan, Satyapal Chahar, Afshin Dowlati, Anant Madabhushi

**ABSTRACT**
Myasthenia gravis-associated thymoma and myasthenia gravis-free thymoma have distinct somatic mutation and gene expression profiles.

AUTHOR(S)
Yi Zhang, Xiaomo Li, Gaojun Lu, Tonghui Ma, Kejian Shi

ABSTRACT
First long-term results on efficacy and safety of long-acting pasireotide in combination with everolimus in patients with advanced carcinoids (NET) of the lung/thymus: Phase II LUNA trial.

AUTHOR(S)
Eric Baudin, Alfredo Berruti, Mario Giuliano, Wasat Mansoor, Catalin Bobirca, Erik Houtsma, Niamh Fagan, Kjell E. Oberg, Piero Ferolla

ABSTRACT
Cancer activation pathways of thymic epithelial tumors (TETs) by targeted gene expression analysis.

AUTHOR(S)
Jose Carlos Benitez, Bastien Job, Vincent Thomas de Montpreville, Ludovic Lacroix, Patrick Saulnier, Riad Arana, Olivier Lambotte, Foundation Cancer and Autoimmune/inflammatory diseases Relationships, Sacha Mussot, Olaf Mercier, Elie Fadel, Jean-Yves Scoazec, Benjamin Besse

ABSTRACT
A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumor (KCSG LU17-21).

AUTHOR(S)

ABSTRACT
Cell-free circulating tumor DNA (cfDNA) analysis of advanced thymic epithelial tumors (TETs).
Outcomes of thymic epithelial tumors (TETs) with pleural metastases: Real-world insight from RYTHMIC.

AUTHOR(S)
Jean-Michel Maury, Jose Carlos Benitez, Marie Eve Boucher, Eric Dansin, Mallorie Kerjouan, Laurence Bigay-Game, Eric Pichon, Francois Thillays, Pierre-Emmanuel Falcoz, Lyubimova Svetlana, Youssef Oulkhouir, Calcagno Fabien, Luc Thiberville, Christelle Clément Duchene, Virginie Westeel, Pascale Missy, Pascal Alexandre Thomas, Thierry Molina, Nicolas Girard, Benjamin Besse

Clinicogenomic characterization of metastatic thymic epithelial tumors.

AUTHOR(S)
Fatemeh Ardeshir-Larijani, Milan Radovich, Bryan P. Schneider, Patrick J. Loehrer Sr.

Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III non-small cell lung cancer: KEYLYNK-012.

AUTHOR(S)


AUTHOR(S)
TPS8581

A randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153.

AUTHOR(S)

ABSTRACT

TPS8583

Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).

AUTHOR(S)
John M. Varlotto, Zhuoxin Sun, Suresh S. Ramalingam, Heather A. Wakelee, Christine M. Lovly, Kurt R. Oettel, Gregory A. Masters, Nate Pennell

ABSTRACT

TPS8584

Thoracic radiotherapy PLUS durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy: Employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy—The TRADE-hypo trial.

AUTHOR(S)

ABSTRACT

TPS8585

DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma—A phase 3 Randomized trial.

AUTHOR(S)
Patrick M. Forde, Anna K. Nowak, Peey-Sei Kok, Chris Brown, Zhuoxin Sun, Valsamo Anagnostou, Kenneth J. O‘Byrne, Sonia Yip, Alistair Cook, Willem J. Lesterhuis, Brett G. Hughes, Nick Pavlakis, Julie R. Brahmer, Hedy L. Kindler, Anne S. Tsao, Marjorie G. Zauderer, Suresh S. Ramalingam, Martin R. Stockler

ABSTRACT
KEYLYNK-013: A phase 3 study of pembrolizumab in combination with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy in patients with newly diagnosed limited-stage SCLC.

AUTHOR(S)
Andreas Rimner, W. V. Lai, Raffaele Califano, Salma K. Jabbour, Corinne Faivre-Finn, Byoung Chul Cho, Terufumi Kato, Jinming Yu, Li Yu, Bin Zhao, Maria Catherine Pietanza, Lauren A. Byers

ABSTRACT

A phase I, open-label, dose-escalation trial of BI 764532, a DLL3/CD3 bispecific antibody, in patients (pts) with small cell lung carcinoma (SCLC) or other neuroendocrine neoplasms expressing DLL3.

AUTHOR(S)
Martin Wermke, Enriqueta Felip, Valentina Gambardella, Yasutoshi Kuboki, Daniel Morgensztern, Zohra Oum'Hamed, Junxian Geng, Matus Studeny, Taofeek K. Owonikoko

ABSTRACT

Trial in progress: A multicenter phase Iib/II study of pelcitoclax (APG-1252) in combination with paclitaxel in patients with relapsed/refractory small-cell lung cancer (R/R SCLC).

AUTHOR(S)
Angel Qin, Gregory P. Kalemkerian, Jyoti D. Patel, Nisha A. Mohindra, Jennifer W. Carlisle, Jacob Sands, Zhicong He, Robert Winkler, Zhiyan Liang, Vakessa Hammock, Riccardo Bombelli, Ming Lu, Yang Xu, Tommy Fu, Cunlin Wang, Dajun Yang, Yifan Zhai
Antti PD-(L)1 in KRAS mutant advanced nsclcs: A meta-analysis of randomized controlled trials.

AUTHOR(S)
Thierry Landre, Gregoire Justeau, Jean-baptiste Assié, Kader Chouahnia, Chérifa Taleb, Christos Chouaid, Boris Duchemann

ABSTRACT
9025

AUTHOR(S)
Hyojin Kim, Sangjoon Choi, Seokhwi Kim, Jaehong Aum, Sergio Pereira, Seonwook Park, Minuk Ma, Seunghwan Shin, Kyunghyun Paeng, Donggeun Yoo, Wonkyung Jung, Chan-Young Ock, Se-Hoon Lee, Jin-haeng Chung, Yoon-La Choi, Tony S. Mok

ABSTRACT
9026
Clinical outcomes for plasma-based comprehensive genomic profiling versus tissue testing in advanced lung adenocarcinoma.

AUTHOR(S)

ABSTRACT
9027
Changes in PD-L1 tumor proportion score are associated with CD274 gene (encoding PD-L1) copy number variation in non-small cell lung cancer.

AUTHOR(S)
Stephanie L. Alden, Biagio Ricciuti, Giuseppe Lamberti, Liam F. Spurr, Lynette M. Sholl, Andrew D. Cherniack, Mark M. Awad, Yvonne Y. Li

ABSTRACT
Concordance of tissue- and plasma-derived genomic profiling in CheckMate 9LA, using the FoundationOne CDx and GuardantOMNI assays.

AUTHOR(S)
Jonathan F. Baden, Mark Sausen, Natallia Kalinava, William J. Geese, David Balli, Jaclyn Neely, George Green

ABSTRACT
The combination of EGFR-TKIs and anlotinib as a first-line therapy for EGFR-mutant advanced non-small cell lung cancer: A multicenter, single-arm, phase II clinical trial.

AUTHOR(S)
Zhiyong He, Jinghui Lin, Yueming He, Jing Zhang, Dongyong Yang, Wenbin Qiu, Jinhuo Lai, Xi Chen, Wenzheng Fang, Feng Ye, Tianwen Xu, Huita Wu, Dongfa Qiu, Wujin Chen, Lifang Cai, Shengchi Chen, Qunying Lin, Li Lin

ABSTRACT
A randomized phase III study comparing carboplatin with nab-paclitaxel versus docetaxel for elderly patients with squamous-cell lung cancer: Capital study.

AUTHOR(S)
Yoichiro Hamamoto, Yoshihito Kogure, Akiko Kada, HiroyaHashimoto, Shinji Atagi, Yuichi Takiguchi, Hideo Saka, Noriyuki Ebi, Akira Inoue, Takayasu Kurata, Takeharu Yamanaka, Masahiko Ando, Shunichiro Iwasawa, Kaoru Kubota, Mitsuhiro Takenoyama, Takashi Seto, Nobuyuki Yamamoto, Akihiko Gemma

ABSTRACT
Response to selpercatinib versus prior systemic therapy in patients (pts) with RET fusion+ non-small-cell lung cancer (NSCLC).

AUTHOR(S)

ABSTRACT
Second-line nintedanib plus docetaxel for patients with lung adenocarcinoma after failure on first-line immune checkpoint inhibitor combination therapy: Initial efficacy and safety results from VARGADO Cohort C.
Phase II trial of atezolizumab (A) + carboplatin (C) + pemetrexed (P) + bevacizumab (B) in pts with stage IV non-squamous non-small cell lung cancer (NSq-NSCLC): Big Ten Cancer Research Consortium Study LUN 17-139.

Efficacy and safety of pan-ErbB inhibitor pyrotinib combined with antiangiogenic agent apatinib for HER2-mutant or amplified metastatic NSCLC: A phase II clinical study.

Treatment outcome and functional characterization of uncommon EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM).

A randomized phase II study comparing nivolumab (NIVO) with carboplatin-pemetrexed (CbPEM) for patients (pts) with EGFR mutation-positive non-small cell lung cancer (NSCLC) who acquire resistance to tyrosine kinase inhibitors (TKIs) not due to a secondary T790M mutation (WJOG8515L).
ABSTRACT

Hidetoshi Hayashi, Shunichi Sugawara, Yasushi Fukuda, Yuki Sato, Satoru Miura, Keiichi Ota, Yuichi Ozawa, Satoshi Hara, Jun- kō Tanizaki, Koichi Azuma, Shota Omori, Motoko Tachihara, Kazumi Nishino, Shinobu Hosokawa, Yasutaka Chiba, Koji Haratani, Kazuko Sakai, Kazuhiro Nakagawa

ABSTRACT

9037

Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: KEYNOTE-598.

AUTHOR(S)

Mehmet N. Sendur, Martin Reck, Delvys Rodriguez-Abreu, Keunchil Park, Dae Ho Lee, Irfan Cicin, Perran F. Yumuk, Francisco J. Orlandi, Tician A. Leal, Olivier Molinier, Nopadol Soparattanapaisarn, Adrian Langleben, Raffaele Califano, Balazs Medgyasszay, Te-Chun Hsia, Gregory A. Otterson, Lu Xu, Thomas A. Burke, Ayman Samkari, Michael J. Boyer

ABSTRACT

9038


AUTHOR(S)

Chanida Vinayanuwattikun, Piyada Sitthideatphaiboon, Chinachote Teerapakpinyo, Krittiya Korphaisarn, Naravat Poungvarin, Poonchavist Chantranuwatana, Shanop Shuanghoti, Chatchawit Aporntewan, Virote Sriuranpong

ABSTRACT

9039

Phase II study of brigatinib in ROS1 positive non-small cell lung cancer (NSCLC) patients previously treated with crizotinib: Barossa cohort 2.

AUTHOR(S)

Haruko Daga, Seiji Niho, Jun Sakakibara-Konishi, Hiroshi Tanaka, Yasushi Goto, Kadoaki Ohashi, Ryo Toyozawa, Masahiro Kodani, Toshiaki Takahashi, Yoshihiro Hattori, Masahiro Morise, Takaya Ikeda, Shingo Matsumoto, Kiyotaka Yoh, Shogo Nomura, Koichi Goto

ABSTRACT

9040

Determination of clinical benefit among patients with radiological stable disease to immune checkpoint inhibitors.

AUTHOR(S)

Jia Luo, Song Wu, Hira Rizvi, Qu Zhang, Jacklynn V. Egger, Juan C. Osorio, Adam J. Schoenfeld, Andrew J. Plodkowski, Michelle S. Ginsberg, Ashok K. Gupta, Rajiv Raja, Mark G. Kris, Matthew D. Hellmann

ABSTRACT
Brigatinib in Japanese patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): First results from the J-ALTA tyrosine kinase inhibitor (TKI)-naive expansion cohort.

AUTHOR(S)
Masashi Kondo, Shunichi Sugawara, Toshihide Yokoyama, Toru Kumagai, Makoto Nishio, Koichi Goto, Yuichiro Ohe, Takashi Seto, Nobuyuki Yamamoto, Kentarou Kudou, Takayuki Asato, Pingkuan Zhang, Kazuhiko Nakagawa

ABSTRACT
A large real-world study on the effectiveness of the combined inhibition of EGFR and MET in EGFR-mutant advanced non-small cell lung cancer (NSCLC).

AUTHOR(S)
Liu Li, Jingjing Qu, Jianfu Heng, Chunhua Zhou, Yi Xiong, Haiyan Yang, Wenjuan Jiang, Liang Zeng, Songlin Zhu, Yongchang Zhang, Jiarong Tan, Ting Hou, Analyn Lizaso, Zhiqiu Chen, Chengping Hu, Pengbo Deng, Nong Yang

ABSTRACT

AUTHOR(S)
Masayuki Shirasawa, Tatsuya Yoshida, Yukiko Shimoda, Daisuke Takayanagi, Kouya Shiraishi, Takashi Kubo, Sachio Mitani, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Hitoshi Ichikawa, Takashi Kohno, Noboru Yamamoto, Shun-ichi Watanabe, Noriko Motoi, Yuichiro Ohe

ABSTRACT
Predicting response to pembrolizumab in non-small cell lung cancer, by analyzing the spatial arrangement of tumor infiltrating lymphocytes using deep learning.

AUTHOR(S)
Efrat Ofek, Jair Bar, Alona Zer, Damien Urban, Chen Mayer, Chen Sade, Ori Zelichov, Alon Groisman, Avi Laniado, Yuval Gabay, Willy Polychenko, Roman Gluskin, Albert Achtenberg, Meora Feinmesser, Iris Barshack

ABSTRACT
Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic non-small cell lung carcinoma.
**AUTHOR(S)**


**ABSTRACT**

9046

Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab ± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).

**AUTHOR(S)**

Johanna C. Bendell, Patricia LoRusso, Michael J. Overman, Anne M. Noonan, Dong-Wan Kim, John Strickler, Sang-We Kim, Stephen J. Clarke, Thomas J. George, Peter S. Grimison, Minal A. Barve, Manik A. Amin, Jayesh Desai, Trisha Wise-Draper, Zachary Cooper, Nairouz Elgeioushi, Nancy K. Mueller, Rakesh Kumar, Kevin Y. Wu, Sandip P. Patel

**ABSTRACT**

9047

Phase 1b/2 study of capmatinib plus gefitinib in patients with EGFR-mutated, MET-dysregulated non-small cell lung cancer who received prior therapy: Final overall survival and safety.

**AUTHOR(S)**

Yi-Long Wu, Li Zhang, Dong-Wan Kim, Xiaoqing Liu, Dae Ho Lee, James Chih-Hsin Yang, Myung-Ju Ahn, Johan F. Vansteenkiste, Wu-Chou Su, Enriqueta Felip, Mariana Carbini, Sabine Glaser, Oezlem Tanriverdi, Andrea Chassot-Agostinho, Daniel S. Tan

**ABSTRACT**

9048

Response to immune checkpoint inhibition as monotherapy or in combination with chemotherapy in metastatic ROS1-rearranged lung cancers.

**AUTHOR(S)**

Noura J. Choudhury, Jaime L. Schneider, Tejas Patil, Viola W. Zhu, Debra A. Goldman, Soo-Ryum Yang, Christina Falcon, Andrew Do, Yunan Nie, Andrew J. Plodkowski, Jamie E. Chaft, Subba Digumarthy, Natasha Rekhtman, Maria E. Arcila, Alexia Iasonos, Sai-Hong I. Ou, Jessica J. Lin, Alexander E. Drilon

**ABSTRACT**

9049

Complete metabolic response in advanced non-small cell lung cancer patients with prolonged response to immune checkpoint inhibitor therapy.
ABSTRACT

9050

Comprehensive investigation of mutational features of adenocarcinoma in situ and invasive adenocarcinoma among Chinese lung cancer patients.

AUTHOR(S)

Chan Xiang, Yuchen Han, Wentao Fang, Haohua Teng, Shennan Chen, Lianying Guo, Zhanxian Shang, Jikai Zhao, Jinzhi Wei, Jiaxin Liu, Lei Zhu, Analyn Lizaso, Yiran Cai, Jing Lin, Li Yan

ABSTRACT

9051

Amivantamab compared with real-world therapies in patients with NSCLC with EGFR Exon 20 insertion mutations who have progressed after platinum doublet chemotherapy.

AUTHOR(S)

Anna R. Minchom, Nicolas Girard, Lyudmila Bazhenova, Sai-Hong I. Ou, Shirish M. Gadgeel, José Trigo, Santiago Viteri, Daniel Backenroth, Archan Bhattacharya, Tracy Li, Parthiv Mahadevia, Joshua Bauml

ABSTRACT

9052


AUTHOR(S)

Hyun Ae Jung, Min Hee Hong, Hyun Woo Lee, Kyung Hee Lee, Ilhwan Kim, Young Joo Min, Hee Kyung Ahn, Byoung Yong Shim, Yoon Hee Choi, Yun-Gyoo Lee, Jeong A. Kim, Joung Soon Jang, Seong-Hoon Shin, Keon Uk Park, Keunchil Park, Jin Hyoung Kang

ABSTRACT

9053

Clinico-pathological and genomic features of NRAS- or HRAS-mutated non-small cell lung cancer (NSCLC) identified in large-scale genomic screening project (LC-SCRUM-Asia).

AUTHOR(S)


ABSTRACT
**SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, for advanced NSCLC with EGFR mutations: Data from a multicenter phase 1 study.**

**AUTHOR(S)**
Meiqi Shi, Jianhua Chen, KunYan Li, Yong Fang, Guilan Wen, Xingya Li, Yungpeng Liu, Yuping Sun, Bo Zhu, Lizhu Lin, Yuankai Shi, Linna Wang, Junqin Yang, Pan Liu, Jifeng Feng

**ABSTRACT**

**Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the phase II GEOMETRY mono-1 study.**

**AUTHOR(S)**
Juergen Wolf, Edward B. Garon, Harry J. Groen, Daniel S. Tan, Isabelle Gilloteau, Sylvie Le Mouhaer, Can Cai, Andrea Chassot-Agostinho, Maria Reynolds, Dawn Odom, Rebecca S. Heist

**ABSTRACT**

**Patient-reported outcomes (PRO) from the phase 2 CodeBreaK 100 trial evaluating sotorasib in KRAS p.G12C mutated non-small cell lung cancer (NSCLC).**

**AUTHOR(S)**
Alexander I. Spira, Frederick H. Wilson, Geoffrey Shapiro, Christophe Dooms, Alessandra Curioni-Fontecedro, Taito Esaki, Fabrice Barlesi, Kim Cocks, Andrew Trigg, Kendall Stevinson, Tara Matsuda, Qui Tran, Jhanelle E. Gray

**ABSTRACT**

**TROPION-PanTumor01: Dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC).**

**AUTHOR(S)**

**ABSTRACT**

**The role of chemotherapy plus immune checkpoint inhibitors in oncogenic driven non-small cell lung cancer: A University of California Lung Cancer Consortium retrospective study.**
**A phase 2, open-label, multicenter study to evaluate the efficacy, safety, and tolerability of KN046 in combination with chemotherapy in subjects with advanced non-small cell lung cancer.**

**Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: A consecutive analysis of NSCLC patients with high PD-L1 expression.**

**EGFR Exon 20 insertion: Prognostic and predictive values in advanced non-small cell lung cancer, a real-world study.**

**Features in genomics and tumor immune microenvironment in NSCLC treated with neoadjuvant PD-1 blockade.**
Subgroup-level network meta-analysis for efficacy of first-line immunotherapy-based treatments in advanced non-small cell lung cancer.

AUTHOR(S)
Fang Wu, Wentao Tian, Chenghui Cao, Jiawen Ke, Nuopei Tan, Yuwen Cai, Yue Zeng, Yue Pan, Xiaohan Liu, Lishu Zhao, Long Shu, Junqi Liu

Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC).

AUTHOR(S)

Taletrectinib (AB-106; DS-6051b) in metastatic non-small cell lung cancer (NSCLC) patients with ROS1 fusion: Preliminary results of TRUST.

AUTHOR(S)
Caicun Zhou, Huijie Fan, Yongsheng Wang, Huijuan Wu, Nong Yang, KunYan Li, Xicheng Wang, Xintian Qin, Qitao Yu, Yong Fang, Min Tao, Xue Meng, Baohui Han, Xiaorong Dong, Bing Yan

Physician concern about delaying lung cancer treatment while awaiting biomarker testing: Results of a survey of U.S. oncologists.

AUTHOR(S)

Neratinib efficacy in a subgroup of patients with EGFR exon 18-mutant non-small cell lung cancer (NSCLC) and central nervous system (CNS) involvement: Findings from the SUMMIT basket trial.
The effects of tislelizumab treatment on the health-related quality of life of non-small cell lung cancer patients who progressed on a prior platinum-containing regimen.

Brigatinib (BRG) in ALK+ crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials.

Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwing).
Phase I study of the aurora kinase A inhibitor alisertib in combination with osimertinib in EGFR-mutant lung cancer.

AUTHOR(S)
Collin M. Blakely, Matthew A. Gubens, Gregory M. Allen, Shrusti Shah, Matthew Jereza, Bianca Bacaltos, Sourav Bandyopadhyay

ABSTRACT

Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP non-matched sub-study S1800A).

AUTHOR(S)

ABSTRACT

PD-(L)1 inhibitors as monotherapy for the first-line treatment of non-small cell lung cancer patients with high PD-L1 expression: A network meta-analysis.

AUTHOR(S)

ABSTRACT

Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20).

AUTHOR(S)

ABSTRACT

Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ≥ 50%: Results from EMPOWER-Lung 1 study.
AUTHOR(S)
Mahmut Gumus, Chieh-I Chen, Cristina Ivanescu, Saadettin Kilickap, Igor Bondarenko, Mustafa Ozguroglu, Miranda Gogishvili, Haci M. Turk, Irfan Cicin, James Harnett, Vera Mastey, Ulrike Naumann, Matthew Reaney, Gerasimos Konidaris, Medha Sasanee, Keri Brady, Siyu Li, Giuseppe Gullo, Petra Rietschel, Ahmet Sezer

ABSTRACT
9078

Real-world patterns of biomarker testing and targeted therapy in metastatic non-small cell lung cancer (mNSCLC) in the community oncology setting.

AUTHOR(S)
Eric S. Nadler, Anupama Vasudevan, Kalatu Davies, Yunfei Wang, Ravindra Gupta, Sarika Ogale

ABSTRACT
9079

Identification of recurrence-associated gene signature and tumor immune microenvironment features in resected stage I NSCLC.

AUTHOR(S)
Fang Wu, Chunhong Hu, Long Shu, Chen Chen, Songqing Fan, Qichun Liang, Hongmei Zheng, Yue Pan, Lishu Zhao, Fangwen Zou, Chaoyuan Liu, Wenliang Liu, Fenglei Yu, Xianling Liu, Lijuan Liu, Lingling Yang, Yang Shao

ABSTRACT
9080

Update analysis of NEJ009: Gefitinib alone (G) versus gefitinib plus chemotherapy (GCP) for non-small cell lung cancer with mutated EGFR.

AUTHOR(S)
Eisaku Miyauchi, Satoshi Morita, Atsushi Nakamura, Yukio Hosomi, Kana Watanabe, Satoshi Ikeda, Masahiro Seike, Yuka Fujita, Koichi Minato, Ryo Ko, Toshiyuki Harada, Koichi Hagiwara, Kunihiko Kobayashi, Toshihiro Nukiwa, Akira Inoue

ABSTRACT
9081

Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study.

AUTHOR(S)
Geoffroy Bilger, Nicolas Girard, Helene Doubre, Matteo Giaj Levra, Etienne Giroux Leprieur, Frederique Giraud, Chantal Decroisette, Alain Livartowski, Marie Ange Massiani

ABSTRACT
9082
Intracranial activity of tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC enrolled in VISION.

AUTHOR(S)
Jyoti D. Patel, Xiuning Le, Remi Veillon, Ian C. Anderson, Christine M. Bestvina, Ingel Demedts, Marina C. Garassino, Julien Mazieres, Masahiro Morise, Egbert F. Smit, S. Peter Eggleton, Aurora OBrate, Gordon Otto, Rolf Bruns, Karl-Maria Schumacher, Paul K. Paik

ABSTRACT
9084
Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥ 50%: EMPOWER-Lung 1 subgroup analysis.

AUTHOR(S)

ABSTRACT
9085
Real-world outcomes and clinical characteristics of patients with brain metastases from EGFR mutated non-small cell lung cancer: Data from a large retrospective study (REFLECT).

AUTHOR(S)
Urska Janzic, Alfredo Addeo, Elizabeth Dudnik, Andriani Charpidou, Adam Pluzanski, Tudor-Eliade Ciuleanu, Ivan Donev, Una Rigney, Judith Elbaz, Jorgen Aaroe, Nir Peled, Maximilian Hochmair

ABSTRACT
9086
STK11/TP53 co-mutated non-small cell lung cancer (NSCLC) to display a unique tumor microenvironment (TME) and metabolic profile.

AUTHOR(S)
Abdul R. Naqash, Charalampos S. Floudas, Asaf Maoz, Joanne Xiu, Yasmine Baca, Jia Zeng, Chul Kim, Julia Judd, Luis E. Raez, Gilberto Lopes, Jorge J. Nieva, Hossein Borghaei, Wolfgang M. Korn, Naoko Takebe, Stephen V. Liu, Hirva Mamdani

ABSTRACT
9087
Chemo-immunotherapy outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer.

Association between improvements in survival of metastatic NSCLC patients and targeted- and immuno-therapy.

First-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥ 50%) advanced non-small cell lung cancer (aNSCLC) in the real world: A national French bispective multicentric cohort—ESCKEYP trial (GFPC 05-2018).

Beyond steroids: Immunosuppressants in steroid-refractory/resistant immune related adverse events.
CNS activity of poziotinib in NSCLC with exon 20 insertion mutations.

**AUTHOR(S)**
Xiuning Le, Marina C. Garassino, Robin Cornelissen, Mark A. Socinski, Nishan Tchekmedyian, Julian R. Molina, Christina S. Baik, Sharon Leu, Lyndah Dreiling, Francois M. Lebel, Jeffrey M. Clarke

**ABSTRACT**
Impact of rapid multigene assays with short turnaround time (TAT) on the development of precision medicine for non-small cell lung cancer (NSCLC).

**AUTHOR(S)**

**ABSTRACT**
Maintenance targeted therapy compared to standard of care (SoC) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): Results from the phase II randomized UNICANCER/IFCT1301- SAFIR02-LUNG intergroup trial.

**AUTHOR(S)**
Benjamin Besse, Maryam Karimi, Pascale Tomasini, Henri Janicot, Judith Raimbourg, Clarisse Audigier-Valette, Anne Madroszyk, Francois Chomy, Eric Dansin, Julien Mazieres, Alexis Cortot, Ivan Bieche, Ludovic Lacroix, Sandrine Boyault, Isabelle Soubeyran, Alain Morel, Alicia Tran-Dien, Alexandra Jacquet, Jean-Charles Soria, Fabrice Barlesi

**ABSTRACT**
Time-dependent efficacy of checkpoint inhibitor nivolumab in metastatic lung cancer patients.

**AUTHOR(S)**
Abdoulaye Karaboué, Thierry Collon, Ida Pavese, Viviane Bodiguel, Elda Zakine, Pasquale Innominato, Mohamed Bouchahda, René Adam, Francis Levi

**ABSTRACT**
Optimal next-generation sequencing (NGS) panel for estimating tumor mutation burden (TMB) and its clinical implication for non-small cell lung cancer (NSCLC).

**ABSTRACT**

9097

Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations.

**AUTHOR(S)**

Sai-Hong I. Ou, Huamao M. Lin, Jin-Liern Hong, Yu Yin, Shu Jin, Jianchang Lin, Minal Mehta, Danny Nguyen, Joel W. Neal

**ABSTRACT**

9098

Impact of immune checkpoint inhibitor (CPI) and EGFR tyrosine kinase inhibitor (TKI) sequence on time to treatment failure (TTF) among EGFR plus NSCLC treated in a community-based cancer research network.

**AUTHOR(S)**

Carissa Jones, Rebecca Lachs, Emma Sturgill, Amanda Misch, Caressa Lietman, Suzanne F. Jones, Melissa L. Johnson, David R. Spigel, Andrew J. McKenzie

**ABSTRACT**

9099

Interim results of viagenpumatucel-L (HS-110) plus nivolumab in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC) in two treatment settings.

**AUTHOR(S)**

Roger B. Cohen, George E. Peoples, Toana Kawashima, Bill Arana, Xiaoxing Cui, Lyudmila Bazhenova, Rachel E. Sanborn, Wael A. Harb, Nathan A. Pennell, Daniel Morgensztern

**ABSTRACT**

9100

Incidence and heterogeneity of C797S and other EGFR resistance mutations on routine comprehensive genomic profiling (CGP).

**AUTHOR(S)**

Pasi A. Janne, Jessica K. Lee, Russell Madison, Jeffrey M. Venstrom, Alexa B. Schrock, Geoffrey R. Oxnard

**ABSTRACT**

9101
RATIONALE-307: Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65.

AUTHOR(S)
Jie Wang, Shun Lu, Xinmin Yu, Yanping Hu, Yuping Sun, Zhijie Wang, Jun Zhao, Yan Yu, Chunhong Hu, Kunyu Yang, Guosheng Feng, Kejing Ying, Wu Zhuang, Jianying Zhou, Jingxun Wu, Shiang Jiin Leaw, Jing Zhang, Xiao Lin, Nong Yang

ABSTRACT
9102

Chronic immune checkpoint inhibitor (ICI) pneumonitis in patients (pts) with non-small cell lung cancer (NSCLC).

AUTHOR(S)
Jessica Stuart, Biagio Ricciuti, Joao Victor M. Alessi, Mizuki Nishino, Mark M. Awad

ABSTRACT
9103

Genomic markers associated with hyperprogression in patients with lung cancer treated with immune checkpoint inhibitors.

AUTHOR(S)

ABSTRACT
9105

Impact of STK11 mutation on first-line immune checkpoint inhibitor (ICI) outcomes in a real-world KRAS G12C mutant lung adenocarcinoma cohort.

AUTHOR(S)
Rebecca S. Heist, Junhua Yu, Elifnur Y. Donderici, Nicole Zhang, Carin R. Espenschied, Kathryn Lang, Beata Korytowsky, Andrew S. Chi, James G. Christensen

ABSTRACT
9106

Association of concomitant NSAID and immunotherapy on outcomes in patients with non-small cell lung cancer: Analysis of the National Veterans Health Administration Database.

AUTHOR(S)

ABSTRACT

AUTHOR(S)
ErinMarie Kimbrough, Hiba I. Dada, Leylah Drusbosky, Yujie Zhao, Rami Manochakian, Yanyan Lou

ABSTRACT

Long-term efficacy and safety of larotrectinib in patients with TRK fusion-positive lung cancer.

AUTHOR(S)

ABSTRACT

Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update.

AUTHOR(S)

ABSTRACT

Capmatinib efficacy in patients with NSCLC identified as METex14 using an NGS-based liquid biopsy assay: Results from the GEOMETRY mono-1 study.

AUTHOR(S)
Rebecca S. Heist, Edward B. Garon, Daniel S. Tan, Harry J. Groen, Takashi Seto, Egbert F. Smit, Mike R. Zou, Yiqun Yang, Ying Li, Andrea Chassot-Agostinho, Juergen Wolf

ABSTRACT

Interim results of a phase II single arm trial combining afatinib with cetuximab in patients with EGFRex20ins positive NSCLC.

AUTHOR(S)
Bianca van Veggel, Anthonie J. van der Wekken, Marthe Paats, Sayed M. Hashemi, Lizza Hendriks, Karolina Sikorska, Daan van den Broek, Kim Monkhorst, Egbert F. Smit, Joop De Langen
**ABSTRACT**

9112

**DNMT3A** mutation to identify a subset of non-small cell lung cancers with increased sensitivity to PD-(L)1 blockade.

**AUTHOR(S)**

Biagio Ricciuti, Joao Victor M. Alessi, Yvonne Y. Li, Marissa N. Lawrence, Hersh Gupta, Mizuki Nishino, Andrew D. Cherniack, Lynette M. Sholl, Mark M. Awad

**ABSTRACT**

9113

Nitroglycerin (NTG) plus whole intracranial radiotherapy for brain metastases (BM) in non-small cell cancer patient (NSCLC): A randomized open label, phase II clinical trial.

**AUTHOR(S)**


**ABSTRACT**

9114

Stereotactic body radiation therapy and in situ oncolytic virus therapy followed by immunotherapy in metastatic non-small cell lung cancer.

**AUTHOR(S)**

Carlo Guerrero, Joe E. Ensor Jr., Kai Sun, Andrew M. Farach, Sindhu Nair, Jun Zhang, Monisha Singh, Jorge G. Darcourt, Priya V. Ramshesh, Edward B. Butler, Bin S. Teh, Mark Sultenfuss, Nakul Gupta, Helen E. Heslop, Jaime A. Mejia, Jenny C. Chang, Eric Bernicker

**ABSTRACT**

9115

Genomic landscape of non-small cell lung cancer (NSCLC) with methylthioadenosine phosphorylase (*MTAP*) deletion.

**AUTHOR(S)**


**ABSTRACT**

9116
Superior overall survival (OS), progression-free survival (PFS), and clinical response (CR) predictions for patients with non-small cell lung cancer (NSCLC) using Cellworks Singula: myCare-022-05.

AUTHOR(S)

ABSTRACT
9117
Use of brain radiotherapy as part of first course of treatment for NSCLC with de novo brain metastasis.

AUTHOR(S)
Rafael Arteta-Bulos, Nadeem Bilani, Leah Elson, Elizabeth B. Elimimian, Diana Saravia, Mihir Naik, Zeina A. Nahleh, Evan W. Alley

ABSTRACT
9118
Clinicopathologic, genomic, and tumor microenvironment correlates of aneuploidy and immunotherapy outcomes in NSCLC.

AUTHOR(S)
Joao Victor M. Alessi, Biagio Ricciuti, Yvonne Y. Li, Hersh Gupta, Giuseppe Lamberti, Gonzalo Recondo, Deepti Venkatraman, Mizuki Nishino, Andrew D. Cherniack, James Lindsay, Bijaya Sharma, Kathleen L. Pfaff, Kristen Felt, Lynette M. Sholl, Scott J. Rodig, Mark M. Awad

ABSTRACT
9119
Population-based impacts of new therapies on outcomes for stage IV non-small cell lung cancer.

AUTHOR(S)
Rebekah Rittberg, Oliver Bucher, Lin Xue, Zeb Aurangzeb, Shantanu O. Banerji, David Dawe

ABSTRACT
9120
Clinicopathologic and genomic correlates of tumor-infiltrating immune cells and immunotherapy efficacy in NSCLC.

AUTHOR(S)
Joao Victor M. Alessi, Biagio Ricciuti, Mizuki Nishino, Jason L. Weirather, Ann-Elisabeth Le, James Lindsay, Bijaya Sharma, Kristen Felt, Lynette M. Sholl, Scott J. Rodig, Mark M. Awad

**ABSTRACT**

*9121*

**Patterns of survival in NSCLC with de novo brain metastasis: SRS, WBRT, and no radiotherapy cohorts.**

**AUTHOR(S)**

Diana Saravia, Nadeem Bilani, Leah Elson, Elizabeth B. Elimimian, Evan W. Alley, Mihir Naik, Zeina A. Nahleh, Rafael Arteta-Bulos

**ABSTRACT**

*9122*

**Analysis of patterns of care and benefit of thoracic radiotherapy for patients with stage IV NSCLC in the immunotherapy-era from a national hospital-based registry.**

**AUTHOR(S)**

Michael Kharouta, Andrew J. Gross, Kevin Kelley, Serah Choi, Tithi Biswas

**ABSTRACT**

*9123*

**Effect of continuing osimertinib with chemotherapy in the post-progression setting on progression-free survival among patients with metastatic epidermal growth factor receptor (EGFR) positive non-small cell lung cancer.**

**AUTHOR(S)**

Tejas Patil, David Chun Cheong Tsui, Andrew Nicklawsky, Erin L. Schenk, William T. Purcell, Paul A. Bunn Jr., Jose M. Pacheco, D. R. Camidge

**ABSTRACT**

*9124*

**Lung cancer in HIV versus non-HIV population: Nationwide analysis of mortality, morbidity, demographics, and healthcare utilization.**

**AUTHOR(S)**

Muhammad J. Tariq, Shweta Gupta

**ABSTRACT**

*9125*
Trial in progress: Blood-based biomarker analysis in high PD-L1 expressing NSCLC treated with PD-1/PD-L1 based therapy with or without the addition of platinum-based chemotherapy.

AUTHOR(S)
Mary J. Fidler, Victoria M. Villaflor, Amol Rao, Balazs Halmos, Erin M. Bertino, Raymond U. Osarogiagbon, David P. Carbone

ABSTRACT
TPS9126

A randomized, phase 3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (TROPION-Lung01).

AUTHOR(S)

ABSTRACT
TPS9127

AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).

AUTHOR(S)
Mark A. Socinski, Alexander I. Spira, Luis G. Paz-Ares, Martin Reck, Shun Lu, Makoto Nishio, Jiang Li, Yunfei Zhou, Joon Whan Rhee, Sandra Chica Duque, Xinmin Yu

ABSTRACT
TPS9128

KRYSRAL-12: A randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRAS$^{G12C}$ mutation.

AUTHOR(S)

ABSTRACT
TPS9129
Camrelizumab monotherapy or in combination with apatinib for PD-L1-positive advanced pulmonary sarcomatoid carcinoma: A multicenter, open-label, single-arm, phase II study.

AUTHOR(S)
Mingfang Zhao, Tao Han

ABSTRACT
TPS9130

A multicenter, randomized, double-blind study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER).

AUTHOR(S)
Li Zhang, Wenfeng Fang, Yunpeng Yang, Qitao Yu, Di Wu, Yingcheng Lin, Hua Zhang, Junfei Zhu, Guowu Wu, Bin Lan, Zeqiang Zhou, Zibing WANG, Xiaolin Lei, Haifeng Lin, Xiaohua HU, Suming Pan

ABSTRACT
TPS9131

CHRYSALIS-2: A phase 1/1b study of lazertinib as monotherapy and in combination with amivantamab in patients with EGFR-mutant NSCLC.

AUTHOR(S)
Catherine A. Shu, Koichi Goto, Byoung Chul Cho, Frank Griesinger, James Chih-Hsin Yang, Enriqueta Felip, John Xie, Jun Chen, Janine Mahoney, Meena Thayu, Roland E. Knoblauch, Leonardo Trani, Joshua Bauml

ABSTRACT
TPS9132


AUTHOR(S)
Joel W. Neal, Palak Kundu, Tomohiro Tanaka, Ida Enquist, Sid Patel, Alessia Balestrini, Jin Wang, Thomas Newsom-Davis, Yasushi Goto, Nick Pavlakis, Sang-We Kim

ABSTRACT
TPS9134

Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC.
AUTHOR(S)

ABSTRACT

TPS9135

Phase II two-arm study of tepotinib plus osimertinib in patients with EGFR-mutant NSCLC and acquired resistance to first-line osimertinib due to MET amplification: INSIGHT 2.

AUTHOR(S)

ABSTRACT

TPS9136

Phase 2 study of PD-1 inhibitor JTX-4014 alone and in combination with vopratelimab, an ICOS agonist, in biomarker-selected subjects with metastatic NSCLC after one prior platinum-containing regimen (SELECT).

AUTHOR(S)
Oleh Kobziev, Iurie Bulat, Yuriy Ostapenko, Zanete Zvirbule, Grygorii Ursol, Vasyl Boyko, Viktor Paramonov, Yasmin Hashambhoy-Ramsay, Courtney Hart, Christopher Harvey, Ashley Graca, Lidya Le, Weidong Zhang, Bo Chao, Judy Jimenez, Krithi Bala, Sarah Maxwell, Haley Laken, Johan Baeck, Ellen M. Hooper

ABSTRACT

TPS9137

An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON).

AUTHOR(S)
Mariam Jamal-Hanjani, Alastair Greystoke, Fiona Thistlethwaite, Yvonne J. Summers, Jennifer Allison, Judith Cave, Kim Orchard, Christian Ottensmeier, Gary Middleton, Leila Khoja, Michael Grant, Shreenal Patel, Jane Robertson, Karl Peggs, Martin Forster

ABSTRACT

TPS9138

HERTHENA-Lung01: A randomized phase 2 study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC.

AUTHOR(S)
Melanoma/Skin Cancers

Back to Program

Showing 72 Presentations

https://meetinglibrary.asco.org/session/13663

Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib + trametinib (dab + tram): Primary results of COMBI-APlus.

AUTHOR(S)

ABSTRACT
9525

Overall survival in patients who received checkpoint inhibitors after completing tebentafusp in a phase 3 randomized trial of first-line metastatic uveal melanoma.

AUTHOR(S)
Marlana Orloff, Richard D. Carvajal, Alexander N. Shoushtari, Joseph J. Sacco, Max Schlaak, Claire Watkins, Shaad E. Abdullah, Howard Goodall, Marcus O. Butler

ABSTRACT
9526
Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator’s choice (IC) in first-line metastatic uveal melanoma.

AUTHOR(S)

ABSTRACT
9527

Results of phase II randomized study of intermittent versus continuous schedule of vemurafenib plus cobimetinib in BRAF-mutated advanced melanoma.

AUTHOR(S)
Maria Gonzalez-Cao, Clara Mayo de las Casas, Juana Oramas, Miguel-Angel Berclano-Guerrero, Luis De la Cruz, Pablo Cerezuela-Fuentes, Ana M. Arance, Eva Muñoz-Couselo, Enrique Espinosa, Teresa Puértolas, Robert Diaz Beveridge, Sebastian Ochenduszko, Maria Jose Villanueva Silva, Laura Basterretxea, Lorena Bellido, Delvys Rodriguez-Abreu, Ana Drozdowskyj, Miguel Angel Molina Vila, Jose A. Lopez-Martin, Alfonso Berrocal

ABSTRACT
9528

A phase 2 clinical trial on trametinib and low-dose dabrafenib in advanced pretreated BRAFV600/\text{NRAS}^{Q61R/K/L} wild-type melanoma (TraMel-WT): Interim efficacy and safety results.

AUTHOR(S)
Gil Awada, Julia K. Schwarze, Jens Tijtgat, Giuseppe Fasolino, Hendrik Everaert, Bart Neyns

ABSTRACT
9529

Discrepancies in response and immune-related adverse events (irAE) of anti-PD-1 monotherapy between races and primary sites in patients (pts) with advanced nonacral cutaneous melanoma (NACM).

AUTHOR(S)

ABSTRACT
9530
Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in patients (pts) with previously treated (2L+) metastatic uveal melanoma (mUM).

AUTHOR(S)

ABSTRACT
9531

Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma: Final results from the dose-finding phase I part of the IMMU-Target trial.

AUTHOR(S)
Lisa Zimmer, Angela Krackhardt, Erwin S. Schultz, Daniela Goeppner, Chalid Assaf, Dietrich Trebing, Elisabeth Livingstone, Dirk Schadendorf

ABSTRACT
9532

Patterns and management of progression on first-line ipilimumab combined with anti-PD-1 (IPI+PD1) in metastatic melanoma (MM) patients.

AUTHOR(S)

ABSTRACT
9533

Characteristics and probability of survival for patients with advanced melanoma who live five or more years after initial treatment with immune checkpoint blockade (ICB).

AUTHOR(S)
Kimberly Loo, Debra A. Goldman, Katherine Panageas, Margaret K. Callahan, Paul B. Chapman, Parisa Momtaz, Alexander N. Shoushtari, Jedd D. Wolchok, Michael A. Postow, Allison Betof Warner

ABSTRACT
9534
Clinical characteristics of SF3B1 mutant (mut) uveal melanoma (UM) and response to immune checkpoint inhibition (ICI).

AUTHOR(S)
Joe M. Grimes, Alexander N. Shoushtari, Marlana Orloff, Shaheer Khan, Cody Chiuzan, Susan J. Hsiao, Diana McDonnell, Brian P. Marr, Richard D. Carvajal

ABSTRACT
9535

Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma.

AUTHOR(S)

ABSTRACT
9536

Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor naïve patients with advanced melanoma.

AUTHOR(S)
Sajeve S. Thomas, Gino K. In, Bernard Doger, Simon Haefliger, Juan Martin-Liberal, Zelanna Goldberg, Alex Cacovean, Rana Fiaz, Guang Chen, Madan H. Jagasia, Friedrich Graf Finckenstein, Maria Fardis, Antonio Jimeno

ABSTRACT
9537

The use of cryoablation to overcome resistance to PD-1 blockade in unresectable melanoma.

AUTHOR(S)
Meghan Mooradian, Florian J. Fintelmann, Howard E. Kaufman, Mari Mino-Kenudson, Jaimie L. Barth, Aleigha Lawless, Tatyana Sharova, Riley Fadden, Krista M. Rubin, Donald P. Lawrence, Dennie T. Frederick, Moshe Sade-Feldman, Ryan J. Sullivan

ABSTRACT
9538

Apatinib in combination with camrelizumab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic acral melanoma.

AUTHOR(S)
Xuan Wang, Chuanliang Cui, Bin Lian, Lu Si, Zhihong Chi, Xinan Sheng, Yan Kong, Lili Mao, Xue Bai, Bixia Tang, Xieqiao Yan, Siming Li, Li Zhou, Jun Guo

**ABSTRACT**

9539

**Predictors of overall survival (OS) in patients (pts) with melanoma brain metastasis (MBM) in the modern era.**

**AUTHOR(S)**

Merve Hasanov, Denai R. Milton, Alicia B. Davies, Elizabeth Sirmans, Chantal M. Saberian, Eliza Posada, Jeffrey E. Gershenwald, Carlos A. Torres-Cabala, Jason T. Huse, Hussein A. Tawbi, Isabella C. Glitza, Jing Li, Caroline Chung, Debra Yeboa, Sylvia Opusunju, Betty Y. Kim, Frederick F. Lang, Lauren E. Haydu, Michael A. Davies, Sherise D. Ferguson

**ABSTRACT**

9540

**KEYNOTE-555 Cohort B: Efficacy, safety, and PK of pembrolizumab (pembro) 400 mg every 6 weeks (Q6W) as 1L therapy for advanced melanoma.**

**AUTHOR(S)**


**ABSTRACT**

9541

**Comparing the clinical efficacies of anti-PD-1 antibody monotherapy and anti-PD-1 and anti-CTLA-4 combination therapy as first-line immunotherapy in Japanese advanced acral melanoma: A retrospective, multicenter study (JAMP-neo study).**

**AUTHOR(S)**

Yasuhiro Nakamura, Yukiko Kiniwa, Hiroshi Kato, Osamu Yamasaki, Takeo Maekawa, Shigeto Matsushita, Tatsuya Takenouchi, Takashi Inozume, Yasuo Nakai, Satoshi Fukushima, Shintaro Saito, Atsushi Fujimoto, Taiki Isei, Natsuki Baba, Taisuke Matsuoka, Ryo Tanaka, Takahide Kaneko, Masazumi Onishi, Shusuke Yoshikawa

**ABSTRACT**

9542

**Durability of response to immune checkpoint inhibitors (ICI) in metastatic Merkel cell carcinoma (mMCC) after treatment cessation.**

**AUTHOR(S)**

Alison M. Weppler, Laetitia Da Meda, Ines Silva, Wen Xu, Giovanni Grignani, Alexander M. Menzies, Matteo S. Carlin, Georgina V. Long, Ina Nordman, Christopher Steer, Megan Lyle, Claudia Trojaniello, Paolo A. Ascierto, Celeste Lebbe, Shahneen K. Sandhu

**ABSTRACT**
Toxicity, response, and survival in older adults with metastatic melanoma treated with checkpoint inhibitors.

AUTHOR(S)

ABSTRACT
Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapy.

AUTHOR(S)
Jessica C. Hassel, Carola Berking, Max Schlaak, Thomas Eigentler, Ralf Gutzmer, Paolo A. Ascierto, Bastian Schilling, Svetlana Hamm, Frank Hermann, Philip G. Reimann, Dirk Schadendorf

ABSTRACT
KEYNOTE-629: Health-related quality of life (HRQoL) with pembrolizumab (pembro) in patients (pts) with locally advanced (LA) or recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC).

AUTHOR(S)

ABSTRACT
Checkpoint inhibition in immunosuppressed or immunocompromised patients with advanced cutaneous squamous cell carcinoma (CSCC): Data from prospective CemiplimAb-rwlc Survivorship and Epidemiology (C.A.S.E.) study.

AUTHOR(S)

ABSTRACT
The influence of harvest method on dendritic cell function and clinical outcomes in a randomized trial of a dendritic cell vaccine to prevent recurrences in high-risk melanoma.

AUTHOR(S)

ABSTRACT
Survival outcomes associated with fewer combination ipilimumab/nivolumab doses in advanced-stage melanoma.

AUTHOR(S)
Vincent T. Ma, Yilun Sun, Merna Sitto, Jessica Waninger, Leslie A. Fecher, Michael Green, Christopher D. Lao

ABSTRACT
Complete responders to checkpoint inhibitors in advanced melanoma: Relapse risk factors, and patients' outcomes.

AUTHOR(S)
Amelie Dutheil, Djaouida Belkadi, Marine Antigny, Severine Roy, Jeremy Lupu, Anaïs Vallet, Emilie Routier, Caroline Robert

ABSTRACT
The risk and tropism of central nervous system metastases (CNS) in patients with stage II cutaneous melanoma.

AUTHOR(S)
Paul Johannet, Min Jae Kim, Melissa Call, Nicholas Gulati, Judy Zhong, Janice M. Mehnert, Iman Osman

ABSTRACT
Impact of systemic therapy sequencing on overall survival for patients with advanced BRAF-mutated melanoma.

AUTHOR(S)
B. Adi Kartolo, Jasna Deluce, Wilma M. Hopman, Linda Liu, Tara D. Baetz, D. S. Ernst, John G. Lenehan

ABSTRACT
IL-6 blockade for prophylaxis and management of immune-related adverse events (irAEs) with anti-PD-1 based immunotherapy.

AUTHOR(S)
Florentia Dimitriou, Sabrina A. Hogan, Phil F. Cheng, Reinhard Dummer, Alexander M. Menzies, Georgina V. Long

ABSTRACT
Safety and efficacy of HX008: A humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma—A single-arm, multicenter, phase II study.

AUTHOR(S)
Bin Lian, Yu Chen, Di Wu, Zhiguo Luo, Zhengyun Zou, Yu Jiang, Hongming Pan, Qingxia Fan, Jianfu Zhao, Qing Xu, Renbing Jiang, Chuanliang Cui, Xuan Wang, Fang Lou, Zhen Guo, Lu Si, Zhihong Chi, Xinan Sheng, Jun Guo

ABSTRACT
Encorafenib plus Binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutant melanoma: First data of the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA.

AUTHOR(S)
Erika Richtig, Ralf Gutzmer, Carmen Loquai, Jochen Utikal, Christoph Hoeller, Rudolf Stadler, Andrea Forschner, Jessica C. Hassel, Daniela Goeppner, Michael Fluck, Sebastian Haferkamp, Martin Kaatz, Manfred Welslau, Reinhard Dummer, Roger A. Von Moos, Andrea Schmidt, Laura Milde, Olivier Michielin, Dirk Schadendorf

ABSTRACT
Plasma thymidine kinase activity (TKa) as a novel prognostic biomarker in metastatic melanoma.

AUTHOR(S)
Hildur Helgadottir, Fernanda C. Svedman, Marie Jalsenius, Veronica Hoiom, Samuel Rotstein, Suzanne E. Brage, Vitali Grozman, Fabian Söderdahl, Lars Ny, Mattias Bergqvist

ABSTRACT
Outcomes of non-treatment naive melanoma patients with central nervous system relapse.
AUTHOR(S)
Thiago Pimentel Muniz, Hadee Lone, Diana P. Arteaga, Diana Gray, Maysa T. Silveira Vilbert Pereira, Luke Mantle, Raviya Singh, Sofia Genta, Samuel Saibil, David Hogg, Anna Spreafico, Marcus O. Butler

ABSTRACT
9557

BRAF and NRAS mutation status and response to checkpoint inhibition in advanced melanoma.

AUTHOR(S)
Olivier J. van Not, Alfonsus J. van den Eertwegh, John B. Haanen, Christian U. Blank, Maureen J. Aarts, Franchette van den Berkmortel, Jan Willem de Groot, Geke Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn Van Rijn, Marion Stevense, Astrid A. Van Der Veldt, Gerard Vreugdenhil, Marye Boers-Sonderen, Han J. Bonenkamp, Anne M. Jansen, Willeke Blokx, Michel W. Wouters, Karijn Suijkerbuijk

ABSTRACT
9558

A phase 1b clinical trial of anti-PD-1 ab (Toripalimab) plus intralesional injection of OrienX010 in stage IV melanoma with liver metastases.

AUTHOR(S)
Jun Guo, Chuanliang Cui, Xuan Wang, Bin Lian, Shanshan Yin, Yue Cong, Zhihong Chi, Lu Si, Xinan Sheng, Bixia Tang, Lili Mao, Xue Bai, Xieqiao Yan, Siming Li, Li Zhou

ABSTRACT
9559

Pyrexia-related outcomes upon application of an adapted pyrexia management algorithm in patients (pts) with BRAF V600: Mutant unresectable or metastatic melanoma treated with dabrafenib plus trametinib (DabTram) in the COMBI-i trial.

AUTHOR(S)
Paolo A. Ascierto, Caroline Robert, Paul D. Nathan, Reinhard Dummer, Hussein A. Tawbi, Keith T. Flaherty, Antoni Ribas, Dirk Schadendorf, Steven Green, Lali Sandalic, Mike R. Lau, Tonatiuh Romero, Georgina V. Long

ABSTRACT
9560

Treatment outcomes in patients (pts) with melanoma brain metastases (MBM) treated with systemic therapy: A systematic literature review (SLR) and meta-analysis.

AUTHOR(S)
Efficacy of cetuximab after immunotherapy (IO) in advanced cutaneous squamous cell carcinoma (CSCC).

AUTHOR(S)
Julian A. Marin-Acevedo, Bethany Withycombe, Youngchul Kim, Zeynep Eroglu, Joseph Markowitz, Andrew S. Brohl, Ahmad A. Tarhini, Kenneth Y. Tsai, Nikhil I. Khushalani

External validation of a Dutch predictive nomogram for complete response to T-VEC in an independent American patient cohort.

AUTHOR(S)
Emma H. Stahlie, Michael Carr, Jonathan S. Zager, Alexander C. Van Akkooi

Outcomes of BRAF mutant metastatic melanoma (MM) patients (pts) after cessation of targeted therapy (TT) with BRAF or BRAF/MEK inhibitor(i).

AUTHOR(S)

Multicentre retrospective assessment of toxicity and response to immunotherapy in elderly patients with metastatic melanoma.

AUTHOR(S)
Shivanshan Pathmanathan, Hari S. Babu, Robert Mason, Saw Htut, Zulfiquar A. Otty, Megan Lyle, Marcin R. Dzienis

Health-related quality of life (HRQoL) in patients (pts) with locally advanced basal cell carcinoma (laBCC) treated with cemiplimab: Analysis of a phase II, open-label clinical trial.
AUTHOR(S)
Alexander J. Stratigos, Chieh-I Chen, Cristina Ivanescu, Karl D. Lewis, Ketty Peris, Oliver E. Bechter, James Harnett, Vera Mastey, Matthew Reaney, Christina Daskalopoulou, Patrick R. LaFontaine, Gerasimos Konidaris, Denise Bury, Suk-Young Yoo, Kosalai K. Mohan, Ebony Coates, Timothy G. Bowler, Matthew G. Fury, Aleksandar Sekulic

ABSTRACT
9566
Pathology of durable stable disease in melanoma patients treated with ipilimumab, nivolumab, or ipilimumab, and nivolumab combination therapy.

AUTHOR(S)

ABSTRACT
9567
Tumor PD-L1 expression and gene panel mutational profile as outcome predictors of PD-1-based checkpoint inhibition therapy in metastatic melanoma: A prospective multicenter DeCOG study.

AUTHOR(S)
Selma Ugurel, Klaus Griewank, Susanne Horn, Rudolf Herbst, Patrick Terheyden, Jochen Utikal, Claudia Pföhler, Jens Ulrich, Alexander Kreuter, Peter Mohr, Ralf Gutzmer, Friedegund E. Meier, Edgar Dippel, Antje Sucker, Jan-Malte Placke, Eva Hadaschik, Jürgen C. Becker, Michael Weichenthal, Dirk Schadendorf

ABSTRACT
9568
Analysis of patients (pts) with in-transit metastases treated with nivolumab (NIVO) or ipilimumab (IPI) in CheckMate 238.

AUTHOR(S)

ABSTRACT
9569
A phase Ib clinical trial of neoadjuvant OriemX010, an oncolytic virus, in combination with toripalimab in patients with resectable stage IIIb to stage IVM1a acral melanoma.

AUTHOR(S)
Xuan Wang, Chuanliang Cui, Lu Si, Caili Li, Jie Dai, Lili Mao, Xue Bai, Zhihong Chi, Xian Sheng, Yan Kong, Bin Lian, Bixia Tang, Xieqiao Yan, Li Zhou, Sining Li, Robert H. Andtbacka, Jun Guo
Management of resected stage III/IV melanoma with adjuvant immunotherapy.

AUTHOR(S)
Rebecca Johnson, Victoria Atkinson, Prachi Bhave, Alison M. Wepler, Geoffrey D. Peters, Afaf Abed, Megan Lyle, Muhammad A. Khattak, Andrew M. Haydon, Matteo S. Carlino, Shahneen K. Sandhu, Georgina V. Long, Alexander M. Menzies

Propensity weighted indirect treatment comparison of nivolumab (NIVO) versus placebo (PBO) as adjuvant therapy for resected melanoma: A number needed to treat and overall survival analysis.

AUTHOR(S)
Jeffrey S. Weber, Tayla Poretta, Brian Stwalley, Leon Sakkal, Ella X. Du, Travis Wang, Yan Chen, Yan Wang, Keith A. Betts, Alexander N. Shoushtari

Adjuvant anti-PD-1 ab (Toripalimab) versus high-dose IFN-a2b in resected mucosal melanoma: A phase II randomized trial.

AUTHOR(S)
Chuanliang Cui, Bin Lian, Lu Si, Zhihong Chi, Xinan Sheng, Yan Kong, Xuan Wang, Hui Tian, Lili Mao, Xue Bai, Bixia Tang, Xieqiao Yan, Siming Li, Li Zhou, Jun Guo

Association of health-related quality of life (HRQoL) and treatment safety with nivolumab (NIVO) in patients (pts) with resected stage IIIB/C or IV melanoma: Analysis of CheckMate 238 four-year follow-up (FU) data.

AUTHOR(S)
Jeffrey S. Weber, Helen Gogas, Xiaowu Sun, Christine Yip, Fiona Taylor, Julia Braverman, Maurice Lobo, Pratik K. Thakkar, Andriy Moshyk, James Larkin, Paolo A. Ascierto

Postoperative radiotherapy in Merkel cell carcinoma (MCC).

AUTHOR(S)
Isolated same-basin lymph node recurrence after precision lymph node excision for clinically evident melanoma metastasis.

AUTHOR(S)

Efficacy of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy.

AUTHOR(S)
Prachi Bhave, Angela M. Hong, Rebecca Johnson, Alexander M. Menzies, Georgina V. Long, Joanna Mangana, Douglas B. Johnson, Zeynep Eroglu, Ozgecan Dulgar, Hui-Ling Yeoh, Andrew M. Haydon, Georg Lodde, Elisabeth Livingstone, Muhammad A. Khatatt, Katharina C. Kähler, Axel Hauschild, Wei Wang, Matteo S. Carlino

The prognostic value of the interferon-gamma (IFNγ) signature in patients with macroscopic stage III melanoma treated with and without adjuvant systemic therapy.

AUTHOR(S)
Incidence, timing, and predictors of CNS metastasis in patients (Pts) with clinically localized cutaneous melanoma (CM).

AUTHOR(S)

Merve Hasanov, Denai R. Milton, Sapna P. Patel, Hussein A. Tawbi, Isabella C. Glitza, Sherise D. Ferguson, Debora A. Ledesma, Carlos A. Torres-Cabala, Alexander J. Lazar, Elizabeth M. Burton, Jeffrey E. Gershenwald, Lauren E. Haydu, Michael A. Davies

ABSTRACT

9580

Genome-wide association study to reveal novel germline markers of melanoma survival.

AUTHOR(S)

Vylyny Chat, Robert Ferguson, Leah Morales, Una Moran, Min Jae Kim, Matija Snuderl, Iman Osman, Jeffrey S. Weber, Tomas Kirchhoff

ABSTRACT

9581

Granulomatous and sarcoid-like immune related adverse events (irAEs) in melanoma patients following CTLA4 blockade adjuvant therapy: An analysis of 1670 high-risk patients.

AUTHOR(S)

Arish Noor, Ibrahim Yassine, Sandra J. Lee, Megan Othus, James Moon, John M. Kirkwood, Vernon K. Sondak, Antoni Ribas, Kenneth F. Grossmann, Ahmad A. Tarhini

ABSTRACT

9582

Adjuvant nivolumab in high-risk stage IIb/IIc melanoma patients: Results from investigator initiated clinical trial.

AUTHOR(S)

Melissa Wilson, Larisa J. Geskin, Richard D. Carvajal, Janice M. Mehnert, Cody Chiuzan, Benjamin Leiby, Katherine Senter, Lynn M. Schuchter, Ryan M. Weight, Michael J. Mastrangelo, Adam C. Berger

ABSTRACT

9583

Increased risk of immune-related hepatitis among adolescent and young adults (AYAs) with melanoma during immunotherapy with checkpoint inhibitors (ICIs).

AUTHOR(S)

Alicia Darwin, Damon R. Reed, Tawee Tanvetyanon
**ABSTRACT**

9584

**S1801: A randomized trial of adjuvant versus neoadjuvant pembrolizumab for melanoma.**

**AUTHOR(S)**


**ABSTRACT**

TPS9585

Combination of radiomic and biomarker signatures as exploratory objective in a phase II trial with intratumoral BO-112 plus pembrolizumab for advanced melanoma.

**AUTHOR(S)**

Ivan Marquez-Rodas, Stéphane Dalle, Eduardo Castanon, Miguel F. Sanmamed, Ana M. Arance, Pablo Cerezuela-Fuentes, Roberto Martin Huertas, Juan F. Rodríguez-Moreno, Maria Gonzalez-Cao, Eva Muñoz-Couselo, Juan Martin-Liberal, Delvis Rodriguez-Abreu, Ángel Alberich-Bayarri, Irene Mayorga-Ruiz, Miguel Angel Molina Vila, Ruth Román, Marya F. Chaney, Javier Sánchez López, Sonia Macià, Marisol Quintero

**ABSTRACT**

TPS9586

CAcTUS: A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumor DNA in guiding a switch between targeted therapy and immune therapy in patients with advanced cutaneous melanoma.

**AUTHOR(S)**


**ABSTRACT**

TPS9587

Clinical trial in progress: Phase II trial of defactinib (VS-6063) combined with VS-6766 (CH5126766) in patients with metastatic uveal melanoma.

**AUTHOR(S)**

Rino S. Seedor, Marlana Orloff, J. Silvio Gutkind, Andrew E. Aplin, Mizue Terai, Erin Sharpe-Mills, Haley Klose, Michael J. Mastrangelo, Takami Sato

**ABSTRACT**

TPS9588
Ipilimumab, nivolumab and tocilizumab as first-line therapy for advanced melanoma.

AUTHOR(S)
Inderjit Mehmi, Omid Hamid, F. S. Hodi, Melinda Vassalo, Saundra Malatyali, Swathi Krishnarajapet, Nan O'Donnell, Angeli Castrence, Eunice Lim, Jill Gormley, Jeffrey S. Weber

ABSTRACT
TPS9589


AUTHOR(S)
Jose Lutzky, Lynn G. Feun, Norma Magallanes, Deukwoo Kwon, J. William Harbour

ABSTRACT
TPS9590

Phase I/II trial of intratumoral administration of hu14.18-IL2, with local radiation, nivolumab, and ipilimumab in subjects with advanced melanoma.

AUTHOR(S)

ABSTRACT
TPS9591

A phase II, open-label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel cell carcinoma progressing on anti-PD-(L)1 antibody therapy: The MERKLIN 2 study.

AUTHOR(S)
Alexander C. Van Akkooi, Paolo A. Ascierto, Paul D. Nathan, Paul Nghiem, Philip Reimann, Frank Hermann, Jürgen C. Becker

ABSTRACT
TPS9592


AUTHOR(S)
TPS9593

Phase II study of binimetinib with imatinib in patients with unresectable KIT-mutant melanoma.

AUTHOR(S)
Katy K. Tsai, Iwei Yeh, Adil Daud, Ari Oglesby

ABSTRACT

TPS9594

Phase Ib/randomized phase II study combining hepatic percutaneous perfusion with ipilimumab plus nivolumab in advanced uveal melanoma: The CHOPIN trial.

AUTHOR(S)
Thaïs M. Tong, Mark C. Burgmans, Monique Van der Kooij, Frank M. Speetjens, Arian R. van Erkel, Rutger W. van der Meer, Shelley van den Bosch, Mare A. Jonker, Inge C. Roozen, Jacob Lutjeboer, Fenna Rijksen, Els L. van Persijn-van Meerten, Chris H. Martini, Remco W. Zoethout, Fred G. Tijl, Christian U. Blank, Ellen Kapiteijn

ABSTRACT

TPS9595

Multicenter phase I/II trial of encorafenib with and without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic BRAF-mutant melanoma.

AUTHOR(S)

ABSTRACT
Resolving driver events in MLL-r negative high-risk infant ALL.

AUTHOR(S)
Jennifer Seelisch, Matthew Zatzman, Federico Comitani, Fabio Fuligni, Ledia Brunga, Patrick A. Brown, Adam Shlien, Sumit Gupta

ABSTRACT
10030

Forecasting asparaginase quantity required to treat pediatric ALL in LMICs using ACCESS FORxECAST.

AUTHOR(S)
Terence M. Hughes, Brianna Empringham, Sumit Gupta, Zachary J. Ward, Jennifer Yeh, Anita K. Wagner, Lewis B. Silverman, Lindsay L. Frazier, Avram Denburg

ABSTRACT
10031

Correlation of ex vivo drug sensitivity with clinical response in pediatric AML.

AUTHOR(S)
Ryosuke Kita, Michelle A. Richardson, Erica K. Anderson, Debbie C. Strachan, Raushan Rashid, Maci Terrell, Andrea N. Marcogliese, Marianne T. Santaguida, Alexandra M. Stevens

ABSTRACT
10032

Preclinical evaluation of the ETS inhibitor TK216 against relapsed and refractory childhood leukemia.

AUTHOR(S)
Ritul Sharma, Satbir Thakur, Mohit Jain, Chunfen Zhang, Anne-Marie Langevin, Aru Narendran

ABSTRACT
10033
Novel methods to assess cell-free circulating tumor DNA in acute lymphoblastic leukemia.

AUTHOR(S)
Meghan G. Haney, Shilpa Sampathi, Yelena Chernyavskaya, Henry Moore, Tom C. Badgett, Jessica S. Blackburn

ABSTRACT
Discovery and validation of a cross-platform 21-gene prognostic signature in neuroblastoma.

AUTHOR(S)
Mehul Gupta, Sunand N. Kannappan, Aru Narendran, Pinaki Bose

ABSTRACT
Racial and ethnic disparities in risk and survival in children with neuroblastoma: An updated analysis.

AUTHOR(S)
Caileigh Pudela, Mark A. Applebaum, Sang Mee Lee, Arlene Naranjo, Julie R. Park, Samuel L. Volchenboum, Tara O. Henderson, Susan L. Cohn, Ami V. Desai

ABSTRACT
Testing of B7-H3 targeting antibody-drug conjugate (ADC) MGC018 in models of pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC).

AUTHOR(S)

ABSTRACT
Late health outcomes in survivors of Wilms tumor: A report from the St. Jude Lifetime (SJLIFE) cohort study.

AUTHOR(S)

ABSTRACT
Predicting response to chemotherapy in neuroblastoma using deep learning: A report from the International Neuroblastoma Risk Group.

AUTHOR(S)
Siddhi Ramesh, Diana Michael, Liu Liu, Nicholas Feinberg, Meaghan Granger, Arlene Naranjo, Susan L. Cohn, Samuel L. Volchenboum, Anoop Mayampurath, Mark A. Applebaum

ABSTRACT

Preclinical evaluation of an engineered oncolytic herpes simplex virus for pediatric osteosarcoma.

AUTHOR(S)
Sara Hutchins, Raoud Marayati, Laura V. Bownes, Colin H. Quinn, Jerry E. Stewart, Gregory K. Friedman, Jennifer M. Coleman, G. Y. Gillespie, James M. Markert, Elizabeth A. Beierle

ABSTRACT

Nonhematologic neoplasia in biallelic BRCA2 mutated Fanconi anemia.

AUTHOR(S)
Vasant Chinnabhandar, Todd E. DeFor, Rebecca Tryon, John E. Wagner, Margaret L. MacMillan

ABSTRACT

Health-related quality of life (HRQoL) among pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN) in the United States (U.S.).

AUTHOR(S)
Xiaoqin Yang, Hyun Kyoo Yoo, Suvina Amin, Wendy Y. Cheng, Heather Sipsma, Sanjana Sundaresan, Lujia Zhang, Mei S. Duh

ABSTRACT

Predicting decreased health-related quality of life (HRQL) in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).

AUTHOR(S)
Fiona Schulte, Yan Chen, Yutaka Yasui, Wendy M. Leisenring, Todd M. Gibson, Paul C. Nathan, Kevin C. Oeffinger, Melissa M. Hudson, Gregory T. Armstrong, Leslie L. Robison, Kevin R. Krull, I-Chan Huang

ABSTRACT
Late morbidity and mortality among survivors of neuroblastoma treated with contemporary therapy: A report from the Childhood Cancer Survivor Study.

AUTHOR(S)

ABSTRACT


AUTHOR(S)

ABSTRACT

Determinants of symptom clusters and associations with health outcomes in childhood cancer survivors: A report from the St. Jude Lifetime Cohort (SJLIFE).

AUTHOR(S)

ABSTRACT

Development and validation of a prediction model for kidney failure in long-term survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).

AUTHOR(S)

ABSTRACT

Health-related unemployment trends among survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).
Accelerated cognitive decline in adult survivors of pediatric central nervous system (CNS) tumors: A report from the Childhood Cancer Survivor Study (CCSS).


Standardization of fertility preservation discussion amongst pediatric oncology and bone marrow transplant patients.

Integration and feasibility of symptom burden assessment and early palliative care into an adolescent and young adult leukemia clinic.
Assessment of physician perceptions of pediatric palliative care for children with cancer in Latin America.

AUTHOR(S)
Michael McNeil, Bella Ehrlich, Marisol Bustamante, Veronica Dussel, Paola Friedrich, Ximena Garcia Quintero, Wendy Cristhyna Gomez Garcia, Dylan E. Graetz, Erica Kaye, Monika Metzger, Carla V. Sabato Danon, Justin N. Baker, Asya Agulnik

ABSTRACT

AUTHOR(S)
Kathy Ruble, Lisa Carey, Juliana Pare-Blagoev, Kimberly Milla, Sydney Henegan, Katrina Cork, Clifton Thornton, Lisa Jacobson

ABSTRACT
Phase II study of nivolumab and ipilimumab in children and young adults with INI1-negative cancers.

AUTHOR(S)

ABSTRACT
TPS10055

FIREFLY-1: A phase 2 study of the pan-RAF inhibitor DAY101 in pediatric patients with low-grade glioma.

AUTHOR(S)

ABSTRACT
TPS10056
Giant cell tumor of bone: Effect of longer dosing intervals of denosumab on tumor control and bone related complications.

AUTHOR(S)
Cindy Jiang, Lili Zhao, Scott Schuetze, Rashmi Chugh

ABSTRACT
11525

Efficacy and safety of JMT103 in patients with giant cell tumor of bone: A multicenter, single-arm, open-label, phase Ib/II study.

AUTHOR(S)
Xiaohui Niu, Feng Wei, Chongqi Tu, Gang Huang, Wenzhi Bi, Jianmin Li, Weitao Yao, Xiaojing Zhang, Jingnan Shen, Guochuan Zhang, Wangjun Yan, Jilong Yang, Jianhua Lin, Zhaoming Ye, Dong Wang, Zheng Guo, Zhichao Tong, Yuhong Zhou, Hairong Xu, Tao Li

ABSTRACT
11526

ABCB1/P-glycoprotein (Pgp) expression as stratification factor for treatment of patients with non-metastatic extremity high-grade osteosarcoma: A merged analysis of an Italian (ISG) and a Spanish (GEIS) sarcoma groups' multicentric prospective trials.

AUTHOR(S)
Emanuela Palmerini, Catalina Marquez, Cristina Meazza, Angela Tamburini, Gianni Bisogno, Francisco José Bautista Sirvent, Virginia Ferraresi, Sebastian D. Asaftei, Giuseppe M. Milano, Roberto Luksch, Adela Canete, Aizpea Echebarria, Víctor Quintero, Cristina Mata, Rossella Bertulli, Alessandra Longhi, Piero Picci, Franca Fagioli, Nadia Hindi, Stefano Ferrari

ABSTRACT
11527

Activity of erlotinib in patients (pts) with advanced chordoma: A retrospective study.

AUTHOR(S)
Olivier Mir, Sylvain Briand, Thierry Lazure, Julien Adam, Rastilav Bahleda, Jean-Yves Blay, Andrea Cavalcanti, Ali N. Chamsseddine, Aurélie Dutour, Matthieu Faron, Leila Haddag, Clemence Henon, Cecile Le Pechoux, Antonin Levy, Carine Ngo, Benjamin Verret, Charles Honoré, Charles Court, Axel Le Cesne

ABSTRACT

11528

GEIS 39: Phase II trial of nabpaclitaxel for the treatment of patient with multiply relapsed/refractory desmoplastic small round cell tumor (DSRCT) and Ewing sarcoma (EwS).

AUTHOR(S)
Jaume Mora, Mariona Suñol, Nadia Hindi, Alicia Castañeda, Andrés Redondo, Francisco José Bautista Sirvent, Robert Diaz Beveridge, Antonio Lopez-Pousa, Jose A. Lopez-Martin, Javier Martin Broto

ABSTRACT

11529

Outcome of patients with recurrent/refractory osteosarcoma enrolled in three recent phase II trials: A report from the Children’s Oncology Group.

AUTHOR(S)
Seema Rao, Ruxu Han, Mark D. Krailo, Allen Buxton, Pooja Hingorani, Alexander J. Chou, Richard G. Gorlick, Damon R. Reed, Katherine A. Janeway, Lisa M. Kopp, Brenda Weigel, Michael Isakoff

ABSTRACT

11530

Comparison of treatment effect and long-term outcomes for pediatric and adult Ewing sarcoma patients in British Columbia, Canada.

AUTHOR(S)
Omar Hajjaj, Lauren Corke, Caron Strahlendorf, Christine E. Simmons

ABSTRACT

11531

Genomic alterations and associated pathway abnormalities in Ewing sarcoma.

AUTHOR(S)
Adam Rock, Warren A. Chow, An Uche, Sherri Z. Millis

ABSTRACT

11532

Accumulation of genome-wide somatic loss of heterozygosity (LOH) as a prominent feature of advanced malignant soft tissue tumors and association
with the BRCA1/2 status, suppression of immune responses, and lower survival rates.

AUTHOR(S)
Katsuhito Takahashi, Yasutomo Miyaji, Ryotaro Ohkuma, Hajime Higuchi, Yoshihiro Komohara, Shinsuke Aida, Jun Yashima, Hiromasa Yamamoto, Ken Suzawa, Yuko Takahashi, Shinichi Toyouka, Hiroya Ashimine, Yu Oyama, Hiroyuki Narahara, Junko Yotsumoto, Hiroo Ishida, Takuya Tsunoda, Yasutsuna Sasaki, Yasuo Ono, Satoshi Teraoka

ABSTRACT

11533


AUTHOR(S)
Cesar Serrano, Claudia Valverde, Josefina Cruz Jurado, Javier Martinez-Trufero, Xavier Guri, Martina Giuppi, Andrés Redondo, Beatriz Suarez-Paniagua, Cleofe Romagosa, Virginia Martinez

ABSTRACT

11534

Chromosomal complexity as a biomarker to de-escalate adjuvant imatinib treatment in high-risk gastrointestinal stromal tumor.

AUTHOR(S)
Kjetil Boye, Ludmila Gorunova, Ioannis Panagopoulos, Ivar Hompland, Bodil Bjerkehagen, Jeanne-Marie Berner, Sverre Heim, Toto Hølmebakk, Francesca Micci

ABSTRACT

11535

Intra-patient dose escalation (IPDE) of ripretinib after disease progression in patients with advanced gastrointestinal stromal tumor (GIST): Analyses from the phase 3 INVICTUS study.

AUTHOR(S)
John R. Zalcberg, Michael C. Heinrich, Suzanne George, Sebastian Bauer, Patrick Schoffski, Cesar Serrano, Robin L. Jones, Hans Gelderblom, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Neeta Somaiah, Julie N. Meade, Vienna L. Reichert, Kelvin Shi, Matthew L. Sherman, Rodrigo Ruiz-Soto, Margaret von Mehren, Jean-Yves Blay

ABSTRACT

11536

Next generation sequencing of sarcomas: Response to crizotinib in two cases with MET amplification.

AUTHOR(S)
Deciphering the molecular landscape and the tumor microenvironment of perivascular epitheloid cell neoplasma (PEComa).

AUTHOR(S)
Andreas Seeber, Lea Holzer, Andrew Elliott, Dietmer Dammerer, Vaia Florou, Roman Groisberg, Benjamin Henninger, Wolfgang M. Korn, Johannes Lanbach, Margaret von Mehren, Jaime Modiano, Steven O’Day, Alexander Perathoner, Andrew Rosenberg, Katja Schmitz, Anton Schwabegger, Martin Thaler, Jonathan C. Trent, Kai Zimmer, Florian Kocher

Whole-genome sequencing to improve sarcoma diagnosis and patient care.

AUTHOR(S)

The sarcoma microbiome as a diagnostic and therapeutic target.

AUTHOR(S)
Gabriel Tinoco, Marium Husain, Rebecca Hoyd, Malvenderjit Jagjit Singh, Yunzhou Liu, Xiaokui Mo, James L. Chen, David A. Liebner, Daniel Spakowicz

Phase 1 trial of autologous dendritic cell vaccination with imiquimod immunomodulation in children and adults with refractory sarcoma.

AUTHOR(S)
Aditi Dhir, Tulay Koru-Sengul, James Grosso, Gina Z. D’Amato, Matteo M. Trucco, Andrew Rosenberg, Eli Gilboa, John M. Goldberg, Jonathan C. Trent, Breelyn A. Wilky

Results of NC-6300 (nanoparticle epirubicin) in an expansion cohort of patients with angiosarcoma.

AUTHOR(S)
ABSTRACT

11543


AUTHOR(S)

Sylvie Bonvalot, Piotr Rutkowski, Juliette Thariat, Sebastien Carrère, Anne Ducassou, Sunyach Marie, Peter Agoston, Angela M. Hong, Augustin Mervoyer, Marco Rastrelli, Cecile Le Pechoux, Victor Moreno, Rubi K. Li, Béatrice Tiangco, Zsuzsanna Papai

ABSTRACT

11544

Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Preliminary results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc) for the non-L sarcoma cohort.

AUTHOR(S)


ABSTRACT

11545

Recurrence and disease-specific survival after 10-year disease-free interval in patients with primary retroperitoneal liposarcoma: Implications for long-term surveillance.

AUTHOR(S)


ABSTRACT

11546

Efficacy and safety of anlotinib plus TQB2450 in patients with advanced soft tissue sarcoma: A multicenter, single armed, phase 1b trial.

AUTHOR(S)

Jiayong Liu, Zhengfu Fan, Wei Guo, Tian Gao, Shu Li, Jie Xu, Chujie Bai, Ruifeng Xue, Lu Zhang, Lu Xie, Zhichao Tan
The impact of multimodality therapies in marginally inoperable soft tissue sarcomas (STS): The Toronto Sarcoma Program (TSP) experience.

AUTHOR(S)
Olga Vornicova, Jay Wunder, Peter W. Chung, Abha A. Gupta, Rebecca A. Gladdy, Charles N. Catton, Samer Salah, Peter C. Ferguson, Kim Tsoi, David B. Shultz, Savtaj S. Brar, Philip Wong, Carol J. Swallow, Albiruni R. Abdul Razak, Esmail M. Al-Ezzi

ABSTRACT

A phase 1b study of avelumab plus DCC-3014, a potent and selective inhibitor of colony stimulating factor 1 receptor (CSF1R), in patients with advanced high-grade sarcoma.

AUTHOR(S)
Evan Rosenbaum, Sujana Movva, Ciara M. Kelly, Mark A. Dickson, Mary Louise Keohan, Mrinal M. Gounder, Katherine A. Thornton, Ping Chi, Jason E. Chan, Benjamin Nacev, Viswatej Avutu, Matthew Biniakewitz, Olivia R. McKennan, Haley Phelan, Silvia Perez, Sinchun Hwang, Samuel Singer, Li-Xuan Qin, William D. Tap, Sandra P. D'Angelo

ABSTRACT

Preliminary results of phase 2 trial of preoperative image guided intensity modulated proton radiation therapy (IMPT) with simultaneously integrated boost (SIB) to the high-risk margin for retroperitoneal sarcomas (RPS).

AUTHOR(S)
Thomas F. DeLaney, John T. Mullen, Yen-Lin Chen, Ivy A. Petersen, Andrew J. Bishop, Sam S. Yoon, Alex B. Haynes, Christina L. Roland, Sonia Cohen, Edwin Choy, Gregory M. Cote, Gunnaugur Nielsen, Christopher Lescinskas, Katherine E. Santoro, Dian Wang, Beow Y. Yeap

ABSTRACT

Durvalumab and pazopanib in patients with advanced soft tissue sarcoma: A single-center, single-arm, phase 2 trial.

AUTHOR(S)
Hyo Song Kim, Hee Jin Cho, Kum-Hee Yun, Young Han Lee, Sung Hyun Kim, Wooyeol Baek, Min Kyung Jeon

ABSTRACT

Immune-desert tumor microenvironment in SMARCA4-deficient thoracic sarcomas with limited efficacy of immune checkpoint inhibitors.
AUTHOR(S)
Justine Gantzer, Guillaume Davidson, Bujamin Vokshi, Noëlle Weingertner, Antoine Bougoûin, Marco Moreira, Veronique Lindner, Guillaume Lacroix, Celine Mascaux, Marie Pierre Chenard, Irwin Davidson, Jean Emmanuel Kurtz, Catherine Sautès-Fridman, Wolf-Herman Fridman, Gabriel Malouf

ABSTRACT
11552


AUTHOR(S)
Abdulazeez Salawu, Christopher Lemieux, Albiruni R. Abdul Razak

ABSTRACT
11553

First-in-human administration of CEB-01, a novel drug delivery implant matrix, in patients with recurrent or locally advanced retroperitoneal soft tissue sarcoma (RPS) after surgery: Preliminary safety and pharmacokinetics report.

AUTHOR(S)
José A. Gonzalez, Ana Sebio, Paula Cerdà, Francesc Cano, José A. Tornero, Luc Marti, Jaume Mora, Lucas Krauel, Antonio Lopez-Pousa

ABSTRACT
11554

Multiomic analysis reveals distinct molecular profiles of uterine and nonuterine leiomyosarcoma.

AUTHOR(S)
Tabitha Copeland, Roman Groisberg, Don S. Dizon, Andrew Elliott, Galina Lagos, Andreas Seeber, Margaret von Mehren, Kenneth Cardona, Michael J. Demeure, Richard F. Riedel, Vaia Florou, Alexander J. Chou, Abhijeet Kumar, Jaime Modiano, Moh’d M. Khushman, Gina Z. D’Amato, Andrea P. Espejo Freire, W. M. Korn, Jonathan C. Trent

ABSTRACT
11555

The efficacy and safety of anlotinib in refractory/recurrent/advanced pediatric solid tumors: A retrospective study.

AUTHOR(S)
Suying Lu, Ye Hong, Huimou Chen, Liuhong Wu, Jia Zhu, Juan Wang, Feifei Sun, Zijun Zhen, Yi Que, Lian Zhang, Xiaofei Sun, Junting Huang, Yizhuo Zhang

ABSTRACT
Early results of Intratumoral INT230-6 alone or in combination with ipilimumab in subjects with advanced sarcomas.

AUTHOR(S)

ABSTRACT

Regorafenib (R) in advanced solitary fibrous tumor (SFT): Results from an exploratory phase II clinical study.

AUTHOR(S)
Silvia Stacchiotti, Giacomo G. Baldi, Salvatore Lo Vullo, Carlo Morosi, Francesca G. Greco, Paola Collini, Marta Barisella, Gianpaolo Dagrada, Nadia Zaffaroni, Alessandro Gronchi, Noemi Simeone, Luigi Mariani, Anna Maria Frezza, Paolo G. Casali

ABSTRACT

A pilot study of the feasibility and utility of a fitness tracker to correlate activity level with patient reported outcomes (PROs) in sarcoma patients undergoing systemic therapy.

AUTHOR(S)
Elizabeth J. Davis, G. D. Ayers, Deborah Wallace, Elizabeth Kaiser, Vicki L. Keedy, Rajiv Agarwal

ABSTRACT

A patient reported outcomes of treatments for desmoid tumors: An international natural history study.

AUTHOR(S)
Danielle Braggio, Amanda Lucas, Lynne Hernandez, Kelly Mercier

ABSTRACT

Treatment patterns, and survival of patients with metastatic undifferentiated pleomorphic sarcoma: A National Cancer Database (NCDB) study.

AUTHOR(S)
Hussain I. Rangoonwala, Mary E. Dahl, Jonathan Gootee, Sai Giridhar Gundepalli, Sarah J. Aurit, Peter T. Silberstein
**A B S T R A C T**

11561

**A phase 2 study using ipilimumab, nivolumab, and trabectedin for previously untreated metastatic soft tissue sarcoma.**

**AUTHOR(S)**

Erlinda M. Gordon, Victoria S. Chua, Ted T. Kim, Neal S. Chawla, Don A. Brigham, Ishrat Bhuiyan, Mark Agulnik, Warren A. Chow, Sant P. Chawla

**A B S T R A C T**

11562

**Results of the phase 1b soft-tissue sarcoma (STS) portion of the global randomized, double-blind, placebo-controlled study of tazemetostat (TAZ) plus doxorubicin (DOX) as frontline therapy for advanced epithelioid sarcoma (ES).**

**AUTHOR(S)**

Sant P. Chawla, Gerald S. Falchook, Melissa A. Burgess, James L. Chen, Robin L. Jones, Victoria S. Chua, Coya Tapia, Jessica Ainscough, Anthony Hamlett, Melinda S. Merchant, Rashmi Chugh

**A B S T R A C T**

11563

**Retrospective world-wide registry on the efficacy of immune checkpoint inhibitors in alveolar soft part sarcoma: Updated results from sixty patients.**

**AUTHOR(S)**

Nadia Hindi, Evan Rosenbaum, Emily Jonczak, Rainer Hamacher, Piotr Rutkowski, Anthony Skryd, Elizabeth Connolly, Jean-Yves Blay, Antonio Gutierrez, Carolina Bogefors, Hans Gelderblom, Kjetil Boye, Clemence Henon, Javier Martinez-Trufero, Jose A. Lopez-Martín, Andrés Redondo, Claudia Valverde, Bruno Vincenzi, William D. Tap, Javier Martin Broto

**A B S T R A C T**

11564

**Palbociclib (P) in patients (pts) with soft tissue sarcoma (STS) with CDK4 amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.**

**AUTHOR(S)**

Scott Schuetze, Michael Roth, Pam K. Mangat, Liz Garrett-Mayer, Funda Meric-Bernstam, Laura C. Farrington, Carmen Calfa, Stacy D. D’Andre, Michael B. Livingston, Ramya Thota, Alissa S. Marr, Margaret von Mehren, Kristopher Wentzel, Richard L. Schilsky
Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the 62092-22092 STRASS trial.

AUTHOR(S)

ABSTRACT
A phase 2 study of talimogene laherparepvec, nivolumab, and trabectedin (TNT) in advanced sarcoma.

AUTHOR(S)

ABSTRACT
Evaluation of homologous recombination deficiency (HRD) score and immunotumor microenvironment (iTME) as biomarkers of soft tissue sarcoma (STS) survival and response to immune checkpoint inhibitor therapy.

AUTHOR(S)
Chenlu Zhang, Xi Guo, Fei Xu, Yang You, Zhiming Wang, Rongyuan Zhuang, Wenshuai Liu, Li-jie Ma, Hanxing Tong, Yong Zhang, Weiqi Lu, Jun Liu, Yuhong Zhou

ABSTRACT
Prospective cohort study of Kaposi sarcoma treated under real-world conditions in Malawi.

AUTHOR(S)
Edwards Kasonkanji, Yolanda Gondwe, Morgan Dewey, Joe Gumulira, Matthew Painschab, Mina Hosseinipour, Dirk Dittmer

ABSTRACT
Active surveillance in primary desmoid tumor (DT): A prospective observational study.

AUTHOR(S)
**Growth rate and site of pulmonary metastasis to predict lung relapse and overall survival in patients affected by bone and soft tissue sarcomas (B-STS).**

**AUTHOR(S)**
Lorenzo D’ambrosio, Francesco Tolomeo, Maria Cristina Bruna, Sandra Aliberti, Alessandra Merlina, Giulia Manessi, Andrea Mogavero, Alessandro Minelli, Tiziana Robba, Delia Campanella, Alberto Pisacane, Elena Maldi, Raimondo Piana, Enrico Ruffini, Claudio Mossetti, Bruno Vincenzi, Giovanni Grignani

**ABSTRACT**

11570

**Immune contexture in high-risk soft tissue sarcomas (STS): A planned analysis of the ISG-STS-1001 randomized trial.**

**AUTHOR(S)**
Sandro Pasquali, Chiara Castelli, Paola Collini, Marta Barisella, Cleofe Romagosa, Silvia Bague, Jean Michel Coindre, Paolo De Tos, Luca Braglia, Emanuela Palmerini, Vittorio Quagliuolo, Javier Martin Broto, Antonio Lopez-Pousa, Giovanni Grignani, Jean-Yves Blay, Robert Diaz Beveridge, Domenico F. Merlo, Silvia Stacchiotti, Paolo G. Casali, Alessandro Gronchi

**ABSTRACT**

11571

**VAC temporization pending final margins after suprafascial myxofibrosarcoma excision to reduce the rate of local recurrence.**

**AUTHOR(S)**

**ABSTRACT**

11573

**Patient reported outcomes in patients with desmoid type fibromatosis.**

**AUTHOR(S)**
Vikas Garg, Sameer Rastogi, Adarsh Barwad, Rambha Panday, Sandeep K. Bhoirwal, Ekta Dhamija

**ABSTRACT**

11574

**Phase II trial of olaparib in combination with ceralasertib in patients with recurrent osteosarcoma.**
AUTHOR(S)

Suzanne J. Forrest, Michael D. Kinnaman, J Andrew A. Livingston, Kieuhoa T. Vo, Priscilla Merriam, Catherine Clinton, Kylene Desmith, Kerri Cavanaugh, Brunella Felicetti, Simon Smith, Emma Dean, Pei-Chi Kao, Wendy B. London, E. A. Sweet-Cordero, Katherine A. Janeway

ABSTRACT

TPS11575

REGOSTA: A randomized, placebo-controlled, double-blinded, multicenter study evaluating the efficacy and safety of regorafenib (REGO) as maintenance therapy after first-line treatment in patients (pts) with osteosarcoma (OS) and non-osteosarcomas (non-OS) of bone (non-Ewing, non-chondrosarcomas and non-chordomas).

AUTHOR(S)


ABSTRACT

TPS11576

Phase 1 expansion trial of the LSD1 inhibitor seclidemstat (SP-2577) with and without topotecan and cyclophosphamide (TC) in patients (pts) with relapsed or refractory Ewing sarcoma (ES) and select sarcomas.

AUTHOR(S)

Damon R. Reed, Sant P. Chawla, Bhuvana Setty, Leo Mascarenhas, Paul A. Meyers, Jonathan Metts, Douglas J. Harrison, Stephen L. Lessnick, Brian D. Crompton, David Loeb, David D. Stenehjem, David S. Wages, Daniela Y. Santiesteban, Nadeem Q. Mirza, Steven G. DuBois

ABSTRACT

TPS11577

A phase 2 study of belinostat and SGI-110 (guadecitabine) for the treatment of unresectable and metastatic conventional chondrosarcoma.

AUTHOR(S)


ABSTRACT

TPS11578

A multicenter, open-label, uncontrolled phase II study of ONO-4538 for cutaneous angiosarcoma (Angio Check study).
AUTHOR(S)

ABSTRACT
TPS11579

A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).

AUTHOR(S)
Makoto Endo, Kazuhiro Tanaka, Yoshihiro Matsumoto, Hiroaki Hiraga, Shintaro Iwata, Satoshi Tsukushi, Munenori Watanuki, Toru Akiyama, Tsukasa Yonemoto, Robert Nakayama, Keisuke Ae, Hiroyuki Kawashima, Hiroyuki Tsuchiya, Hirohisa Katagiri, Akihito Nagano, Satoshi Takenaka, Tomoko Kataoka, Ryunosuke Machida, Haruhiko Fukuda, Toshifumi Ozaki

ABSTRACT
TPS11580

ENVASARC: A pivotal trial of envafolimab, and envafolimab in combination with ipilimumab, in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.

AUTHOR(S)
Sandra P. D'Angelo, Steven I. Robinson, Joelle Lam, Bonne J. Adams, James L. Freddo, Charles P. Theuer, Robert G. Maki

ABSTRACT
TPS11581

IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (letecel; GSK3377794) in HLA-A*02+ patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2).

AUTHOR(S)

ABSTRACT
TPS11582

A randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition in metastatic soft tissue sarcoma.

AUTHOR(S)
Vanessa A. Eulo, Breelyn A. Wilky, Jingqin Luo, Angela C. Hirbe, Mia C. Weiss, Peter J. Oppelt, Sarah Abaricia, Jacqui Toeniskoetter, Tyler Ruff, Robert G. Maki, Brian A. Van Tine